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ABSTRACT 
Internal nucleoside methylation of eukaryotic RNA in the form of N6-methyladenosine 
(m6A) and 5-methylcytosine (m5C) have been known to exist for decades, however 
absence of facile methods to map modified sites have limited the understanding of their 
role. With the availability of next-generation sequencing, these drawbacks have been 
overcome, revealing non-random distribution of internal methylation across different 
transcript biotypes. Recently, we implemented a bisulfite sequencing-based technique 
for transcriptome-wide detection of m5C (bsRNA-seq) and mapped thousands of m5C 
sites in the human transcriptome including in ncRNA and mRNA. Biased distribution of 
m
5C within mRNAs was evident, consistent with roles in post-transcriptional gene 
regulation. Two RNA methyltransferases are known to be active in humans, NSUN2, 
which is overexpressed in various tumours, and TRDMT1. The aims of this thesis were 
to determine the RNA targets of NSUN2 and TRDMT1, explore the molecular 
functions of m5C in mRNA and compare RNA m5C profiles of normal prostate cells 
(PrEC), prostate cancer cells (LNCaP) and cervical cancer cells (HeLa) using improved 
high-throughput methods. 
 
RNAi-mediated knockdown of NSUN2 and TRDMT1 in HeLa cells coupled with 
bsRNA-seq revealed 4,241 candidate m5C sites across tRNA, ncRNA and mRNA; 393 
of these sites were called as NSUN2 targets and 120 as TRDMT1 targets. NSUN2 
mediated the bulk of tRNA methylation, targeting several structural positions and a 
broad range of isotypes and isoacceptors, while TRDMT1 was specific to one structural 
position across four isoacceptors, consistent with previously published work. 
Interestingly, m5C was evident in tRNAs prior to end processing and splicing, 
indicating that methylation occurs early during tRNA biogenesis. Five tRNAs 
exhibiting m5C sites were independently validated by locus-specific bsRNA-
sequencing. Importantly, five m5C sites in ncRNAs and nine in mRNAs were 
independently validated as NSUN2 targets with NSUN2 exhibiting multisite specificity, 
indicating its importance as a ncRNA and mRNA modifying enzyme. 
 
Enrichment of Ago2 footprints upstream of m5C sites and depletion of miRNA target 
regions at m5C sites was evident in the CDS and 3’ UTR, suggestive of regulatory 
interactions between m5C and RISC. A subtle decrease in average steady-state levels of 
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NSUN2-targeted mRNAs was evident in the NSUN2 knockdown sample, suggesting a 
role for m5C in mRNA stability. Investigation of the correlation of m5C with translation 
state of individual mRNAs revealed two examples with opposing trends, suggesting 
context-dependent effects of m5C on translation. 
 
Comparison of the RNA m5C profiles of PrEC and LNCaP cells revealed 5,653 
candidate m5C sites in common across tRNA, ncRNA and mRNA, with few discernible 
differential m5C sites. Inspection of differential sites suggested that many might have 
resulted from technical imperfections of bsRNA-seq, which was independently 
confirmed. A comparison of prostate cells with HeLa cells showed high concordance of 
m
5C patterns across all three cell lines, with independent examples validated, indicating 
that m5C is conserved across multiple cellular contexts.  
 
The discovery that m5C is abundant in mRNA across different cellular contexts and 
correlative links between the presence of m5C in mRNA and several aspects of post-
transcriptional gene regulation highlight a functional importance for m5C in mRNA. 
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1.1 INTRODUCTION TO RNA MODIFICATIONS 
The following introduction has been adapted from a recent literature review I published 
[1]. 
 
A wealth of chemically diverse nucleobase and ribose modifications have been 
characterised in RNA, amounting to over 100 distinct ribonucleosides that are known 
across all phyla and types of RNA [2, 3]. Much of this diversity occurs among tRNAs 
and the other non-coding (nc) RNAs of the translational apparatus. Messenger (m) RNA 
is comparatively devoid of modifications, both in terms of diversity and density. The 
RNA modification database [2] lists thirteen non-standard nucleosides as present in 
eukaryotic cellular mRNA (Figure 1.1). These include 7-methylguanosine (m7G) and 
several other base and/or ribose-methylated nucleosides that are accounted for by the 
presence of the 5’ cap structure m7G(5’)ppp(5’)N (termed “cap 0”) and its further 
methylated variants that are either common to many eukaryotes (“cap 1” & “cap 2”) [4, 
5] or selectively found in certain species such as the “cap 4” of Trypanosomes or the 
trimethylguanosine ‘TMG cap’ of C. elegans trans-spliced mRNAs [6]. This leaves four 
modifications, inosine (I), pseudouridine (ψ), N6-methyladenosine (m6A) and 5-
methylcytidine (m5C) that were reported to occur internally within mRNAs. A-I as well 
as C-U editing by ADAR and APOBEC enzymes changes base-pairing thus having 
clearly predictable effects on RNA function such as codon alteration or changes to RNA 
structure, as reviewed elsewhere [7, 8]. ψ is abundant in transfer (t) RNAs and 
ribosomal (r) RNAs and enhances their function by stabilising their structure [9-15]. 
Natural occurrence of ψ in mRNA remained unknown until recently, with early studies 
suggesting that artificial ψ in mRNAs facilitated non-canonical base pairing in the 
ribosome decoding centre [16, 17]. By contrast, m6A and m5C do not change base 
identity and thus would be expected to have more subtle or hidden effects. For example, 
m6A has been shown to block the non-standard A:G base pairing, which can play 
important structural roles [18]. 
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Figure 1.1. Schematic representation of known eukaryotic mRNA modifications.  
The internal base modifications ψ, m6A and m5C are highlighted as blue, red and green 
lollipops, respectively. 
 
A flurry of research conducted during the mid-seventies in the United States, Japan and 
Australia focused on the methylation state of eukaryotic mRNA and rapidly pieced 
together the puzzle of the cap structure present on eukaryotic cellular and viral mRNA 
[19]. This spawned a whole field of research characterising the enzymology of the cap 
structure and its functions in multiple aspects of RNA metabolism, particularly during 
processing, translation and decay of mRNA [6]. Generally, these pioneering studies 
attributed about half of the detectable methyl groups to modifications within the 
extended cap structure while the other half was seen to occur internally within mRNA, 
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or more accurately polyadenylated RNA, which might also have included some ncRNA 
species. With this caveat, m6A was established as the most abundant internal mRNA 
modification with estimates typically ranging from 1-5 internal residues per molecule of 
either cellular (mammalian, insect, plant) or viral mRNA [20-39], though not all 
mRNAs contain m6A residues. Characterisations of the m6A methyltransferase in 
human (MT-A70) [40], plant (MTA) [41] and yeast (Ime4) [42], also known as 
METTL3 (for methyltransferase like 3), have since advanced this research as has the 
identification of a consensus sequence context, originally proposed to be RRm6ACH (R 
= A, G; H = A, C, U) in its most extended form [43]. Sites for m6A have also been 
mapped in three mRNAs, one each of viral, mammalian and yeast origin [44-46] and 
over the years some evidence was gathered for cellular and molecular functions of this 
modification in mRNA. 
 
Some of the early studies also detected m5C as an internal modification in mammalian 
cellular or viral mRNA [26, 30, 47, 48]. Specifically, methylation in hamster cell 
mRNA was reported to be split into approximately 50% deriving from the cap structure, 
while 40% and 10% came from internal m6A and m5C, respectively [26]. This 
represents relatively sparse modification levels (e.g. m6A: on average 0.72 sites/1000 nt, 
1.8/mRNA, 0.3% of all internal adenosines; m5C: 0.18 sites/1000 nt, 0.45/mRNA, 
0.07% of all internal cytidines), although it still compares favourably to A-I editing 
frequency (highest levels in brain: 0.059 sites/1000 nt, 0.15/mRNA, 0.02% of all 
internal adenosines; levels in other tissues are up to ~10 fold lower) [49]. Adenovirus 
and Sindbus virus mRNA were also found to contain detectable levels of m5C; for the 
latter it represented a substantial proportion of internal methylation [30, 47, 48]. While 
there is considerable information on the occurrence and roles of m5C in tRNA and 
rRNA (reviewed in refs. [50-52]), no sites had been mapped in any mRNA and no 
further research into the role of m5C as a modification of mRNA had been published 
until recently. Similarly, despite ψ being the most abundant RNA modification, its 
presence in mRNA remained elusive up until recently. 
 
An overriding impediment to further progress in understanding the role of internal 
mRNA methylation and pseudouridylation has been the lack of suitable methods to map 
multiple modified sites with ease and sensitivity. In this chapter, I will review the 
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current state of this field with a particular emphasis on recent studies that have 
overcome these hurdles and provided the first transcriptome-wide maps of ψ [53-55], 
m
6A [56, 57] and m5C [58]. 
 
1.2 TRANSCRIPTOME-WIDE MAPPING OF ψ, M6A 
AND M5C 
Traditional techniques to detect RNA modifications often rely on combinations of 
metabolic (radioactive) labelling, purification of a particular transcript class or 
individual RNA from cellular material, followed by hydrolysis and identification of 
modified nucleosides through chromatographic separation [50, 51, 59]. For instance, 
both m6A and m5C were initially identified as internal mRNA modifications in this way, 
e.g. ref. [26], using 14C-labelling of methyl groups and oligo(dT)-mediated purification 
of mRNAs via their then newly discovered poly(A) tail [60]. Mapping modifications to 
particular sequence positions required additional laborious and relatively insensitive 
approaches, and in combination this precluded progress with mapping internal mRNA 
base methylation for all but a few cases [44-46]. This changed recently with the 
development of transcriptome-wide, high-throughput sequencing-based approaches that 
have adapted methods developed for DNA in epigenetics research (Table 1.1) [56-58]. 
The association of m5C with epigenetic regulation of genome activity is well established 
and many methods are available to map its presence in genomic DNA; often these have 
been combined with microarray or high-throughput sequencing as the ultimate readout. 
Typically, they are based on either recording patterns of DNA cleavage by methylation-
sensitive restriction enzymes, enrichment of DNA fragments by binding to antibodies 
against m5C, or the bisulfite sequencing chemistry [61, 62].  
 
1.2.1 PREVALENCE AND GLOBAL DISTRIBUTION OF ψ 
Up until recently, ψ was only detected in tRNAs, rRNAs, small nuclear (sn) RNAs and 
small nucleolar (sno) RNAs, however three recent global approaches have detected ψ in 
mRNAs, thoroughly extending what was previously known about this modification. As 
these studies have been published very recently and the technique used for the detection 
of ψ is substantially different to those used to detect m6A and m5C in RNA, I will only 
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briefly summarise what has been found thus far, including the biological implications of 
this modification in mRNA. 
 
The transcriptome-wide approaches used for the detection of ψ took advantage of its 
selective modification with N-cyclohexyl-N’-(2-morpholinoethyl)-carbodiimide metho-
p-toluenesulphonate (CMC) as identified by previous primer-extension methods [63-
65]. The modification of ψ by CMC creates a block for reverse transcription one 
nucleotide 3’ to ψ. This was then coupled with next-generation sequencing, providing 
single nucleotide resolution of ψ, termed pseudo-seq [53], ψ-seq [54] or PSI-seq [55]. 
The preparation of samples for sequencing were similar between each study, with the 
pseudo-seq study performing poly(A)+ selection of S. cerevisiae and human cervical 
cancer cell (HeLa) RNA, fragmentation and denaturation of the RNA, CMC treatment, 
followed by library preparation and next-generation sequencing. The ψ-seq study 
performed poly(A)+ selection of S. cerevisiae and human embryonic kidney cell 
(HEK293) RNA, CMC treatment, fragmentation of the RNA followed by library 
preparation and next-generation sequencing. The PSI-seq study also performed 
poly(A)+ selection of S. cerevisiae RNA, fragmentation of the RNA, CMC treatment, 
followed by library preparation and next-generation sequencing. 
 
Pseudo-seq confidently detected 260 novel candidate ψ sites in 238 mRNAs and 74 
novel candidate ψ sites in 38 ncRNAs in yeast. In HeLa cells, pseudo-seq confidently 
detected 96 novel candidate ψ sites in 89 mRNAs and 12 ψ novel candidate sites in 9 
ncRNAs [53]. In both yeast and humans, ψ was found to be distributed in untranslated 
regions (UTR) and coding regions (CDS) of mRNA. Examination of ψ synthases (Pus) 
yeast deletion strains revealed that the majority of ψ sites in mRNAs and ncRNAs were 
mediated by Pus1, with a smaller number of sites mediated by Pus2, Pus4 and Pus7. 
Interestingly, ψ was investigated under different growth phases of yeast, with 
differential ψ sites detected in mRNAs and ncRNAs, indicating that ψ in these 
transcripts is regulated in response to environmental signals. Similarly, some ψ sites in 
human mRNAs were reported to be regulated by different cellular growth states. 
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ψ-seq confidently detected 328 candidate ψ sites across mRNA and ncRNA in yeast, 
108 of which were Pus-dependent sites [54]. In HEK293 cells, 353 candidate ψ sites in 
mRNAs and 43 candidate ψ sites in ncRNAs were detected confidently. As with 
pseudo-seq, candidate ψ sites were distributed throughout mRNAs and differential ψ 
patterns were observed under different yeast growth phases. Interestingly, heat shock 
induced the formation of Pus7-mediated ψ in mRNA and deletion of Pus7 was reported 
to decrease its target mRNAs, suggesting a stabilising role for this modification in 
mRNA.  
 
PSI-seq was performed for two replicates of yeast log-phase samples and one heat 
shocked yeast sample. This technique confidently detected 103 candidate ψ sites in 56 
mRNAs in log-phase 1, 335 candidate ψ sites in 150 mRNAs in log-phase 2 and 335 
candidate ψ sites in 208 mRNAs in heat shocked yeast, in addition to the 43 known ψ 
sites in 18S and 25S rRNA [55]. There was a modest overlap in candidate sites detected, 
with 5 sites overlapping between the log-phase replicates, 9 sites overlapping between 
log-phase 1 and heat shock, and 14 sites overlapping between log-phase 2 and heat 
shock. However, two mRNAs, RPL11A and TEF1, exhibited ψ in all three datasets and 
were identified as Pus1- and Pus4-mediated sites, respectively. Interestingly, the 
candidate ψ site in RPL11A was conserved in S. mikitae and S. pombe, and the 
candidate ψ site in TEF1 was conserved in S. mikitae, indicating that ψ is likely to have 
functional importance in mRNA. As with pseudo-seq and ψ-seq, ψ was distributed 
throughout the mRNA with no biases evident. However, gene ontology (GO) analysis 
of the PSI-seq data revealed a significant enrichment of cytoplasmic translation GO 
term, suggesting a potential role in post-transcriptional gene regulation.  
 
Thus, all three studies have shown the presence of ψ in mRNA, albeit at low levels, as 
well as various ncRNA in yeast and humans. ψ is largely conserved across different 
species and appears to be sensitive to different growth phases, suggesting that this 
modification in mRNA may be important for development. Early investigation into the 
molecular function of this modification suggests potential roles in post-transcriptional 
gene regulation. Further explorations into the molecular and biological functions of this 
modification are warranted. 
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1.2.2 PREVALENCE AND GLOBAL DISTRIBUTION OF M6A 
Recent work addressing the transcriptome-wide distribution of m6A adapted approaches 
equivalent to MeDIP-seq (methylated DNA immunoprecipitation sequencing). Similar 
protocols were developed independently by two separate groups who termed it either 
MeRIP-seq (methyl-RNA immunoprecipitation sequencing) and applied it to total 
mouse brain and HEK293T cells [56], or m6A-seq, which was performed on human 
hepatocellular carcinoma cells (HepG2) and mouse liver [57]; see Table 1.1 for a 
comparison of both methods. In each case, cellular RNA was enriched for mRNA, 
broken into fragments of ~100 nucleotide (nt) length and immunopurified using an anti-
m
6A antibody immobilised on beads, followed by next-generation sequencing analysis 
of input as well as enriched RNA on Illumina® next-generation sequencing systems 
(Figure 1.2A). The similarities and differences in approach were expertly summarised in 
ref. [66]. Briefly, Meyer et al. [56] used depletion of rRNA, two rounds of 
immunopurification and elution by proteinase K digestion, whereas Dominissini et al. 
[57] used poly(A)+ selection, a single round of immunopurification and elution with 
N6-methyladenosine. In addition to these differences in experimental approach, the two 
studies also varied in the computational algorithms that were applied to the alignment of 
sequencing reads and the detection of candidate m6A regions. As investigated in ref. 
[66], these bioinformatics methods are critical to the overall outcome as the presence 
and exact position of m6A is not directly measured but instead inferred by threshold-
based detection of peaks in read density across transcript regions. 
 
MeRIP-seq confidently detected 13,471 candidate m6A sites in RNA derived from 
4,654 genes in mouse brain [56]. 94.5% of these were found within mRNAs, whereas 
the remainder mapped to several classes of (long) ncRNA. Analyses of HEK293T cells 
returned 18,756 m6A peaks in RNA derived from 5,768 genes [56]. This demonstrated 
that, while many m6A sites were conserved between mouse and human RNAs, over 
2,000 transcripts were uniquely methylated in either mouse brain or HEK293T cells. 
Strengths of the MeRIP-seq study are that results were compared across different next-
generation sequencing platforms using different anti-m6A antibodies and biological 
replicate samples. Furthermore, three mRNA candidates were independently validated 
through sequence-specific RNA pull-down and anti-m6A immunoblotting. m6A-seq 
analysis of the HepG2 transcriptome yielded 12,769 candidate m6A sites distributed 
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among 6,990 mRNAs and 250 ncRNAs [57]. On average, ~1.7 m6A sites per gene were 
detected, broadly in agreement with earlier research as mentioned above [20-37]. 
Applying the same approach to mouse liver RNA revealed 4,513 m6A peaks within 
3,376 mRNAs and 66 ncRNAs [57]. Of 2,023 expressed genes conserved between 
human and mouse, 997 had candidate m6A sites in orthologous positions.  
 
Recent optimisation of the m6A-seq protocol has enabled the detection of m6A in S. 
cerevisiae undergoing meiosis to near single nucleotide resolution by decreasing the 
fragment size and implementing a ligation-based strand-specific library preparation 
protocol, allowing the capturing of m6A within the sequenced fragment [67]. This 
yielded a total of 1,308 candidate m6A sites in 1,183 mRNAs within 3 nt of the known 
m
6A consensus sequence. The candidate m6A sites identified during meiosis were also 
conserved across S. mikatae, with 229 m6A-containing transcripts in common with S. 
cerevisiae. 
 
The discovery of the RNA:m6A methyltransferases, METTL3, and more recently, 
METTL14, have further advanced research into this modification. Implementation of 
photoactivatable ribounucleoside crosslinking and immunoprecipitation (PAR-CLIP) to 
locate the binding sites of METTL3 and METTL14 yielded a total of 2,110 and 1,147 
transcripts, respectively [68]. Binding sites of the methyltransferases sites were detected 
predominantly in intergenic regions and introns, although there were a larger proportion 
of binding sites in mRNAs compared to ncRNAs. There was also high overlap between 
the target transcripts, with ~56% in common between METTL3 and METTL14. 
Another recent study that performed PAR-CLIP of METTL3 in HEK293 cells revealed 
922 binding sites distributed across mRNA (>90%) as well as microRNA (miRNA) and 
large intergenic ncRNAs (lincRNAs) [69]. Both of these studies showed wide 
distribution of m6A sites in mRNA and to a lesser extent, ncRNA, however the presence 
of other RNA:m6A methyltransferases that may mediate m6A formation remain to be 
explored. 
 
Thus, all studies indicated widespread occurrence of m6A in human, mouse and yeast 
transcriptomes, particularly in mRNAs, with highly significant evolutionary 
conservation of some sites as well as pronounced variability in others.  
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1.2.3 PREVALENCE AND GLOBAL DISTRIBUTION OF M5C 
Recent efforts to map m5C sites in RNA capitalised on the bisulfite sequencing 
technique so popular in DNA studies. The method, originally developed in Australia, 
relies on the differential chemical reactivity of m5C compared to unmethylated cytidine 
when treated with sodium bisulfite [70, 71]. Unmethylated cytidine is deaminated to 
uracil whilst m5C remains unconverted and is still read as ‘C’ in subsequent sequencing. 
Two groups independently developed adaptations of bisulfite sequencing to RNA. 
Schaefer et al. adapted a commercial DNA bisulfite sequencing kit to RNA and 
published a series of papers focused on the role of m5C in tRNA biology [59, 72, 73]. 
Squires et al. started with a bisulfite treatment protocol originally devised to detect 
tRNA modifications by primer extension. They re-optimised treatment parameters and 
combined it with a next-generation sequencing readout [74]. This approach, termed 
bsRNA-seq (sequencing of whole bisulfite-converted transcriptomes) in the following, 
was used to obtain a first transcriptome-wide map of m5C sites in HeLa cells [58]. 
Cellular RNA was enriched for mRNA through a combination of rRNA depletion and 
poly(A)+ selection and then subjected to bisulfite treatment, which also fragmented the 
RNA. cDNA libraries of insert sizes ranging from 50-120 nt were then sequenced on the 
SOLiDTM next-generation sequencing platform (Figure 1.2B) and mapped to references 
of all known human transcripts using SOCS-B, an alignment tool designed to map 
bisulfite-converted SOLiDTM colour-space reads [75]. In principle, candidate m5C sites 
are thus detectable with nucleotide precision through identification of mapped positions 
that exhibit unconverted Cs. Notwithstanding this methodological advantage, some 
caveats also apply to this approach. For instance, bisulfite treatment is sensitive to 
incomplete denaturation of RNA secondary structure and some cytosine modifications 
other than m5C may also be resistant to bisulfite treatment [58]. Also, during 
computational analysis trade-offs again need to be made between sensitivity and 
accuracy in the final candidate m5C site selection when choosing mapping parameters 
and thresholds for read coverage and proportion of cytidine conversion [58]. An 
interesting option might be to complement bsRNA-seq with MeRIP-seq using available 
antibodies against m5C. Recently, a study applied MeRIP-seq for validation of 
candidate m5C sites detected within archaeal RNAs by bsRNA-seq [76]. Thus, 
application of MeRIP-seq for m5C detection in RNA is a promising alternative method. 
 
  
 
!
Introduction 
!
! !
11 
bsRNA-seq detected 10,530 candidate m5C sites, of which 8,495 were mapped in 
mRNAs whereas 255 were found in tRNAs and 1,780 sites in other (long) ncRNAs. 
Analysis of unmethylated spike-in RNA and endogenous tRNA mapping data suggested 
that bsRNA-seq performed well. The spike-in control displayed complete cytidine 
conversion, while 21 of the 28 previously known m5C sites in tRNA were detected and 
approximately 80% of the 234 identified novel candidate sites in tRNA were situated in 
anticipated structural positions. 13 candidate m5C sites were chosen for independent 
validation by Sanger bisulfite sequencing, which confirmed 12 sites, including 3 within 
mRNAs. Conservation of m5C sites was not assessed as RNA from other cellular 
sources or species was not analysed. 
 
In addition to bsRNA-seq and MeRIP-seq, newly developed techniques for 
transcriptome-wide detection of m5C have recently come to the fore with the discovery 
of NSUN2 and TRDMT1 as human RNA:m5C methyltransferases. The first technique, 
termed 5-azacytidine-mediated immunoprecipitation (Aza-IP), takes advantage of the 
DNA/RNA methyltransferase inhibitor, 5-azacytidine (5-aza-C), which is randomly 
incorporated into nucleic acids as a cytidine analogue [77]. Prior to methylation, 
NSUN2 and TRDMT1 covalently bind to the RNA and this bond is rendered 
irreversible in the presence of 5-aza-C. The complex is then immunoprecipitated and 
subjected to next-generation sequencing for identification of NSUN2 and TRDMT1 
targets. The Aza-IP study, which was performed on HeLa cells, reported NSUN2 and 
TRDMT1-mediated m5C sites predominantly in tRNAs, with a smaller proportion in 
ncRNAs, and 8 were validated by Sanger bisulfite sequencing [77]. One mRNA 
exhibited a candidate m5C site in this study, found to be mediated by TRDMT1. The 
second technique, termed methylated individual-nucleotide resolution crosslinking and 
immunoprecipitation (miCLIP) involved the mutation of the second conserved cysteine 
of NSUN2, which normally aids in the release of the methylated RNA [78]. This 
resulted in the formation of an irreversible bond between NSUN2 and the RNA target, 
which was immunoprecipitated and subjected to next-generation sequencing. miCLIP 
identified 80% of NSUN2-mediated m5C sites in tRNAs while the remainder in 
ncRNAs and mRNAs in HEK293 cells and human fibroblasts [78]. While both of these 
studies were performed transcriptome-wide, a caveat of these approaches was the 
inability to detect m5C sites mediated by other methyltransferases, although this remains 
to be explored (see section 1.3).  
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In summary, bsRNA-seq, Aza-IP and miCLIP demonstrated the widespread presence of 
m
5C throughout coding [58, 78] and non-coding sequences [58, 77, 78] in a human 
transcriptome.  
 
Table 1.1. Comparison of MeRIP-seq, m6A-seq and bsRNA-seq techniques, analyses and 
findings. 
The table is adapted from ref. [66]. 
Study MeRIP-seq [56] m6A-seq [57] bsRNA-seq [58] 
Tissue/cell line C57BL/6 brain HEK293T 
C57BL/6 
liver HepG2 HeLa 
Organism Mouse Human Mouse Human Human 
Replicates 3 1 1 
RNA preparation RibominusTM GenEluteTM mRNA 
RiboMinusTM, 
Streptavidin 
Magnetic Beads 
m6A/m5C 
enrichment 
method 
IP-Synaptic Systems, 
NEB, 2 IP rounds 
IP-Synaptic Systems, 1 IP 
round Bisulfite conversion 
RNA fragment 
size/cDNA size 
selection 
100 nt 100 nt 
Various fragment 
sizes, cDNA size 
selection 50-120 nt 
RNA sequencing 
platform 
Illumina® 
GAII & 
HiSeq2000 
Illumina® 
HiSeq2000 Illumina
®
 GAII SOLiDTM 3 
Sequenced control Yes, input control 
Yes, conversion and 
non-conversion 
controls 
Aligners BWA, TopHat Novoalign, BowTie SOCS-B 
m6A/m5C site 
detection method 
MeRIPPeR 
Fisher’s exact test of IP 
read enrichment 
Proprietary 
Computed Winscore >2 
(4x enrichment) + filtering 
Threshold 
parameters 
 
≤80% cytosine 
conversion, 
coverage of ≥10, ≤2 
mismatches 
Peaks/sites 
reported 
 
13,471 
 
18,756 12,769 4,513 
 
10,530 
 
Genes/transcripts 
reported 4,654 genes 5,768 genes 
7,240 
transcripts 
3,442 
transcripts 5,359 genes 
Enrichment of 
candidate site Stop codon, internal exons 
Stop codon, TSS, internal 
exons, AS exons 
5’ UTR, 3’ UTR, 
Argonaute binding 
sites 
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Figure 1.2. Transcriptome-wide approaches to map m6A and m5C in RNA.  
A) MeRIP-seq or m6A-seq employs immunoprecipitation of fragmented RNA using an anti-
m
6A antibody prior to next-generation sequencing. Peaks representing m6A sites are detected 
relative to RNA-seq read coverage generated from input RNA, B) bsRNA-seq uses bisulfite 
conversion chemistry and next-generation sequencing to detect m5C sites. After mapping to the 
reference by allowing ambiguity of C or T positions with sufficiently high coverage, the 
proportion of unconverted cytosines is determined, representing candidate m5C sites. Bottom 
panels show examples of m6A sites detected in MAP3K1 (left) [57] and a m5C site detected in 
CINP (right) [58]. Sites called as m6A or m5C are indicated above the panels by red or green 
arrows, respectively. (Bottom left image reprinted with permission from ref. [57]. Copyright 
2012 Nature Publishing Group; bottom right image reprinted with permission from ref. [58]. 
Copyright 2012 Oxford University Press.) 
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1.3 ENZYMOLOGY 
Methyltransferases are an abundant class of cellular proteins (e.g. 208 are found in the 
human proteome, 86 in S. cerevisiae) [79, 80]. They act by transferring a methyl group 
to their substrate, usually from S-Adenosyl-L-methionine (AdoMet) as a co-factor. 
Based on structural criteria, methyltransferases are grouped into several superfamilies 
[81]. The largest among the three major superfamilies is the Rossmann-fold 
methyltransferase family (RFM), which targets a wide range of substrates including 
DNA, protein, RNA, lipids, polysaccharides and small molecules. RFM 
methyltransferases share a set of sequence/structural motifs commonly called motifs I-X 
after the linear order in which they appear in the DNA:m5C methyltransferases. They 
correspond to the key protein features associated with AdoMet-binding (I-III), catalysis 
(X, IV, VI and VIII) and elements implicated in preservation of the common fold (V 
and VII). Of note, both DNA and RNA methyltransferases can exhibit permuted 
topologies with changes to the linear order of these conserved motifs [82]. The SPOUT 
methyltransferases (named after the founding members spoU and TrmD) form the 
second largest, though relatively poorly characterised, family expected to mainly target 
RNA but also protein (at arginine residues) [83]. Finally, the SET methyltransferases 
(short for (Su(var)3-9, Enhancer of Zeste, Trithorax) modify protein at lysine residues, 
mainly histones and ribosomal proteins [84]. Methylation is involved in approximately 
two-thirds of all known RNA modifications, thus over sixty distinct RNA 
methyltransferases have been described [52]; all eukaryotic cases belong to either the 
RFM or SPOUT superfamilies [85]. Three modes of RNA substrate recognition are 
known for RNA modifying enzymes. First, the catalytic and RNA-binding functions 
reside within the same protein domain. Second, separate catalytic and RNA-binding 
domains are fused together within the same polypeptide or are contributed by distinct 
subunits of a tight complex. Third, the methyltransferase, together with auxiliary 
proteins, employs a guide RNA to recognise the substrate [85]. 
 
All known RNA:m5C and RNA:m6A methyltransferases belong to the RFM 
superfamily [79] and show some homology to their DNA counterparts [86, 87]. For 
instance, sequence/structural alignments of 5-methylpyrimidine generating enzymes 
suggested that during evolution the RNA:m5U-forming enzymes spawned the 
RNA:m5C methyltransferases, which gave rise to DNA:m5C methyltransferases [82, 
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86], although other models have also been advanced [88]. Phylogenetic analysis of 
eukaryotic RNA:m5C methyltransferases identified five subfamilies termed RCMT1, -2, 
-7, -8 and -9 (for RNA (cytosine-5)-methyltransferases) (Table 1.2) [51, 86, 89]. 
RCMT2 includes the S. cerevisiae methyltransferase Nop2 (nucleolar protein 2) and its 
mammalian orthologue, the proliferation-associated nucleolar antigen P120/NSUN1 
(NOP2/Sun domain family, member 1), which are involved in rRNA processing and 
large ribosomal subunit assembly [90, 91]. Nop2 also mediates m5C at C2870 in 25S 
rRNA [92]. RCMT8 includes the S. cerevisiae methyltransferase Rcm1, and its 
mammalian orthologue, NSUN5A (NOP2/Sun domain family, member 5A), the former 
of which mediates m5C at C2278 in 25S rRNA [86, 92]. The S. cerevisiae 
methyltransferase Nop8, and its mammalian orthologue NSUN4 (NOP2/Sun domain 
family, member 4), are important for ribosomal biogenesis [93-96]. NSUN4 has 
recently been reported to mediate m5C at C911 in 12S rRNA in mice [97]. Prototypic 
members of the RCMT7 subfamily are the S. cerevisiae Ncl1/Trm4 (nuclear protein 
1/tRNA methyltransferase 4) [98] and its mammalian orthologue NSUN2 (NOP2/Sun 
domain family, member 2, also known as MISU [Myc-induced SUN-domain-containing 
protein]) [99, 100]. Mammalian DNMT2/TRDMT1 (DNA methyltransferase 2/tRNA 
aspartic acid methyltransferase 1) is an outlier as it is structurally more similar to DNA 
methyltransferases [101]. Finally, the RNA:m6A methyltransferase METTL3 
(methyltransferase like 3) features a circularly permutated version of the RFM domain 
and belongs to a protein family that includes bacterial DNA:m6A methyltransferases 
[87]. 
 
How cells deploy their repertoire of methyltransferases to methylate mRNAs internally 
is poorly understood. Below I summarise what is known about those m6A and m5C 
methyltransferases (“writers”) that have already been implicated in methylation of 
mRNA. I also refer to the emerging literature on demethylases (“erasers”) that may 
serve to dynamically remove methyl marks from mRNA and effector proteins 
(“readers”) that may interpret methylation marks to serve a molecular function. 
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Table 1.2. Examples of human RNA:m5C and m6A methyltransferases (MTases) and their 
orthologues in S. cerevisiae.  
Modification m5C m6A 
MTase-
family 7β strands RFM 
RFM 7β 
rearranged 
Examples NSUN1 NSUN2 NSUN4 NSUN5 TRDMT1 METTL3 
Known 
substrates 
tRNA? 
rRNA? 
tRNA 
ncRNA 
mRNA 
Mitochondrial 
rRNA rRNA? 
tRNA 
mRNA mRNA 
S. cerevisiae 
orthologue Nop2 Ncl1 Nop8 Rcm1 - Ime4 
 
1.3.1 RNA:M6A METHYLTRANSFERASES METTL3 AND 
METTL14 
1.3.1.A DISCOVERY 
A mRNA:m6A methyltransferase activity was first characterised in an in vitro 
methylation system based on HeLa nuclear extract and model RNA substrates [38, 102, 
103]. It was shown that the enzyme is composed of three dissociable components, MT-
A1 (~30 kDa apparent molecular mass), -A2 (~200 kDa) and –B (~875 kDa), which 
were all necessary for full activity [102]. MT-A2 was shown to contain a ~70 kDa 
AdoMet-binding subunit. Microsequencing and cDNA cloning subsequently identified 
this as the methyltransferase, which was named MT-A70 [40] (later renamed as 
METTL3 for methyltransferase-like 3) [102].  
 
Structure prediction and phylogenetic analysis revealed a METTL3 family of proteins 
comprising three paralogous eukaryotic lineages (with METTL3 representing lineage 
A) as well as one small subfamily of bacterial DNA:m6A methyltransferases [87]. 
Methyltransferase activity has since been confirmed for METTL3 orthologues in A. 
thaliana (called MTA for mRNA adenosine methylase) [41] and S. cerevisiae (Ime4  
for inducer of meiosis 4) [42]. Interestingly, efficient mRNA methylation in yeast 
requires formation of the MIS complex between Mum2, Ime4 and Slz1 [104]. The A. 
thaliana Mum2 orthologue, FKBP12 interacting protein 37 kDa (FIP37), also interacts 
with MTA [41]. Similarly, through GST-pulldown and co-immunoprecipitation 
experiments efficient mRNA methylation in mammals was reported to require the 
formation of a complex consisting of METTL3, the METTL3 homologue METTL14, 
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and the Mum2 orthologue, Wilms tumour 1 associated protein (WTAP) [68, 69, 87, 
105].  
 
1.3.1.B STRUCTURE/CATALYSIS 
METTL3 and its orthologues exhibit a permuted topology of the methyltransferase 
domain (amino acids (aa) 350-570 of the 580 aa long human enzyme) otherwise 
characteristic of b class DNA amino-methyltransferases (Figure 1.3A) [87]. 
Subdomains for AdoMet binding and catalysis can readily be discerned, however it 
lacks an intervening subdomain for nucleic acid recognition typically found in b class 
DNA amino-methyltransferases [106]. Thus, the WTAP component of the 
methyltransferase complex may provide RNA targeting. The yeast MIS complex 
component Mum2 was suggested to activate Ime4 catalytic activity and/or target it to 
mRNA substrates [104]. The latter option is given additional credence by the fact that 
FIP37 in plants and WTAP in humans are RNA-binding proteins implicated in mRNA 
splicing [41]. Perhaps WTAP constitutes the MT-B component of the purified human 
mRNA:m6A methyltransferase, which was also suggested to bind RNA [102, 104]. 
WTAP lacks any obvious catalytic domains and has been suggested to be indispensible 
for regulating mRNA:m6A methyltransferase activity and localisation of the complex 
into nuclear speckles [69, 107]. Thus, WTAP most likely functions as a regulatory 
subunit of the methyltransferase complex.  
 
1.3.1.C SUBSTRATE SPECIFICITY 
Painstaking early work in yeast, plants and mammals established that m6A is present 
only within the Gm6AC and Am6AC trinucleotide contexts, with a 75% preference for 
Gm6AC [24, 41, 44, 108-110]. An extended consensus sequence context was proposed 
to be RRm6ACH (R = A, G; H = A, C, U; Figure 1.3C) [43]. Until recently, mapping of 
specific sites or regions for m6A had been achieved for only three native mRNAs [44-
46]. Seven m6A sites were mapped at nucleotides 6394, 6447, 6507, 6718, 7414, 7424, 
and 8014 in Rous sarcoma virus genomic RNA [46, 111, 112]. m6A sites further were 
narrowed to regions near the 3’ end for bovine prolactin and yeast ime2 mRNAs [44, 
45]; for prolactin mRNA a single site in the context AGm6ACU was pinpointed [103]. 
The thousands of m6A-containing peaks mapped in human and mouse transcriptomes in 
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the recent MeRIP-seq [56] and m6A-seq studies [57] also showed non-random 
distribution across mRNA regions (see below). Importantly, peaks from both studies 
were highly enriched in the motif RRm6ACU, thus concurring with and refining the 
previous consensus [66]. Specific investigation into the sequence specificity of both 
METTL3 and METTL14 also revealed the same extended motif [68, 69, 105]. It has 
been reported that METTL3 and METTL14 function synergistically to catalyse the 
formation of m6A. Incubation of METTL3 and METTL14 individually with a RNA 
probe containing the m6A consensus motif revealed that each enzyme methylated RNA 
at relatively low levels [68]. However, co-incubation of METTL3 and METTL14 with 
the RNA probe resulted in stronger levels of methylation. This is highlighted by high 
overlap in METTL3 and METTL14 target transcripts [68, 105]. While a large 
proportion of m6A sites were found to be mediated by METTL3 and METTL14, m6A 
sites were found in mRNAs that were not mediated by either enzyme [68, 105]. 
 
A common observation in all this work was that not every cellular mRNA contained 
m6A and that many more suitable sequence motifs were present in a mRNA than were 
actually methylated. It remains unclear what additional features of the mRNA substrate 
are recognised to achieve such selective methylation, however the structural context 
does not appear to be a major requirement for METTL3 and METTL14 activity. A C-
to-U mutation in the RRm6ACU consensus motif resulted in substantially decreased 
methylation efficiency compared to the standard consensus sequence [68]. RNA probes 
synthesised with the consensus motif located in the stem or a loop revealed slightly 
higher activity towards the motif in the stem, however very high activity of the 
methyltransferase complex was evident for a probe exhibiting a random structure [68]. 
 
In some eukaryotes, m6A is also present in snRNA [110, 113] and rRNA [2, 3], 
although the enzymatic pathways of m6A formation in these RNA types remain largely 
unknown [52]. The m6A sites in human 18S, and probably 28S, rRNA match the 
context consensus found in mRNAs, while that in U6 snRNA does not. A snRNA:m6A 
methyltransferase activity was partially characterised in HeLa nuclear extract and found 
to be biochemically distinct from the mRNA:m6A methyltransferase [110]. Genetic 
depletion of MTA/Ime4 in A. thaliana or S. cerevisiae led to clear loss of m6A in 
polyadenylated RNA [41, 42, 114]; a residual amount in plant tissues was likely due to 
incomplete shut-down of MTA expression [114], although it could in principle be due 
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to activity of the METTL3 homolog AT4G09980 (a member of lineage B in ref. [87]). 
Thus, it appears that METTL3/MTA/Ime4 and METTL14 are responsible for a large 
proportion of m6A formation in cellular mRNA, with a small proportion of sites 
possibly being mediated by another methyltransferase.  
 
1.3.2 RNA:M6A READER YTHDF2 
1.3.2.A DISCOVERY 
YTHDF2 (YTH domain family member 2) is part of the YTH domain family of 
proteins that are widespread across eukaryotes and bind single-stranded (ss) RNA [115, 
116]. The founding member of this family, YT521-B, is a nuclear protein that was 
identified in yeast two-hybrid screens along with splicing factors and was found to 
interact with several splicing factors through two-hybrid and coimmunoprecipitation 
assays [117]. Further investigation revealed that YT521-B modulates alternative splice 
site selection in a concentration-dependent manner [117]. YT521-B and the S. 
cerevisiae RNA binding protein meiotic mRNA interception (Mmi1), the latter of which 
eliminates meiotic-specific mRNAs [118, 119], are the only characterised YTH family 
members and the function of other members remain unexplored. Very recently, 
YTHDF2 was reported to bind a m6A-containing RNA bait, suggesting that this protein 
may mediate various cellular processes including alternative splicing in response to 
binding m6A [57, 120]. 
 
1.3.2.B STRUCTURE/CATALYSIS 
The YTH domain family members were found to contain YTH domains through a 
YT521-B homology search using BLAST [115]. A conserved portion of the rat YT521-
B was identified between residues 356 and 499, and further BLAST searches revealed 
multiple proteins from a number of organisms containing this domain. The YTH 
domain was predicted to bind RNA, with portions of this domain showing similarity to 
the RNA recognition motif [115]. This binding was confirmed by expression of YT521-
B in D. melanogaster, revealing that this domain bound ssRNA, but not DNA or 
double-stranded (ds) RNA [116]. YTFDH2 exhibits the RNA-binding YTH domain in 
the carboxy-terminal and a P/Q/N-rich region at the amino-terminal (Figure 1.3A) 
[120]. Proteins containing P/Q/N-rich regions have been reported to aggregate within 
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processing bodies (P bodies), with many of these proteins involved in mRNA 
degradation [121]. In vitro pulldown assays have revealed that C-YTHDF2 enriches 
m
6A-containing mRNA from total RNA and N-YTHDF2 colocalised with the P body 
marker DCP1a [120]. This suggests that the YTH domain located in the C-terminus 
binds m6A-containing mRNA and the P/Q/N-rich N-terminus is involved in localising 
the m6A-containing mRNA to P bodies possibly for degradation.  
 
Two studies have recently determined the crystal structure of YTHDF2 in complex with 
m6A-containing RNA, providing information on the mechanism of recognition of m6A 
[122, 123]. A basic patch of residues was identified to be important for binding to the 
backbone of the mRNA, including R411, K416 and R441 and R527 [123]. K416A and 
R527A mutations resulted in decreased binding affinity to both unmethylated mRNA 
and m6A-containing mRNA, indicating that these residues are not involved in the 
recognition of m6A. Comparison of the crystal structure of YTHDF2 in complex with 
m
6A-containing RNA to that without RNA revealed a conformational change such that 
m6A was tightly locked in an aromatic cage consisting of W486, W432 and W491 [122, 
123]. Mutations of several residues within the aromatic cage resulted in significantly 
reduced binding affinity of YTHDF2 to m6A-containing RNA compared to 
unmethylated RNA, indicating that this aromatic ring is largely responsible for m6A 
recognition [122, 123]. 
 
1.3.2.C SUBSTRATE SPECIFICITY 
As a newly characterised YTH domain family member, the substrate specificity of 
YTHDF2 still remains to be explored in further detail. Based on gel-shift assays, 
YTHDF2 preferentially bound a m6A-containing RNA probe compared to an 
unmethylated probe, and there was a slight preference for the consensus sequence [120]. 
YTHDF2 PAR-CLIP revealed an enrichment of the Gm6AC motif, in agreement with 
the previously identified m6A consensus [120]. The majority of YTHDF2 binding sites 
were located in mRNAs, but 1% was also in ncRNAs. Interestingly, overlapping of m6A 
peaks identified by m6A-seq with YTFDH2 PAR-CLIP peaks in this study revealed a 
50% overlap, indicating that not all m6A peaks are bound by YTFDH2 [120]. It is 
unclear what additional features are required for recognition by YTHDF2, however 
there may be other m6A readers. This has been highlighted by the ability of YTFDH1 
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and YTFDH3 to bind m6A-containing RNA, suggesting that these enzymes may also 
function as m6A readers [57, 120]. 
 
1.3.3 RNA:M6A DEMETHYLASES FTO AND ALKBH5 
1.3.3.A DISCOVERY 
Two related proteins, fat mass and obesity associated (FTO) and ALKBH5 (alkylation 
repair homolog 5), were recently described as m6A demethylases acting on RNA [124, 
125]. Originally discovered in a study of the Fused toes (Ft) mutation in mice [126], the 
FTO gene came into sharp focus when genome-wide association studies (GWAS) 
strongly associated it with body mass index (BMI), risk of obesity and type 2 diabetes 
mellitus in multiple populations [127-131]. 
 
1.3.3.B STRUCTURE/CATALYSIS 
FTO and ALKBH5 are both members of the AlkB (alkylated DNA repair protein B) 
family of nonheme Fe(II)/2-oxoglutarate (2-OG)- dependent dioxygenases [132-134]. 
E. coli AlkB is an enzyme that repairs cytotoxic 1-methyladenine and 3-methylcytosine 
in DNA, releasing the methyl groups as formaldehyde [135]. The crystal structure of 
FTO revealed an amino-terminal AlkB-like catalytic core domain with the characteristic 
double-stranded b-helix (aa 32-325) and a carboxy-terminal domain (CTD aa 326-505) 
with a novel, predominantly helical structure (Figure 1.3A). Tight interactions between 
the two domains are important for FTO activity. The insertion of an 11 amino acid-loop 
within the catalytic core, conserved between FTO orthologues but absent in other AlkB 
members, indicated a bias of FTO against double-stranded nucleic acids and thus a 
likely preference for RNA [136, 137]. Double FTO mutants, either H231A D233A- 
mutating two Fe (II) ligands- or R316Q R322Q -mutating two 2-OG ligands, each 
completely lost m6A-demethylation activity [124]. Similarly, mutation of the Fe (II) 
ligand residues H204 or H266 in ALKBH5 also severely abrogated activity [125]. FTO 
possesses a bipartite nuclear localisation signal at the N-terminus [126] consistent with 
its nuclear localisation [132] and enrichment in nuclear splicing-related speckles [124]. 
ALKBH5 also co-localises with mRNA processing factors in nuclear speckles [125]. 
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1.3.3.C SUBSTRATE SPECIFICITY 
Recombinant FTO was initially shown to preferentially demethylate 3-methylthymine 
or 3-methyluracil in synthetic, ssDNA and ssRNA, respectively [132, 138]. However, 
more recent work demonstrated a clear preference of FTO for m6A in ssRNA in vitro 
[124]. The prevalence of m6A in eukaryotic mRNA, but virtual absence in genomic 
DNA, thus suggested that the physiological substrate of FTO is RNA, not DNA. This 
was confirmed by FTO knockdown and/or overexpression in several human cell lines, 
and detection of commensurate increases or decreases in m6A content of poly(A)+ RNA 
[124]. Analogous experiments with ALKBH5 essentially gave the same results; 
additionally it was found in vitro to have a mild preference for m6A within the 
consensus motif and appeared not to act on rRNA in vivo [125]. Interestingly, ALKBH5 
was also found as a mRNA-binding protein in recent quantitative proteomics screens 
[139, 140].!
 
In summary, FTO and ALKBH5 together represent a major proportion of the m6A 
demethylase activity in mammalian cells and tissues. Both enzymes are broadly, though 
not completely evenly, expressed and display very similar enzymatic/molecular 
characteristics. Beyond their preference for m6A in ssRNA it is essentially unknown if 
and how they might select their targets for demethylation. Orthologues of both FTO and 
ALKBH5 are mostly confined to vertebrates [134, 141]. Given the much wider 
occurrence of m6A in RNA, it seems likely that additional, as yet undiscovered m6A 
demethylases exist in other organisms. 
 
1.3.4 RNA:M5C METHYLTRANSFERASE NSUN2 
1.3.4.A DISCOVERY 
NSUN2 belongs to the RCMT7 subfamily of eukaryotic RNA:m5C methyltransferases. 
The S. cerevisiae enzyme Ncl1/Trm4 was discovered first through searches for novel 
NOP2/Sun domain-containing proteins [98, 142], followed some years later by a 
characterisation of the orthologues in human (hTrm4; through homology with yeast 
Trm4) [100] and mouse (MISU; in a screen for genes activated by Myc) [99]. 
  
 
!
Introduction 
!
! !
23 
1.3.4.B STRUCTURE/CATALYSIS 
NSUN2 and its mammalian orthologues have highly similar sequences [100, 143] and 
contain eight of the signature motifs for RFM methyltransferases in a characteristic 
permuted topology (Figure 1.3B) [86, 89]. The enzyme contains the conserved 
methyltransferase domain in its amino-terminal half, followed by a characteristic 
carboxy-terminal extension. Limited proteolysis of yeast Ncl1 showed that these two 
regions form separable domains. The amino-terminal domain (NTD, aa 1-437) is active 
as a methyltransferase but its catalytic efficiency is enhanced by the CTD (aa 438-684) 
[143]. The CTD on its own has low affinity for RNA and it does not markedly augment 
the RNA-binding properties of the whole enzyme, thus it might promote formation of a 
productive conformation of the enzyme/substrate complex. Since the NTD lacks a 
variable region for target recognition as typically seen in DNA:m5C methyltransferases, 
it is unclear how the enzyme specifically recognises its RNA substrates. The conserved 
cysteine residues in motif IV and VI of Ncl1, Cys260 and Cys310, respectively, are 
important for catalysis, with Cys310 being essential for the initial nucleophilic attack at 
position C6 of the target cytosine and Cys260 assisting with the breakdown of the 
covalent adduct [144-146]. Mammalian NSUN2 was shown to be catalytically active 
using an in vivo complementation approach in S. cerevisiae and in vitro assays [99, 
100]. The enzyme has no classical nuclear localisation signal; nevertheless, yeast Ncl1 
localises to nucleoli and the nucleoplasm with some concentration at the nuclear 
periphery [142]. A similar pattern was described for mammalian NSUN2 [99, 100], 
although some fluctuation was seen during the cell cycle with a minority of cells in G2 
phase displaying localisation to cytoplasmic vesicles. In M phase cells, NSUN2 was 
found along the spindle and at centrioles [99]. 
 
1.3.4.C SUBSTRATE SPECIFICITY 
Biochemical studies identified yeast Ncl1 as a multisite-specific tRNA:m5C 
methyltransferase responsible for modifying yeast tRNAs at all known sites, i.e. 
structural positions 34, 40, 48 and 49 [98]. Positions 48 and 49 are commonly modified, 
whereas 34 and 40 are modified only in the intron-containing precursors of 
tRNALeu(CAA) and tRNAPhe(GAA), respectively. By contrast, human NSUN2, when 
expressed in yeast cells appeared unable to modify positions 48 and 49 of tRNA and 
restricted to modifying C34 in tRNALeu(CAA), acting at the level of the intron-containing 
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tRNA precursor. NSUN2 specificity was found to be influenced by both the structural 
(intron retention results in an elongated anticodon stem) and sequence context, though 
no consensus was derived [100]. The view that mammalian NSUN2 has a much 
narrower substrate specificity was nevertheless called in question by several more 
recent findings. First, when validating the bsRNA-seq data set [58], m5C modification 
levels at structural positions 48 and 49 of tRNAAsp(GUC) were substantially reduced after 
siRNA-mediated NSUN2 knockdown. This was also seen in human NSUN2-mutant 
cells [147]. Second, recombinant NSUN2 was shown to methylate position 48 in 
tRNALeu(CAA) with or without an intron and positions 48, 49 and 50 in tRNAGly2(GCC) in 
vitro [148] (Figure 1.3D). Third, tRNA methylation analysis of Trdmt1 and NSun2 
single-knockout mice demonstrated complementary target-site specificities for the two 
enzymes (TRDMT1: C38 and NSUN2: C34, 40, 48, 49, 50; across four diagnostic 
tRNAs) and double-knockout mice showed a complete loss of m5C in the tRNA fraction 
[149]. Fourth, examination of the substrate specificity of NSUN2 by Aza-IP and 
miCLIP in human and mouse cells revealed a number of additional m5C sites in non-
canonical tRNA structural positions [77] as well as tRNA isotypes and isoacceptors [77, 
150]. Fifth, NSUN2 was shown to methylate sites in the RPPH1 subunit of RNase P, 
vault (vt) RNAs and various ncRNAs [58, 77, 78], as well as CINP, NAPRT1 and 
NDUFB7 mRNAs [58]. Sixth, NSUN2 was further found to bind the 3’ UTR of cyclin-
dependent kinase inhibitor 2A, (CDKN2A, p16Ink4A) mRNA, though curiously 
implicated in m6A modification in this case [151]. Finally, NSUN2 was identified as a 
mRNA-binding protein by immunoprecipitation and RNA-seq [152] and quantitative 
proteomics screens [139, 140].  
 
Collectively, these results indicate that both mammalian NSUN2 and yeast Ncl1 are 
multisite-specific tRNA:m5C methyltransferases responsible for all (yeast) or most 
(mammalian) tRNA m5C sites. At least the mammalian enzyme extends its activity to 
other ncRNA and mRNA. Whether NSUN2 is largely or solely responsible for the 
widespread occurrence of m5C in these RNA biotypes as well remains to be tested. 
Some scope exists here for roles of eight other NSUN2/NOP2-related proteins in 
humans, NSUN1-7, with NSUN5 encoded by three genes NSUN5A-C [51]. Apart from 
NSUN2, enzyme activity and substrate specificity have not been characterised for any 
of these homologues in humans, although most of them retain a potentially active 
catalytic domain.  
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1.3.5 RNA:M5C METHYLTRANSFERASE TRDMT1 
1.3.5.A DISCOVERY 
A first TRDMT1-like protein was discovered in S. pombe by homology to bacterial 
DNA methyltransferases [153], followed by identification of mammalian TRDMT1 
[154, 155]. It is the most widely conserved ‘DNMT-type’ enzyme with orthologues in 
protists, plants, fungi, and animals. Phylogenetic evidence suggests that the 
evolutionary ancestor of TRDMT1 was a DNA methyltransferase and an early 
TRDMT1 enzyme changed preference to RNA. DNMT1 and 3 have evolved as 
independent lineages [156]. Despite its prevalence, progress in understanding the 
physiological role of TRDMT1 initially lagged behind, due to difficulties in 
demonstrating activity with dsDNA as a substrate [157, 158].  It was then discovered 
that human TRDMT1 has robust RNA methyltransferase activity modifying 
tRNAAsp(GUC) at position C38 [159]. This was confirmed by others for TRDMT1 in 
human cells [160], D. melanogaster [59, 73] and the parasite E. histolytica [161]. 
Whether its (weak) DNA methyltransferase activity still has a biological role is in 
dispute [157, 158]. 
 
1.3.5.B STRUCTURE/CATALYSIS 
TRDMT1 contains all the sequence motifs in the linear order characteristic of 
DNA:m5C methyltransferases [154-156] (Figure 1.3B) and the TRDMT1 crystal 
structure strongly resembles those of prokaryotic DNA methyltransferases [162]. 
TRDMT1 employs a DNA methyltransferase-like catalytic mechanism of RNA 
methylation [160]. It is initiated by a nucleophilic attack of a cysteine residue (C79) 
located in sequence motif IV, supported by a glutamate (E119) from motif VI and two 
arginine residues (R160 and R162) from motif VIII [160]. Unlike all other mammalian 
DNA methyltransferases, TRDMT1 does not possess a large N-terminal extension. In 
DNMT1, 3A and 3B, this extension is important for specific targeting of the DNA 
substrate [157]. The tRNA binding site on human TRDMT1 has been mapped through a 
combination of directed mutagenesis and structural modelling. It consists of a cleft next 
to the AdoMet binding pocket that mainly interacts with the anticodon stem and loop of 
the tRNA substrate [163]. 
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TRDMT1 does not have a canonical nuclear localisation signal and different findings 
have been reported on its intracellular localisation. For instance, expression of tagged 
versions showed it to be primarily cytoplasmic in NIH3T3 cells [159] while in 
Dictyostelium it appeared to be primarily nuclear [164]. In D. melanogaster, tagged 
TRDMT1 resides in both the nucleus and cytoplasm and its localisation is highly 
dynamic during the cell cycle. It enters nuclei during prophase and shows a spindle-like 
localisation pattern during mitotic divisions [165]. Studies with endogenous and tagged 
proteins in HeLa cells indicate that TRDMT1 is normally present in the nucleus, but 
under conditions of stress, it relocalises to the cytoplasm and concentrates in stress 
granules and P bodies [166], consistent with findings in D. melanogaster [73]. 
 
1.3.5.C SUBSTRATE SPECIFICITY  
The initial report was that human TRDMT1 modifies solely tRNAAsp(GUC) at position 
C38. This was shown with tRNA substrates from mouse, D. melanogaster and A. 
thaliana [159]. More recently it was demonstrated that D. melanogaster TRDMT1 can 
also modify tRNAGly(GCC) and tRNAVal(AAC) at the equivalent position [73] (Figure 
1.3D). Aza-IP performed on HeLa cells also revealed these tRNAs as TRDMT1 targets, 
as well as tRNAVal(CAC) in the equivalent position [77]. This exquisite specificity is not 
well understood but it probably involves in part the recognition of tRNA secondary 
structure and it might be noted that in each substrate the modified cytosine is in a CpG 
context. The bsRNA-seq study did not reveal any non-tRNA substrates for TRDMT1, 
although only a limited panel of five exemplary RNAs were screened [58]. What 
warrants the listing of TRDMT1 in this context is that Aza-IP identified one mRNA 
target for this enzyme [77]. 
 
No m5C demethylase or reader has thus far been described. 
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Figure 1.3. m6A and m5C writers, erasers and readers known to act on mRNA.   
A) Schematic representations of the domain structures of the m6A methyltransferase METTL3, 
reader YTHDF2 and demethylase FTO and B) the m5C methyltransferases TRDMT1 and 
NSUN2. Roman numerals refer to secondary structure elements constituting the RFM 
methyltransferase fold. Elements making up particular enzyme domains or specific amino acid 
residues are colour-coded as follows: green: AdoMet binding; red: catalytic domain; blue RNA 
recognition; purple 2-oxoglutarate (2-OG) and iron (Fe) binding; see text for details and 
references. C) Sequence logo representing the preferred sequence context for m6A in human 
mRNAs as determined by m6A-seq. (Reprinted with permission from ref. [57]. Copyright 2012 
Nature Publishing Group). D) Elements recognised by NSUN2 and TRDMT1 in mRNA are not 
known. Shown are positions in the tRNA cloverleaf structure that are methylated by the two 
enzymes in animal tRNAs. 
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1.4 ROLE IN BIOLOGY AND HUMAN HEALTH 
To my knowledge there are no reports thus far demonstrating a direct causative link 
between internal mRNA methylation patterns and a specific physiological process or 
disease. Nevertheless, it has been commonly observed that the relative abundance of 
m
6A within mRNA populations can vary with cellular context and between species, e.g. 
refs. [20, 22, 24, 25, 32-37, 41, 44, 114]. Little is known about changes to the 
proportion of m5C in cellular mRNAs under different conditions. The recent 
transcriptome-wide mapping studies added some new information. Anti-m6A 
immunoblotting demonstrated presence of the modification in poly(A)+ RNA across a 
panel of murine tissues with highest levels in liver, kidney and brain. m6A was 
detectable in poly(A)+ RNA throughout murine neural development with a dramatic 
increase by adulthood [56]. This resonates with dynamic changes in m6A levels during 
plant development and during meiosis in S. cerevisiae (see below) [42, 114, 167]. 
Together with the reversible nature of m6A through demethylation, this might warrant 
usage of the term ‘epitranscriptomics’ [66] or ‘RNA epigenetics’ [168, 169]. m6A-seq 
analyses of responses by HepG2 cells to hepatocyte growth factor or interferon g 
addition, UV irradiation and heat shock showed some changes, although the majority of 
m
6A sites were shared between conditions. Comparisons of RNAs from HepG2 cells, 
mouse liver and human brain revealed that the principal characteristics of the m6A 
methylome are not unique to cancer [57]. GO analyses of both sets of m5C or m6A-
containing mRNAs did not reveal strong enrichments. Rather, it showed that both types 
of methylation affect mRNAs involved in a variety of cellular functions [56, 58]. 
 
Use of pharmacological methylation inhibitors also provided some insight. For instance, 
the antiviral adenosine analogue Neplanocin A (NPC) and the amino acid analogue 
cycloleucine have both been used to trigger accumulation of undermethylated cellular 
RNA and study the consequences for RNA processing, transport, translation and steady-
state levels, e.g. refs. [38, 170-178]. However, both drugs generally decrease AdoMet 
levels and thus have pleiotropic effects at the cellular level. The ribonucleoside 
analogue, 5-aza-C, is an anti-cancer drug that promotes DNA hypomethylation and 
tumour-suppressor gene reactivation. 5-aza-C is incorporated into DNA, leading to 
covalent trapping of DNA methyltransferases. However, 5-aza-C is preferentially 
incorporated into RNA and also known to inhibit tRNA methylation [179-181], acting 
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at least in part through inhibition of TRDMT1 by a mechanism similar to that described 
for DNA [72]. The Aza-IP study also demonstrated that NSUN2 is inhibited by 5-aza-C 
[77]. The anti-cancer properties of 5-aza-C will thus likely also include effects on tRNA 
function; whether it also inhibits m5C formation in mRNA remains to be shown.  
 
In addition to the findings described above, considerable and highly specific 
information on knockdown/knockout phenotypes of several RNA:m5C as well as m6A 
methyltransferases, readers and demethylases is available. Aspects of these phenotypes 
will very likely be attributable to defective mRNA methylation and thus I provide a 
summary of these observations in the following. 
 
1.4.1 RNA:M6A METHYLTRANSFERASES METTL3 AND 
METTL14 
There are no known disease-causing mutations for METTL3 or METTL14 and the 
consequences of a knockout of mammalian METTL3 or METTL14 have not yet been 
explored in great detail. Silencing of METTL3 in HepG2 cells resulted in apoptosis and 
pronounced changes in gene expression [57]. ~2,000 genes were differentially 
expressed and a further ~500 genes, whose overall level was unchanged, exhibited 
alternative splicing (see next section). Methylated mRNAs were enriched in both sets. 
GO analysis of differentially expressed genes showed significant enrichment of the p53-
signalling pathway. Isoform switching was further noted for many mRNAs encoding 
components of this pathway, suggesting that modulation of p53 signalling through 
splicing might be relevant to induction of apoptosis by silencing of METTL3 [57]. 
Several recent METTL3 knockdown studies have also highlighted its role in cell 
survival and development; knockdown of METTL3 in mouse embryonic stem cells 
(ESCs) resulted in flatter and compact cells with subsequent loss of their self-renewal 
capacity [105], while in HeLa cells led to decreased cell viability [68]. In agreement 
with Dominissini et al., genes targeted by METTL3 were enriched for functional 
pathways related to cell death and cellular response to stress [68]. Finally, silencing of 
METTL3 in human and mouse cells resulted in elongation of the circadian period 
through changes in the transcription of RNA-processing machinery [182].  
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The biological role of METTL14 still remains to be explored in further detail, however 
its knockdown in HeLa cells resulted in cell death, consistent with the phenotype 
associated with METTL3 knockdown [68]. 
 
A panel of mammalian cell lines, including tumorigenic, non-tumorigenic and virally-
transformed cells, were all found to express a short form and a long form of METTL3 
mRNA [183]. The total amount of METTL3 mRNA was similar between lines, but up to 
nine times more of the long than the short splice variant was detected in tumorigenic 
cell lines, compared to a 1.5-fold difference in the non-tumorigenic cell lines. Since the 
short mRNA lacks exons 2 and 4 and is likely non-functional, these findings are 
consistent with earlier reports of an 8-15-fold increase of METTL3 enzyme activity as a 
correlate of cellular transformation. Simple increases in cellular proliferation did not 
account for this effect [184].  
 
Both METTL3 and WTAP appear to function in a number of developmental processes 
in zebrafish. Morpholino knockdown of WTAP in embryos resulted in multiple 
developmental defects while knockdown of METTL3 resulted in more modest defects 
[69]. Interestingly, simultaneous knockdown of both enzymes led to severe 
developmental defects and increased apoptosis, consistent with observations in 
mammalian cells. This suggests that at least two components of the methyltransferase 
complex are important for development.  
 
Knockout of MTA in A. thaliana arrests embryos at the globular stage of development, 
resulting in embryonic lethality. Expression of MTA in wild-type plants is strongly 
associated with dividing tissues, particularly reproductive organs, shoot meristem and 
emerging lateral roots [41]. Consistent with this, severe reduction of MTA and m6A 
levels during later growth stages led to altered trichome branching and changes in leaf 
as well as flower structures indicative of reduced apical dominance and problems with 
organ definition [114]. D. melanogaster embryos with homozygous inactivation of Dm 
ime4 died at larval and pupal stages; rescue of this phenotype was dependent on the 
enzyme’s catalytic activity. Dm ime4 is highly expressed in ovaries and testes. 
Hypomorphic alleles of Dm ime4 revealed reduced fertility of both sexes and a critical 
function in Notch signalling during oogenesis, although no specific RNA target was 
identified [185]. S. cerevisiae ime4 is a non-essential gene that is not appreciably 
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expressed during normal growth but strongly induced in starved diploid cells, 
concurrent with an increase in mRNA m6A content [42, 167]. Increases in m6A as well 
as the ensuing entry into meiosis and spore formation are all dependent on Ime4’s 
catalytic activity [42, 44, 104]. 
 
The picture that emerges from these observations is that m6A formation by the 
METTL3, METTL14 and WTAP complex and their orthologues is typically an 
essential function in multicellular organisms and it has important roles in cell 
differentiation and developmental decisions.  
 
1.4.2 RNA:M6A READER YTHDF2 
Several phenotypes were found resulting from translocation events and microsatellite 
polymorphisms of YTHDF2. Reciprocal translocations of YTHDF2 with RUNX1 along 
with two other translocation events were detected in patients exhibiting acute myeloid 
leukaemia (AML) [186]. RUNX1 encodes a transcription factor involved in regulating 
differentiation of haemotopoietic stem cells into mature blood cell [187]. The predicted 
effect of this hybrid transcript is the production of a truncated N-terminus RUNX1 
protein without translating YTHDF2. However, as several translocation events were 
reported, it is difficult to discern whether this phenotype can be attributed to the 
YTHDF2 and RUNX1 reciprocal translocation. Interestingly, a microsatellite 
polymorphism located in the fourth intron of the YTHDF2 gene has been reported to be 
associated with human longevity [188]. This genotype was also associated with 
increased YTHDF2 mRNA in immortalised lymphocytes. 
 
Functional clustering of YTHDF2 target transcripts against non-target transcripts 
revealed functions in gene expression and cell death and survival, consistent with the 
phenotypes associated with knockdown of components of the methyltransferase 
complex [120]. As with the m6A methyltransferase complex, knockdown of YTHDF2 in 
HeLa cells resulted in drastically reduced cell viability [120].  
 
Thus, YTHDF2 may function in binding m6A-containing RNA to regulate cell 
differentiation and survival.  
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1.4.3 RNA:M6A DEMETHYLASES FTO AND ALKBH5 
Interest in FTO skyrocketed when GWAS in multiple populations identified common 
genetic variants in the FTO gene as risk alleles for increased body mass, obesity and 
type 2 diabetes mellitus, reviewed in refs. [128, 137, 169, 189-192]. This was further 
extended to potential roles of FTO in neurological diseases including depression [193], 
dementia and Alzheimer’s disease [194, 195]. An autosomal-recessive lethal syndrome 
in a consanguineous family was found to be due to an inactivating FTO mutation 
(R316Q in the catalytic core domain). All affected individuals suffered from severe 
intrauterine and postnatal growth retardation, microcephaly, severe psychomotor delay, 
functional brain deficits, as well as characteristic facial dysmorphism, and died before 
the age of three. Homozygous mutant skin fibroblast cultures showed impaired 
proliferation and accelerated senescence [196]. 
 
FTO is expressed from embryonic day 8.5 in the mouse [126, 197] and is widely 
expressed in human and murine adult tissues, with particularly high expression in many 
brain regions [129, 132, 198, 199]. Several mouse models with impaired or increased 
FTO function have been generated [200], with a number of these exhibiting impaired 
regulation of fat mass and/or energy expenditure [198, 201-203]. However, the direct 
role of FTO in regulating fat mass has been recently called into question. One study has 
suggested that the obesity associated non-coding sequences within FTO directly interact 
with the promoter region of IRX3 and FTO in humans, mice and zebrafish [204]. A 
direct link was reported between Irx3 expression and regulation of body mass and 
composition, with Irx3-deficient mice exhibiting 25-30% reduction in body weight. 
This indicates that the association of FTO with IRX3 may be causative of obesity rather 
than FTO itself, and that m6A does not function in regulating fat mass and obesity. 
However, a number of developmental defects have also been reported in mice 
exhibiting loss of FTO. The original Fused toes (Ft) homozygous mutant mice exhibited 
severe developmental defects with death during gestation [126, 197]. However, the 1.6 
Mb deletion of 6 genes including Fto in these mice is not specific enough to assign this 
phenotype to a lack of FTO. Whole-body homozygous Fto knockout mice were viable, 
although they exhibited high perinatal lethality and postnatal growth retardation [198, 
203]. Recently, a series of mice with distinct temporal and spatial loss of Fto expression 
were reported [205]. Global germline loss of Fto resulted in high perinatal lethality and 
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a reduction in body length in addition to a reduction in fat and lean mass. Adult onset 
global knockout mice circumvented the lethality. Ablation of FTO in mediobasal 
hypothalamic regions of the brain had only mild effects [205]. 
 
Finally, a role for FTO in cellular nutrient sensing through signalling by the mammalian 
target of rapamycin complex 1 (mTORC1) has been described. Cells lacking FTO 
catalytic activity display decreases in activation of the mTORC1 pathway and mRNA 
translation, as well as increased autophagy, all of which are likely to contribute to the 
FTO phenotype of stunted growth seen in humans and mouse models [206].  
 
No association of ALKBH5 with human disease has thus far been reported. Murine 
Alkbh5 mRNA was detected in all organs studied, with the highest expression found in 
testes. Alkbh5-deleted male mice displayed impaired fertility resulting from apoptosis 
that affects meiotic metaphase-stage spermatocytes [125]. Transcriptome profiling of 
wild-type and Alkbh5-deleted mouse testes revealed a total of 1,551 genes with 
significant differences in expression. 646 genes were differentially expressed at the gene 
level and 1,752 showed differentially expressed isoforms. These genes belonged to a 
range of ontologies, including spermatogenesis-related functions and members of the 
p53 functional interaction network, consistent with the induction of apoptosis and 
differentiation defects. 
 
Although a number of studies have suggested that FTO is involved in regulating 
obesity, the recent discovery that IRX3 is causative of obesity indicates that m6A 
patterns are not involved in regulating this phenotype. Rather, FTO is suggested to be 
important for the developmental process. Similarly, ALKBH5 appears to be important 
for growth and differentiation, consistent with the roles identified for the m6A 
methyltransferase complex and YTHDF2. 
 
1.4.4 RNA:M5C METHYLTRANSFERASE NSUN2 
The earliest link of NSUN2 to human disease stems from its identification as a direct 
target of Myc, a well-known proto-oncogene [99]. NSUN2 showed low expression in 
normal tissues but was induced in a variety of tumours, including oral and colorectal 
cancers [99, 207, 208]. Myc-induced proliferation required NSUN2, and growth of 
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human squamous-cell-carcinoma xenografts in nude mice was decreased by NSUN2 
RNAi [99]. In 2012, it was shown that mutations in the NSUN2 gene cause autosomal 
recessive intellectual disability syndromes. Three separate studies presented one 
missense, two nonsense and two splicing mutations found in five independent 
consanguineous families [147, 209, 210]. Common features of homozygous patients 
were moderate to severe intellectual disability, facial dysmorphism, short stature, 
microcephaly and muscular hypertonia. Consistent with the neurological defects in 
patients, murine NSUN2 was enriched in Purkinje cells of the cerebellum [210] and D. 
melanogaster lacking the NSUN2 orthologue CG6133 had severe short-term memory 
loss [209]. The missense mutation Gly679Arg was shown to cause mislocalisation from 
a nuclear/nucleolar distribution to a nucleoplasmic and cytoplasmic pattern [210]. 
Consistent with a role in neurological development, Nsun2 deficient mice exhibited an 
accumulation of 5’ tRNA fragments, activating stress pathways and leading to increased 
apoptosis in the cortical, hippocampal and striatal neurons [150]. 
 
Levels and localisation of wild-type NSUN2 can vary during the cell cycle [99, 208]. 
One study found that NSUN2 was concentrated in the nucleolus during G1/S/G2 phases 
but showed perichromosomal and cytoplasmic enrichment during mitosis. NSUN2 was 
further phosphorylated by Aurora-B (targeting Ser139) during mitosis, when nucleoli 
disassemble. Aurora-B phosphorylation inhibited interaction of NSUN2 
methyltransferase activity as well as its interaction with the nucleolar proteins 
NPM1/nucleophosmin/B23 and nucleolin/C23 [208]. In the other study, NSUN2 was 
also predominantly nucleolar in G1 phase. Levels were highest in S phase cells where 
NSUN2 distributed more evenly throughout the nucleus. In G2 phase cells, NSUN2 was 
partially detected in cytoplasmic vesicles and in M phase cells NSUN2 decorated the 
spindle. The nucleolar localisation of NSUN2 was dependent on RNA polymerase III 
activity; its knockdown decreased nucleolar size and inhibited cell-cycle progression 
[99]. Interestingly, cultured cells depleted of NSUN2 exhibit increased apoptosis, 
reduced proliferation and a variety of spindle defects leading to abnormal mitosis. 
NSUN2’s effects on mitotic spindle stability were independent of its methyltransferase 
activity. Given the above it has been hypothesised that NSUN2 plays a dual role during 
the cell cycle, one requiring its methyltransferase activity and another in mitotic spindle 
stability [211]. 
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Homozygous Nsun2 deleted mice were viable, but were ~30% smaller than wild-type 
controls at three months. Homozygous males were sterile due to a requirement of 
NSUN2 for testis differentiation. Interestingly, NSUN2 was found to localise to the 
chromatoid body, a cytoplasmic RNA processing organelle essential for post-
transcriptional regulation of gene expression in haploid germ cells [212]. Both genders 
showed cyclic alopecia at around ten months of age. Reporter tagging showed that 
NSUN2 was dynamically expressed from E3.5 during embryogenesis and high in adult 
skin. Detailed analysis of the hair loss phenotype showed that NSUN2 was required to 
balance stem cell self-renewal and differentiation in the epidermis [213]. Interestingly, 
mice lacking both NSUN2 and TRDMT1 showed a striking synthetic lethal interaction 
(see below) [149]. 
 
In summary, NSUN2 displays strong links to cell cycle control as well as (stem) cell 
differentiation and proliferation. Of note, the mitotic spindle-related role of NSUN2 
does not require its methyltransferase activity. Excess activity of NSUN2 is involved in 
cancer, whereas loss of function causes complex developmental phenotypes including 
stunted growth and intellectual deficits. In addition to NSUN2, two other RNA 
methyltransferases, FTSJ1 (TRM7 in S. cerevisiae; 2’-O-methylation in tRNA) and 
TRMT1 (TRM1 in S. cerevisiae; guanine dimethylation in tRNA), have also been 
shown to cause intellectual disability [214-216]. 
 
1.4.5 RNA:M5C METHYLTRANSFERASE TRDMT1 
Mutations of TRDMT1 have thus far not been found in human disease. Mice, D. 
melanogaster or A. thaliana homozygous for inactivating mutations in TRDMT1 failed 
to show any overt phenotypes under laboratory conditions [159]. Closer inspection of 
TRDMT1-deficient flies revealed an increased sensitivity to oxidative and thermal 
stress, perhaps related to TRDMT1’s demonstrated function in preventing stress-
induced cleavage of tRNAs [73]. TRDMT1-overexpressing flies and amoebas had 
increased stress tolerance [217, 218]. By contrast, morpholino knockdown of TRDMT1 
in zebrafish embryos led to lethal differentiation defects in the retina, liver, and brain. 
This effect was dependent on the presence of TRDMT1 in the cytoplasm but not the 
nucleus [219]. TRDMT1 is detectable in a range of human and mouse tissues, with 
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highest expression in testes, ovary and thymus [155]. Taken together, information 
remains sparse on the relevance of TRDMT1 for normal cell and organismic function. 
 
Interestingly, a recent study reported severe synthetic genetic interactions between 
TRDMT1 and NSUN2 in mice [149]. Efforts to breed double knockout mice revealed 
severe intrauterine and perinatal lethality. Pups that were born alive were small and 
underdeveloped in several tissues, including malformation of the cerebral cortex, an 
immature skeleton and reduction in brown adipose tissue. Mutant fibroblasts isolated 
from embryos had a reduced ability to differentiate into adipocytes. While the m5C 
content of mRNAs was not assessed in these cells, they exhibited complete loss of m5C 
in tRNA, consistent with the complementary tRNA site specificities of the two 
enzymes. As a consequence, levels of affected tRNAs and global protein synthesis rates 
were also reduced. These findings, together with a lack of appreciable changes to 
mRNA levels, suggested the severe Nsun2/Trdmt1 double knockout phenotype was in 
large part due to defects in tRNA function [149]. 
 
In summary, the enzymes discussed are typically found to be of importance for proper 
embryonic and neural development and function (Table 1.3). Roles in germ cells, and 
links to cell differentiation, growth/transformation as well as cell cycle regulation are 
also frequently observed. A major impediment to understanding the molecular 
(patho)physiology of mRNA methylation is that the full extent of each enzyme’s 
specificity for particular RNA biotypes, or lack thereof, is not known. For METTL3, 
METTL14, YTHDF2, FTO and ALKBH5 the available evidence is firmly in favour of 
mRNAs as their substrate, although activity towards other transcript classes cannot be 
excluded. A major role for NSUN2 and TRDMT1 clearly is to modify tRNAs. 
Nevertheless, there is clear evidence that NSUN2 further acts on mRNAs and other 
ncRNAs. A big gap in our knowledge is how transcriptome-wide methylation patterns 
differ between health and disease states or how they respond to experimental 
intervention. The newly developed global approaches to map m6A and m5C can now be 
applied to close this gap. 
 
  
 
Table 1.3. Biological functions and links to human health of RNA:m5C and m6A methyltransferases, readers and demethylases. 
Modification m6A  m5C 
MTase/ 
reader/ 
demethylase 
METTL3 YTHDF2 FTO ALKBH5 NSUN2 TRDMT1 
Biological 
Functions 
 
 
! Required for 
embryonic 
development in 
plants and flies [41, 
185] 
! Required for meiosis 
and sporulation in 
yeast [42] 
! Hypomorph yields 
fertility defects in 
flies [185] 
! Knockdown in 
mESCs causes loss 
of self-renewal 
capacity [105] 
! Knockdown in HeLa 
cells resulted in 
decreased cell 
viability [68]  
! Knockdown causes 
elongation of 
circadian period 
[182] 
! Knockdown in HeLa 
cells causes reduced 
cell viability [120] 
! Germline 
inactivation causes 
severe growth 
retardation and 
multiple 
malformations in 
mice [196, 198, 203] 
! Overexpression or 
conditional loss in 
adult mice causes 
body mass 
phenotypes [202, 
205] 
! Role in cellular 
nutrient sensing 
[206] 
 
 
! Germline        
   deletion causes male 
infertility in mice 
[125] 
 
 
! Germline deletion in 
mice causes growth 
retardation, cyclic 
alopecia and male 
infertility [213] 
! Required for mitotic 
spindle stability 
[208] 
 
 
 
 
! No phenotype in 
mice 
! Stress tolerance 
phenotypes in flies 
and amoebae [73, 
217, 218] 
! Knockdown in 
zebrafish is 
embryonic lethal 
[219] 
 
  
 
Links to 
human health 
! Overexpression in 
cancer [183] 
 
 
! Reciprocal 
translocation with 
RUNX1 detected in 
AML patients [186] 
! Microsatellite 
polymorphism in 
intron associated 
with longevity in 
humans [188]!
! Common variant 
associated with risk 
for obesity [127, 
129, 131, 220] 
depression [193], 
dementia and 
Alzheimer’s disease 
[194, 195] 
Mutations cause 
lethal brain and 
growth deficits 
[196] 
! No links reported 
 
! Overexpressed in 
cancer and tumours 
[99, 207, 208] 
Mutations cause 
dysmorphogenesis 
and intellectual 
disability [147, 209, 
210] 
! Inhibited by 5-aza-C 
(anti-cancer drug) 
[72] 
 
 
 
 
 39 
!
Introduction 
!
! !
1.5 MOLECULAR FUNCTION 
Recent studies investigating m6A have reported several molecular functions for this 
modification in mRNA, whereas little definitive evidence exists for specific molecular 
consequences of the presence of m5C in mRNA. One lead for the function of m5C in 
mRNA might come from the study of innate immunity. Cells can detect dsRNA derived 
from invading viruses and trigger subsequent activation of adaptive immune responses 
through RIG-1-like (retinoic acid-inducible protein 1) and TLR (Toll-like) receptors. 
Additionally, RIG-1 and MDA5 (melanoma differentiation-associated gene 5) recognise 
foreign RNAs exhibiting a 5’ triphosphate [221] or a cap lacking 2’-O-methylation, 
[222], respectively. Of note here, it was found that cellular responses to introduced 5’ 
triphosphate carrying RNAs can be attenuated by incorporating a range of modified 
nucleosides at internal positions. RIG-1 activation was lessened by ψ and 2-thiouridine 
substitution [221] and TLR activation was prevented by substitution with 2-thiouridine, 
5-methyluridine, ψ, m6A, and m5C in a dose-dependent manner [223]. Expression of 
introduced mRNA in cells was also typically affected by the presence of modified 
nucleosides. For instance, expression of reporter mRNAs was increased when 
substituted at high level with ψ or m5C, while other modified nucleosides either had 
little effect or, in the case of 2-thiouridine and m6A, abolished expression [224]. A high 
profile application of these findings was the efficient generation of induced pluripotent 
stem cells (iPSCs) using transfection of ψ- and m5C-substituted mRNAs encoding the 
Yamanaka transcription factors KLF4, c-MYC, OCT4 and SOX2 to bypass antiviral 
responses [225]. Another study demonstrated that nonsense codons could be converted 
into sense codons by targeted pseudouridylation [17]. These results illustrate how 
mRNA modifications can trigger marked biological responses. Nevertheless, given the 
high substitution level required for these effects it is unclear whether they resemble the 
typical function of m6A or m5C when present in mRNA at physiological and therefore 
typically much lower density. 
 
Transcriptome-wide mapping of m6A and m5C in different cellular contexts is expected 
to pave the way for a broad-based elucidation of the function of mRNA methylation and 
the existing datasets have already yielded interesting, if largely correlative data [56-58, 
66]. More recent studies of m6A have extensively investigated the molecular function of 
 40 
!
Introduction 
!
! !
this modification in mRNA, yielding substantial evidence for a role in post-
transcriptional gene regulation.  
 
1.5.1 BIASED DISTRIBUTION OF M6A IN MRNA 
The MeRIP-seq study [56] noted that the vast majority of detected peaks were 
intragenic, with 50.9% residing in the CDS, 41.9% in UTRs and 2% in introns, although 
the latter figure could be an underestimate since sequencing libraries were not enriched 
for pre-mRNA. 93% of the UTR peaks fell into 3’ UTRs, with only 7% in 5’ UTRs. 
Although about half of all methylated mRNAs had only a single peak, those that had 
several displayed a strong tendency for contiguous or clustered peaks. Superimposing 
peak distribution along all methylated mRNAs revealed a prevailing pattern. m6A 
density was low in the 5’ UTR and in the 5’ region of the CDS, with a steady increase 
towards the 3’ end. m6A within the 3’ UTR was enriched near the stop codon and 
density fell again towards the 3’ end. With respect to other mRNA landmarks, no 
association between polyadenylation signals or splice junctions and sites of m6A was 
found. Instead, an interesting link to miRNA biology was uncovered. 67% of 3’ UTRs 
containing m6A also exhibited a predicted miRNA target site, higher than the ~30% 
expected by chance. There was an anti-correlation between m6A sites, which tended to 
be near the stop codon, and miRNA target sites, which tended to be near the 3’ end of 
the 3’ UTR. In the brain, targets of highly expressed miRNAs were furthermore 
enriched among the m6A-containing mRNAs. Overall, this suggested that miRNA 
levels might control mRNA methylation and/or that a spatial separation within the 3’ 
UTR might be needed for the two to somehow affect each other [56]. 
 
The m6A-seq study [57] reported qualitatively very similar findings, with peaks 
concentrated in intragenic regions, although only 1/3 to 1/2 of peaks were in common 
between both studies [66]. On average ~1.7 m6A sites were detected per mRNA. 
Analysing m6A site distribution along mRNAs, an enrichment near transcription start 
sites was noted, together with a moderate enrichment elsewhere in the 5’ UTR. The 
enrichment near the mRNA 5’ end was likely due to the common occurrence of (N6-,2’-
O-)-dimethyladenosine (m6Am) at the first transcribed position adjacent to the cap 
structure. Interestingly, the enzyme responsible for formation of m6Am appears to be 
distinct from METTL3 [40] and m6Am/Am ratios vary in a tissue- and mRNA-specific 
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manner [226]. m6A sites in the CDS were frequent (37% of all peaks), although less 
dense than expected at random, whereas a strong enrichment in the region ±200 nt from 
the stop codon was seen (28% of all peaks) with a depletion in the remainder of the 3’ 
UTR (Figure 1.4A). A relative enrichment of m6A sites in long internal exons and 
analyses of gene expression in METTL3 knockdown cells revealed multiple patterns 
suggestive of a link to (alternative) splicing. First, down-regulated genes in the 
METTL3 depleted cells were enriched for examples of m6A sites in intronic regions. 
Second, mRNAs with differentially spliced exons were enriched for m6A sites. Third, 
the density of m6A sites was higher in mRNAs derived from multi-isoform genes than 
from single isoform genes. The authors further noted overlap of m6A sites with multiple 
cis-acting RNA elements, among them conserved sequence motifs, internal ribosome 
elements, zip-code and destabilising elements. Together with the concentration around 
stop codons this was taken as highly suggestive of potentially diverse roles of m6A in 
the regulation of mRNA translation or stability [57]. 
 
Prior studies are broadly consistent with the new global mapping data in that they 
showed m6A to be present at 1-5 internal residues per molecule sited throughout the 
length of the mRNA, often at sub-stoichiometric levels per site [20-39]. Some sites 
were found to be clustered together as in the case of Rous sarcoma virus RNA [46]. 
Mature bovine prolactin mRNA exhibited a cluster of m6A residues within the 3' region 
of the molecule, about 2/3 of them concentrated within a 108 nt region in the 3’ UTR 
[45, 227]. The prolactin pre-mRNA furthermore had a predominant m6A site in its final 
intron [228], indicating that mRNA methylation can take place in the nucleus before 
splicing. Intronic sites have also been detected in Simian Virus 40 RNA [35]. 
Enrichment in mRNA 3’ regions was typically, though not exclusively, seen. Bulk 
analysis of A. thaliana cellular mRNAs showed that m6A is strongly enriched (>90%) 
near the 3’ end in a region 100-150 nt before the poly(A) tail [114]. In meiotic S. 
cerevisiae cells, m6A was distributed across all mRNA size ranges and the ime1, -2, and 
-4 mRNAs were specifically shown to contain m6A. Again, m6A sites in ime2 mRNA 
were narrowed down to a region in its 3’ half [44]. By contrast, older reports found that 
m6A was not present in the 3’ third of HeLa cellular mRNA [28]; m6A and m5C sites 
were seen only distant from the poly(A) tail of HeLa or Adenovirus RNA [30], and 
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Simian Virus 40 RNAs contained on average three m6A sites in the 5’ portion of the 
CDS [229]. 
 
1.5.2 MOLECULAR FUNCTION OF M6A 
Treatment of cells with methylation inhibitors such as cycloleucine, NPC or S-
tubericidinylhomocysteine has been used in different contexts to trigger accumulation 
of undermethylated cellular RNA and study the consequences for mRNA processing, 
transport, translation and steady-state levels, reviewed in refs. [38, 114]. An 
accumulation of viral or cellular pre-mRNA in the nucleus was often seen, consistent 
with a role of mRNA methylation in splicing and/or nuclear mRNA export [172, 175, 
176, 228, 230]. Several of the aforementioned studies saw no change in mRNA 
translation efficiency; however, others did observe reduced translation of 
hypomethylated mRNA [174, 177]. Since all these studies were performed by generally 
depleting cellular AdoMet levels it is not certain whether these effects were due to a 
depletion of m6A or other methylated nucleosides in mRNAs, or indeed due to 
hypomethylation of other cellular components. Nevertheless, they are consistent with 
functions of m6A in mRNA splicing, stability and translation as suggested by MeRIP-
seq and m6A-seq [56, 57]. Further support for such functions comes from the 
aforementioned formation of complexes between Ime4/MTA/METTL3-METTL14 with 
Mum2/FIP37/WTAP, an RNA-binding protein involved in mRNA splicing [41, 68, 69, 
104] and the recent discovery of the alternative splicing-related protein YTHDF2 as a 
m6A reader [57, 120]. 
 
More recent efforts to understand the molecular function of m6A have implemented 
transcriptome-wide techniques and have provided almost definitive roles for this 
modification in mRNA. Several studies have reported that depletion of METTL3, 
METTL14 or WTAP resulted in increased stability of mRNA targets [105, 107] and 
variations in alternative splicing [69]. Consistent with this finding, depletion of 
YTHDF2 resulted in increased levels of target mRNAs with prolonged lifetime and an 
increase in the m6A/A ratio in total mRNA, mRNA associated with 40S-80S and 
mRNA from polysomes, indicating that YTHDF2 functions in destabilising m6A-
containing mRNA [120]. YTHDF2 was also found to mediate relocalisation of m6A-
containing mRNA to P bodies where mRNA decay occurs, consistent with the role of 
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6A in mRNA destabilisation [120]. In contrast, the mRNA stabiliser human antigen 1 
(HuR) was reported to preferentially bind unmethylated mRNA in METTL3 and 
METTL14 knockdown cells compared to control cells, suggesting that m6A may hinder 
HuR binding and mediate binding of YTHDF2 for degradation of m6A-containing 
mRNA [105]. A recent study has also supported the role of m6A in alternative splicing 
regulation. This study reported that FTO depletion promoted the RNA-binding affinity 
of serine/arginine-rich splicing factor 2 (SRSF2), leading to increased inclusion of 
exons [231].  
 
The roles of m6A determined in these studies are largely in concordance and strongly 
support the molecular function of m6A in regulating mRNA stability and alternative 
splicing. 
 
1.5.3 BIASED DISTRIBUTION OF M5C IN MRNA 
The bsRNA-seq study [58] also noted an uneven distribution of m5C in the HeLa cell 
transcriptome. m5C sites were enriched in several ncRNA types including tRNAs while 
mRNAs had a relatively low density of sites. Nevertheless, 83% of all detected m5C 
sites were found in mature mRNAs. Within mRNAs, sites were depleted relative to 
random distribution in the CDS but significantly enriched in the 5’ and 3’ UTRs, 
respectively (Figure 1.4B). Intron sequences were not surveyed. Enrichment of human 
regulatory RNA motifs [232] and, notably, Argonaute (Ago) 1-4 footprints [233] near 
m5C sites in mRNA was further observed. This suggested a role of m5C miRNA 
biology and more broadly in the post-transcriptional control of gene expression. 
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Figure 1.4. Biased distribution of m6A and m5C within mRNAs.  
A) Metagene profiles of murine mRNAs displaying m6A distribution in areas near the mRNA 5’ 
end (transcription start site (TSS); left) and around the stop codon (right). Normalised next-
generation sequencing read coverage from anti-m6A immunoprecipitation (blue) and input RNA 
libraries (red) is shown. (Reprinted with permission from ref. [57]. Copyright 2012 Nature 
Publishing Group). B) Metagene profiles based on human bsRNA-seq data [58] showing 
relative enrichment of m5C in the mRNA 5’ and 3’ UTRs and relative depletion within the CDS. 
UTRs and CDS of each mRNA were divided into an equal number of intervals and the fraction 
of m5C candidate sites falling into each interval is plotted in blue. The fraction of all cytosines 
with ≥10 read coverage is plotted as background in red. 
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1.5.4 MOLECULAR FUNCTION OF M5C  
No published prior attempts have been made to elucidate a molecular function of m5C 
in mRNA. Nevertheless, the bsRNA-seq study [58] implicated NSUN2 as a 
methyltransferase that interacts with and modifies mRNA, and, as detailed above, there 
is evidence to corroborate this from three independent studies [139, 140, 152]. 
Interestingly, NSUN2 was further shown to promote the stability of the mRNA 
encoding the cell cycle regulator CDKN2A/p16INK4 [151]. A NSUN2 binding site was 
mapped in the 3’ UTR of p16INK4 mRNA. In vitro methylation assays demonstrated 
specific methylation of this region by recombinant NSUN2, which was reduced by 
mutation of a local AAC motif centred on position 988. While the presence of this motif 
strongly suggests involvement of m6A methylation, this is curiously at odds with the 
known specificity of NSUN2 for m5C. p16INK4 mRNA is further known to be 
destabilised by interactions of AU-rich element RNA binding protein 1 (AUF1), 
ELAV1 and Ago2 with its 3’ UTR. A series of chimeric reporter studies and pull-down 
experiments then indicated that NSUN2-mediated methylation prevented the 
localisation of p16INK4 3′ UTR containing transcripts to processing bodies as well as 
antagonising the interaction and destabilising effects of HuR/AUF1/Ago2 on p16INK4 
mRNA [151]. With the caveat that this study suggested an involvement of the m6A 
modification, these results indicate that mRNA methylation by NSUN2 can promote 
mRNA stability directly as well as through antagonising other regulatory RNA binding 
proteins (RBPs). 
 
Altogether the evidence is clear that internal methylation is more than mere ‘decoration’ 
of the mRNA. A regulatory role is already strongly indicated for m6A by the reversible 
and context-specific nature of its occurrence. Patterns of specific depletion or 
enrichment near landmarks along mRNAs suggest that both, m5C and m6A interact in 
some way with mechanisms of post-transcriptional gene control, particularly through 
miRNAs. Finally, multiple circumstantial pieces of evidence link m6A to regulation of 
RBP-mRNA interactions, and as a consequence mRNA splicing, translation or stability. 
Additional transcriptomic profiles of m5C and m6A as well as wider availability of 
transcriptome-wide RBP footprint datasets will no doubt expand, refine and perhaps in 
some cases revise current working hypotheses of m5C and m6A function. Figure 1.5 
summarises the reported and putative molecular steps that have been proposed thus far 
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to underpin such functions of either m6A or m5C, as well as some additional plausible 
scenarios. 
 
 
Figure 1.5. Reported roles for m6A in mRNA and speculative roles of m5C in mRNA.  
Pictograms of reported molecular functions of m6A and several plausible molecular 
consequences of the presence of m5C (represented by blue lollipops) are shown along a stylised 
mRNA. These in turn could affect different aspects of mRNA utilisation. Evidence consistent 
with some of the depicted scenarios has been published and others have been proposed. See 
main text for details and references. 
 
1.6 AIMS 
It is clear that RNA modifications such as m6A and m5C are non-randomly distributed 
throughout the transcriptome, suggesting that they are functionally important. A number 
of studies have provided evidence for the molecular function of m6A in regulating 
mRNA stability and alternative splicing, although the function of m5C is still largely 
speculative. Understanding the molecular and biological functions of these 
modifications would provide further insight into their role in human diseases and could 
be a therapeutic target in the future. 
 
The overall aim of this thesis is to gain insight into the RNA targets of NSUN2 and 
TRDMT1, as well investigate the molecular functions of m5C in mRNA. In order to 
understand the biological role of m5C in RNA and the different cellular contexts that 
m5C exists in, the RNA m5C profiles between normal and cancer cells were compared. 
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Transcriptome-wide bisulfite sequencing, termed bsRNA-seq, will be used in addition 
to a bioinformatics pipeline to investigate the RNA m5C profiles. 
 
1.6.1 DETAILED AIMS 
To achieve the overall aims of determining the substrate range of NSUN2 and 
TRDMT1, exploring the molecular functions of m5C in mRNA and investigating the 
presence of m5C across different cellular contexts, the project was divided into the 
following four specific aims: 
 
Aim 1: To prepare prostate epithelial cells (PrEC), lymph node metastatic prostate 
cancer cells (LNCaP) and RNAi-mediated knockdown of NSUN2 and TRDMT1 in 
HeLa cells for the detection of m5C in RNA, and to improve and establish techniques 
for the detection of m5C in RNA (Chapter 3) 
 
Aim 2: To determine the substrate range of NSUN2 and TRDMT1 in RNA (Chapter 4) 
 
Aim 3: To explore the molecular functions of m5C in mRNA (Chapter 5) 
 
Aim 4: To explore the role of RNA m5C in cancer by examining the RNA m5C profiles 
of PrEC and LNCaP cells, and to compare this with HeLa cells to confirm patterns of 
m5C across multiple cell lines (Chapter 6) 
  
!
!
 
CHAPTER TWO 
MATERIALS & METHODS 
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2.1 MATERIALS 
2.1.1 CHEMICALS, REAGENTS AND CONSUMABLES 
Common chemicals and reagents used in this study and their suppliers are listed below. 
 
Manufacturer Chemicals/reagents/consumables 
5 Prime 
(Hilden, Germany) 
Phase Lock Gel Heavy (1.5 mL) 
Amresco 
(Solon, OH, USA) 
EZ-Vision® Three DNA Dye, DTT, glycine 
BD Biosciences 
(Franklin Lanes, NJ, USA) 
Bacto™ agar, Bacto™ tryptone peptone digest, 
Bacto™ yeast extract 
Beckman Coulter 
(Brea, CA, USA) 
Agencourt AMPure XP-PCR Purification, 14 x 89 
mm polyallomer centrifuge tubes 
Bio-Rad 
(Hercules, CA, USA) 
Micro Bio-Spin™ Chromatography Columns 
Coles 
(Hawthorn East, VIC, Australia) 
Skim milk powder 
Corning 
(Tewksbury, MA, USA) 
T-75 flasks, 6-well plates, Costar® Spin-X® Plastic 
Centrifuge Tube Filters, Axygen® 8-strip thin wall 
PCR tube strips and caps 
Diagenode 
(Liège, Belgium) 
DNA methylation control pack 
Eppendorf 
(Hamburg, Germany) 
1.5 mL tubes, 2.0 mL tubes, 1.5 mL safe-lock tubes 
Fisher Biotec 
(Wembley, WA, Australia) 
Sets of dNTPs (100 mM each) 
GE Healthcare 
(Little Chalfort, BKM, UK) 
Amersham Hybond™-P PVDF transfer membrane, 
Amersham Hybond™-N+ membrane, Whatman™ 
chromatography paper 
Life Technologies 
(Carlsbad, CA, USA) 
Glycogen (5 mg/mL), Lipofectamine®2000 Reagent, 
Lipofectamine RNAiMax, Opti-MEM® Reduced 
Serum Media, NuPAGE® Novex® 4-12% Bis-Tris 
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Gels, NuPAGE® LDS Sample Buffer, NuPAGE® 
MES SDS Running Buffer, Novex® TBE-Urea Gels 
10%, Novex® TBE-Urea Sample Buffer, Fetal 
Bovine Serum, DMEM, Dulbecco’s phosphate 
buffered saline (PBS), T-Medium, 0.25% Trypsin-
EDTA, L-glutamine, UltraPure™ Phenol:Water 
(3.75:1 v/v), Fast SYBR® Green Master Mix, 
TURBO™ DNase, RNaseOUT™, SYBR® Gold 
Nucleic Acid Stain, UltraPure™ DNase/RNase-Free 
Distilled Water (dH2O), ampicillin, 3M sodium 
acetate (NaAc) (pH 5.5), Tris-HCl pH 8.0, TaqMan® 
Universal Master Mix, Eukaryotic 18S rRNA 
Endogenous Control (VIC®), yeast tRNA 
Lonza 
(Basel, Switzerland) 
PrEBM Basal Medium, PrEGM SingleQuot Kit 
Suppl. & Growth Factors, Hanks balanced salt 
solution, Trypsin neutralising solution, Trypsin-
EDTA, SeaKem® LE Agarose 
Merck Millipore 
(Billerica, MA, USA) 
Cytobuster™ Protein Extraction Reagent, 
EMSURE® ethanol absolute for analysis (EtOH), 
EMSURE® methanol for analysis, EMSURE® 
isopropanol for analysis, ReBlot Plus Strong 
Antibody Stripping Solution 10x, ReBlot Plus Mild 
Antibody Stripping Solution 10x, Novagen® 
RedAlert™ 10x Western Blot Stain 
National Diagnostics 
(Atlanta, GA, USA) 
SequaGel - UreaGel System 
New England Biolabs 
(Ipswich, MA, USA) 
BSA 100x, Buffer EcoRI 
Promega 
(Madison, WI, USA) 
X-Gal, Tris base 
Roche Applied Science 
(Indianapolis, IN, USA) 
Complete protease inhibitor cocktail tablets (EDTA-
free) 
Sartorius AG Minisart® syringe filters 
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(Gottingen, Germany) 
Sigma-Aldrich 
(St Louis, MO, USA) 
Ethidium bromide, Tri Reagent®, BSA, sodium 
metabisulfite, hydroquinone, Penicillin-
Streptomycin, Tween® 20, DMSO, Trypsin-EDTA, 
formamide, EDTA, PBS, NaOH, chloroform, 
luminol sodium salt, cycloheximide, HEPES, PMSF, 
bromophenol blue, xylene cyanol, phenol red, 
IGEPAL® CA-630, KCl, coumaric acid, NaN3, 
MnCl4, RbCl, NaMOPS, hydrogen peroxide (35% by 
weight), boric acid, Acetic acid (HAc), glycerol, 
SDS, methylene blue 
Terumo 
(Tokyo, Japan) 
20 CC/mL syringe 
 
Thermo Scientific 
(Waltham, MA, USA) 
Nunc® CryoTube® vials (1.8 mL), Nunc® cell culture 
dish (15 cm), IPTG solution 
VWR International 
(Radnor, PA, USA) 
Ammonium acetate, CaCl2, Potassium acetate (KAc), 
MgCl2, NaCl, sucrose 
 
2.1.2 KITS 
Manufacturer Kit 
Agilent Technologies 
(Santa Clara, CA, USA) 
RNA 6000 Nano Kit, High Sensitivity DNA Kit 
Illumina 
(San Diego, CA, USA) 
TruSeq DNA LT Sample Prep Kit v2, MiSeq 
Reagent Kit v2 (300 cycles) 
Kapa Biosystems 
(Woburn, MA, USA) 
Library Quantification Kit- Illumina/Universal 
Life Technologies 
 
Qubit® dsDNA BR Assay Kit, RiboMinus™ 
Eukaryote Kit for RNA-Seq, SOLiD™ Total RNA-
Seq Kit, MEGAscript® T7 Kit 
Promega PureYield™ Plasmid Miniprep System, pGEM®-T 
Easy Vector System, Wizard® SV Gel and PCR 
Clean-Up System 
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Qiagen 
(Hilden, Germany) 
QiaQuick Gel Extraction Kit, MinElute® PCR 
Purification Kit 
Thermo Scientific 
(Wilmington, DE, USA) 
Pierce™ BCA Protein Assay Kit 
 
2.1.3 ANTIBODIES 
Manufacturer Antibody Dilution used 
Abcam 
(Cambridge, UK) 
Rabbit polyclonal anti-DNMT1 antibody  1:800 
Agilent Technologies Polyclonal rabbit anti-mouse 
immunoglobulin HRP 
1:1000 
Diagenode 5-mC monoclonal antibody 3D33 1:500 
Millipore Goat anti-rabbit IgG antibody, peroxidase 
conjugated 
1:1000 
Proteintech 
(Chicago, IL, USA) 
Rabbit anti-NSUN2 polyclonal antibody, 
rabbit anti-TRDMT1 polyclonal antibody 
1:1000 
Sigma-Aldrich 
 
Monoclonal anti-α-tubulin antibody 
produced in mouse 
1:1000 
 
2.1.4 ENZYMES 
Manufacturer Enzyme 
Epicentre Biotechnologies 
(Madison, WI, USA) 
Tobacco Acid Pyrophosphatase 
Life Technologies RNaseOUT™ Recombinant Ribonuclease Inhibitor, 
Superscript® III Reverse Transcriptase, TURBO™ 
DNase, Platinum® Taq DNA Polymerase 
New England Biolabs EcoRI, T4 Polynucleotide Kinase 
Roche Applied Science 
(Penzberg, Upper Bavaria, Germany) 
FastStart Taq DNA Polymerase 
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2.1.5 BUFFERS AND SOLUTIONS 
2.1.5.A BUFFERS AND SOLUTIONS FOR GENERAL MOLECULAR BIOLOGY 
1x TAE: 
40 mM Tris base (pH 8.2), 20 mM HAc and 1 mM EDTA  
 
1x TBE: 
89 mM Tris base (pH 7.6), 89 mM boric acid, 2 mM EDTA 
 
1x TE: 
10 mM Tris-HCl (pH 7.5), 1 mM EDTA 
 
2x RNA loading dye: 
95% formamide, 0.02% SDS, 0.2% bromophenol blue, 0.01% xylene cyanol 
1 mM EDTA 
 
20x random primer mix: 
35 µM hexamers, 25 µM T12VN 
 
Table 2.1. Oligo sequences for the random primer mix. 
Oligo Sequence 
Hexamers NNNNNN 
T12VN NVTTTTTTTTTTTT 
 
2.1.5.B BUFFERS AND SOLUTIONS FOR DOT BLOT ASSAYS AND WESTERN 
BLOTTING 
Antibody storage solution: 
5% BSA, 0.02% NaN3, 1x PBS, phenol red 
 
1x transfer buffer: 
25 mM Tris, 192 mM glycine, 10% methanol 
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1x PBS-T: 
1x PBS, 0.1% Tween® 20 
 
Blocking buffer: 
5% skim milk powder, 1x PBS, 0.1% Tween® 20 
 
Methylene blue solution: 
0.02% methylene blue, 0.3 M NaAc (pH 5.5) 
 
ECL (enhanced chemiluminescence) solution: 
Solution A: 0.4 mM coumaric acid, 2.5 mM luminol, 100 mM Tris-HCl, pH 8.0 
Solution B: 21% hydrogen peroxide, 100 mM Tris-HCl, pH 8.0 
Mix solutions together 
 
2.1.5.C BUFFERS AND SOLUTIONS FOR BSRNA-SEQ AND MISEQ 
AMPLICON SEQUENCING 
1x PAGE elution buffer 
2.5 mM ammonium acetate in TE buffer 
 
1x EBT: 
10 mM Tris-HCl (pH 8.5), 0.1% Tween® 20 
 
Library dilution buffer: 
10 mM Tris-HCl (pH 8.0), 0.05% Tween® 20 
 
2.1.5.D BUFFERS AND SOLUTIONS FOR TISSUE CULTURE 
Supplemented PrEBM media (PrEGM): 
PrEBM basal medium was supplemented with PrEGM SingleQuot Kit Suppl. & Growth 
Factors to make PrEGM. PrEGM was stored at 4°C for a maximum of one month. 
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Supplemented T-media: 
T-medium was supplemented with 10% FBS and 2 mM L-glutamine. Supplemented T-
medium was stored at 4°C for a maximum of one month. 
 
Supplemented DMEM media: 
DMEM medium was supplemented with 5% FBS and 2 mM L-glutamine. 
Supplemented DMEM medium was stored at 4°C for a maximum of one month. 
 
PrEC freezing media: 
90% PrEGM, 10% FBS, 10% DMSO 
 
LNCaP freezing media: 
90% supplemented T-medium, 10% DMSO 
 
2.1.5.E BUFFERS AND SOLUTIONS FOR SUCROSE DENSITY GRADIENT 
CENTRIFUGATION 
Sucrose gradient buffer: 
20 mM HEPES (pH 7.6), 125 mM KCl, 5 mM MgCl2, 0.1 mg/mL cycloheximide, 1 
mM DTT, 0.5 M PMSF 
 
Lysis buffer: 
20 mM HEPES (pH 7.6), 125 mM KCl, 5 mM MgCl2, 0.1 mg/mL cycloheximide, 2 
mM DTT and 0.5 M PMSF, 1x complete protease inhibitor, 0.5% IGEPAL® CA-630, 
100 U/mL RNaseOUT™ 
 
2.1.6 DNA MARKERS 
Manufacturer Marker 
Bioline 
(London, UK) 
HyperLadder™-V 
Life Technologies 1 Kb Plus DNA ladder, 10 bp DNA ladder 
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2.1.7 OLIGONUCLEOTIDES 
Synthetic DNA oligonucleotides (purified by standard desalting) for RT-qPCR, PCR 
and Sanger sequencing were synthesised by Integrated DNA Technologies (Coralville, 
IA, USA). Primers that were designed for RT-qPCR and PCR are listed in the relevant 
sections of this chapter. 
 
2.1.8 SIRNAS 
SiRNAs were purchased from Dharmacon (Lafayette, CO, USA). 
 
Table 2.2. siRNAs and their corresponding sequences used for RNAi-mediated 
knockdown. 
siRNA Catalogue 
number Targeted sequences Gene 
siGENOME Human NSUN2 
siRNA SMARTpool M-018217-01-0005 
5’-UAAGAAAGAUGGCGUGUGU-3’ 
5’-GAGUUGGUAUCCUGAAGAA-3’ 
5’-GAGCGAUGCCUUAGGAUAU-3’ 
5’-GGAGACGGCACUAUGAGAA-3’ 
NSUN2 
siGENOME Human TRDMT1 
siRNA SMARTpool M-006671-01-0005 
5’-GCGAUAUGCUCUUCUGUUA-3’ 
5’-CAGAAGAAAUUCACAGGAA-3’ 
5’-GAACGUUGAACCAAAUAUU-3’ 
5’-CAAAUUCAAGGCUACGAUA-3’ 
TRDMT1 
siGENOME Human DNMT1 
siRNA SMARTpool M-004605-01-0005 
5’-GGAAGAAGAGUUACUAUAA-3’ 
5’-GAGCGGAGGUGUCCCAAUA-3’ 
5’-GGACGACCCUGACCUCAAA-3’ 
5’-GAACGGCGCUCAUGCUUAC-3’ 
DNMT1 
siGENOME non-targeting 
siRNA Pool #1 D-001206-13-05 
5’- UAGCGACUAAACACAUCAA-3’ 
5’- UAAGGCUAUGAAGAGAUAC-3’ 
5’- AUGUAUUGGCCUGUAUUAG-3’ 
5’- AUGAACGUGAAUUGCUCAA-3’ 
N/A 
 
2.1.9 IN VITRO TRANSCRIPTS 
The in vitro transcripts synthesised and used for this study included humanised Renilla 
Luciferase (R-Luc) and non-humanised R-Luc. The humanised R-Luc in vitro transcript 
was transcribed from the humanised R-Luc insert located in pCl-Neo. The Filipowicz 
Lab cloned the humanised R-Luc insert into pCl-neo and provided it for this study 
[234]. The pCl-neo plasmid containing the R-Luc insert is known as humanised R-Luc 
or hRL 3xB pA in this study. The non-humanised R-Luc in vitro transcript was 
transcribed from the R-Luc insert in the pRL-TK vector. The in vitro transcription 
method is detailed in section 2.2.2.G. The sequences for these in vitro transcripts are 
provided in Appendix 8.1. 
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2.1.10 PLASMIDS 
Manufacturer Plasmid 
Promega pGEM®-T Easy Vector, pCl-neo, pRL-TK  
 
2.1.11 BACTERIAL STRAINS 
Escherichia coli (E. coli) DH5α 
 
2.1.12 BACTERIAL GROWTH MEDIA  
Transformation buffer 1 (TFB1): 
30 mM KAc, 79 mM MnCl2, 13 mM CaCl2, 100 mM RbCl, 15% glycerol 
 
0.294 g KAc, 0.989 g MnCl2 and 0.147 g CaCl2 and 15 mL 100% glycerol were added 
to 75 mL Milli-Q H2O and the pH brought to 5.8 with HAc. 1.2 g of RbCl was then 
added and the final volume brought to 100 mL with Milli-Q H2O. The buffer was then 
filter-sterilised using a 0.22 µm vacuum filter and stored at 4°C. 
 
Transformation buffer 2 (TFB2): 
13 mM NaMOPS, pH 7.0, 100 mM CaCl2, 10 mM RbCl, 15% glycerol 
 
0.294 g NaMOPS, pH 7.0 was added to 1.1 g CaCl2, 0.12 g RbCl and 15 ml 100% 
glycerol. The final volume was brought to 100 mL with Milli-Q H2O. The buffer was 
then filter-sterilised using a 0.22 µm vacuum filter and stored at 4°C. 
 
Luria Broth (LB): 
10 g/L Bacto™ tryptone peptone digest, 5 g/L Bacto™ yeast extract, 10 g/L NaCl made 
up to 1 L with Milli-Q H2O before autoclaving. 
 
Luria broth (LB) agar: 
6.5 g Bacto™ agar was added to 400 mL LB and autoclaved. Once cooled to 55°C, 
ampicillin (100 µg/mL) was added and mixed. Plates were then poured under aseptic 
conditions and stored at 4°C. 
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2.2 METHODS 
2.2.1 TISSUE CULTURE TECHNIQUES 
2.2.1.A MAINTENANCE OF HELA CELLS 
HeLa cells were cultured in supplemented DMEM medium and were routinely passaged 
at 90-100% confluency in either a 1:5 or 1:10 split ratio in a T-75 flask (flask with a 75 
cm2 surface area). For passaging, cells were washed with 5 mL pre-warmed PBS and 2 
mL pre-warmed 0.25% Trypsin-EDTA was added to the flask and incubated at 37°C for 
5 min. The trypsin was inactivated by addition of 8 mL supplemented DMEM. HeLa 
cells were maintained at 37°C with 5% CO2. 
 
2.2.1.B MAINTENANCE OF PREC CELLS 
PrEC cells were cultured in PrEGM according to the manufacturer’s protocol in a T-75 
flask. 2,500 PrEC cells were seeded per cm2 and media replaced every two days to 
ensure optimal growth. Upon reaching 80-90% confluency, cells were passaged. Cells 
were washed with 6 mL pre-warmed Hanks balanced salt solution and 2 mL pre-
warmed Trypsin-EDTA was added to the flask and incubated at room temperature for 5 
min. The trypsin was inactivated by addition of 12 mL trypsin neutralising solution to 
the flask and the cells were centrifuged at 1,200 rpm for 5 min before resuspending in 
PrEGM. PrEC cells were maintained at 37°C with 5% CO2 until the 9th passage, at 
which the cells were discarded. 
 
2.2.1.C MAINTENANCE OF LNCAP CELLS 
LNCaP cells were cultured in supplemented T-medium and were routinely passaged at 
90-100% confluency in a 1:3 split ratio in a T-75 flask. For passaging, cells were 
washed with 5 mL pre-warmed PBS and 2 mL pre-warmed 0.25% Trypsin-EDTA was 
added to the flask and incubated at 37°C for 5 min. Trypsin was inactivated by addition 
of 5 mL supplemented T-medium and the cells centrifuged at 1,200 rpm for 5 min 
before resuspending in supplemented T-medium. LNCaP cells were maintained at 37°C 
with 5% CO2. 
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2.2.1.D CRYOPRESERVATION AND REVIVAL OF CELL LINES 
Mammalian cell lines were preserved by cryopreservation in liquid nitrogen. Once 
confluent, cells were trypsinised and resuspended in ~1.5 mL freezing solution. 5-6 x 
105 PrEC cells were stored in each cryovial and one confluent T-75 flask of LNCaP 
cells were stored in each cryovial. Cells were frozen to -80°C at a rate of ~1°C/min 
using a Nalgene freezing container for 24 h. For long-term storage, cryovials were 
transferred to liquid nitrogen. Revival of cells from liquid nitrogen storage was 
performed by thawing the cells quickly at 37°C and transferring them to ~9 mL of pre-
warmed supplemented growth medium. Cells were then transferred to a T-75 flask 
containing an additional 5 mL supplemented growth medium. The medium was 
replaced 24 h post-thawing to remove traces of DMSO. Once confluent, cells were 
passaged as previously described. 
 
2.2.1.E REVERSE TRANSFECTION OF CELLS WITH SIRNAS 
For reverse transfection of siRNAs, siGENOME Human siRNA SMARTpools (Table 
2.2) were reverse transfected using Lipofectamine® RNAiMAX. All transfections were 
performed in triplicate and in a 6-well plate format. 5 µL Lipofectamine® RNAiMAX 
was incubated with 245 µL Opti-MEM® Reduced Serum Medium for 5 min and added 
to 250 µL Opti-MEM® Reduced Serum Medium containing 150 pmoles siRNA. This 
was incubated at room temperature for 20 min to allow siRNA/Lipofectamine® 
RNAiMAX complexes to form. 500 µL of the complex was added to each well and 
cells were seeded at a density of 1.5 x 105 for HeLa cells or 4 x 105 for LNCaP cells. 
The volume was made up to 2.5 mL with supplemented growth medium without 
antibiotics that was specific to the cells and were maintained in an incubator at 37°C 
with 5% CO2. Cells were split if necessary and reverse transfected again 72 h post-
initial transfection and harvested 144 h post-initial transfection using 1 mL Tri 
Reagent® for RNA isolation or 300 µL Cytobuster™ Protein Extraction Agent for 
protein isolation.  
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2.2.2 NUCLEIC ACID TECHNIQUES  
2.2.2.A RNA ISOLATION AND PRECIPITATION 
Total RNA from adherent cells was extracted using Tri Reagent® according to the 
manufacturer’s protocol. Briefly, medium was aspirated from the cells and 1 mL of Tri 
Reagent® was added to the cells per 10 cm2, vortexed and placed in an Eppendorf tube. 
The Tri Reagent® suspension was incubated for 5 min at room temperature and 0.2 mL 
of chloroform per 1 mL Tri Reagent® was added to the suspension, mixed and 
incubated for 2 min at room temperature followed by centrifugation at 12,000 x g for 15 
min at 4°C. The aqueous phase was transferred to another 1.5 mL Eppendorf tube 
containing 1 µL glycogen and the RNA precipitated with 0.5 mL isopropanol per 1 mL 
Tri Reagent®. The precipitated RNA was mixed, incubated for 10 min at room 
temperature and centrifuged at 12,000 x g for 10 min at 4°C. The RNA was washed 
with 75% EtOH, mixed, and centrifuged at 7,500 x g for 5 min at 4°C. Following the 
removal of the supernatant, the RNA pellet was air dried briefly in a biohazard cabinet 
and resuspended in dH2O. The isolated RNA was precipitated again overnight at -80°C 
with 0.1 volumes of 3 M NaAc, 3 volumes of 100% EtOH and 1 µL glycogen. The 
suspension was centrifuged at 17,000 x g for 30 min at 4°C and the RNA washed with 
75% EtOH as previously described and resuspended in dH2O. RNA was stored at -
80°C. 
 
2.2.2.B REMOVAL OF GENOMIC DNA FROM RNA 
For all downstream applications, RNA was subjected to genomic DNA removal using 
TURBO™ DNase according to the manufacturer’s protocol. Briefly, up to 10 µg total 
RNA was treated with 2 U TURBO™ DNase in 1x TURBO™ DNase Buffer and 
incubated at 37°C for 30 min. TURBO™ DNase was removed by phenol/chloroform 
extraction (see next section). 
 
2.2.2.C PHENOL/CHLOROFORM EXTRACTION 
The reaction was made up to 100 µL in dH2O and transferred to a Phase Lock Gel 
Heavy tube that had been centrifuged previously at 16,000 x g for 30 sec to settle the 
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gel bed. An equal volume of UltraPure™ Phenol:Water (3.75:1 v/v) and chloroform 
were added, and the solution mixed vigorously by hand for 15 sec. The mixture was 
centrifuged at 16,000 x g for 5 min at room temperature. An equal volume of 
chloroform was added again and the process repeated. The RNA-containing solution 
was transferred to a new Eppendorf tube and precipitated overnight in EtOH as 
previously described. 
 
2.2.2.D AGAROSE GEL ELECTROPHORESIS 
1-2% agarose gels were used for the analysis of PCR products or plasmid constructs. 
Agarose gels were prepared by mixing agarose with 1x TAE and pouring it into a 
horizontal gel box and allowing to set for 30 min-1 h. 1x EZ-Vision® Three DNA Dye 
was added to the DNA samples and size markers prior to loading. Agarose gels were 
run in 1x TAE at 100 V for 30-40 min and visualised by short wavelength UV light and 
photographed using the Syngene Gene Genius Bio Imaging System (Synoptics Ltd, 
Cambridge, UK). 
 
2.2.2.E BISULFITE CONVERSION OF RNA  
Sodium bisulfite solution was prepared using 40% (w/v) sodium metabisulfite and 600 
µM hydroquinone. The pH was adjusted to 5.1 by addition of 10 M NaOH and the final 
solution filtered through a 0.22 µm filter. As a control for bisulfite conversion, 1/1000 
of humanised and non-humanised R-Luc in vitro transcript was spiked into 2-4 µg 
DNase-treated RNA prior to bisulfite treatment. The RNA mixture was denatured by 
heating to 75°C for 5 min then 100 µL of pre-heated sodium bisulfite solution was 
added to each RNA mixture, mixed and incubated at 75°C for 4 h in the dark with 100 
µL mineral oil layered on top to prevent evaporation. The reaction mixture was desalted 
by two passages through Micro Bio-spin 6 chromatography columns according to the 
manufacturer’s protocol. RNA was desulfonated by addition of 1 volume of 1 M Tris-
HCl (pH 9.0) and incubated for 1 h at 75°C in the dark with 150 µL mineral oil, 
followed by overnight EtOH precipitation as previously described. RNA was 
resuspended in dH2O. 
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2.2.2.F REVERSE TRANSCRIPTION 
Reverse transcription of isolated RNA was performed using Superscript® III Reverse 
Transcriptase (RT) according to the manufacturer’s protocol. 50 ng-2 µg DNase treated 
RNA, 1 µL 20x random primer mix, 1 µL 1 mM dNTP mix and dH2O to 13 µL were 
incubated at 65°C for 5 min, and then placed on ice for 1 min. For reverse transcription, 
a mixture of 1x First-strand Buffer, 1 µL 0.1 M DTT, 40 U RNaseOUT™ and 200 U 
Superscript® III (or dH2O for -RT controls) were added to the denatured RNA sample 
and incubated at 25°C for 5 min, 50°C for 60 min and then at 70°C for 15 min. For 
bisulfite PCR, 200 ng cDNA was diluted 1:10 in dH2O. For RT-qPCR, 1 µg cDNA was 
diluted 1:10 in dH2O. 
 
2.2.2.G IN VITRO  TRANSCRIPTION 
For in vitro transcription, the MEGAscript® T7 Kit (Life Technologies, Carlsbad, CA, 
USA) was used according to the manufacturer’s protocol. Briefly, linearised template 
DNA (~1 µg) was incubated with 1x Reaction Buffer, 7.5 mM each of ATP, CTP, GTP 
and UTP and 2 µL enzyme mix at 37°C for 2-4 h. Template DNA was removed by 
adding 2 U TURBO™ DNase and incubating at 37°C for 30 min. TURBO™ DNase 
was removed by phenol/chloroform extraction and RNA precipitated overnight in EtOH 
as previously described. After precipitation and resuspension in dH2O, 10 µg of the in 
vitro transcript was treated with 2 U TURBO™ DNase again to remove any residual 
template DNA. The size of the in vitro transcript was assessed on a RNA 6000 Nano 
Chip on the Agilent® 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) 
according to the manufacturer’s instructions. 
 
2.2.2.H DNA/RNA DOT BLOT ASSAY 
Methylated and unmethylated DNA controls were serially diluted two-fold from 100 
ng-12.5 ng, denatured either in 2 µL 0.1 M NaOH at 99°C for 5 min and snap cooled on 
ice followed by neutralisation with 0.1x 6.6 M ammonium acetate, or 2x RNA loading 
dye at 75°C for 5 min and snap cooled on ice. Yeast tRNA and HeLa RNA were serially 
diluted two-fold from 5 µg-625 ng in dH2O, denatured with or without 2x RNA loading 
buffer at 75°C and snap cooled on ice. ~10 µL of each sample was dotted onto an 
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Amersham Hybond™-N+ membrane using a pipette and allowed to dry. The membrane 
was then UV crosslinked twice using the “auto-crosslink” function (120 mJ/cm2) on the 
Stratalinker® 1800 UV Crosslinker (Stratagene, La Jolla, CA, USA). The membrane 
was blocked in blocking buffer for 1 h at room temperature while rocking, then 
incubated with the anti-m5C antibody overnight at 4°C while rocking. The membrane 
was washed with 1x PBS-T three times over 30 min, incubated with a anti-mouse 
secondary antibody in blocking buffer for 1 h at room temperature while rocking, then 
washed again in 1x PBS-T three times for 30 min. Enough ECL solution to cover the 
membrane was added and incubated in the dark for 5 min. Membranes were visualised 
using the ImageQuant LAS 4000 (GE Healthcare, Little Chalfort, BKM, UK). To check 
hybridisation of nucleic acids to the membrane, the membrane was incubated with 
methylene blue solution for 5 min at room temperature while rocking, followed by 
rinsing with dH2O. The membrane was photographed using the upper white light setting 
on the Syngene Gene Genius Bio Imaging System. 
 
2.2.3 NUCLEIC ACID QUANTIFICATION AND INTEGRITY 
ANALYSIS 
2.2.3.A NANODROP SPECTROPHOTOMETRIC ANALYSIS FOR 
QUANTIFICATION 
The NanoDrop spectrophotometer (Thermo Scientific, Wilmington, DE, USA) provides 
nucleic acid quantity and purity by assessing the 220-320 nm light absorbance profile 
using an inbuilt algorithm. Quantification of nucleic acids by this method was 
performed using 1.5 µL of purified and undiluted nucleic acid according to the 
manufacturer’s protocol. 
 
2.2.3.B QUBIT FLUOROMETRIC QUANTIFICATION 
MiSeq DNA quantification was performed using the Qubit dsDNA BR Assay Kit and 
assayed using the Qubit Fluorometer (Life Technologies, Carlsbad, CA, USA) 
according to the manufacturer’s protocol. In total, 2 µL of DNA per sample was 
assayed. 
 
 64 
!
Materials & methods 
!
! !
2.2.3.C AGAROSE GEL ELECTROPHORESIS FOR INTEGRITY ANALYSIS 
For some experiments, 1% agarose gel electrophoresis was performed with 300 ng 
RNA. Prior to pouring the agarose into the horizontal gel box, ethidium bromide (EtBr) 
was added to a final concentration of 0.5 mg/mL. The samples were electrophoresed at 
100 V for 30 min. Bands corresponding to 28S and 18S rRNA were visually assessed 
for RNA integrity. The 28S band should be ~2 times brighter than the 18S band, and 
minimal degradation should be observed on the gel. 
 
2.2.3.D AGILENT RNA 6000 NANO KIT FOR INTEGRITY ANALYSIS 
For whole-transcriptome sequencing, RNA integrity was determined using the Agilent® 
2100 Bioanalyzer according to the RNA 6000 Nano Kit protocol. High quality RNA 
should have an RNA Integrity Number (RIN) > 8.  
 
2.2.4 POLYMERASE CHAIN REACTION (PCR) 
2.2.4.A BISULFITE PCR 
PCR was performed using diluted cDNA and indicated primers (Table 2.3). Fragments 
were amplified in a 25 µL reaction volume with Platinum® Taq DNA Polymerase using 
standard PCR conditions (1x PCR Buffer, 0.5 µL 10 mM dNTP mix, 0.5 µL 10 µM of 
each primer, 0.75 µL 50 mM MgCl2 and 0.1 µL Platinum® Taq DNA Polymerase). A 
“touchdown” PCR program was used, which occurred in two phases. The first phase 
used an initial annealing temperature that was ~5°C above the highest primer melting 
temperature and decreased by 1°C for each successive cycle to 5°C below the lowest 
primer melting temperature: 95°C for 2 min,  (Tm + 5°C - Tm - 5°C) cycles at 95°C for 
30 sec, Tm + 5°C to Tm - 5°C for 30 sec, 72°C for 15-30 sec. The second phase 
implemented standard PCR conditions: 25-40 cycles at 95°C for 30 sec, the lowest 
annealing temperature for 30 sec, 72°C for 15-30 sec, followed by a final extension at 
72°C for 5 min. All PCR products were validated by agarose gel electrophoresis and 
purified using either the QiaQuick Gel Extraction Kit or the MinElute PCR Purification 
Kit according to the manufacturer’s instructions. 
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Table 2.3. Bisulfite PCR primers and experimental conditions. 
Name Sequence Gene Primer Type 
A.Luc1 FWD CTTTAAAAAACCTCCCACACCT 
Non-humanised R-Luc 
in vitro transcript 
Forward 
A.Luc2 REV TGATGAAATGGGAAAATATAT Reverse 
A.Luc4 FWD CATTATAATTCCTAACAATTT Forward 
A.Luc4 REV GAAGAAGGAGAAAAAATGGTT Reverse 
CAGE1PG_BS_F CCACAATACTCACATAATC  
CAGE1 (intron) 
Forward 
CAGE1PG_BS_R GAAATTTTGAGGATAGAGAG Reverse 
CINP endogenous FWD CTCTAACCAAAAAACCCCAA 
CINP 
Forward 
CINP endogenous REV TATGTGGAGAGTGATAGTAGG Reverse 
FTSJ3_BS_F CACCAAAATTTTATTCTCCA 
FTSJ3 
Forward 
FTSJ3_BS_R AAAGGTTGAAGGTTATGTTG Reverse 
MCFD2_BS_F3 CCACCAACAACTTACACCAT 
MCFD2 
Forward 
MCFD2_BS_R3 GGGGTTATAGGGTTTATGTAAG Reverse 
NAPRT1 endo FWD 
 
ACCACTCCTCCACACACTATA 
NAPRT1 
Forward 
NAPRT1 endo REV 
 
TGGTGAGGGTTTTGGGGTGGA Reverse 
NDUFB7 WT FWD 
 
CTCCCACTCAAACTCCTTCAT 
NDUFB7 
Forward 
NDUFB7 WT REV 
 
AAGGAGTGTGAGATGGTGG Reverse 
NEK7_BS_F2 CATCAAAAAACACACTAAAC 
NEK7 
Forward 
NEK7_BS_R2 GTTGGGATGTTTATATTTTTG Reverse 
NSUN5P2_BS_F2 CTACTACCTACAATAAAAACC 
NSUN5P2 
Forward 
NSUN5P2_BS_F2 GTAAAAAGTTGTAGTTGGTG Reverse 
OSBPL8_BS_F CCCATACAAAACTCCCAAAA 
OSBPL8 
Forward 
OSBPL8_BS_R GTGGATTTTGGGGTTGAAAG Reverse 
PLD3_BS_F CCAAACTACTATACACACCAA 
PLD3 
Forward 
PLD3_BS_R TTGTGGGTTTTGGAGTTTTG Reverse 
PWP2_BS_F2 CCAAATAACAAAACACTTC 
PWP2 
Forward 
PWP2_BS_R2 GTTTGAGTTGGATATTAGTG Reverse 
RPPH1 endogenous FWD  
 
CCATTAAACTCACTTCACT 
RPPH1 
Forward 
RPPH1 endogenous REV  
 
TGAGTTTTGGGGAGGTGAGTT Reverse 
RPS3_BS_F CCACAATACTCACATAATC 
RPS3 
Forward 
RPS3_BS_R GAAATTTTGAGGATAGAGGG Reverse 
RTN3_BS_F2 CAACAATACACAACAATTACAA 
RTN3 
Forward 
RTN3_BS_R2 GGGAGTTAGTAGGTATGTTG Reverse 
SCARNA2_BS_F CAAAATCACCTCAATAATCA 
SCARNA2 
Forward 
SCARNA2_BS_R TTTTATTTGATTGGATTGTG Reverse 
SCO1_BS_FWD CTAAAAACTTCCAAAAAACAAAC 
SCO1 
Forward 
SCO1_BS_REV GAGTTTTGGGGTTTAGTTG Reverse 
SNORD62A_BS_F CTCTCAATCACTATCCTCTT SNORD62A Forward 
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SNORD62A_BS_R2 GATTTTTTTGATTTTTTATTGTGG Reverse 
SOX4_BS_F CCACACCTTATACAACAAAT 
SOX4 
Forward 
SOX4_BS_R TTGGTGTAGAAAAAGAGTTG Reverse 
SRRT_BS_F2 CCAACATAAAACATCTCATAAC 
SRRT 
Forward 
SRRT_BS_R2 GGATGATTGGAATGATAGAG Reverse 
SZRD1_BS_F CTCATCTATCCTAACAACTA 
SZRD1 
Forward 
SZRD1_BS_R TGTAAGAAAAAGTGTATGGG Reverse 
SZRD1CDS_BS_F CTACCATTCCCACAAAAAAC 
SZRD1 
Forward 
SZRD1CDS_BS_R GAGTAGTTGTGTGTATTTGG Reverse 
Asp tRNA for CTCCCCATCAAAAAATCAA 
tRNAAsp(GUC) 
Forward 
Asp tRNA rev TTTTTGTTAGTATAGTGGTG Reverse 
tRNAGluCTC_BS_F CCCTAACCAAAAATCAAAC 
tRNAGlu(CUC) 
Forward 
tRNAGluCTC_BS_R GTGGTTTAGTGGTTAGGATT Reverse 
tRNAGlyGCC_BS_F CATAAACCAAAAATCAAACCC 
tRNAGly(GCC) 
Forward 
tRNAGlyGCC_BS_R GTATGGGTGGTTTAGTGGTA Reverse 
Leu CAA endogenous F TATCAAAAATAAAATTCAAACCC 
tRNALeu(CAA) 
Forward 
Leu CAA endogenous R TTAGGATGGTTGAGTGGTT Reverse 
tRNAThrTGT_BS_F CCCCAACAAAAATTAAACTC 
tRNAThr(UGU) 
Forward 
tRNAThrTGT_BS_R GTTTTATAGTTTAGGGGTTA Reverse 
tRNAValAAC_BS_F CACCCAATTTCAAACCAC 
tRNAVal(AAC) 
Forward 
tRNAValAAC_BS_R GTTTTTGTAGTGTAGTGGTTA Reverse 
tRNAValCAC_BS_F TATTTCCACCCAAAATCAAA 
tRNAVal(CAC) 
Forward 
tRNAValCAC_BS_R GTTTTTGTAGTGTAGTGGTTA Reverse 
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2.2.4.B REAL TIME QUANTITATIVE PCR (RT-QPCR) FOR EXPRESSION 
ANALYSIS 
Specific forward and reverse primers were designed using Primer3 [235, 236] and were 
used with Fast SYBR® Green Master Mix for RT-qPCR (Table 2.4). Primers were 
designed such that they spanned exon-exon junctions to avoid amplification of genomic 
DNA. Each reaction was performed in triplicate using 2 µL diluted cDNA mixed with 8 
µL master mix (5 µL Fast SYBR® Green Master Mix, 0.5 µL of 5 µM of each primer 
and 2 µL dH2O). PCR amplification was performed in a 384-well plate format on the 
QuantStudio 12K Flex system (Life Technologies, Carlsbad, CA, USA). The reaction 
conditions were: initial denaturation at 95°C for 20 sec, 40 cycles of 95°C for 1 sec and 
the specific annealing temperature for 20 sec, followed by melt curve analysis. PCR 
products were run on a 2% agarose gel at 100 V for 30 min to confirm correct amplicon 
size.  
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Table 2.4. RT-qPCR primers and experimental conditions. 
Name Sequence Gene 
Annealing 
Temperature 
(°C) 
Primer 
Type 
ACTB_qPCR_F CTGGAACGGTGAAGGTGACA 
ACTB 60 
Forward 
ACTB_qPCR_R CTGGAACGGTGAAGGTGACA Reverse 
B2M_qPCR FWD ACTGAATTCACCCCCACTGA 
B2M 60 
Forward 
B2M_qPCR REV CCTCCATGATGCTGCTTACA Reverse 
NSUN2 real time FWD TGGAATAAACGTCAGCCAAA 
NSUN2 60 
Forward 
NSUN2 real time REV GGGCTCAGCTGTGTGCTT Reverse 
DNMT2 real time FWD TCCTAAAGAAATAGCAAATCTCCTTG 
TRDMT1 60 
Forward 
DNMT2 real time REV CGCTGTTTCACTGTTATCTTCTCA Reverse 
DNMT1 real time FWD CCCAAGTAACTGGGATTAGAGC 
DNMT1 60 
Forward 
DNMT1 real time REV GGTTTGCCTGGTGCTTTTC Reverse 
Fil Rluc QPCR FOR GGCGAGAAAATGGTGCTTGAG 
hRL 3xB 60 
Forward 
Fil Rluc QPCR REV TCCTTGAATGGCTCCAGGTAGG Reverse 
H2AFV_qPCR_F GAAGCATTACCTGCCAGCTC 
H2AFV 60 
Forward 
H2AFV_qPCR_R TTGAAGACTCGCACCACAAG Reverse 
HPRT real time FWD TGACACTGGCAAAACAATGCA 
HPRT 60 
Forward 
HPRT real time REV GGTCCTTTTCACCAGCAAGCT Reverse 
MCFD2_qPCR_F TCCATCATTGTTCTTGTCATCA 
MCFD2 60 
Forward 
MCFD2_qPCR_R ACAGCCATCACTCATGTCCA Reverse 
MRPL9_qPCR_F CACCTCACACCAATACTCGC 
MRPL9 60 
Forward 
MRPL9_qPCR_R AAATAGTTGCCCGCCACTTC Reverse 
NAPRT1_qPCR_F AACTGCAGCATGTCCATGAG 
NAPRT1 60 
Forward 
NAPRT1_qPCR_R GAATGAAGCTGACCGAGGAC Reverse 
NDUFB7_qPCR_F CCTTCATGCGCATCACATAG 
NDUFB7 60 
Forward 
NDUFB7_qPCR_R GTGACAGCTTCCCCAACTTC Reverse 
OSBPL8_qPCR_F2  ACTCCAAAGCATCCATCCAG 
OSBPL8 60 
Forward 
OSBPL8_qPCR_R2 GTGAAGGGTCCAAAAGGTGA Reverse 
RTN3_qPCR_F2 CCAGGTAGGCTTTGAATGGA 
RTN3 60 
Forward 
RTN3_qPCR_R2 TGGCAGCTTTCAGTGTCATC Reverse 
SDHA_qPCR_F CAGTGCCAACGTCCACATAG 
SDHA 60 
Forward 
SDHA_qPCR_R GCCAGGGAAGACTACAAGGT Reverse 
SZRD1_qPCR_F TCTTAGGGGTCTGCAGTGCT 
SZRD1 60 
Forward 
SZRD1_qPCR_R  AGCCTAGGCCTCTGAGGAAC Reverse 
TBP_qPCR_F AGCATCTCCAGCACACTCTT 
TBP 60 
Forward 
TBP_qPCR_R CCGGCTGTTTAACTTCGCTT Reverse 
TCF25_qPCR_F  CAAACGCAAAGAAGGAGAGG 
TCF25 60 
Forward 
TCF25_qPCR_R CAACGTGTGTACCCCAAGTG Reverse 
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2.2.4.C TAQMAN® NON-CODING RNA ASSAY 
For quantification of 18S rRNA using the TaqMan® non-coding RNA assay, each 
reaction was performed in triplicate using 2 µL cDNA with 8 µL master mix (5 µL 
TaqMan® Universal Master Mix, 0.5 µL Eukaryotic 18S rRNA Endogenous Control 
(VIC®) and 2 µL dH2O). PCR amplification was performed in a 384-well plate format 
on the ABI 7900HT Real-Time PCR System (Life Technologies, Carlsbad, CA, USA). 
The reaction conditions were: 50°C for 2 min, 95°C for 10 min, 40 cycles of 95°C for 3 
sec and 60°C for 1 min. 
 
2.2.5 PROTEIN TECHNIQUES 
2.2.5.A PROTEIN ISOLATION 
Cells grown in 6-well plates were washed with ice cold PBS. 300 µL Cytobuster™ 
Protein Extraction Agent was added to each well and incubated at room temperature for 
5 min. The cells were transferred to Eppendorf tubes and centrifugation performed at 
16,000 x g for 5 min at 4°C. The supernatant was transferred to a new tube and stored at 
-80°C. 
 
2.2.5.B PROTEIN QUANTIFICATION 
Protein was quantified using the Pierce™ BCA Protein Assay Kit according to the 
manufacturer’s protocol. Briefly, BSA protein standards (0-2000 µg/mL) were prepared 
in duplicate in a 96-well plate and 25 µL of protein sample of interest was added to the 
96-well plate in duplicate. 200 µL working reagent (50:1, Reagent A:B) was added to 
each standard and unknown sample, mixed and incubated with cover foil at 37°C for 30 
min. After cooling the plate down to room temperature, the absorbance was measured at 
562 nm on the FluoSTAR OPTIMA plate reader (BMG Labtech, Ortenberg, Germany). 
 
2.2.5.C SDS PAGE AND WESTERN BLOTTING 
A mixture of 1x LDS Sample Buffer and 2.8 µL 0.1 M DTT were added to 10 µg 
protein to a final volume of 28 µL. The protein sample was boiled for 2 min and chilled 
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on ice for another 2 min. The protein sample was loaded into NuPAGE® Novex® Bis-
Tris 4-12% gels and run at 180 V for 50 min. Proteins were transferred onto a PVDF 
membrane in 1x transfer buffer at 100 V for 1 h at 4°C. Protein transfer efficiency was 
observed using RedAlert™ western blot stain. The membrane was blocked in blocking 
buffer for 1 h at room temperature while rocking. The membrane was incubated with 
the primary antibody for either 1 h at room temperature or overnight at 4°C while 
rocking, then washed with 1x PBS-T three times over 30 min. The membrane was 
incubated with the secondary antibody in blocking buffer for 1 h at room temperature 
while rocking, then washed again in 1x PBS-T three times for 30 min. Enough ECL 
solution to cover the membrane was added and incubated in the dark for 5 min. 
Membranes were visualised using the ImageQuant LAS 4000 (GE Healthcare, Little 
Chalfort, BKM, UK). 
 
2.2.5.D DENSITOMETRY OF WESTERN BLOTS 
In order to determine the intensity of protein bands on western blots and quantify the 
relative amounts of protein, ImageJ software was used. Effort was made to ensure that 
protein bands were not saturated. TIFF image files from the ImageQuant LAS 4000 
were converted to greyscale by selecting the 8-bit image option. Equal sized rectangular 
selections were made for each band on the gel and the intensity of each band plotted 
using the “Plot lanes” function under the “Analyze” menu. To remove background 
noise, a straight line was drawn across the base of each peak, enclosing it. The wand 
tool was used to select each peak, providing intensity measurements. The intensity of 
each band was normalised to the intensity of the loading control. 
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2.2.6 SUCROSE DENSITY GRADIENT CENTRIFUGATION FOR 
POLYSOME ANALSYSIS 
2.2.6.A SUCROSE GRADIENT CONSTRUCTION 
17.5%, 25.6%, 33.8%, 41.9% and 50% sucrose solutions were prepared by dissolving 
the required amount of sucrose in sucrose gradient buffer. The sucrose was dissolved by 
placing the tubes on a rotator for 15 min followed by filtering through a 0.2 µm filter. 
Starting with the highest density sucrose, 2 mL was carefully laid at the bottom of a 14 
x 89 mm polyallomer centrifuge tube, and placed in a -80°C freezer for a minimum of 
15 min before applying the next layer. This process was repeated until all sucrose 
densities were layered. Sucrose gradients were stored at -80°C for several months. Prior 
to polysome analysis, sucrose gradients were thawed overnight at 4°C. 
 
2.2.6.B CELL LYSIS 
HeLa cells were plated in a 15 cm dish at a density of 7 x 106 cells. 24 h post-plating, 
the cells were treated with 0.1 mg/mL cycloheximide for 3 min at 37°C, placed on ice, 
and the media removed. The cells were washed twice in ice-cold PBS containing 0.1 
mg/mL cycloheximide and drained for 2 min. The cells were lysed in 800 µL lysis 
buffer, scraped into an Eppendorf tube and vortexed for 2 min at 4°C. The lysate was 
incubated on ice for 10 min followed by centrifugation at 16,000 x g at 4°C for 10 min. 
The cleared lysate was carefully layered on top of the thawed sucrose gradient and 
centrifuged at 35,000 rpm for 2 h and 15 min at 4°C using SW40Ti rotor (Beckman 
Coulter). 
 
2.2.6.C POLYSOME PROFILING AND FRACTION COLLECTION 
The fractionation was conducted bottom up while the absorbance profile at 260 nm was 
recorded, using the BR-188 Density Gradient Fractionation System (Brandel, 
Gaithersburg, MD, USA). Prior to fraction collection, the baseline was set using Milli-Q 
H2O. A 14 x 89 mm polyallomer centrifuge tube containing Milli-Q H2O was attached 
to a syringe and H2O was pushed through the system, with the baseline adjusted 
according to the manufacturer’s protocol. Once set, the centrifuge tube containing the 
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sample was gently attached to the apparatus and the needle pierced through the bottom 
of the tube. The chase solution used was 60% sucrose in Milli-Q H2O. The speed of the 
apparatus was set to 0.75 mL/min and fractions were collected every 37 seconds, 
resulting in 24 fractions. 
 
2.2.6.D PREPARATION OF POLYSOME FRACTIONS FOR RNA EXTRACTION 
Prior to RNA extraction, 1 ng of hRL 3xB plasmid, 2 µL glycogen and 3 volumes of 
EtOH were added to each of the fractions, followed by precipitating overnight at -80°C. 
The fractions were centrifuged at 16,000 x g for 20 min at 4°C. The supernatant was 
discarded and the pellet was carefully washed in 70% EtOH before spinning again at 
16,000 x g for 5 min at 4°C. After discarding the supernatant and air-drying the pellet, 1 
mL Tri Reagent® was added to the pellet and vortexed until dissolved. The sample was 
incubated for 5 min at room temperature to allow the nucleoprotein complexes to 
dissociate. Following this, the standard Tri Reagent® protocol was implemented for 
RNA extraction. 
 
2.2.7 CLONING AND SANGER SEQUENCING 
2.2.7.A PREPARATION OF E. COLI  DH5Α  FOR CLONING 
To prepare E. coli DH5α cell stock for bacterial transformation, a frozen scraping was 
added to 1 mL LB and incubated for 3 h at 37°C with shaking at 220 rpm. The 1 mL 
was then inoculated into 100 mL LB and incubated at 37°C with shaking at 220 rpm 
until bacteria reached log phase (OD600 ~0.4-0.5). Bacteria were chilled on ice for 10 
min and centrifuged at 3,000 rpm for 5 min at 4°C. The supernatant was removed and 
the pellet was gently resuspended in 30 mL ice cold TFB1 and chilled on ice overnight, 
followed by centrifugation at 3,000 rpm for 5 min at 4°C. The supernatant was removed 
and the cells were gently resuspended in 4 mL of ice cold TFB2, aliquoted into 
Eppendorf tubes (100 µL) and snap frozen immediately on dry ice. DH5α cell stocks 
were stored at -80°C until use. 
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2.2.7.B CLONING OF PCR PRODUCTS AND BACTERIAL TRANSFORMATION 
Approximately 50-200 ng purified PCR products were ligated to pGEM®-T Easy 
Vector according to the manufacturer’s protocol, followed by bacterial transformation. 
The ligation product from the pGEM®-T Easy Vector Cloning System was incubated 
with 45 µL competent E. coli DH5α cells on ice for 30 min. Cells were heat-shocked at 
42°C for 30 sec and placed on ice for 2 min. The cell/DNA solution was diluted with 
350 µL LB and incubated at 37°C at 220 rpm for 1 h. The entire solution was then 
spread onto LB agar plates containing 50 µg/mL X-Gal, 40 µg/mL IPTG and 100 
µg/mL ampicillin, and incubated overnight at 37°C. White colonies (X-Gal selection) 
were selected for further analysis. 
 
2.2.7.C PLASMID DNA EXTRACTION 
A single colony was picked and incubated in 5 mL LB containing 100 µg/mL ampicillin 
for 16 h at 37°C with shaking at 220 rpm. Plasmid DNA was isolated using the 
PureYield™ Plasmid Miniprep System according to the manufacturer’s protocol. 
Purified plasmid DNA was quantified using the NanoDrop and digested with EcoRI for 
2 h at 37°C to confirm ligation of insert. The digest was run on a 1% agarose gel at 100 
V for 30 min.  
 
2.2.7.D SANGER SEQUENCING OF PLASMIDS 
The purified plasmid DNA was submitted to either the Australian Cancer Research 
Foundation (ACRF) at the Garvan Institute of Medical Research in Sydney, or the 
Biomolecular Resource Facility (BRF) at the John Curtin School of Medical Research 
in Canberra for BigDye® Terminator Sequencing. Approximately 40 ng of plasmid 
DNA and 3.2 pmoles M13 reverse primer were submitted to ACRF. Approximately 100 
ng/µL plasmid DNA and 1.6 µM M13 reverse primer were submitted to BRF. Analysis 
of Sanger sequencing data was performed using the EMBL-EBI CLUSTALW2 
Multiple Sequence Alignment Program (EMBL-EBI, Cambridgeshire, UK). 
 
 74 
!
Materials & methods 
!
! !
2.2.8 NEXT-GENERATION SEQUENCING 
2.2.8.A TRANSCRIPTOME-WIDE BISULFITE SEQUENCING (BSRNA-SEQ) 
Preparation of RNA for bsRNA-seq 
For bsRNA-seq, RNA was extracted from cells using Tri Reagent® and genomic DNA 
was removed using TURBO™ DNase as previously described. RNA quality was then 
assessed on the Agilent® 2100 Bioanalyzer RNA 6000 Nano Chip. Following this, 40 
µg total RNA was depleted of rRNA using the RiboMinus™ Eukaryote Kit for RNA-
seq according to the manufacturer’s protocol and depletion assessed using the Agilent® 
2100 Bioanalyzer RNA 6000 Nano Chip. 2-2.5 µg of rRNA-depleted RNA was then 
subjected to bisulfite conversion as described above. To ensure efficient bisulfite 
conversion (>98.5%), an 50-300 ng bisulfite-converted RNA was reverse-transcribed 
followed by PCR amplification of sections of the R-Luc in vitro transcript and 
tRNAAsp(GUC), which were subjected to Sanger sequencing. To confirm fragmentation of 
RNA required for bsRNA-seq, RNA was analysed using the Agilent® 2100 Bioanalyzer 
RNA 6000 Nano Chip. 
 
End polishing of RNA 
To ensure ligation of 5’ SOLiD™ adaptors during the sequencing library preparation, 
the mRNA was de-capped; 500 ng of bisulfite-converted RNA was treated with 5 U 
Tobacco Acid Pyrophosphatase at 37°C for 1.5 h followed by phenol/chloroform 
extraction and overnight EtOH precipitation. The RNA was then resuspended in dH2O. 
To ensure ligation of 3’ SOLiD™ adaptors, 3’ phosphate groups that may exist after 
bisulfite conversion were removed by treating the RNA with 10 U T4 Polynucleotide 
Kinase and 1 mM dATP in 1x T4 Polynucleotide Kinase Buffer at 37°C for 1 h. The 
RNA was phenol/chloroform extracted as previously described, followed by overnight 
EtOH precipitation. The RNA was then resuspended in dH2O. 
 
Ligation of adapters to RNA 
Whole transcriptome libraries were prepared using the SOLiD™ Total RNA-Seq Kit. 
To prepare for the ligation of adaptors, 2 µL SOLiD™ Adaptor Mix and 3 µL 
Hybridisation Solution were incubated with 100 ng RNA at 65°C for 10 min and 16°C 
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for 5 min. Following this, 10 µL 2x Ligation Buffer and 2 µL Ligation Enzyme Mix 
were added to the hybridisation reaction, mixed and incubated in a thermal cycler with 
the lid off at 16°C for 16 h. 
 
Reverse transcription 
To reverse transcribe the adaptor bound RNA, 11 µL dH2O, 4 µL 10x RT buffer, 2 µL 
dNTP Mix and 2 µL SOLiD™ RT Primer were added to the ligation mix followed by 
mixing and incubating at 70°C for 5 min and snap cooling on ice for 1 min. 1 µL 
ArrayScript™ Reverse Transcriptase was added to the reaction, gently mixed and 
incubated in a thermal cycler at 42°C for 30 min. 
 
Size selection of cDNA 
After reverse transcription, 10 µL cDNA was run on a 10% Novex® TBE-urea gel in 1x 
TBE at 180 V for 45 min along with the 10 bp DNA ladder. The gel was stained with 1x 
SYBR® Gold Nucleic Acid Stain for 5 min, and visualised using medium wavelength 
UV light and photographed using the Typhoon™ FLA 9000 (GE Healthcare, Little 
Chalfort, BKM, UK). cDNA of size between 100-160 nt, corresponding to an insert size 
of 50-120 nt, were excised from the gel. The size-selected area for each sample was 
divided into four vertical strips and placed in individual 0.2 mL tubes. 
 
PCR amplification and purification of libraries 
For PCR amplification of the libraries, two vertical strips from the size selection gel per 
sample were placed into separate tubes and 76.8 µL dH2O, 10 µL 10x PCR Buffer, 8 µL 
dNTP Mix, 2 µL SOLiD™ 5’ PCR Primer and 1.2 µL AmpliTaq® DNA Polymerase 
were added to each tube. 2 µL of barcoded 3’ PCR Primers were added to each tube, 
with each tube having a separate index number. The reactions were then subjected to 
PCR using the following conditions: 95°C for 5 min, 18 cycles of 95°C for 30 sec, 62°C 
for 30 sec and 72°C for 30 sec, followed by a final extension at 72°C for 7 min. 
 
For PCR product purification, up to 20 µL of each sample was combined with 1x 
Novex® TBE-Urea Sample Buffer and separated on a polyacrylamide gel (5% stacking 
gel, 8% resolving gel, SequaGel- UreaGel System) in 1x TBE at 300 V for 37 min. The 
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gel was stained with 1x SYBR® Gold Nucleic Acid Stain for 5 min and visualised using 
medium wavelength UV light and photographed using the Typhoon™ FLA 9000. PCR 
products corresponding to ~200 nt were excised from the gel and placed in an 0.5 mL 
tube that had been pierced with a 19-G needle at the base. The 0.5 mL tube was placed 
in a 1.5 mL Eppendorf tube and subjected to centrifugation for 1 min at 13,000 rpm in 
order to fragment the gel. To elute the DNA from the gel, 700 µL 1x PAGE Elution 
Buffer was added to the fragmented gel and placed on a rotator at room temperature 
overnight. The gel/buffer mixture was centrifuged briefly and the liquid transferred to a 
tube containing a Costar® Spin-X® Plastic Centrifuge Tube Filter prior to centrifuging at 
13,000 rpm for 30 sec to remove any residual gel. The DNA was EtOH precipitated on 
dry ice for 1 h and centrifuged at 20,000 x g for 1 h at 4°C. The DNA was washed twice 
with 70% EtOH and after briefly air-drying, the sample was resuspended in 10 µL 
dH2O. To confirm size, concentration and purity, 1 µL purified DNA was run on a 
polyacrylamide gel as well as an Agilent High Sensitivity DNA Chip. The products 
were diluted to similar concentrations (600 pM) and prepared for sequencing using 
emulsion PCR (ePCR) on the SOLiD™ EZ Bead™ Emulsifier according to 
manufacturer’s instructions. The libraries were then sequenced using the SOLiD™ 5500 
XL platform (Life Technologies, Carlsbad, CA, USA). 
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Figure 2.1. Method for preparation of RNA for bsRNA-seq. 
Total RNA was depleted of rRNA using the RiboMinus™ Eukaryote Kit for RNA-Seq and the 
R-Luc in vitro transcripts were spiked in. The RNA was bisulfite converted and an aliquot 
reverse transcribed to inspect bisulfite conversion efficiency by Sanger sequencing. The 
bisulfite-converted RNA was end-polished using Tobacco Acid Pyrophosphatase and T4 
Polynucleotide Kinase before commencement of library preparation. 
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Figure 2.2. Whole-transcriptome library preparation method for bsRNA-seq. 
The SOLiD™ Total RNA-Seq Kit was used for preparation of bsRNA-seq libraries. Step 1: The 
RNA was hybridised and ligated to SOLiD™ adaptors. Step 2: The RNA was reverse transcribed 
using universal primers. Step 3: The cDNA was run on a 10% TBE-Urea gel and fragments 
between 100 and 160 nt were size selected and purified. Step 4: The purified cDNA library was 
enriched by PCR using universal 5’ primers and 3’ barcoded primers. Step 5: The enriched 
library was purified by running on polyacrylamide gel. Step 6: The yield and size distribution 
was assessed by running a polyacrylamide gel and an Agilent High Sensitivity DNA chip. Step 
7: Libraries were pooled and ePCR was performed on the SOLiD™ EZ Bead™. Picture 
modified from the SOLiD™ Total RNA-Seq manual.  
 
2.2.8.B SOLID™ BSRNA-SEQ ANALYSIS PIPELINE 
Global mapping of sequencing data 
Sequencing data was initially mapped to complete and non-CpG in silico bisulfite 
converted human Refseq transcriptomes, and any unmapped reads from this were 
mapped to complete and non-CpG in silico bisulfite converted hg19 reference genomes. 
The mapping was based on the method and implementation of the DNA methylation 
detection algorithm, B-SOLANA [237], but modified to be applicable at the RNA level. 
This was done by using Tophat [238], which enabled mapping of splice junction reads 
to the Refseq transcriptome in order to detect known transcript isoforms, followed by 
mapping to the reference genome. To ensure maximal specificity of candidate m5C 
sites, only uniquely mapped reads were retained. Uniquely mapped reads were defined 
by the Bowtie parameters --best and --strata, where only reads with a single 
best mapping are used (i.e. least number of mismatches). Additional parameters 
included  -n 3 -1 35 -e 200, where -n sets the limit for the number of 
mismatches in colour-space in the first -1 bases of the 50 nt SOLiD™ sequencing 
reads, and -e sets the limit for the sum of the Phred quality values at all mismatch 
positions in the 50 nt sequencing read. In general, bad quality reads have higher 
numbers of mismatches and as such were excluded from further analysis. 
 
Local mapping of sequencing data 
For local mapping of specific highly repetitive sequences, B-SOLANA was 
implemented as above but sequencing data was mapped to specific complete in silico 
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bisulfite converted reference sequences. To map mature tRNA sequences, sequencing 
reads were mapped to the full set of Rfam tRNA annotations in hg19 that matched the 
tRNA database (tRNAdb) (i.e. excluded mitochondrial tRNA sequences) with the in 
silico addition of non-templated CCA to the 3’ end. For tRNA sequences that are 
identical, only one single sequence was selected that was representative of the entire 
population. rRNA sequences were mapped to the rRNA tandem repeat sequences as 
follows: Human ribosomal DNA complete  repeating unit (18S rRNA, 5.8S rRNA, 28S 
rRNA, 5’ external transcribed spacer and internal transcribed spacers) and Human 5S 
DNA. The R-Luc in vitro transcript was mapped to the R-Luc reference sequences 
derived from the plasmid sequence.  
 
Calling of candidate m5C sites 
Proportion statistic: The primary statistic used for detection of candidate m5C sites was 
a proportion statistic ! = !!!!!! , where C is the number of unconverted cytosines and T is 
the number of converted cytosines. ! was used to add pseudocounts ( !!" counts in 
prostate and  !!  counts in HeLa) to prevent issues associated by division by zero. This 
was transformed to adapt standard RNA-seq expression analysis approaches to such 
proportion data. Firstly, the data was transformed into an approximate Gaussian 
distribution by an arc sin of square root transformation (!′ = !"#!! .!"#$%& !). [239], 
followed by a log transformation, as the arc sin transformed data was closer to a log-
normal distribution. 
 
Non-specific filtering: Non-specific (i.e. blinded to experimental/control labels) filtering 
to initially exclude candidate m5C sites that are lowly expressed was performed by 
requiring ≥5 reads across all samples used in the model. The HeLa methyltransferase 
knockdown dataset and prostate dataset were processed separately. For differential 
methylation, filtering of low methylation sites across controls whilst allowing low 
methylation in the experimental samples (knockdown for HeLa methyltransferase 
knockdown dataset or differential methylation for prostate dataset) was performed. At 
least three samples in the HeLa dataset required ≥1% methylation (p < 0.05; binomial 
test) and at least two samples in the prostate dataset required ≥5% methylation. For 
 81 
!
Materials & methods 
!
! !
calling of methylation sites in HeLa cells or commonly methylated sites in PrEC and 
LNCaP cells, all samples required >0% methylation. 
 
Statistical model: A weighted moderated linear model based on p’ was used for 
differential methylation estimation using Limma [240]. The moderated t-test uses 
information across methylation sites to improve the variance estimate of the datasets. 
The weights incorporated count noise estimated by quadratic fit of variance versus total 
read counts over each site, using the Voom method [240]. A two-sample t-test was 
implemented to detect candidate differential m5C sites (i.e. knockdown vs. control and 
cancer vs. normal) and a one-sample t-test against a 0% methylation level for calling of 
candidate m5C sites. 
 
Differential m5C site calling: A balanced design with NSUN2 and TRDMT1 
knockdown sets against the non-targeting control (NTC) and DNMT1 knockdown 
samples was initially used to detect individual sites controlled by both NSUN2 and 
TRDMT1. As no such sites were detected, it was assumed that most sites were 
controlled by either NSUN2 or TRDMT1 exclusively, and to increase power, an 
unbalanced design was implemented; for example, NSUN2 versus TRDMT1, DNMT1 
and NTC as controls. Therefore, the experimental design was unbalanced with a single 
“experimental” sample and effectively three control “biological replicates”. Although 
the NTC sample is the only true unmanipulated control, knockdown of DNMT1 should 
have minimal effect on RNA methylation being a DNA methyltransferase and as 
mentioned, TRDMT1 is responsible for a different subset of sites to NSUN2, so could 
be used as a control relative to NSUN2. This was also the case for the opposite, where 
NSUN2, DNMT1 and NTC behaved as controls for detecting TRDMT1-regulated sites.  
For the prostate dataset, a balanced design of two LNCaP and two PrEC samples were 
used. The false discovery rate (FDR) was estimated by the Benjamini-Hochberg 
method, using a cut-off of 30% for the HeLa cell dataset, and 40% for the prostate cell 
datasets. 
 
Overall m5C site calling: To call candidate m5C sites across all samples, a one-sample 
moderated t-test was used, comparing a “control” set against a constant zero 
methylation. The control set used for the HeLa methyltransferase knockdown dataset 
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included TRDMT1, DNMT1 and NTC samples for sites detected as NSUN2-regulated 
or potentially other RNA methyltransferases, and NSUN2, DNMT1 and NTC for sites 
detected as TRDMT1-regulated or potentially other RNA methyltransferases. For the 
prostate dataset, all samples were compared against a 0% methylation level. The FDR 
was estimated by Adaptive Benjamini-Hochberg using a cut-off of 1%. 
 
Post-filtering: Post-filtering was performed to exclude potential candidate m5C sites 
overlapping known single nucleotide polymorphisms (SNPs) and editing sites. 
Candidate m5C sites were required to be homogeneous (C + T ≥ 95%) to exclude calls 
in bases of high read error rate or unannotated SNPs. Candidate m5C sites overlapping 
dbSNP 137 (all SNPs) or the DARNED editing database were excluded. Differential 
somatic mutations, non-canonical editing sites and unannotated SNPs were detected 
using RNA-seq data. For the prostate dataset, RNA-seq data was provided by Professor 
Susan Clark’s lab at the Garvan Institute of Medical Research. For the HeLa 
methyltransferase knockdown dataset, HeLa ENCODE RNA-seq data (Caltech HeLa 
S3 1x75) was used. Bases that did not match the reference (<90% of reads) were 
excluded. Finally, candidate m5C sites that exhibited <10% mean methylation across all 
control samples were removed. 
 
2.2.8.C FUNCTIONAL GENOMIC ANALYSES FOR M5C IN RNA 
Analysis of m5C prior to end processing of tRNAs 
Sequencing reads from globally mapped tRNAs that had ≥1 candidate m5C site from the 
HeLa NTC library were separated into two subsets; those showing ≥1 T-to-C 
mismatches and those with no mismatches. All other sequencing reads were discarded. 
Mean coverage plots were generated across the 5’ and 3’ ends of tRNAs that contained 
candidate m5C sites based on bsRNA-seq. 
 
Location bias analysis of m5C in mRNA 
Location bias analysis of candidate m5C sites across the 5’ UTR, CDS and 3’ UTR was 
performed using binomial tests by determining the total number of candidate m5C sites 
detected in each region relative to the proportion of total potential m5C sites (for 
cytosines ≥5 reads) within each genomic region. 
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Motif enrichment analysis of m5C sites  
CMFinder [241] was used to find de novo enriched structural motifs over 100 nt 
flanking regions around subsets of candidate m5C sites in mRNAs (3’ UTR and CDS). 
CMFinder is a RNA motif prediction tool for unaligned sequences. It is an expectation 
maximisation algorithm that uses covariance models for motif description, integrating 
multiple techniques to effectively search motif space and a Bayesian framework to 
predict secondary structures. Structures were selected based on the following criteria: 1) 
significant enrichment, 2) substantial coverage of candidate m5C sites (>30% of 
candidate m5C sites showed the structure), 3) the distribution of candidate m5C sites 
localised on or surrounding the structural motif. The R script for the generation of 
structural motifs is provided in Appendix 8.2. 
 
Sequence logos were generated over subsets of candidate m5C sites in mRNAs using 
the seqLogo R package [242] and using the genomic coordinates of the candidate m5C 
sites. For the generation of sequencing logos, the nucleotides at each position were 
scaled according to their frequency and the entire stack of nucleotides at a given 
position is represented as the information content. As the nucleotides did not have equal 
probability of being in a certain position, a formula based on the uncertainty measure 
was used, developed by Claude Shannon [243]. The uncertainty measure is defined as !! = ! !, ! !"#!!!!!! !(!, !), where !! is the uncertainty at position i, b is one of the 
four bases, and !(!, !) is the frequency of bases at position i. The total information at a 
certain position is represented by the decrease in uncertainty as the m5C site is aligned 
using !!"#$"%&!(!) = 2− (!! + !!), where !!"#$"%&"(!) is the amount of information 
present at position i, 2 is the maximum uncertainty at a given position and !! is a 
correction factor that is required if there are a small number of samples. The size of 
each base within the logo was determined by multiplying the frequency of each base by 
the information content using ! !, ! !!"#$"%&"(!).  
 
Analysis of steady-state levels of NSUN2-targeted mRNAs 
The expression levels in counts per million (CPM) of the set of mRNAs exhibiting 
candidate m5C sites called as NSUN2 targets were compared with the set of all mRNAs 
showing no candidate m5C sites. The log fold-change was determined between the 
 84 
!
Materials & methods 
!
! !
NSUN2 knockdown samples and control samples (NTC and TRDMT1) by differential 
expression analysis using Limma: 
 !"#!!"!!"#!! −!"#$(!"#!!"!!"#$!!, !"#!!"!!"#) 
 
The significance of the expression fold-change difference between the NSUN2-targeted 
mRNAs and unmethylated mRNAs was determined by the Wilcoxon test. The DNMT1 
knockdown sample was removed from the analysis on the basis of its known effect on 
gene expression levels. 
 
Analysis of the relationship of m5C with Ago2 
bsRNA-seq data was integrated with publicly available HeLa Ago2 HITS-CLIP dataset 
from [233] and HuR PAR-CLIP dataset from [244]. Spatial distribution summary plots 
were generated by anchoring at candidate m5C sites in mRNAs within the CDS or 3’ 
UTR with 500 nt flanking regions showing Ago2 HITS-CLIP or HuR PAR-CLIP 
footprint density. The introns were computationally removed for the generation of 
spatial distribution plots. For the random shuffled control, candidate m5C sites were 
assigned to random positions within each genomic region. The significance of Ago2 
footprints relative to the random shuffled control was determined using a permutation 
test with 10 iterations. 
 
Analysis of the relationship of m5C with conserved miRNA target sites 
Genome-wide 7-mer motifs that showed a phyloP [245] conservation score > 1.3 
(across 46-way vertebrate species) were divided into two sets based on whether they 
were the reverse complement of miRNA seed regions in miRBase v19. Spatial 
distribution summary plots were generated by anchoring at the candidate m5C site 
within the CDS or 3’ UTR, with a 200 nt flank, showing the density of conserved 
miRNA target sites. The introns were computationally removed for the generation of 
spatial distribution plots. As controls, the density of 7-mer motifs that were not the 
reverse complement of miRNA seed regions in miRBase v19, and density of conserved 
miRNA target sites for unmethylated cytosines were also plotted. For the random 
shuffled control, candidate m5C sites were assigned to random positions within each 
genomic region. The significance of the density of miRNA target regions relative to the 
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random shuffled control was determined using a permutation test with 10 iterations. 
 
Gene set enrichment and GO analyses 
Gene set enrichment (GSEA) and GO analyses were performed using gage [246] and 
topGO [247] R packages, respectively. The analyses of the genes from the list of 
candidate m5C sites in HeLa cells and candidate m5C sites called as NSUN2 or 
TRDMT1 targets were performed relative to the genes showing expression in the 
bsRNA-seq data. Genes showing expression were defined as having ≥5 reads in at least 
one cytosine in the gene.  
 
2.2.8.D TRUSEQ AMPLICON SEQUENCING USING ILLUMINA® MISEQ 
Bisulfite PCR and preparation of amplicons for MiSeq 
For amplicon sequencing of bisulfite converted RNA using the MiSeq platform 
(Illumina, San Diego, CA, USA), touchdown PCR was performed using Platinum® Taq 
DNA polymerase and annealing temperatures specific to the primers (see section 
2.2.4.A). PCR for each primer set was performed in triplicate and run on a 1-2% 
agarose gel to confirm amplification. Triplicates were pooled and purified using the 
Wizard SV Gel and PCR Clean-Up System according to the manufacturer’s protocol. 
Amplicons were then quantified using the Qubit dsDNA BR Assay Kit according to the 
manufacturer’s protocol. 30 ng of each purified amplicon for each sample was pooled 
and concentrated, then made up to 55 µL with dH2O. The pooled amplicons will be 
referred to as DNA in the following methods. Amplicon sequencing library preparation 
was performed according to the TruSeq DNA LT Sample Prep Kit protocol with some 
modifications, as described below.  
 
End Repair 
10 µL End Repair Control and 40 µL End Repair Mix were added to 50 µL of DNA and 
the mixture and gently mixed. The reaction mix was incubated for 30°C for 30 min. 
Following end repair, the reaction mix was purified using either the MinElute PCR 
Purification Kit (amplicons <100 nt) according to the manufacturer’s instructions, or 
AMPure XP beads (amplicons >100 nt). For purification using AMPure XP beads, 136 
µL of beads was diluted in 24 µL dH2O, and 160 µL added to the reaction mixture and 
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incubated for 15 min at room temperature. The tubes containing the mixture were 
placed on a magnetic rack for 5 min and the supernatant removed. The beads were 
washed twice with 200 µL 80% EtOH and allowed to air dry for 15 min at room 
temperature. The beads were resuspended in 17.5 µL Resuspension Buffer and 
incubated at room temperature for 2 min. The sample was then placed on a magnetic 
rack for 5 min and 15 µL of the liquid transferred to a new tube. 
 
A-tailing and ligation of adaptors  
2.5 µL A-tailing Control and 12.5 µL A-tailing Mix were mixed with 15 µL DNA and 
incubated at 37°C for 30 min. For ligation of the adaptors, 2.5 µL Ligation Control, 2.5 
µL Ligation Mix and 2.5 µL DNA Adaptor Index were added to the DNA, mixed and 
centrifuged at 280 x g for 1 min followed by incubating at 30°C for 15 min. As multiple 
libraries were being sequenced simultaneously, indexed adaptors were used. 5 µL Stop 
Ligation Buffer was then added to the reaction mix. The reaction was purified using 
42.5 µL undiluted AMPure XP beads as described previously, resuspended in 52.5 µL 
Resuspension Buffer and 50 µL of the reaction mix was transferred to a new tube. The 
purified reaction mix was purified again using 50 µL undiluted AMPure XP beads, 
resuspended in 22.5 µL Resuspension Buffer and 20 µL of the purified sample was 
transferred to a new tube. 
 
PCR amplification to enrich libraries 
25 µL PCR master mix and 5 µL PCR Primer Cocktail were added to 20 µL of DNA 
and mixed. The reaction mixture was then placed in a thermal cycler with the following 
reaction conditions: 98°C for 30 sec, 10 cycles of 98°C for 30 sec, 60°C for 30 sec and 
72°C for 30 sec, followed by a final extension at 72°C for 5 min. The PCR reaction was 
purified using 50 µL undiluted AMPure XP beads, resuspended in 32.5 µL 
Resuspension Buffer and 30 µL of the purified PCR reaction was transferred to a new 
tube. The sample was stored at -20°C. 
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Quality control and quantification of libraries 
To determine the average size of the libraries, 1 µL of each library was run on a 2% 
agarose gel at 100 V for 40 min. In addition, 2 µL of the pooled amplicons for each 
sample prior to library preparation were run on the same gel. 
 
For accurate quantification of the amplicon libraries, samples were quantified using the 
Qubit dsDNA BR Assay Kit. Following dilution to ~50 nM after determining the 
average library size, the libraries were quantified either by qPCR using the Illumina® 
Library Quantification Kit or a DNA High Sensitivity DNA chip on the Agilent 
Bioanalyzer, according to the manufacturers’ protocols. 
 
Sample sheet preparation and loading of the libraries into the cartridge 
The workflow selected for each MiSeq run on the sample sheet was “Fastq only”. This 
generated fastq files only and also enabled the deselection of adaptor trimming, 
allowing trimming and mapping to be performed separately.  
 
The libraries were diluted and pooled prior to loading into the cartridge according to the 
concentrations obtained from the qPCR or the DNA High Sensitivity DNA chip. 
Libraries were diluted to 10 nM in buffer EBT and 10 µL of each library was pooled 
together, followed by a further dilution to 2 nM in EBT. At this point, the pooled 
libraries were either denatured and diluted further, or submitted to the BRF for this 
process. In either case, the pooled libraries and PhiX control were denatured separately 
at 1 nM with 0.1 M NaOH for 5 min at room temperature. Following further dilutions to 
20 pM and 7-9 pM in HT1, the PhiX control was spiked into the pooled libraries to a 
final concentration of 10%. Air bubbles were removed from the thawed cartridge, and 
600 µL of the final sample was loaded into the cartridge. The sequencing run selected 
was 2 x 150 bp. 
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Figure 2.3. TruSeq DNA LT sample preparation method.  
The TruSeq DNA LT Sample Prep Kit was used for preparing libraries. Step 1: Bisulfite-
converted RNA was initially reverse transcribed using Superscript® III Reverse Transcriptase. 
Step 2: Specific amplicons were amplified in triplicate using Platinum® Taq DNA Polymerase. 
Step 3: Amplicons were purified and pooled for each sample. Step 4: The pooled amplicons 
were end repaired. Step 5: The pooled amplicons were A-tailed. Step 6: Indexed adaptors were 
ligated to the ends of the pooled amplicons. Step 7: The libraries were enriched by PCR and 
validated and quantified before sequencing on the Illumina® MiSeq platform. 
1) Reverse transcription of bisulfite-converted RNA
2) PCR amplification
Validation of library and 150 bp paired-end 
sequencing of amplicons
3) Purification & pooling of amplicons
4) End repair (blunt ends)
5) Add A-tail to 3’ ends
AAAA
AAAA
6) Ligate indexed adaptors
7) Enrich & linearise with PCR
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2.2.8.E TRUSEQ AMPLICON SEQUENCING ANALYSIS PIPELINE 
Trimming of adaptors and poor quality ends of reads 
Illumina® adaptor sequences that were ligated to the ends of amplicons to facilitate 
sequencing were first trimmed from the 150 bp paired-end reads by Trimmomatic [248] 
in palindromic mode (i.e. adaptor trimming 5’ and 3’ ends simultaneously), allowing 
single base precision. Bases at the 5’ end that were below the Phred quality score of 3 
and bases at the 3’ end that were below the Phred quality score of 15 were removed. If 
any four base window within the read had a Phred quality score of <15, then the rest of 
the read was trimmed. The parameters for adaptor trimming were: 
 
java -Xms16g -Xmx16g –classpath /home/bparker/bin/Trimmomatic-
0.32/trimmomatic-0.32.jar org.usadellab.trimmomatic.TrimmomaticPE -
phred33 ILLUMINACLIP:illuminaClipping.fa:4:30:10:1:true LEADING:3 
TRAILING:15 SLIDINGWINDOW:4:15 MINLEN:36 
 
Aligning of data 
Sequencing reads were aligned to the reference sequence with Bismark, using Bowtie2 
internally and implementing the parameters bismark --non_directional --
bowtie2 [249]. The reference sequence used to align the sequencing reads 
corresponded to the segment of RNA interrogated prior to bisulfite conversion. A single 
mismatch was allowed in the alignment, and candidate m5C sites in overlapped paired-
end reads were only counted once. The number of C and T calls at all C positions was 
extracted from the aligned sequencing reads in order to determine the proportion of 
m5C. 
 
2.2.8.F GENERATING COVERAGE PLOTS AND HEATMAPS 
Coverage plots were generated using the plot function in R Studio. The coverage for 
each transcript was normalised to the library size to convert to reads per million (RPM) 
before being plotted on a log scale in R Studio. 
 
Heatmaps were generated using the heatmap function in the gplots package in R. 
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3.1 INTRODUCTION 
Prior to the availability of next-generation sequencing technologies, detection of 
nucleoside modifications in RNA relied on laborious techniques, either through 
metabolic or radioactive labelling, followed by hydrolysis and identification of 
modified nucleosides through chromatographic separation [50, 51, 59]. These 
techniques lacked sensitivity, and detection using these methods did not reveal the 
identity of transcripts or location of the modification. Now with the availability of next-
generation sequencing platforms, detection of modified nucleosides and transcriptome-
wide mapping of their positions is increasingly possible.  
 
Several techniques that aid in the detection of modified nucleosides in RNA have come 
to the fore in the last six years. Recently, for the detection of m6A in RNA, studies have 
coupled m6A immunoprecipitation with next-generation sequencing, revealing its 
presence in a wide variety of transcript biotypes [56, 57]. Although this technique did 
not provide single nucleotide resolution, these studies have increased our understanding 
of the abundance of m6A and follow-up studies are currently being conducted in order 
to understand the molecular function of this modification in more detail. For the 
detection of m5C in RNA, the bisulfite sequencing technique that is the gold standard 
for the detection of DNA methylation has been adapted for use in RNA. Schaefer et al. 
adapted a commercial DNA bisulfite conversion kit for use on RNA, which was 
coupled with next-generation sequencing of PCR amplicons, focusing on m5C in tRNAs 
and rRNAs [59]. Recently, we performed the first transcriptome-wide detection of m5C 
in HeLa cells, coupling bisulfite conversion of RNA with transcriptome-wide 
sequencing, termed bsRNA-seq [58]. This revealed thousands of candidate m5C sites in 
a wide variety of transcript biotypes at single nucleotide resolution, many of which were 
validated by Sanger bisulfite sequencing.  
 
The overall aim of this chapter was to prepare cells for bsRNA-seq for the detection of 
m5C in RNA and to establish and improve methods for the detection of m5C in RNA. 
This involved RNAi-mediated knockdown of the NSUN2 and TRDMT1 
methyltransferases (plus controls) in HeLa cells and the passaging of normal prostate 
epithelial cells (PrEC) and lymph node metastatic prostate cancer cells (LNCaP) cells. 
RNA extracted from these cells was then subjected to bisulfite conversion and library 
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preparation for bsRNA-seq. bsRNA-seq was performed on the SOLiD™ 5500XL 
platform and a bioinformatics pipeline modified from our previous study was used for 
the detection of candidate m5C sites [58]. For subsequent validation of candidate m5C 
sites, a high-throughput method was developed using the Illumina® MiSeq platform as a 
replacement for Sanger bisulfite sequencing.  
 
3.2 RESULTS 
In addressing the aims of this thesis, the following biological samples were prepared. 
 
To perform an initial screen to understand the substrate range of NSUN2 and TRDMT1 
and to explore the molecular functions of m5C in mRNA, RNAi-mediated knockdown 
of NSUN2 and TRDMT1 in HeLa cells was coupled with bsRNA-seq. The results of this 
approach will be addressed in Chapters 4 and 5. Non-targeting control (NTC) siRNAs 
were further transfected and the DNA methyltransferase DNMT1 was also knocked 
down to serve as a control. Dr. Jeffrey E. Squires performed the RNAi-mediated 
knockdown in HeLa cells (one sample each), confirmation of knockdown and bisulfite 
conversion, and the preparation of the bsRNA-seq libraries for these samples. Dr. 
Natalie J. Beveridge prepared three additional biological replicates of the RNAi-
mediated knockdown of NSUN2, TRDMT1 and DNMT1 and transfection of NTC 
siRNAs, which I used for subsequent validation of candidate m5C sites.  
 
To compare the RNA m5C profiles of normal and cancer cells, I cultured and processed 
two biological replicate samples of each PrEC and LNCaP cells for bsRNA-seq, 
including confirmation of bisulfite conversion and bsRNA-seq library preparation for 
these samples. The same samples were also used for the validation of candidate m5C 
sites. I also performed transfection of NSUN2 siRNAs and NTC siRNAs into LNCaP 
cells for validation of candidate m5C sites, which will be addressed in more detail in 
Chapter 6. 
 
Dr. David T. Humphreys performed the emulsion PCR (ePCR) and prepared the 
sequencing runs for all bsRNA-seq runs and Dr. Brian J. Parker performed the mapping 
of all sequencing data and detection of candidate m5C sites. All m5C sites detected by 
bsRNA-seq in this study will be referred to as “candidate m5C sites”. 
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3.2.1 PREPARATION OF CELL LINES AND RNA FOR 
BSRNA-SEQ 
3.2.1.A PREPARATION OF CELLS AND RNAI-MEDIATED KNOCKDOWN OF 
NSUN2, TRDMT1 AND DNMT1 
For the preparation of PrEC and LNCaP cells, cells were thawed and passaged twice to 
ensure complete recovery from the thawing process prior to extracting RNA using Tri 
Reagent®. Cells were ~70% confluent prior to harvesting and two separate batches of 
PrEC and LNCaP cells were passaged at different times to serve as biological replicates.  
 
Similarly, HeLa cells were thawed and passaged twice prior to transfection. RNAi-
mediated knockdown of the RNA methyltransferases in HeLa cells was performed 
using siGENOME SMARTpool siRNAs, which contain pools of four siRNAs targeting 
various regions of the target transcript. The siRNAs used in this study included those 
targeted against NSUN2, TRDMT1, DNMT1, as well as a pool of four non-targeting 
control (NTC) siRNAs. For RNAi-mediated knockdown, a reverse-transfection protocol 
was employed, where the seeding of HeLa cells and transfection of cells were 
performed simultaneously. RNAi-mediated knockdown was performed over a 6-day 
period, which involved reverse-transfection of the cells, followed by the splitting of 
cells and an additional reverse-transfection 3 days after the initial transfection. 
Optimisation of the knockdown had been performed previously in our lab over 3, 4, 5 
and 6 days and the depletion of methylation was investigated. Substantial depletion of 
m5C in tRNAs was only observed after 6 days, due to the long half-lives of these 
transcripts (data not shown). 
 
The cells were viable after 6 days of knockdown, although slower growth was evident 
in all knockdown samples. Knockdown of each methyltransferase was confirmed by 
RT-qPCR, which indicated more than 80% knockdown of NSUN2 and TRDMT1, and 
~60% knockdown of DNMT1 (Figure 3.1). Depletion of the methyltransferases on the 
protein level could not be examined with these samples for bsRNA-seq, due to failure 
of the antibodies available at the time. Importantly, assessment of the depletion of 
methylation at the known m5C sites targeted by NSUN2 and TRDMT1 in tRNAAsp(GUC) 
and tRNALeu(CAA) was made after bisulfite conversion of the RNA. Depletion of 
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methylation at the NSUN2 and TRDMT1 target sites indicates effective functional 
depletion of the enzymes (see section 3.2.1.C).  
 
 
Figure 3.1. Confirmation of methyltransferase knockdown in HeLa cells by RT-qPCR. 
Data has been normalised to HPRT and is relative to NTC (n=1). 
 
3.2.1.B BISULFITE CONVERSION OF RNA 
The RNA extracted from HeLa, PrEC and LNCaP cells was treated with TURBO™ 
DNase and depleted of rRNA using the RiboMinus™ Eukaryote Kit for RNA-Seq prior 
to bisulfite conversion. Depletion of rRNA prior to next-generation sequencing was 
necessary as its abundance results in biased sequencing reads towards rRNA, 
overshadowing sequencing reads towards more informative parts of the transcriptome 
such as mRNA. Depletion of rRNA was confirmed by a RNA 6000 Nano Chip, which 
showed almost complete depletion of 18S and 28S rRNA peaks in all samples, with 
only a peak at ~100 nt (migration time of 26-27 sec) evident, representing small 
transcripts including tRNAs (Figure 3.2A and B). However, this peak may also include 
small amounts of degraded rRNA that may not have been removed efficiently. mRNA 
is not visible on a RNA 6000 Nano Chip chromatogram of total RNA. Depletion of 18S 
rRNA in PrEC and LNCaP cells was confirmed by RT-qPCR, with >98% depletion 
observed (Figure 3.2 D).  
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Figure 3.2. Assessment of rRNA depletion by the RNA 6000 Nano Chip and RT-qPCR. 
A) Agilent Bioanalyzer trace of DNase-treated RNA from HeLa, PrEC and LNCaP samples 
prior to rRNA depletion. The 18S and 28S bands are indicated. B) Agilent Bioanalyzer trace of 
HeLa, PrEC and LNCaP samples after rRNA depletion. The majority of 18S and 28S rRNA 
have been depleted. C) The sizes of the ladder corresponding to the same migration time as the 
samples are also indicated. D) RT-qPCR to assess depletion of 18S rRNA in the first replicate 
of PrEC and LNCaP cells after rRNA depletion. 18S rRNA levels are relative to ACTB. 
KD=knockdown. 
 
Following confirmation of rRNA depletion, 2-2.5 µg RNA was denatured and bisulfite 
converted. Bisulfite conversion takes advantage of the differential chemical reactivity of 
m
5C compared to unmethylated cytosines; unmethylated cytosines are deaminated to 
uracil while m5C remains as a cytosine (Figure 3.3). One of the challenges associated 
with bisulfite conversion is the propensity of cytosines located within highly structured 
regions of RNA to remain unconverted and therefore appear as clusters of non-
converted cytosines. We have previously detected clusters of non-converted cytosines in 
both cytoplasmic and mitochondrial large subunit rRNAs, which are among the most 
highly structured RNAs [58]. To ensure efficient bisulfite conversion of cytosines, the 
RNA was denatured. However, too much denaturation and long incubation times with 
sodium bisulfite can lead to severe fragmentation of the RNA and therefore our 
treatment conditions represent a compromise between efficient RNA denaturation and 
limiting fragmentation [58]. Thus, it was expected that highly structured transcripts may 
still exhibit clusters of non-converted cytosines. 
 
Humanised and non-humanised Renilla Luciferase (R-Luc) in vitro transcripts were 
spiked into the RNA samples prior to bisulfite treatment as controls for bisulfite 
conversion. Both in vitro transcripts contained no m5C sites and therefore all cytosines 
should be converted to uracil during the process. 
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Figure 3.3. Schematic demonstrating the bisulfite conversion of RNA. 
Unmethylated cytosines in RNA are converted to uracil after bisulfite conversion while m5C 
remains as a cytosine. Red indicates the m5C site and blue indicates unmethylated cytosines 
converted to uracil after bisulfite conversion. 
 
3.2.1.C ASSESSMENT OF BISULFITE CONVERSION AND KNOCKDOWN 
EFFICIENCIES 
Bisulfite conversion and knockdown efficiencies were examined by Sanger bisulfite 
sequencing of several controls prior to bsRNA-seq library preparation. A 50-300 ng 
aliquot of bisulfite-converted RNA was reverse transcribed and the controls were PCR 
amplified. To confirm efficient bisulfite conversion, segments of the R-Luc in vitro 
transcript controls were PCR amplified and subjected to Sanger bisulfite sequencing. To 
confirm the knockdown efficiency of the RNA methyltransferases, the known m5C sites 
in tRNAAsp(GUC) and tRNALeu(CAA) were examined. NSUN2 is known to methylate C48 
and C49 in tRNAAsp(GUC) and C34 in tRNALeu(CAA), while TRDMT1 is known to 
methylated C38 in tRNAAsp(GUC), therefore these tRNAs served as appropriate controls. 
PCR amplification and Sanger bisulfite sequencing of the tRNAs were performed to 
confirm depletion of m5C at the enzyme target sites and therefore knockdown of 
NSUN2 and TRDMT1. Also, while the reaction to convert m5C to uracil is substantially 
slower than conversion of unmethylated cytosines to uracil, the m5C sites in these 
tRNAs were examined in PrEC and LNCaP cells to ensure conversion of m5C to uracil 
did not occur.  
 
Primers for the PCR amplification of segments of the R-Luc in vitro transcripts were 
designed in such a way that they avoided areas of bisulfite-converted cytosines. 
Inefficient bisulfite conversion may result in unconverted cytosines, so it was necessary 
to ensure the primers detected this. (Figure 3.4A). Minimal amplification of sequences 
GACCUGUUAUUACGAACCAGGCAUCAGUCUUGGCCUAACUUAGGCGAAC
GAUUUGUUAUUACGAAUUAGGUAUUAGUUUUGGUUUAAUUUAGGUGAAU
Bisulfite conversion 
RNA
m5C
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containing unconverted cytosines in this case increased confidence in the bisulfite 
conversion efficiency. Primers for the amplification of the control tRNAs and validation 
of candidate m5C sites were designed such that they spanned converted cytosines to 
avoid preferentially amplifying unconverted sequences, decreasing the likelihood of 
false positives (Figure 3.4B). To ensure that the primers were unique in amplifying the 
candidate of interest, the primer sequences were entered into BiSearch, a primer-design 
and search tool for bisulfite PCR [250]. Additionally, amplicons were designed to be 
between 70 bp-200 bp in length, depending on the surrounding sequences and the 
transcript biotype in which the candidate m5C site is located. Smaller amplicons were 
preferable in order to avoid amplification of clustered regions of unconverted cytosines 
that may be attributed to the secondary structure of the RNA. We have previously found 
that amplification of longer amplicons from rRNA led to an increase in the detection of 
clusters of non-converted cytosines.  
 
A “touchdown” PCR was used in all cases, preventing amplification of non-specific 
products by initially using a higher annealing temperature and decreasing by 1°C per 
cycle until ~5°C below the lowest primer melting temperature. All PCR products were 
run on an agarose gel, purified and subjected to ligation into the pGEM®-T Easy vector 
using T4 DNA ligase. Following bacterial transformation, culturing of colonies 
containing inserts and plasmid DNA purification, the DNA was submitted for Sanger 
bisulfite sequencing using the M13 reverse primer. For each amplicon, ~10 clones were 
selected for sequencing. 
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Figure 3.4. Schematic demonstrating the bisulfite conversion of RNA, reverse 
transcription, primer design and PCR amplification.  
A) Primers designed for the R-Luc in vitro transcripts (orange arrows) avoided areas of 
converted cytosines to prevent preferential amplification of converted sequences, which may 
falsely indicate efficient bisulfite conversion. B) Primers designed for the tRNA controls and 
validation of candidate m5C sites (green arrows) spanned areas containing converted cytosines 
to preferentially amplify converted sequences. Blue bases represent converted (unmethylated) 
cytosines and red bases represent m5C. Primers were designed to amplify products that were 70 
bp-200 bp. 
 
Positive control and candidate m5C sites
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GAGGUGUUAUUAGGAAUUAGGUAUUA..........GUUUUGGUAUAAUUUAGGUGAAU
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ATTCACCTAAATTAAACCAAA..........CTGATACCTAAATCCTAATACAACTC
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Sanger bisulfite sequencing of two segments of the R-Luc in vitro transcript revealed 
100% conversion of all cytosines in these segments for all samples except LNCaP 1, 
which exhibited 99.8% conversion. These findings indicate efficient bisulfite 
conversion of all samples (Figure 3.5).   
 
For the HeLa methyltransferase knockdown samples, depletion of m5C in tRNAAsp(GUC) 
and tRNALeu(CAA) was examined (Figure 3.6A). As mentioned previously, NSUN2 is 
known to target C48 and C49 in tRNAAsp(GUC) and C34 in tRNALeu(CAA), and TRDMT1 
is known to target C38 in tRNAAsp(GUC). 75% depletion of m5C at C48 and 50% 
depletion of m5C C49 in tRNAAsp(GUC), as well as ~80% depletion of m5C at C34 in 
tRNALeu(CAA) was evident in the NSUN2 knockdown sample compared to the NTC 
sample. ~80% depletion of m5C was evident at C38 in tRNAAsp(GUC) in the TRDMT1 
knockdown sample compared to the NTC sample. As tRNAs are known to have 
exceptionally long half-lives of up to several days [251-253] and pronounced depletion 
of m5C was still observed at tRNA sites targeted by NSUN2 and TRDMT1, this 
confirmed sufficient knockdown of NSUN2 and TRDMT1 in HeLa cells.  
 
As expected, the DNMT1 knockdown and NTC samples showed high levels of m5C at 
these positions, indicating that conversion of m5C did not occur in these samples.  
 
Methylation of both tRNAs was also examined in PrEC and LNCaP cells in order to 
determine if conversion of m5C to uracil occurred. Sanger bisulfite sequencing of both 
tRNAs revealed high levels of m5C at the known sites (Figure 3.6B). Thus, while 
almost complete conversion of cytosines was evident in segments of the R-Luc in vitro 
transcript, high levels of m5C were evident at known m5C sites indicating that 
conversion of m5C did not occur. 
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Figure 3.5. Confirmation of efficient bisulfite conversion by Sanger bisulfite sequencing. 
A) HeLa methyltransferase knockdown samples and B) PrEC and LNCaP samples. Two 
segments of a R-Luc in vitro transcript were amplified by PCR after bisulfite conversion and 
reverse transcription, and the bisulfite conversion efficiency assessed by Sanger bisulfite 
sequencing. Each column of squares represents a cytosine within the transcript and each row of 
squares represents a clone that was sequenced. Numbers represent the location of cytosines 
relative to the start of the transcript.  
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Figure 3.6. Confirmation of NSUN2 and TRDMT1 knockdown and bisulfite conversion 
efficiency by Sanger bisulfite sequencing. 
Sanger bisulfite sequencing of endogenous tRNAAsp(GUC) containing known m5C sites at C38, 
C48 and C49 and tRNALeu(CAA) containing a known m5C site at C34. A) Sanger bisulfite 
sequencing of the HeLa methyltransferase knockdown samples revealed depletion of m5C at the 
known NSUN2 and TRDMT1 target sites. B) Sanger bisulfite sequencing of PrEC and LNCaP 
samples revealed high levels of m5C at the known sites. Each column of squares represents a 
cytosine within the transcript and each row of squares represents a clone that was sequenced. 
The tRNA structural positions containing m5C sites are indicated in red. 
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3.2.2 PREPARATION OF LIBRARIES FOR BSRNA-SEQ 
Prior to transcriptome-wide sequencing, the RNA is normally fragmented by RNase III 
digestion or chemical hydrolysis. Sequencing of whole-transcriptome libraries on the 
SOLiD™ platform requires the RNA to be fragmented to a size between 35 nt to several 
thousand nucleotides depending on the sample, with an average size of 125-200 nt. 
Bisulfite conversion of RNA is a harsh process that results in its fragmentation and 
therefore fragmentation by RNase III or chemical hydrolysis was not necessary for the 
generation of bsRNA-seq libraries. Fragmentation of the bisulfite-converted RNA was 
assessed using a RNA 6000 Nano Chip, which showed sufficient fragmentation of the 
RNA within the desired size range (Figure 3.7). The bisulfite-converted RNA was then 
“end-polished” to aid in the ligation of adaptors during the library preparation. This 
involved de-capping of mRNA by Tobacco Acid Pyrophosphatase to ensure ligation of 
the 5’ adaptors, and removal of any 3’ phosphate groups that may exist after bisulfite 
conversion to ensure ligation of the 3’ adaptors.  
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Figure 3.7. Confirmation of fragmentation of RNA from bisulfite conversion. 
Bisulfite-converted RNA was subjected to a RNA 6000 Nano Chip on the Agilent Bioanalyzer 
to confirm fragmentation. The median fragment size obtained after bisulfite conversion and the 
marker are indicated. The sizes of the ladder corresponding to the same migration time as the 
samples are also indicated. 
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The libraries were prepared using the SOLiD™ Total RNA-Seq Kit, as described in 
Chapter 2. All HeLa methyltransferase knockdown samples were sequenced on a single 
run. PrEC 2 and LNCaP 2 were sequenced at a later date to PrEC 1 and LNCaP 1 to 
improve the accuracy of the initial screen. 
 
First, adaptor sequences were ligated to the 5’ and 3’ ends of the RNA, which were used 
to reverse transcribe the RNA. Following sample clean-up using the MinElute® PCR 
Purification Kit, the cDNA was size-selected at a range of 100-160 nt, corresponding to 
an insert size of 50-120 nt (Figure 3.8). This ensured the selection of fragmented tRNAs 
and mRNAs.  
 
 
Figure 3.8. Representative cDNA size selection of the bsRNA-seq libraries. 
A) 5 µL cDNA from each sample along with 1x Novex® TBE-Urea Sample Buffer was run on a 
10% TBE-Urea gel at 180 V for ~45 min. The gel was stained with 1x SYBR® Gold Nucleic 
Acid Stain for 5 min and visualised, B) The cDNA was size-selected between ~100-160 nt, 
divided into four vertical strips, and the two inner strips were placed in separate 0.2 mL PCR 
tubes for PCR amplification. The sizes of the 10 bp DNA ladder are indicated. 
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The gel slice from each cDNA size selection was divided into four vertical strips, with 
the two inner strips being placed in separate 0.2 mL PCR tubes for PCR amplification. 
The samples were multiplexed allowing simultaneous sequencing of samples, which 
was achieved by the incorporation of 3’ barcoded PCR primers. As each PrEC and 
LNCaP cell replicate was sequenced separately, two different 3’ barcoded primers were 
used per sample. This was to avoid incorrectly assigning a sequencing read to the wrong 
barcoded sample as the SOLiD™ sequencing platform requires multiples of four 
barcodes. Only one 3’ barcoded primer was required for each HeLa sample as there 
were four samples. 18 cycles of PCR were performed on all samples to enrich the 
libraries. After PCR amplification, the products were purified by size selection using 
polyacrylamide gel electrophoresis followed by EtOH precipitation (Figure 3.9). This 
ensured the removal of adaptors and primer dimers that may have formed during the 
PCR amplification step. The purification and size of the products were confirmed by a 
second polyacrylamide gel and a DNA High Sensitivity DNA Chip on the Agilent 
Bioanalyzer, respectively (Figure 3.10). As can be seen in Figure 3.10A, the 
concentration of each library varied, however this was adjusted for prior to ePCR to 
ensure equal loading of each library for sequencing. According to the polyacrylamide 
gel and the Agilent Bioanalyzer, all samples had the expected size range of ~150-170 
nt. The increased length of the PCR amplified libraries was a result of the addition of 
the barcoded primer.  
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Figure 3.9. Size selection of amplified libraries by polyacrylamide gel electrophoresis. 
A) Up to 20 µL amplified library along with 1x Novex® TBE-Urea Sample Buffer was 
separated on a polyacrylamide gel at 300 V for 37 min. The gel was stained with 1x SYBR® 
Gold Nucleic Acid Stain for 5 min and visualised. B) The band corresponding to ~200 nt was 
excised, removing all adaptors and primer dimers that could hinder the sequencing reaction. 
Expected sizes of adaptors and primer dimers are indicated. The sizes of HyperLadder V 
(HypV) are also indicated.  
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Figure 3.10. Confirmation of the bsRNA-seq purity and library size. 
To confirm the purification process, A) 1 µL of the purified library was run on a polyacrylamide 
gel, confirming the presence of a single amplified product at ~200 nt. B) For further verification 
of the size and to determine the concentration of the libraries, the purified library was run on a 
High Sensitivity DNA Chip on the Agilent Bioanalyzer, confirming the expected size. 
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The libraries were pooled evenly to a total concentration of 600 pM and subjected to 
ePCR. In this reaction, the PCR products were mixed into a water-in-oil emulsion along 
with primer-coated beads, such that each water droplet contained a single PCR product. 
A polymerase then coated the beads with the amplified PCR product and the beads were 
then immobilised for sequencing on the SOLiD™ 5500XL platform.  
 
For an indication of the bisulfite conversion efficiency on a global scale and the 
efficiency of the sequencing protocol, the beads were visualised on a satay plot for 
primer B cycle one, which provided information on the distribution of bases of the first 
nucleotide of the insert (Figure 3.11). The SOLiD™ platform uses a di-base encoding 
system, which relies on sequencing by ligation, rather than sequencing by synthesis as 
used in other platforms. With the use of a di-base probe that consists of a fluorescent 
dye at the 5’ end, sequencing of every first and second base in each ligation reaction is 
performed with the fluorescent dye representing two nucleotides of the sequencing read 
(Figure 3.12). This allows each base to be interrogated twice and reduces the read error 
rate. For example, if only one of the two base interrogations leads to a mismatch, this 
most likely indicates a read error, whereas if both base interrogations lead to a mismatch 
it is most likely a SNP. This feature is quite advantageous for bisulfite sequencing, 
where bisulfite-induced mismatches occur. With the bisulfite conversion of either DNA 
or RNA, the distribution of colours changes (Table 3.1).  
 
Sequencing of the last base of the adaptor, which is a T, and the first base of the insert 
revealed clear depletion of cytosines through lack of signal in the TXR channel (Figure 
3.11). This provided an indication that the bisulfite conversion efficiency was high on a 
global level, for at least the first base of the insert. 
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Figure 3.11. Representative satay plot of the bsRNA-seq libraries for primer B cycle one.  
On the SOLiD™ 5500XL platform, primer B sequences the last nucleotide of the adaptor, which 
is a T, as well as the first base of the insert. The TXR dye (orange) encodes TC, and there was a 
clear depletion of TC dinucleotides during cycle one of sequencing, indicating efficient bisulfite 
conversion of cytosines located in the first position of the insert. 
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Figure 3.12. SOLiD™ sequencing uses di-base encoding, where one colour represents two 
bases. 
A) The decoding matrix allows the conversion of colour-space to base-space, as long as one of 
the two bases is known. B) An example of how sequencing in colour-space allows double 
interrogation of each base. Adapted from Applied Biosystems. 
 
 
Table 3.1. The distribution of colours of standard RNA and bisulfite-converted RNA using 
SOLiD™ sequencing. 
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3.2.3 MAPPING OF BSRNA-SEQ DATA AND DETECTION OF 
CANDIDATE M5C SITES 
The following sections document details of the mapping of the bsRNA-seq libraries and 
the general features of the libraries. Dr. Brian J. Parker performed the mapping of the 
bsRNA-seq libraries and detection of candidate m5C sites. The statistical model used for 
the detection of candidate m5C sites was developed by Dr. Brian J. Parker and Dr. Jiayu 
Wen.  
 
3.2.3.A MAPPING AND GENERAL FEATURES OF THE BSRNA-SEQ 
LIBRARIES 
The alignment algorithm used for the mapping of the bsRNA-seq data was B-
SOLANA, which was specifically designed to map bisulfite-converted DNA 
sequencing reads in colour-space [237]. While there are a number of alignment 
algorithms available that are specific to bisulfite sequencing of DNA, B-SOLANA is 
advantageous for bsRNA-seq as it is accurate and fast. SOCS-B, another bisulfite 
sequencing alignment algorithm we have previously used [58], becomes 
computationally intensive with large genomes such as the human genome, and is 
therefore quite slow. B-SOLANA improves speed and unique mapping rate by aligning 
against both fully in silico bisulfite converted and non-CpG in silico bisulfite converted 
references simultaneously with Bowtie. Following this, B-SOLANA determines the 
methylation levels. 
 
The alignment algorithms available for the mapping of bisulfite-converted data are 
specifically designed for DNA. As such, it was necessary to adapt B-SOLANA for use 
with bisulfite-converted RNA. One of the major differences with m5C in RNA is that it 
does not necessarily occur in a CpG context and clusters of m5C sites in RNA have not 
yet been detected in a similar manner to m5C in DNA [58]. Adjustments to the B-
SOLANA alignment algorithm were applied for use with RNA using Tophat, while also 
keeping the features associated with mapping bisulfite-converted DNA. This enabled 
the mapping of splice junction reads to in silico bisulfite-converted Refseq 
transcriptomes in order to reliably detect known transcript isoforms, and then to in silico 
bisulfite-converted hg19 reference genomes (Figure 3.13A).  
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Several ncRNAs including rRNAs and tRNAs are either highly repetitive or identical 
sequences can be derived from multiple locations in the genome, which can cause 
multi-mapping issues. As such, specific “local” mapping was applied for rRNAs and 
tRNAs (Figure 3.13B). In addition, the R-Luc in vitro transcripts were mapped locally 
from the sequences derived from the plasmid they were generated from.  
 
Although rRNA was depleted prior to bsRNA-seq, it was expected that a large 
proportion of rRNA would still be present in the library as no depletion method to date 
has been successful in completely removing rRNA. As such, efforts were made to map 
remaining rRNA sequencing reads to rRNA tandem repeat sequences as references. The 
non-CpG in silico bisulfite conversion of the references was not applied for the local 
mapping to limit detection of non-converted cytosines due to the strong secondary 
structure of rRNA. 
 
tRNAs were mapped both genome-wide to all Rfam tRNA annotations and locally to 
Rfam tRNA annotations that matched tRNAdB. The genome-wide mapping of tRNAs 
was used for the detection of candidate m5C sites in these transcripts. To focus on 
candidate m5C sites in tRNAs in greater detail, local mapping was applied. The 
references used for the local mapping incorporated an in silico non-template 3’ CCA 
addition, which specifically allowed mapping of mature tRNA sequences. Additionally, 
as identical tRNA sequences may be derived from multiple locations in the genome, a 
single representative reference was used to map identical mature sequences in the local 
mapping. As the global mapping does not specifically map mature tRNA sequences, it 
was possible to distinguish between identical tRNA sequences in some cases when 
sequencing reads extended beyond the mature ends of the tRNA. For this study, the 
genome-wide mapping of tRNAs will be referred to as “global mapping”, and the 
mapping of mature tRNAs will be referred to as “local mapping”. 
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Figure 3.13. Schematic of the global and local mapping of 50 nt SOLiD™ sequencing reads 
by B-SOLANA. 
A) Global mapping: the references were both completely in silico bisulfite converted and non-
CpG in silico bisulfite converted prior to mapping. The 50 nt SOLiD™ sequencing reads were 
then mapped to both in silico bisulfite converted human Refseq transcriptomes. Sequencing 
reads that did not map to this reference were mapped to both in silico bisulfite converted human 
hg19 genomes. B) Local mapping: the references were completely in silico bisulfite converted 
prior to mapping. Sequencing reads were then mapped to complete in silico bisulfite converted 
Rfam tRNA annotations that matched tRNAdB with a 3’ CCA addition, rRNA tandem repeat 
sequences and R-Luc in vitro transcript sequences. 
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In all cases of mapping, the Bowtie parameters --best and --strata were applied 
to ensure that only sequencing reads with a single best mapping were used and only 
mapped once to the best mapping transcript, minimising multi-mapping. These 
parameters were applied to ensure that those sequencing reads that mapped to multiple 
locations in the genome were removed from the analysis to prevent ambiguity. 
Additional parameters that were applied allowed a maximum of three colour-space 
mismatches in the first 35 nt of the 50 nt SOLiD™ sequencing reads, and a Phred score 
sum of 200 at all mismatch positions in the 50 nt sequencing read (not just the first 35 
nt). While these are stringent criteria for the mapping of the sequencing reads, the high 
Phred score sum allowed for several base-space mismatches, particularly towards the 3’ 
end of the sequencing read. This was because in our approach, non-converted cytosines 
and therefore candidate m5C sites directly contribute to the mismatch score. 
 
Between 5.0x107-12.1x107 sequencing reads were generated for the HeLa 
methyltransferase knockdown libraries, of which ~38% were mappable (Table 3.2). For 
the PrEC and LNCaP libraries, between 1.32x108-1.83x108 sequencing reads were 
generated of which ~44-76% were mappable. Despite each library being diluted to 
equivalent concentrations prior to sequencing, variations in the HeLa methyltransferase 
knockdown libraries were evident, with the NSUN2 knockdown library having less than 
half the amount of sequencing reads compared to the TRDMT1 knockdown and 
DNMT1 knockdown libraries. Similarly, the NTC library had a lower amount of 
sequencing reads compared to the TRDMT1 knockdown and DNMT1 knockdown 
libraries. This suggests that less of the NSUN2 knockdown and NTC libraries were 
loaded for sequencing. The PrEC and LNCaP libraries yielded relatively even numbers 
of sequencing reads even though the replicate libraries were prepared separately.  
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Table 3.2. The number of total mappable sequencing reads in each bsRNA-seq library. 
Library  Total sequencing 
reads 
Total mappable 
reads % mappable reads 
NSUN2 50,689,481 18,963,160 37.4% 
TRDMT1 114,757,033 43,524,151 37.9% 
DNMT1 120,221,774 45,944,290 38.2% 
NTC 76,306,528 28,580,132 37.5% 
PrEC 1 133,905,207 59,111,682 44.1% 
PrEC 2 182,032,122 87,990,804 48.3% 
LNCaP 1 132,529,838 60,361,771 45.5% 
LNCaP 2 144,990,405 110,538,861 76.2% 
 
As expected, ~40-75% of the sequencing reads mapped to rRNA (Figures 3.14 and 
3.15). ~14-24% sequencing reads mapped to mRNAs, 2-7% to tRNAs and the 
remainder to other ncRNAs. It is clear that RNA extractions, library preparations and 
sequencing runs performed at different times, as is the case for each replicate of the 
PrEC and LNCaP samples, resulted in variations in the number of mappable sequencing 
reads (Table 3.2) and the distribution of the sequencing reads across different transcript 
biotypes (Figure 3.15). In the first library preparation for PrEC and LNCaP cells, the 
proportion of sequencing reads mapping to rRNA was significantly higher than the 
second library preparation. This may be attributed to batch variations in the 
RiboMinus™ Eukaryote Kit for RNA-Seq. The variability observed between the PrEC 
and LNCaP replicates may be prevented in the future by performing all experimental 
procedures simultaneously for all samples. 
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Figure 3.14. Distribution of sequencing reads of the HeLa methyltransferase knockdown 
bsRNA-seq libraries. 
The sequencing reads were mapped using B-SOLANA to the appropriate in silico bisulfite-
converted reference sequences. The distribution of sequencing reads in tRNAs are based on the 
global mapping. 
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Figure 3.15. Distribution of sequencing reads of the PrEC and LNCaP bsRNA-seq 
libraries. 
The sequencing reads were mapped using B-SOLANA to the appropriate in silico bisulfite-
converted reference sequences. The distribution of sequencing reads in tRNAs are based on the 
global mapping. 
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3.2.3.B DETECTION OF CANDIDATE M5C SITES IN RNA 
bsRNA-seq was performed on HeLa methyltransferase knockdown cells to determine 
the substrate range of NSUN2 and TRDMT1 and also to investigate the molecular 
functions of m5C in mRNA. bsRNA-seq was performed on PrEC and LNCaP cells to 
compare their RNA m5C profiles, and to compare this with HeLa cells to confirm 
patterns of m5C across multiple cell lines. Thus, for the detection of candidate m5C 
sites, the HeLa methyltransferase knockdown dataset and PrEC and LNCaP dataset 
were processed separately.  
 
Prior to detection of candidate m5C sites, non-specific filtering was applied to each 
dataset individually. Initially, all samples used in the model for each dataset required ≥5 
reads at the candidate m5C site, removing lowly expressed reads which may have led to 
incorrect detection of differential candidate m5C sites. Second, non-specific filtering of 
low non-converted cytosines was applied in order to exclude noise due to spurious non-
conversion. For differential methylation, 3 out of 4 samples from the HeLa 
methyltransferase knockdown dataset required >1% non-conversion, and at least 2 out 
of 4 samples required ≥5% non-conversion for the PrEC and LNCaP dataset. For 
detecting candidate m5C sites in HeLa cells or candidate m5C sites in common between 
PrEC and LNCaP cells, >0% non-conversion was required in all samples.  
 
Detection of candidate m5C sites mediated by NSUN2 and TRDMT1 in HeLa cells 
Prior to identification of candidate m5C sites selectively mediated by NSUN2 or 
TRDMT1, all candidate m5C sites were first examined to determine whether any were 
targeted by both RNA methyltransferases by comparing both enzyme knockdown 
samples against the DNMT1 knockdown and NTC samples as controls. This revealed 
that no such sites were detectable in the bsRNA-seq data. To identify candidate m5C 
sites that were mediated by either NSUN2 or TRDMT1, a two-sample moderated t-test 
was used. As no replicates were sequenced, the experimental design was set up in such 
a way that there was one “experimental” sample and three “controls”. Such an 
experimental design was required in order to implement statistical analyses for the 
detection of candidate m5C sites. That is, if the NSUN2 knockdown sample was treated 
as the experimental sample, then the TRDMT1 knockdown, DNMT1 knockdown and 
NTC samples were treated as controls to detect candidate m5C sites that were mediated 
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by NSUN2. Although the NTC sample was the only true control, DNMT1 should not 
target RNA for methylation and TRDMT1 should exclusively target sites other than 
those of NSUN2 for methylation, as described previously. The NSUN2 knockdown, 
DNMT1 knockdown and NTC samples were also treated as controls to detect sites that 
were mediated by TRDMT1. As RNAi-mediated knockdown was implemented in this 
study, it was expected that complete ablation of m5C at NSUN2 or TRDMT1 target 
sites would not necessarily be observed. Due to the low sample replication, a FDR≤30% 
was set as the threshold for the detection of candidate m5C sites mediated by NSUN2 
and TRDMT1 to strike a balance between true positive enrichment while maintaining 
the proportion of false negatives at an acceptable level. 
 
Detection of candidate differential m5C sites in PrEC and LNCaP cells 
To detect candidate differential m5C sites in PrEC and LNCaP cells, a balanced design 
of two LNCaP and two PrEC samples was used, and a moderated two-sample t-test was 
implemented. Therefore, for detecting candidate m5C sites that were hypermethylated in 
PrEC cells, the LNCaP samples were defined as controls, and vice-versa. Due to the low 
sample replication and an evident paucity of candidate differential m5C sites between 
PrEC and LNCaP cells, a FDR≤40% was set as the threshold to obtain a set of such 
sites for further inspection. 
 
Detection of all candidate m5C sites in HeLa cells 
While determining the substrate range and specificity of NSUN2 and TRDMT1 was one 
of the aims of this study, it was also of interest to detect all candidate m5C sites in HeLa 
cells. The same unbalanced design was applied as described previously, using three 
control samples. A one-sample moderated t-test was used for the detection of candidate 
m5C sites by comparing the cytosines in the control samples against a 0% methylation 
level to determine if they were statistically significantly increased. The TRDMT1 
knockdown, DNMT1 knockdown and NTC samples were treated as controls to detect 
candidate m5C sites that were mediated by NSUN2 or potentially other 
methyltransferases, and the NSUN2 knockdown, DNMT1 knockdown and NTC 
samples were treated as controls to detect candidate m5C sites that were mediated by 
TRDMT1 or other methyltransferases. Combining the results from both sets of analyses 
provided the total number of candidate m5C sites detected in HeLa cells, regardless of 
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whether they were mediated by NSUN2 or TRDMT1. As a result of the higher number 
of control samples used to detect all candidate m5C sites in HeLa cells compared to 
candidate m5C sites mediated by NSUN2 and TRDMT1, a stringent FDR≤1% threshold 
was applied. 
 
Detection of candidate m5C sites in common between PrEC and LNCaP cells 
To detect candidate m5C sites in common between PrEC and LNCaP cells, all four 
samples were used as controls. A one-sample moderated t-test was used for the 
detection of candidate m5C sites by comparing the cytosines in the control samples 
against a 0% methylation level to determine if they were statistically significantly 
increased. As a result of the higher number of control samples used to detect candidate 
m5C sites in common between PrEC and LNCaP cells compared to candidate 
differential m5C sites, a FDR≤1% threshold was applied. 
 
Post-filtering of candidate m5C sites 
Post-filtering of candidate m5C sites was performed in order to remove any potential 
artefacts. Candidate m5C sites had to be homogenous, where ≥95% of reads had to be a 
C or T, and any sites that overlapped a SNP or editing site were excluded. Finally, while 
many candidate m5C sites would have been detected using the described proportion 
statistic, the amount of methylation for some of these may be too low for validation and 
further exploration. As such, for a site to be considered methylated, ≥10% mean 
methylation across all control samples was required. 
 
Figure 3.16 shows a schematic for the detection of candidate m5C sites in the different 
samples. Details into the number of candidate m5C sites detected in HeLa cells and 
PrEC and LNCaP cells will be addressed in Chapters 4 and 6, respectively. 
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Figure 3.16. Schematic demonstrating the detection of candidate m5C sites. 
A) Left: detection of candidate m5C sites mediated by NSUN2 or TRDMT1. Right: detection of 
all candidate m5C sites in HeLa cells. KD=knockdown. B) Left: detection of candidate 
differential m5C sites in PrEC and LNCaP cells. Right: detection of candidate m5C sites in 
common between PrEC and LNCaP cells.   
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3.2.4 DETECTION OF M5C IN RNA USING AN ANTIBODY 
To ensure the accuracy of candidate m5C sites detected using bsRNA-seq, it was 
desirable to validate these sites using different methods. Previously, this was performed 
by Sanger bisulfite sequencing, which is laborious, low-throughput and still relies on 
bisulfite conversion of RNA [58]. There is also the possibility that other modifications 
besides m5C may be resistant to bisulfite conversion. As such, attempts were made to 
optimise an antibody for the detection of m5C in RNA using MeRIP. As mentioned in 
the Chapter 1, recent studies have implemented MeRIP for the detection of RNA 
modifications and this is rapidly becoming a favourable technique in this field. It is 
versatile in that either RT-qPCR could be used to detect modification enrichments in 
candidate transcripts, or next-generation sequencing could be used to detect peaks 
transcriptome-wide corresponding to regions containing the modification (MeRIP-seq). 
Although this technique does not detect modifications at single nucleotide resolution, it 
would be a favourable validation tool, which could remove any ambiguity that bisulfite 
conversion may cause. 
 
A single study thus far has implemented MeRIP-seq for the validation of m5C sites 
detected by transcriptome-wide bisulfite sequencing in archaea [76]. As such, the same 
m
5C antibody was purchased for this study and a dot blot was initially performed to 
confirm that the antibody did detect m5C in RNA. Yeast tRNA was used as a control 
due to its abundance in m5C, and HeLa cell RNA was also used as the biological sample 
of interest. In addition to using RNA, methylated and unmethylated DNA controls were 
used and were purchased from the manufacturer of the antibody. These controls were 
double-stranded DNA of ~300 bp in length and were produced by PCR. The original 
DNA was derived from two different chromosomes of A. thaliana and the difference 
between the two controls was that the methylated DNA contained a single m5C site and 
the cytosines in the unmethylated control were all unmethylated. 
 
Two-fold serial dilutions of each DNA control were made from 100 ng-12.5 ng in 2-5 
µL 0.1 M NaOH, denatured at 99°C for 5 min, placed on ice and neutralised with 6.6 M 
ammonium acetate (Figure 3.17). Two-fold serial dilutions of the RNA samples were 
made from 5 µg-625 ng. A higher amount of RNA was used due to the substantially 
lower amount of m5C compared to DNA. The RNA was denatured at 75°C for 5 min 
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then placed on ice. Each sample was spotted onto a nylon membrane and dried until the 
spots disappeared to prevent quenching during the crosslinking procedure. The nucleic 
acids were UV crosslinked twice using the “auto-crosslink” function (120 mJ/cm2). 
Following this, the membrane was incubated with the m5C antibody in blocking buffer 
overnight at 4°C, washed in 1x PBS-T, incubated with an anti-mouse secondary 
antibody in blocking solution and washed again. The nucleic acids were detected using 
ECL. 
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Figure 3.17. Preparation of DNA and RNA dot blots for the detection of m5C.  
Two-fold serial dilutions of DNA (100ng-12.5 ng) and RNA (5 µg-625 ng) were made. DNA 
was denatured in 0.1 M NaOH at 99°C for 5 min, placed on ice then neutralised with 0.1 
volumes of 6.6 M ammonium acetate. RNA was denatured at 75°C for 5 min then placing on 
ice. ~10 µL of the nucleic acids were spotted onto a positively charged nylon membrane and 
air-dried until spots were no longer visible. The membrane was UV crosslinked twice and 
blocked in blocking buffer for 1 h at room temperature. The membrane was incubated with the 
anti-m5C antibody overnight at 4°C, washed with washing buffer, incubated with an anti-mouse 
secondary antibody and washed again. The membrane was exposed using ECL. 
 
m
5C was detected at all concentrations in the methylated DNA control, and as expected 
no m5C was detected in the unmethylated DNA control (Figure 3.18A). However, m5C 
could not be detected in yeast tRNA or HeLa cell RNA at all concentrations. Staining of 
the membrane with methylene blue indicated successful hybridisation of all samples, 
suggesting that the antibody may have failed to detect m5C in RNA due to inefficient 
denaturation (Figure 3.18B). It is possible that heat denaturation may not be sufficient 
to denature strong secondary structures, such as those in rRNAs and tRNAs, for the 
antibody to detect m5C. To try and overcome this issue, the DNA and RNA samples 
were heat denatured in 2x RNA loading buffer containing formamide at 75°C for 5 min 
followed by snap cooling on ice. Formamide acts as both a stabiliser of RNA and 
denaturing agent by disrupting hydrogen bonds between nitrogen bases, preventing 
conformational changes. This, in combination with heat and cooling on ice, should aid 
in reducing strong secondary structures of RNA. As positive controls, the DNA controls 
were denatured in 0.1 M NaOH as described previously. As with the previous attempt, 
the antibody successfully detected m5C in the methylated DNA control regardless of the 
denaturation process and despite reduced binding efficiency when denatured with 
formamide (Figure 3.19A). Despite the changes to the denaturation process, the 
antibody failed to detect m5C in both RNA samples (Figure 3.19B). 
 
Unfortunately the antibody could not successfully detect m5C in RNA in this thesis, and 
therefore could not be used for MeRIP. The likely cause of the issue appeared to be 
inefficient denaturation of the RNA for the antibody to access m5C sites.  
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Figure 3.18. Dot blot assay for the detection of m5C in DNA and RNA. 
A) Dot blot to detect m5C in DNA and RNA. Methylated and unmethylated DNA controls were 
denatured in 0.1 M NaOH at 99°C for 5 min, placed on ice and neutralised in 0.1 volumes of 6.6 
M ammonium acetate. RNA was denatured at 75°C for 5 min then placed on ice. B) Staining of 
the membrane with 0.02% methylene blue indicated binding of the nucleic acids. 
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Figure 3.19. Dot blot assay for the detection of m5C in DNA and RNA after denaturation 
in 2x RNA loading buffer. 
A) Dot blot to detect m5C in DNA and RNA. Methylated and unmethylated DNA controls were 
denatured either by heating with 0.1 M NaOH, as previously described, or heating to 75°C for 5 
min in formamide then placing on ice. RNA was denatured in formamide at 75°C for 5 min. 
then placed on ice. B) Staining of the membrane with 0.02% methylene blue revealed binding 
of the nucleic acids. 
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3.2.5 VALIDATION OF M5C SITES USING ILLUMINA® 
MISEQ 
The use of Sanger bisulfite sequencing for the validation of candidate m5C sites is a 
laborious, expensive and low-throughput technique that requires sequencing of multiple 
clones. As a result, MiSeq amplicon sequencing was implemented for the validation of 
candidate m5C sites in this study.  This method enabled the high-throughput sequencing 
of multiple amplicons generated from bisulfite PCRs with high coverage, providing 
higher confidence in the validation of candidate m5C sites. Furthermore, it allowed for 
multiplexing of samples so that they could be sequenced on a single run, making it a 
very cost-effective technique. Although this does rely on bisulfite conversion of RNA, it 
is significantly less laborious than Sanger bisulfite sequencing and implemented a 
different sequencing platform to that used for bsRNA-seq.  
 
Unless stated otherwise, I performed all of the experimental work for the sequencing of 
the MiSeq libraries. Dr. Wenjia Qu from the Garvan Institute of Medical Research 
provided the protocol originally optimised for bisulfite-converted DNA. I optimised this 
protocol for use with bisulfite-converted RNA. 
 
3.2.5.A SELECTING CANDIDATE M5C SITES FOR VALIDATION 
After determining candidate m5C sites based on the mapping by B-SOLANA, a 
selection was made for validation. Candidates that were selected for validation had 
reasonable coverage across the transcript and ≥10% mean methylation across the 
control samples. To ensure selection of high-confidence candidates, sequencing reads 
spanning the candidate m5C site were also inspected in Integrated Genomics Viewer 
(IGV) to ensure they were of high quality. Figure 3.20 displays an IGV snapshot of 
sequencing reads spanning the known m5C site at C34 in tRNALeu(CAA) in the HeLa 
NTC sample from the local mapping of the bsRNA-seq data. High confidence candidate 
m5C sites exhibit high quality base calling and are present in multiple sequencing reads 
with different alignment start and end points (i.e. no clonal reads). PCR amplification 
during library preparation may cause clonal read biases, particularly for low abundant 
transcripts. This may result in the incorrect detection of candidate m5C sites and 
therefore it was necessary to remove candidates that exhibited this. 
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Figure 3.20. Representative snapshot from IGV depicting a subset of sequencing reads 
mapping to tRNALeu(CAA). 
The grey bars represent 50 nt sequencing reads mapped to part of the tRNALeu(CAA) locus in the 
HeLa NTC sample based on the local mapping (chr1:249,168,062-249,168,114, + strand). 
Unconverted cytosines represent m5C sites at C34. High quality detection of the m5C site by 
bsRNA-seq is indicated by an opaque base. Low quality bases appear as transparent. Many 
sequencing reads containing the m5C site exhibit different alignment start points, indicating high 
confidence m5C sites.  
 
3.2.5.B PREPARATION OF LIBRARIES FOR MISEQ AMPLICON SEQUENCING 
As two replicates per cell line were sequenced for the prostate dataset, the bisulfite-
converted RNA used for bsRNA-seq was also used for MiSeq amplicon sequencing. In 
addition, NSUN2 was knocked down in LNCaP cells, which will be addressed in more 
detail in Chapter 6. Figure 3.21 shows a schematic of the PrEC and LNCaP sample 
preparation process for bsRNA-seq and MiSeq amplicon sequencing.  
 
Reference 
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T G A G T G G T T T A A G G T G T T A G A T T C A A G G T A A G T A T T T T G T T T T T G G G T
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Figure 3.21. Preparation of PrEC and LNCaP cells for bsRNA-seq and MiSeq amplicon 
sequencing. 
A) Each of the two replicates for PrEC and LNCaP cells were prepared for bsRNA-seq 
separately, including growth, RNA extraction, bisulfite conversion, library preparation and 
sequencing. The bioinformatics pipeline implemented was performed on both replicates 
simultaneously. B) The same replicates were used for MiSeq amplicon sequencing, however a 
new batch of LNCaP cells was transfected with NSUN2 siRNA and NTC siRNA. The RNA from 
this was bisulfite converted and subjected to PCR amplification of candidates in triplicate 
alongside the PrEC and LNCaP replicates. MiSeq libraries were prepared and subjected to MiSeq 
amplicon sequencing. 
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As only a single sample of each HeLa methyltransferase knockdown sample was used 
for bsRNA-seq, replicate knockdowns of the methyltransferases were performed in 
triplicate (Figure 3.22). A single sample for each replicate knockdown was used for the 
validation of candidate m5C sites by MiSeq amplicon sequencing. The knockdown of 
each methyltransferase was confirmed by RT-qPCR, western blotting and Sanger 
bisulfite sequencing of tRNAAsp(GUC) and tRNALeu(CAA) (Figure 3.23). Specific 
antibodies were successfully obtained prior to the replicate methyltransferase 
knockdown and confirmed protein depletion (Figure 3.23B). The western blot that 
confirmed protein knockdown was performed by Mr. Andrew Shafik. Interestingly, 
although only ~40% of DNMT1 mRNA was knocked down, almost complete depletion 
of DNMT1 protein was evident. This most likely is a result of the timing of the 
experiment, where depletion of mRNA occurred initially, followed by depletion of 
protein. It is possible that the time point selected for the harvesting of cells was the 
point at which mRNA levels were rising again, but protein levels were still relatively 
low.  
 
As with the first samples used for bsRNA-seq, Sanger bisulfite sequencing was 
performed to confirm depletion of m5C at known NSUN2 and TRDMT1 target sites in 
the biological replicates prior to MiSeq amplicon sequencing. 75% depletion of m5C 
was evident at C38 in tRNAAsp(GUC) in the TRDMT1 knockdown sample compared to 
the NTC sample (Figure 3.23C). In the NSUN2 knockdown sample, 30% depletion of 
m5C at C48 and 20% depletion of m5C at C49 in tRNAAsp(GUC) was evident compared to 
the NTC sample. >50% depletion of m5C was evident at C34 in tRNALeu(CAA) in the 
NSUN2 knockdown sample compared to the NTC sample (Figure 3.23D). 
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Figure 3.22. Preparation of RNAi-mediated knockdown of NSUN2, TRDMT1 and DNMT1 
in HeLa cells for bsRNA-seq and MiSeq amplicon sequencing.  
A) RNAi-mediated knockdown of NSUN2, TRDMT1, DNMT1 and transfection of a NTC 
siRNA was performed. RNA was extracted, depleted of rRNA and bisulfite converted. SOLiD™ 
library preparation and bsRNA-seq were performed simultaneously for all samples. B) 
Replicate RNAi-mediated knockdown of the methyltransferases was performed in triplicate and 
RNA was extracted and bisulfite converted for one sample of each knockdown and control. 
PCR amplification of candidates was performed in triplicate and MiSeq libraries were prepared 
and subjected to MiSeq amplicon sequencing. 
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Figure 3.23. Confirmation of knockdown of NSUN2, TRDMT1 and DNMT1 in HeLa cells 
as biological replicates. 
A) RT-qPCR confirmed knockdown of each methyltransferase on the mRNA level. The results 
were normalised to HPRT mRNA levels (n=3, error=SEM), B) Western blotting confirmed 
knockdown of each methyltransferase on the protein level. The amount of protein relative to the 
NTC sample after knockdown based on densitometry is indicated below the blot, C) Sanger 
bisulfite sequencing of tRNAAsp(GUC) showed depletion of m5C at C38 in the TRDMT1 
knockdown sample and C48 and C49 in the NSUN2 knockdown sample, D) Sanger bisulfite 
sequencing of tRNALeu(CAA) showed depletion of m5C at C34 in the NSUN2 knockdown sample.  
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Prior to MiSeq library preparation, 200 ng bisulfite-converted RNA was reverse 
transcribed using the SuperScript® III Reverse Transcriptase Kit. Bisulfite primers to 
amplify candidates were designed as described in section 3.2.1.C, and PCR 
amplification was performed in triplicate using Platinum® Taq DNA Polymerase in 
order to minimise PCR amplification biases. To confirm successful amplification of 
PCR products, 2.5 µL of each amplicon (all triplicates) was electrophoresed on a 2% 
agarose gel at 100 V for 40 min. Once confirmed, triplicate amplicons were pooled and 
purified using the Wizard SV Gel and PCR Clean-Up System according to the 
manufacturer’s protocol and eluted in 15-30 µL dH2O. The concentration of each 
amplicon was determined using the Qubit dsDNA BR Assay Kit according to the 
manufacturer’s protocol and a minimum of 20 ng of each amplicon was required for 
successful sequencing on the MiSeq platform. If not enough was present, PCRs were 
repeated. For each sample, 20-30 ng of each amplicon was pooled into a single 1.5 mL 
tube and concentrated down to 55 µL. 
 
To prepare amplicon sequencing libraries, the TruSeq DNA LT Sample Prep Kit v2 was 
used with some modifications. 50 µL of pooled amplicons were end-repaired and 
purified by AMPure XP beads for each sample (amplicons >100 nt). Initially, AMPure 
XP beads where used for the purification of all amplicons, which resulted in the loss of 
amplicons <100 nt. As a result, amplicons <100 nt were purified by the MinElute PCR 
Purification Kit. Following purification, the amplicons were subjected to A-tailing and 
adaptor ligation, of which indexed adaptors were used to allow multiplexing. All DNA 
fragments were then purified twice with AMPure XP beads followed by PCR to enrich 
the DNA fragments according to the manufacturer’s protocol. PCR-enriched DNA 
fragments were purified once more with AMPure XP beads. For validation of the 
libraries and determining the average library size, 1 µL each library and 2 µL pooled 
amplicons prior to library preparation were electrophoresed on a 2% agarose gel at 100 
V for 40 min (Figure 3.24). An increase in the length of the DNA fragments after 
library preparation was evident as a result of the ligated adaptors.  
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Figure 3.24. Validation of MiSeq amplicon libraries by agarose gel electrophoresis. 
Pooled amplicons and final libraries for each sample were electrophoresed on a 2% agarose gel 
at 100 V for 40 min. In this case, libraries contained amplicons from transcripts that averaged 
~200 nt in size prior to library preparation. After library preparation, the pooled amplicons were 
~320 nt. As expected, the DNA fragments were more abundant after library preparation. The 
sizes of the 1 Kb Plus DNA Ladder are indicated.  
 
3.2.5.C QUANTIFICATION AND LOADING OF MISEQ LIBRARIES  
Importance of library concentration for cluster generation 
Several methods were used to quantify the MiSeq libraries to determine the optimal 
concentration for the sequencing run. Prior to sequencing, cluster generation occurs on 
the flow cell. Clusters are small regions of amplified DNA with each containing a 
different amplified fragment of DNA. This enables enough DNA to be detected during 
sequencing. Cluster generation involves several major steps. First, the DNA fragments 
are hybridised to the flow cell and are amplified in a process known as “bridge 
amplification”. Second, the fragment is then linearised to prepare it for sequencing and 
blocked to prevent addition of nucleotides during the sequencing process. Third, the 
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sequencing primers are hybridised to the DNA fragments. The optimal cluster density 
for a sequencing run is 700 K-1000 K/mm2, and this is highly dependent on the amount 
of library that is loaded into the cartridge. Loading too little DNA for the sequencing 
run can result in too few clusters, which can potentially make sequencing 
uneconomical. Overloading DNA results in higher cluster densities, leading to cluster 
overlap and a reduction in the amount of data obtained. 
 
Library quantification methods 
After library preparation and validation, the libraries were quantified using the Qubit 
dsDNA BR Assay Kit according to the manufacturer’s protocol and diluted to ~50 nM 
based on the estimated library size. Either qPCR, a High Sensitivity DNA Chip or the 
Qubit dsDNA BR Assay Kit was used to quantify each library necessary for the 
sequencing run. For quantification by qPCR, the Illumina® Library Quantification Kit 
was used according to the manufacturer’s protocol with a few modifications. This kit 
specifically amplifies DNA containing the Illumina® adaptor sequence. Two-fold serial 
dilutions of the libraries were made from 1:1,000 to 1:32,000 in library dilution buffer. 
The manufacturer’s protocol recommended diluting to 1:8,000, but it was found that 
this dilution was not low enough to be in the range of the standard curve, therefore not 
allowing accurate quantification of the libraries. The concentration of the libraries based 
on qPCR was determined by averaging the results for the dilutions that were within the 
range of the standard curve. Quantification of the libraries using qPCR resulted in 
higher concentrations compared to the Qubit dsDNA BR Assay Kit.  
 
In one instance, qPCR, a High Sensitivity DNA Chip and Qubit dsDNA BR Assay Kit 
were used for the quantification of the same libraries as a comparison. Interestingly, the 
Agilent Bioanalyzer yielded the lowest concentration, followed by the Qubit dsDNA 
BR Assay Kit and then qPCR (data not shown). In fact, all three quantification methods 
yielded vastly different results. Multiple MiSeq runs were performed for this study, with 
different quantification methods used to determine the amount to load into the cartridge. 
The libraries were equally pooled to 10 nM and diluted further to 2 nM at which point 
they were denatured using 0.2 M NaOH. The libraries were then diluted further to 7-9 
pM prior to loading into the cartridge. In all instances, 150 bp paired-end sequencing 
was performed. 
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Spike-in control for sequencing 
For each MiSeq sequencing run, a PhiX library was spiked into the final pooled 
libraries to a final proportion of 10%. The PhiX library is an adaptor-ligated library 
derived from the PhiX genome and is used as a control for sequencing runs. In this case 
it behaved as a troubleshooting control for cluster generation, enabling us to determine 
if any issues that arose were related to the sample preparation. 
 
3.2.6 GENERAL FEATURES AND MAPPING OF THE MISEQ 
LIBRARIES 
3.2.6.A MAPPING OF MISEQ AMPLICON SEQUENCING DATA 
Prior to mapping, the Illumina® adaptors and poor quality reads were removed in silico 
using Trimmomatic in palindromic mode, allowing removal of 5’ and 3’ adaptors 
simultaneously. Once the adaptors were trimmed, the sequencing reads were aligned by 
Bismark, using Bowtie2 internally [249] (Figure 3.25). Bismark is an alignment 
algorithm designed for bisulfite-converted DNA sequencing data, performing both the 
alignment of single- and paired-end reads of directional and non-directional libraries, as 
well as the detection of m5C sites. Initially, the sequencing reads were in silico 
converted to C-to-T and G-to-A versions, which were then aligned to equivalently 
converted reference sequences of the candidates interrogated. This alignment was 
performed in order to determine the single best location the sequencing reads mapped 
to; if this was ambiguous, the read was discarded. Only a single mismatch was allowed 
when aligning the reads. Following this, the proportion of methylation was determined 
by comparing the sequencing reads with the corresponding reference sequence, and the 
number of C and T calls at all C positions were extracted from the aligned reads. This 
allowed detection of m5C sites in all sequence contexts.  
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Figure 3.25. Schematic of the alignment of 150 bp paired-end reads from Illumina® MiSeq 
amplicon sequencing using Bismark. 
Illumina® adaptors were trimmed in silico in palindromic mode using Trimmomatic. 
Sequencing reads were converted to C-to-T and G-to-A versions and were mapped to equivalent 
conversions of the reference sequence by Bismark to determine the single best location the 
sequencing reads mapped to. In this example, the best alignment is from alignment 1. Finally, to 
determine the proportion of m5C, sequencing reads prior to the in silico conversions were 
compared to the original reference sequence. The red base represents the m5C site, green bases 
represent C-to-T converted bases and orange bases represent G-to-A converted bases. 
 
3.2.6.B GENERAL FEATURES OF THE MISEQ AMPLICON LIBRARIES 
In this thesis, multiple MiSeq runs were performed for the validation of candidate m5C 
sites. The initial MiSeq run was performed in Professor Susan Clark’s lab at the Garvan 
Institute of Medical Research. I performed all experimental work including the 
preparation of the sequencing run. Library preparations for subsequent MiSeq 
sequencing runs were performed by myself, but the final dilution, spike in of the PhiX 
control and preparation of the sequencing runs were performed by Ms. Angela Higgins 
at the BRF at ANU. 
Adaptors are trimmed in silico
C-to-T in silico conversion 
of reads
G-to-A in silico conversion 
of reads
...TAGGATTTAGGTATCAGTTTTGGTTTAATT...
...TAGGATTTAGGTATTAGTTTTGGTTTAATT...
Align reads to C-to-T and 
G-to-A converted reference 
sequences
G-to-A converted reference sequenceC-to-T converted reference sequence
...TAGGATTTAGGTATCAGTTTTGGTTTAATT...
...TAGGATTTAGGTATTAGTTTTGGTTTAATT...
...TAAAATTTAAATATCAATTTTAATTTAATT...
...CAGGACTCAGGCATCAGTCTTGGTCTAATT...
...TAGGATTTAGGTATCAGTTTTGGTTTAATT...
Proportion of methylation determined by comparing 
reads with corresponding reference sequence
...CAGGACTCAGGCATCAGTCTTGGTCTAATT... Reference sequence
Bisulfite-converted sequencing read with adaptors
1
2
3
4
...CAAAACCCAAACACCAACCCCAACCCAACC...
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Table 3.3 provides the general features of the libraries sequenced on the Illumina® 
MiSeq platform for this thesis, including the quantification method used to load the 
libraries, concentration of the library loaded for sequencing, cluster density, the 
proportion of reads with a quality score (Q)≥30 and the average proportion of mappable 
sequencing reads. The cluster density and proportion of Q≥30 are determined directly 
by the MiSeq platform and provide an indication of the quality of the sequencing run. 
The quality score is the probability of a base being incorrectly called and a Q≥30 
indicates a 99.9% accuracy in base calling. 
 
The quantification method used for the first MiSeq run performed at the Garvan 
Institute of Medical Research was based on qPCR and yielded a cluster density in the 
optimal range and over 74% mappable reads. For the following MiSeq sequencing run 
performed at the BRF, the library was quantified by a High Sensitivity DNA Chip. This 
provided a significantly lower concentration compared to the qPCR and yielded a 
higher cluster density and lower percentage of mappable reads. The subsequent 
sequencing runs were prepared based on the qPCR, which led to relatively optimal 
cluster densities and a high proportion of mappable reads. 
 
Table 3.3. General features of the MiSeq amplicon libraries. 
MiSeq 
run  
Final 
quantification 
method 
Concentration 
loaded for 
sequencing 
(pM) 
Cluster 
density 
(K/mm2) 
% ≥Q30 
% average 
mappable 
reads 
1 qPCR 9 700 88.0 74.5 
2 Bioanalyzer 8 1290 79.3 44.5 
3 qPCR 7 596 97.2 88.7 
4 qPCR 8 699 95.2 81.8 
5 qPCR 9 734 97.0 88.8 
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Validation of candidate m5C sites in RNA 
Using this technique, a number of candidate m5C sites detected from the bsRNA-seq 
were validated. For the HeLa knockdown samples, 8/9 m5C sites in tRNAs, 5/5 m5C 
sites in other ncRNAs and 9/10 m5C sites in mRNAs were validated. This will be 
discussed in more detail in Chapter 4. For the PrEC and LNCaP samples, 7/7 m5C sites 
in tRNAs, 2/2 m5C sites in other ncRNAs and 7/10 m5C sites in mRNAs were validated. 
This will be discussed in more detail in Chapter 6. 
 
3.2.7 BISULFITE CONVERSION AND KNOCKDOWN 
EFFICIENCY BASED ON BSRNA-SEQ AND MISEQ 
In this section, I will describe the bisulfite conversion efficiency of all samples and the 
knockdown efficiency of the HeLa methyltransferase knockdown samples based on 
bsRNA-seq and MiSeq amplicon sequencing. The heatmaps I generated in this section 
and the remainder of this thesis using the R programming language demonstrate the 
percentage of non-conversion of cytosines within the segment of the transcript 
interrogated by bsRNA-seq or MiSeq amplicon sequencing. That is, the percentage of 
cytosines that were not converted to uracil, which may be attributed to m5C sites or 
inefficient bisulfite conversion. However, the percentage of non-conversion at a known 
m5C site or validated m5C site will be described in terms of methylation percentage. 
 
3.2.7.A R-LUC IN VITRO TRANSCRIPTS 
Although the bisulfite conversion efficiency was assessed by Sanger bisulfite 
sequencing prior to library preparation, this was only examined for a small portion of 
the R-Luc in vitro transcripts. As such, the entire transcripts were examined from the 
bsRNA-seq for both the HeLa methyltransferase knockdown samples and PrEC and 
LNCaP samples. As expected, both in vitro transcripts exhibited high coverage and very 
little non-conversion (Figures 3.26 and 3.27). The mean cytosine conversion was 
calculated for each in vitro transcript, indicating >99.8% conversion in all samples. This 
reiterates that the bisulfite conversion efficiency was high for all samples (Table 3.4). 
 
A small portion of the non-humanised R-Luc in vitro transcript was amplified and 
sequenced using MiSeq amplicon sequencing for validation, also revealing efficient 
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bisulfite conversion of the biological replicate HeLa methyltransferase knockdown 
samples and PrEC and LNCaP samples (Figures 3.26A and 3.27A; bottom panel). 
Examples of the typical read coverage throughout the amplicon and between samples 
from MiSeq amplicon sequencing are indicated for the R-Luc in vitro transcripts in 
Figures 3.26A and 3.27A. The coverage was relatively even throughout the amplicon 
and similar coverage was evident between samples, indicating even pooling. The range 
of coverage for subsequent MiSeq amplicon sequencing data will be indicated in the 
figure legends. In many cases, the range of coverage indicated in the following chapters 
may be quite large. This is chiefly due to variations in the concentrations for each 
MiSeq sequencing run that was performed. 
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Figure 3.26. Bisulfite conversion efficiency of the R-Luc in vitro transcripts assessed by 
bsRNA-seq and MiSeq amplicon sequencing of the HeLa methyltransferase knockdown 
samples. 
A) Non-humanised R-Luc in vitro transcript, B) Humanised R-Luc in vitro transcript. The top 
two panels show the coverage in RPM and the proportion of non-conversion based on the 
bsRNA-seq. The bottom two panels in A) show the coverage of a segment of the R-Luc in vitro 
transcript and proportion of non-conversion based on MiSeq amplicon sequencing. 
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Figure 3.27. Bisulfite conversion efficiency of the R-Luc in vitro transcripts assessed by 
bsRNA-seq and MiSeq amplicon sequencing of PrEC and LNCaP cells. 
A) Non-humanised R-Luc in vitro transcript, B) Humanised R-Luc in vitro transcript. The top 
two panels show the coverage in RPM and the proportion of non-conversion based on the 
bsRNA-seq. The bottom two panels in A) show the coverage of a segment of the R-Luc in vitro 
transcript and proportion of non-conversion based on MiSeq amplicon sequencing. 
 
Table 3.4. Mean cytosine conversion of the R-Luc in vitro transcripts based on bsRNA-seq. 
Sample 
Mean conversion percentage (%) 
Humanised R-Luc in vitro 
transcript 
Non-humanised R-Luc in 
vitro transcript 
NSUN2 99.87 99.87 
TRDMT1 99.89 99.87 
DNMT1 99.89 99.86 
NTC 99.87 99.86 
PrEC 1 99.87 99.90 
PrEC 2 99.90 99.86 
LNCaP 1 99.90 99.84 
LNCaP 2 99.92 99.88 
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3.2.7.B KNOWN M5C SITES IN TRNAASP(GUC) AND TRNALEU(CAA) 
The known m5C sites of tRNAAsp(GUC) and tRNALeu(CAA) were also examined in all 
samples using bsRNA-seq, and validated using MiSeq amplicon sequencing. Both 
tRNAs exhibited high coverage from the bsRNA-seq, which declined towards the 3’ 
end of the tRNAs (Figures 3.28 and 3.29; top panels). Strong depletion of m5C was 
observed at C48 and C49 of tRNAAsp(GUC) and C34 of tRNALeu(CAA) in the NSUN2 
knockdown sample according to the bsRNA-seq (Figure 3.28; middle panels). The 
depletion of m5C at C48 and C49 in tRNAAsp(GUC) in the replicate NSUN2 knockdown 
was more modest, although strong depletion of methylation was observed at C34 of 
tRNALeu(CAA) (Figure 3.28; bottom panels). Depletion of m5C at C38 of tRNAAsp(GUC) in 
both TRDMT1 knockdown samples was also evident. High levels of methylation were 
observed in the DNMT1 knockdown and NTC samples, indicating that m5C was not 
converted to uracil. While Sanger bisulfite sequencing provided an indication of 
enzyme knockdown efficiency, the high-throughput nature of bsRNA-seq and MiSeq 
amplicon sequencing provided higher confidence that NSUN2 and TRDMT1 were 
knocked down. 
 
Both replicates of the PrEC and LNCaP samples showed high coverage of tRNAAsp(GUC) 
and tRNALeu(CAA) through the majority of the transcripts and high methylation levels at 
all known m5C sites (Figure 3.29). As with the HeLa methyltransferase knockdown 
samples, this indicated that conversion of the m5C sites to uracil did not occur. 
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Figure 3.28. bsRNA-seq and MiSeq amplicon sequencing of tRNAAsp(GUC) and tRNALeu(CAA) 
in the HeLa methyltransferase knockdown samples. 
The top panel displays the coverage throughout the transcript in RPM based on bsRNA-seq, the 
middle panel displays the proportion of non-conversion based on bsRNA-seq, and the bottom 
panel displays the proportion of non-conversion in a segment of the transcript based on MiSeq 
amplicon sequencing. The bsRNA-seq data is based on the local mapping of tRNAs. A) 
tRNAAsp(GUC), B) tRNALeu(CAA). Sequencing reads from MiSeq amplicon sequencing were 
mapped to spliced and unspliced tRNALeu(CAA). The shades of grey in the middle panel indicate 
regions of the transcript where coverage was <5 reads based on bsRNA-seq. The line in the 
heatmap of the spliced tRNALeu(CAA) indicates the region spliced.  The tRNA structural positions 
with m5C sites are indicated in red below the heatmap. N and T indicate m5C sites mediated by 
NSUN2 and TRDMT1, respectively. The coverage from MiSeq amplicon sequencing ranged 
from 600-14,000 mappable sequencing reads. 
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Figure 3.29. bsRNA-seq and MiSeq amplicon sequencing of tRNAAsp(GUC) and tRNALeu(CAA) 
in PrEC and LNCaP cells. 
The top panel displays the coverage throughout the transcript in RPM based on bsRNA-seq, the 
middle panel displays the proportion of non-conversion based on bsRNA-seq, and the bottom 
panel displays the proportion of non-conversion in a segment of the transcript based on MiSeq 
amplicon sequencing. The bsRNA-seq data is based on the local mapping of tRNAs. A) 
tRNAAsp(GUC). B) tRNALeu(CAA). Sequencing reads from MiSeq amplicon sequencing were 
mapped to spliced and unspliced tRNALeu(CAA). The shades of grey in the middle panel indicate 
regions of the transcript where coverage was <5 reads based on bsRNA-seq. The line in the 
heatmap of the spliced tRNALeu(CAA) indicates the region spliced. The tRNA structural positions 
with the m5C sites are indicated in red below the heatmap. The coverage from MiSeq amplicon 
sequencing ranged from 1,000-75,000 mappable sequencing reads. 
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3.3 DISCUSSION 
In order to examine the RNA m5C profiles in several cell lines and the substrate range 
of NSUN2 and TRDMT1, it was necessary to improve and establish methods to detect 
m
5C in RNA. In addition, it was essential to prepare cells for bsRNA-seq and establish 
a knockdown model of NSUN2 and TRDMT1. Bisulfite conversion of RNA coupled 
with next-generation sequencing, termed bsRNA-seq, and a subsequent bioinformatics 
pipeline were implemented for the detection of candidate m5C sites. For the validation 
of candidate m5C sites, attempts were made to use an anti-m5C antibody for MeRIP 
however the antibody failed to detect m5C in RNA. I have improved the method for the 
validation of candidate m5C sites using a high-throughput approach on the Illumina® 
MiSeq platform. In this section, I will discuss the outcomes of this work.  
  
3.3.1 KNOCKDOWN OF NSUN2  AND TRDMT1  IN HELA 
CELLS 
The process of knocking down NSUN2 and TRDMT1 was not trivial as in addition to 
reducing the amount of enzyme it was necessary to deplete m5C at known target sites of 
these enzymes. Some transcript biotypes have half-lives of up to several days, with 
tRNAs and rRNAs being exceptionally long [251-253]. Thus, it was necessary to 
perform the RNAi-mediated knockdown of NSUN2 and TRDMT1 over a several day 
period. Dr. Jeffrey E. Squires previously performed a time course with a transfection 
period of 3, 4, 5 and 6 days. Sanger bisulfite sequencing of tRNAAsp(GUC) and 
tRNALeu(CAA)  at each time point revealed that the 6-day transfection period resulted in 
the best depletion of m5C in these tRNAs, indicating that the majority of the tRNAs had 
turned over during a time at which the methyltransferase activities were substantially 
reduced. Interestingly, depletion of m5C at C48 and C49 in tRNAAsp(GUC) in the NSUN2 
knockdown samples was more modest compared to the depletion of m5C observed at 
C34 in tRNALeu(CAA). A recent study reported a similar result for tRNAGly(GCC) when 
NSUN2 was knocked down, where only partial reduction in methylation was observed at 
the NSUN2 target sites of C48, C49 and C50 [77]. It is possible that some tRNAs have 
a longer half-life than others, resulting in incomplete turnover of the transcript. Also, as 
the methyltransferases were only depleted in a transient manner, tRNAs that were 
transcribed later during the transfection period may still be present and methylated. This 
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is supported by a recent study that performed bisulfite sequencing on tRNAAsp(GUC) from 
Nsun2 knockout mice and showed complete ablation of methylation at C48 and C49 
[149]. As almost complete depletion of methylation was observed at C38 in the 
TRDMT1 knockdown sample, this suggests that knockdown of this enzyme was more 
efficient.  
 
Although it was expected that there would be an underrepresentation of candidate m5C 
sites called as NSUN2 and TRDMT1 targets from the bsRNA-seq due to their transient 
depletion, the fact that depletion of m5C at the known target sites in tRNAs was evident 
indicates that m5C sites mediated by NSUN2 and TRDMT1 in transcript biotypes with 
shorter half-lives should be called as NSUN2 and TRDMT1 targets in this thesis. 
 
3.3.2 FEATURES OF THE BSRNA-SEQ LIBRARIES 
3.3.2.A DISTRIBUTION OF SEQUENCING READS 
The library construction was based on the size selection of cDNA products from 50-120 
nt in order to capture both fragmented tRNA and mRNA sequences. While this method 
was successful in capturing tRNAs, other ncRNAs and mRNAs, ~40-75% of the 
sequencing reads in all libraries mapped to rRNAs. This was not unexpected as current 
rRNA depletion methods available are yet to completely remove rRNA due to its 
substantial abundance. We have previously detected a large proportion of sequencing 
reads from our previous bsRNA-seq study mapping to rRNA despite rRNA depletion 
and poly(A)+ selection of HeLa cell RNA [58]. Interestingly, the second replicate 
library preparation for the PrEC and LNCaP samples exhibited less sequencing reads 
mapping to rRNA compared to the first library preparation, which consisted up to 75% 
rRNA. This is most likely attributed to batch variation of the rRNA depletion kit. To 
remove unwanted transcripts such as rRNA in the future, a technique that involves 
probe-directed degradation (PDD) of unwanted RNA species could be used [254]. This 
technique relies on the hybridisation of DNA oligonucleotides to unwanted RNA 
species during the single-stranded cDNA library stage, followed by digestion with 
Duplex Specific Nuclease, which specifically digests dsDNA. This technique is 
advantageous in that it removes unwanted sequences during the cDNA library 
preparation stage, minimising RNA degradation. Furthermore, the flexibility in the 
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probe design means that other unwanted abundant transcripts can be removed. Removal 
of the unwanted abundant transcripts using PDD could potentially allow higher 
coverage of other transcript biotypes, including mRNAs and tRNAs.  
 
Despite the substantial amount of rRNA in the libraries, the size selection used for 
bsRNA-seq library preparation successfully selected for mRNAs, tRNAs and other 
ncRNAs; ~13-23% of the sequencing reads mapped to mRNA, 2-4% to tRNA, and the 
remainder to various ncRNA. Thus, this library preparation enabled the sequencing of 
many transcript biotypes for candidate m5C site detection. 
 
3.3.2.B ALIGNMENT OF SEQUENCING READS AND DETECTION OF 
CANDIDATE M5C SITES  
The bioinformatics pipeline implemented in this study had been modified from the first 
transcriptome-wide detection of m5C in RNA we performed [58]. Previously, SOCS-B 
was used, which is an alignment algorithm specific for bisulfite converted SOLiD™ 
sequencing reads. A limitation of SOCS-B is that it is computationally intensive and can 
be time consuming in aligning the reads; it is for this reason that B-SOLANA was 
chosen. B-SOLANA is an alignment algorithm specifically developed for the mapping 
of bisulfite-converted DNA in colour-space, like SOCS-B. For the alignment of DNA, 
two in silico bisulfite conversions of the reference genome are performed; one in which 
all cytosines are converted, and one in which all cytosines except those in a CpG 
context are converted, allowing detection of m5C sites in CpG clusters. It was necessary 
to adapt B-SOLANA for the alignment and detection of candidate m5C sites in RNA. 
 
As m5C sites in RNA have not yet been detected in clusters of CpGs and they do not 
necessarily occur in a CpG context, candidate m5C sites were detected as mismatches. 
The Bowtie parameters used for the mapping of the bsRNA-seq data were set to a 
maximum of three colour-space mismatches (~1.5 bases) within the first 35 nt of the 
sequencing read (i.e. the higher-quality 5’ end of the read). Any sequencing reads that 
contained more mismatches within the first 35 nt were discarded. This could potentially 
be an issue for transcripts that exhibit multiple candidate m5C sites in close proximity to 
each other, such as tRNAs, as reads derived from such a region may fail to be mapped 
(Figure 3.30). As a compromise, a Phred score sum of 200 was set as a threshold, which 
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allowed for more mismatches in the last 15 nt of the sequencing read and increased the 
possibility of detecting multiple candidate m5C sites in the same sequencing read. A 
caveat of this approach, however, is the increased probability of detecting sequencing 
errors and low quality bases towards the 3’ end of the sequencing read. However, in the 
case of tRNAAsp(GUC), these parameters allowed for the detection of all three known m5C 
sites in all libraries (Figures 3.28A and 3.29A). Examination of the sequencing reads in 
IGV revealed that when the sequencing reads spanned tRNAAsp(GUC) such that the C38, 
C48 and C49 were located in the first 35 nt, no more than two m5C sites were detected 
in a single sequencing read as a result of the mismatch threshold applied (data not 
shown). Therefore, the three m5C sites were distributed over multiple sequencing reads. 
When C48 and C49 were located towards the 3’ end of the sequencing read, all three 
m
5C sites could be detected as a result of the increased number of mismatches allowed 
towards the 3’ end. 
 
With the exception of tRNAs, multiple m5C sites within close proximity have not yet 
been detected in other transcript biotypes. Previously, we found that 8.7% of the 
cytosines detected by bsRNA-seq in tRNAs contained m5C, while only 1.2% of 
cytosines in other ncRNAs and 0.4% of cytosines in mRNAs contained m5C [58]. 
Therefore, it was expected that the underrepresentation of candidate m5C sites as a 
result of the alignment algorithm would be minimal in this thesis. 
 
The issues associated with the detection of candidate m5C sites in the bsRNA-seq data 
by B-SOLANA were not evident using Bismark for the alignment of the MiSeq 
amplicon sequencing data. Mapping of the MiSeq amplicon sequencing data by 
Bismark involved converting sequencing reads into C-to-T and G-to-A versions that 
were aligned to equivalently converted reference sequences. One of these conversions 
will result in no mismatches and align perfectly to the reference sequence (Figure 3.25). 
For example, if methylated Cs in a sequencing read are represented by a C, then this 
will be converted to Ts after the C-to-T conversion, and will map perfectly to the 
equivalent conversion of the reference. Following this, the sequencing reads prior to C-
to-T and G-to-A conversion were aligned with the original reference sequence to detect 
m5C sites regardless of the context of the site. 
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Figure 3.30. Schematic displaying the issues associated with multiple m5C sites within a 
single 50 nt SOLiD™ colour-space sequencing read.  
Prior to mapping, the reference sequence was in silico bisulfite converted. Sequencing reads that 
exhibited more than three colour-space mismatches within the first 35 nt of the read compared 
to the reference sequence were discarded. The m5C sites are indicated in red. 
 
The in silico non-CpG conversion of the references was not applied for the alignment of 
the bsRNA-seq data locally to rRNAs in order to limit the detection of non-converted 
cytosines attributed to incomplete denaturation of the secondary structure. The 
experimental procedures employed in this study were also performed in such a way to 
efficiently denature RNA while limiting its fragmentation, as too much fragmentation 
could affect the mapping of the sequencing reads. While these procedures were applied, 
it was expected that a low amount of clusters of non-conversion may still be detected as 
a result of the higher amount of mismatches allowed towards the 3’ end of the 
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sequencing read. As expected, clusters of non-conversion were detected in 28S rRNA in 
this thesis, however the amount of clusters observed was substantially less than the 
amount detected in our previous study (see Chapter 4) [58].  
 
Although these are drawbacks with the alignment of the bsRNA-seq data, it was 
necessary to adapt B-SOLANA for the alignment of bisulfite-converted RNA 
sequencing reads as no alignment algorithm has been developed specifically for the 
detection of m5C sites in RNA. Thus, a compromise was made between limiting the 
alignment of sequencing reads with multiple errors and allowing the detection of 
candidate m5C sites in RNA.  
 
3.3.2.C EXPERIMENTAL DESIGN FOR THE DETECTION OF HIGH-
CONFIDENCE CANDIDATE M5C SITES  
The experimental design for bsRNA-seq of the HeLa methyltransferase knockdown 
samples was set up as an initial screen for RNA targets of NSUN2 and TRDMT1, and 
as such a single sample was sequenced for each condition. Similarly, the experimental 
design for the bsRNA-seq of PrEC and LNCaP cells was set up as an initial comparison 
of candidate m5C sites detected in different cellular contexts, which was enabled by the 
sequencing of two biological replicates. These biological replicates were performed at a 
later date to increase the accuracy of the initial screen. 
 
Prior to candidate m5C site detection, non-specific filtering was applied to remove low 
levels of non-conversion to exclude noise caused by spurious non-conversion. 
Additionally, candidate sites required ≥5 reads in all samples used in the model to 
prevent incorrect calling of a candidate differential m5C site as a result of low 
expression. For example, if a candidate m5C site is detected in a transcript in the 
TRDMT1 knockdown, DNMT1 knockdown and NTC samples, but the NSUN2 
knockdown sample does not have sufficient coverage of that transcript, then this 
candidate m5C site may be incorrectly assigned as a NSUN2-mediated site. Similarly, if 
a candidate m5C site is detected in a transcript in LNCaP cells and there is insufficient 
coverage of this transcript in PrEC cells, this may be incorrectly assigned as a candidate 
m5C site hypermethylated in LNCaP cells. To detect high-confidence candidate m5C 
sites, a proportion statistic in combination with a moderated t-test was used to either 
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compare the proportion of m5C between samples for the detection of candidate 
differential m5C sites, or against 0% methylation to call candidate m5C sites.  
 
The use of three controls for the detection of candidate m5C sites in the HeLa 
methyltransferase knockdown dataset allowed for the detection of high-confidence 
candidate m5C sites. Although the control samples involved three different treatments, 
they behaved as “pseudo-replicates” for this study; DNMT1 does not target RNA for 
methylation and NSUN2 and TRDMT1 were found to target different sites. Therefore, 
for the detection of all candidate m5C sites in HeLa cells, the NSUN2 knockdown, 
TRDMT1 knockdown and NTC samples, followed by the TRDMT1 knockdown, 
DNMT1 knockdown and NTC samples were used as controls.  ≥10% mean methylation 
was required across these controls. For the detection of candidate m5C sites mediated by 
NSUN2 or TRDMT1, three controls were used as described for the detection of all 
candidate m5C sites, which required ≥10% mean methylation. The proportion of m5C in 
the NSUN2 knockdown and TRDMT1 knockdown samples was then compared against 
the three controls for the detection of NSUN2 and TRDMT1 target sites. As one 
“experimental” sample was used for the detection of candidate m5C sites mediated by 
NSUN2 or TRDMT1, it was expected there would be an underestimation of the number 
of candidate m5C sites found to be targeted by these two enzymes in this thesis. 
 
The sequencing of biological replicates of PrEC and LNCaP cells enabled the detection 
of candidate m5C sites in common between each cell line by requiring ≥10% mean 
methylation across all four samples. For the detection of candidate differential m5C sites 
in PrEC and LNCaP cells, ≥10% mean methylation was required in either both PrEC 
samples or both LNCaP samples.   
 
To limit the amount of false positive sites detected using this bioinformatics pipeline, 
candidate m5C sites that were not homogenous (i.e. <95% of the reads were not a C or 
T) and overlapped SNPs or editing sites based on the available databases were removed. 
Two issues could occur if a candidate m5C site overlapped a SNP. The first is that if a 
C-to-T SNP existed at the site for half of the sequencing reads, then this would result in 
the underestimation of the proportion of m5C at this site. The second issue is that for the 
detection of candidate differential m5C sites in PrEC and LNCaP cells, a site may be 
incorrectly called if only one cell line exhibits a SNP. 
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3.3.2.D BISULFITE CONVERSION EFFICIENCY 
It was important in this study to control for the bisulfite conversion efficiency in order 
to limit the amount of false positive m5C sites detected due to lack of cytosine 
conversion. As such, non-human in vitro transcripts containing no m5C sites were 
spiked into the RNA samples prior to bisulfite conversion. Sanger bisulfite sequencing 
of two segments of a R-Luc in vitro transcript prior to library preparation revealed high 
bisulfite conversion efficiency for those segments. The bisulfite conversion efficiency 
was also examined for the entire R-Luc in vitro transcripts based on bsRNA-seq, 
revealing >99.8% conversion of cytosines. Sequencing of tRNAAsp(GUC) and 
tRNALeu(CAA) showed high levels of methylation at the known m5C sites in all samples, 
with the exception of the NSUN2 and TRDMT1 knockdown samples where depletion 
of methylation at target sites was observed. This indicated that the bisulfite conversion 
technique employed in this study resulted in efficient conversion of unmethylated 
cytosines and did not result in conversion of known m5C sites. 
 
3.3.2.E RNA MODIFICATIONS RESISTANT TO BISULFITE CONVERSION 
Although bisulfite sequencing of RNA is currently the gold standard for detecting m5C, 
it does come with a potential drawback. A potential issue with bisulfite conversion is 
that there may be other modifications besides m5C that are resistant to conversion, 
although the types of modifications that may be resistant still remain to be explored. 
Indications of this were made when bisulfite conversion was originally optimised for 
RNA, and N4, 2’-O-dimethylcytidine (m4Cm) at position 1402 of bacterial 16S rRNA 
was detected by locus-specific bisulfite sequencing [59]. The equivalent region in 
mitochondrial 12S rRNA from the hamster is methylated in the motif Gm4CCm5CG 
[255]. However, we have previously investigated the orthologous region in humans by 
bsRNA-seq and Sanger bisulfite sequencing of HeLa cells and could only detect the 
m5C site [58]. Furthermore, the bsRNA-seq data from this study also showed cytosine 
conversion at this site for all samples (see Chapter 4), suggesting that this modification 
is not resistant to the bisulfite conversion protocol employed in this thesis. Schaefer et 
al. also suggested that other modifications, such as N4-methylcytidine (m4C) and 3-
methylcytosine (m3C), could affect the deamination process during bisulfite conversion. 
m3C has been detected in human 18S and 28S rRNA by hydrolysis and 
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chromatography, although the location of these sites were never mapped [256]. 
Furthermore, m3C has been detected in S. cerevisiae tRNAs at C32 of tRNAThr1 and 
tRNASer1 [257, 258]. Recently, a study that involved predicting modifications in human 
tRNAs based on differences in RT incorporation found 13 m3C sites [259]. Three of 
these m3C sites were validated by m3C immunoprecipitation, and were located at C3 of 
tRNAMet(CAU), C32 of mitochondrial tRNAMet(CAU) and tRNAThr(UGU). Non-converted 
cytosines were not detected at these positions in this thesis (data not shown), suggesting 
that either this modification is not present in PrEC, LNCaP or HeLa cells or that this 
modification is not resistant to bisulfite conversion.  
 
An advantage of this study is that sequencing of both the NSUN2 and TRDMT1 
knockdown samples, which have the potential to target many sites for methylation, may 
provide enough information to narrow down the modification at a position. For 
example, if depletion of methylation is observed at a m5C site in a transcript in the 
NSUN2 knockdown sample compared to the controls, then it is clear that the 
modification must be m5C or potentially an oxidised form of this modification, such as 
5-hydroxymethylcytosine (hm5C), which is resistant to bisulfite conversion in DNA 
[260, 261]. However, the presence of hm5C naturally in RNA remains elusive. One 
study thus far has shown that ten-eleven translocation (TET) hydroxylases, which are 
responsible for oxidising m5C to hm5C in DNA [262], also possess this activity for 
RNA in vitro, suggesting that this modification may also be present naturally in RNA 
[263]. Interestingly, hm5C in DNA can be further oxidised to 5-formylcytosine (f5C) 
followed by 5-carboxylcytosine (ca5C) by the TET hydroxylases, both of which are not 
resistant to bisulfite conversion [264, 265]. Recently, a technique to distinguish between 
m5C and hm5C by taking advantage of the different chemical reactivity between these 
modifications has been developed by oxidising hm5C to f5C then performing bisulfite 
conversion, termed oxBS-seq [266]. In addition to this, standard bisulfite sequencing is 
performed, allowing distinction between m5C and hm5C by subtraction of the readouts. 
It would be worthwhile in the future to optimise this technique for RNA to not only 
distinguish between m5C and hm5C, but also provide the first transcriptome-wide 
detection of hm5C. 
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3.3.3 DETECTION OF M5C USING AN ANTIBODY 
To overcome potential issues associated with bisulfite conversion resistance of other 
modifications, attempts were made to optimise an anti-m5C antibody for the purpose of 
MeRIP. This technique could be coupled with next-generation sequencing to identify 
m
5C regions transcriptome-wide, or RT-qPCR to detect enrichment of candidate m5C 
sites relative to a negative control. This technique is well established in DNA, and as 
such anti-m5C antibodies were readily available for use in RNA.  
 
Several studies have used MeRIP-seq for the detection of m6A in RNA. On the 
contrary, only a single study has used this technique for the validation of candidate m5C 
sites detected by bsRNA-seq [76]. Although this technique does not provide single 
nucleotide resolution, the use of MeRIP would be favourable, both as a validation tool 
and for coupling with bsRNA-seq, which may help eliminate biases associated with 
both techniques. Therefore, the use of MeRIP for the detection of m5C warranted further 
exploration. 
 
The antibody implemented for this study was identical to that used in the m5C MeRIP-
seq study [76]. Optimisation of the anti-m5C antibody for the detection of m5C in RNA 
was initially performed using dot blot assays. Yeast tRNA was selected for the 
optimisation procedure due to its high abundance in m5C. HeLa cell RNA was also used 
as a true biological sample and it was expected that the amount of m5C detected in this 
sample would be substantially less than the highly modified tRNA. As controls, 
methylated DNA and unmethylated DNA were used, which were purchased from the 
manufacturer of the antibody. To ensure that the secondary structure did not impede the 
hybridisation of the antibody to RNA, the RNA samples were either heat denatured with 
or without formamide. The DNA controls were heat denatured with formamide and 
snap cooled on ice, or with 0.1 M NaOH, snap cooled on ice and neutralised with 6.6 M 
ammonium acetate. In all cases, m5C was detected in the methylated DNA control and 
not in the unmethylated DNA control, indicating that the dot blot assay was successful. 
However, regardless of the denaturation procedure, m5C was not detected in yeast 
tRNA or HeLa cell RNA. Staining of the membranes with methylene blue indicated that 
all samples hybridised successfully, suggesting that the secondary structure of the RNA 
may have impeded binding of the antibody to m5C despite denaturation. That this 
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antibody failed to detect m5C in RNA is unexpected considering it has been previously 
used for the detection of m5C by MeRIP-seq in archaea [76]. Furthermore, the antibody 
was raised against m5C conjugated to ovalbumin lacking the deoxyribose or ribose 
sugar, indicating that it could not distinguish between m5C in DNA or RNA. To 
determine the source of the issue, I contacted the authors regarding the protocol that was 
used in this publication but specific details were not provided. 
 
The dot blot assay used in this thesis was comparable to that used for detecting m6A in 
RNA in a previous study, although the denaturation procedures differed slightly. For the 
m6A study, the RNA was denatured by mixing glyoxal loading dye with the RNA and 
heating at 50°C for 20 min [56]. Glyoxal denatures the RNA by glyoxalating the bases, 
preventing base pairing and reducing RNA secondary structure formation in a similar 
manner to formamide. Further investigation into denaturation procedures would be 
important in order to use the m5C antibody for MeRIP in the future. In addition to 
denaturing RNA, it may be beneficial to fragment the RNA prior to hybridisation to the 
membrane; this would minimise secondary structure formation, making the RNA more 
accessible for the antibody. As this procedure is necessary for MeRIP, it would be ideal 
to use this approach for optimisation.  
 
3.3.4 IMPROVEMENTS TO BISULFITE SEQUENCING 
VALIDATION TECHNIQUES 
Several bisulfite sequencing methods were implemented for the detection of known 
m5C sites and validation of candidate m5C sites in RNA. Sanger bisulfite sequencing 
was performed to ensure bisulfite conversion was efficient and knockdown of the 
methyltransferases was sufficient. We have also previously implemented Sanger 
bisulfite sequencing for validation of novel candidate m5C sites in a number of 
transcript biotypes [58]. While this method proved to be useful, it was labour-intensive 
and low-throughput. Due to the larger number of samples in this study, it was necessary 
to implement a high-throughput approach that still involved locus-specific sequencing 
using the Illumina® MiSeq platform. This initially involved bisulfite PCR amplification 
of candidates in triplicate in order to reduce PCR amplification biases, followed by 
pooling of the amplicons, library preparation and high-throughput sequencing. There 
are a number of advantages to using this approach; it is less laborious and very high-
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throughput, allowing multiplexing of samples. Furthermore, since this approach was 
used for locus-specific sequencing, the MiSeq platform was capable of sequencing up to 
hundreds of thousands of reads per amplicon, providing higher confidence in the 
validation of candidate m5C sites compared to Sanger bisulfite sequencing.  
 
A caveat of the MiSeq approach was the inconsistency in library quantification 
throughout the library preparation and library validation process, which can affect 
cluster generation and the success of the sequencing run. Although quantification using 
the Qubit fluorometer, DNA High Sensitivity Chip and qPCR yielded vastly different 
results, it was interesting that the former two methods provided lower concentrations 
than the qPCR. As mentioned previously, the qPCR specifically amplifies DNA 
containing the Illumina® adaptors. Thus, it would be expected that this method would 
yield a lower concentration in comparison to the Qubit fluorometer and Agilent 
Bioanalyzer, as these methods would quantify all species of DNA including those 
fragments that don’t contain adaptors and adaptor primers.  
 
Loading of the libraries based on a High Sensitivity DNA Chip resulted in a high cluster 
density beyond the optimal range. This was most likely a result of the Agilent 
Bioanalyzer quantification method underestimating the true concentration, leading to 
overloading of the libraries onto the flow cell. This in turn caused overlapping of 
clusters, reducing the quality of mappable reads. Quantification of Illumina® libraries is 
a renowned issue and a study performed at the The Wellcome Trust Sanger Institute has 
focused on improving quantification of Illumina® Genome Analyzer libraries and 
sequencing runs [267]. They reported that quantifying libraries by spectrophotometry 
resulted in inconsistencies in the cluster density that was typically lower than the 
optimal range. This is not unexpected as all DNA species, including those that do not 
contain adaptors would be quantified. Interestingly, it was reported that quantification 
of libraries using the Agilent Bioanalyzer resulted in much more consistent cluster 
densities that were in the desired range. However, there were a few situations in which 
this quantification method led to high cluster densities, which they explained was a 
result of ssDNA generated during the PCR enrichment step of the library preparation 
not being easily quantified when mixed with dsDNA. Perhaps this is the issue that arose 
for the MiSeq run in this thesis. Nonetheless, the Agilent Bioanalyzer may be useful in 
determining the average fragment size after library preparation, which is necessary for 
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the quantification of libraries. For this study, agarose gel electrophoresis was used to 
determine the average fragment size, and the library concentrations determined 
according to this fragment size by qPCR resulted in successful sequencing runs.  
 
Despite the discrepancies associated with the quantification of the libraries, it is clear 
from this thesis that loading of the libraries based on concentrations determined by 
qPCR resulted in optimal cluster densities, read quality and high and consistent 
coverage of amplicons. The known m5C sites in tRNAAsp(GUC) and tRNALeu(CAA) were 
detected and validated as NSUN2 or TRDMT1-mediated m5C sites. Thus, validation of 
candidate m5C sites detected using bsRNA-seq by MiSeq amplicon sequencing proved 
to be a robust technique.  
 
3.3.5 CONCLUSIONS 
In this chapter, I have described the preparation of cell lines for the detection of m5C in 
RNA, as well as the improvement of techniques to detect m5C in RNA, both in terms of 
experimental procedures and bioinformatics pipelines. The RNAi-mediated knockdown 
of NSUN2 and TRDMT1 led to sufficient depletion of m5C at the known target sites in 
transcripts exhibiting long half-lives. The bisulfite conversion procedure used in this 
study was efficient, with unmethylated cytosines converted to uracil and minimal 
conversion of m5C to uracil based on the controls. The bsRNA-seq bioinformatics 
pipeline used for the alignment of sequencing reads and detection of candidate m5C 
sites was adapted for use with RNA and was an important resource for the detection and 
comparison of m5C sites in RNA under different conditions in this thesis. Finally, I have 
established a high-throughput and reliable procedure for the validation of candidate m5C 
sites in RNA using the Illumina® MiSeq platform.   
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3.4 CHAPTER HIGHLIGHTS 
• Two biological replicates of PrEC and LNCaP cells were prepared for bsRNA-seq.  
• RNAi-mediated knockdown of NSUN2, TRDMT1 and DNMT1 was successfully 
performed in HeLa cells, resulting in depletion of the respective mRNAs and 
enzymes. A single sample of each knockdown was prepared for bsRNA-seq as an 
initial screen to identify targets of NSUN2 and TRDMT1. 
• RNAi-mediated knockdown of NSUN2 and TRDMT1 resulted in depletion of m5C at 
known target sites of NSUN2 and TRDMT1. 
• Efficient bisulfite conversion was evident in all samples. 
• bsRNA-seq libraries were prepared using the SOLiD™ Total RNA-Seq Kit and the 
library construction was based on the size selection of cDNA products from 50-120 
nt in order to capture both fragmented tRNA and mRNA sequences. 
• B-SOLANA, an alignment algorithm specific for bisulfite-converted DNA, was 
adapted for use with bisulfite-converted RNA. 
• A proportion statistic and moderated t-test were applied to detect high confidence 
candidate m5C sites. For the HeLa methyltransferase knockdown samples, this 
enabled the detection of candidate m5C sites mediated by NSUN2 and TRDMT1, as 
well as all candidate m5C sites in HeLa cells. For PrEC and LNCaP cells, this 
allowed for the detection of candidate differential m5C sites and candidate m5C sites 
in common between each cell line. 
• Potential artefacts were limited by removing candidate m5C sites that overlapped 
SNPs or editing sites or <95% of the bases were not a C or T. 
• To be considered a candidate m5C site by bsRNA-seq, ≥5 reads were required in all 
samples used in the model and ≥10% mean methylation was required across all 
control samples. 
• Attempts were made to optimise an anti-m5C antibody for MeRIP, however this 
antibody failed to detect m5C in RNA based on dot blot assays. 
• A high-throughput method for the validation of candidate m5C sites was established 
using the Illumina® MiSeq platform, which allowed sequencing of bisulfite PCR 
amplicons with substantial read depth, increasing confidence in the validation of 
candidate m5C sites.        
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4.1 INTRODUCTION 
The recent advancement in next-generation sequencing technologies for the detection of 
RNA modifications has prompted further investigations into their enzymology. 
Currently, two RNA methyltransferases are known to catalyse m5C formation in 
humans; NSUN2 and TRDMT1. Although studies over the last several years have 
investigated the substrate range of these enzymes in certain transcript biotypes, this field 
still remains to be explored in further detail. Previously, we have used a candidate 
approach coupling RNAi-mediated knockdown of NSUN2 and TRDMT1 with Sanger 
bisulfite sequencing and discovered that NSUN2 has a wider substrate range than 
previously anticipated, targeting at least three structural positions in tRNAs as well as 
one ncRNA and three mRNAs [58]. More recent studies have employed next-generation 
sequencing to determine the RNA substrates of NSUN2 and to a lesser extent, 
TRDMT1, revealing various ncRNA targets of NSUN2 [77, 78, 149]. However, the 
understanding of m5C in mRNA is still limited. One study has reported a single mRNA 
target [77], while another study detected 312 mRNA targets but did not investigate this 
any further [78]. Thus, it was of interest to explore NSUN2 RNA targets in more detail 
and to determine the specificity of NSUN2 for these transcripts. 
 
The aim of this chapter was to perform an initial screen to identify RNA targets of 
NSUN2 and TRDMT1 based on the coupling of RNAi-mediated knockdown of NSUN2 
and TRDMT1 with bsRNA-seq. Using this data, the distribution of all candidate m5C 
sites in RNA in HeLa cells was also explored. Candidate m5C sites were thoroughly 
investigated in tRNAs and the findings independently confirmed recently published 
work by others. Candidate m5C sites in other ncRNAs and mRNAs were also 
extensively investigated, including the location bias, structural context and sequence 
context of this modification, providing a wealth of novel findings.  
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4.2 RESULTS 
The following sections document the distribution, abundance, sequence and structural 
context of candidate m5C across transcript biotypes in HeLa cells, with a particular 
focus on candidate m5C sites called as NSUN2 targets. Mapping of the bsRNA-seq and 
MiSeq data were performed by Dr. Brian J. Parker, who also performed the subsequent 
global analyses in consultation with myself. I performed the experimental validations, 
secondary analyses and graphical representations generated by the R programming 
language. 
 
4.2.1 M5C SITES DETECTED IN HELA CELLS 
As detailed in Chapter 3, bsRNA-seq and the subsequent bioinformatics analyses were 
performed on a single sample for each control and knockdown condition. Sanger 
bisulfite sequencing and bsRNA-seq revealed efficient bisulfite conversion of all 
samples and sufficient knockdown of NSUN2 and TRDMT1 based on the depletion of 
m
5C at known positions in tRNAAsp(GUC) and tRNALeu(CAA). The single biological 
replicates used for the validation of candidate m5C sites by MiSeq amplicon sequencing 
also showed efficient bisulfite conversion and sufficient knockdown of the 
methyltransferases. 
 
4.2.1.A TOTAL M5C SITES IN HELA CELLS 
Using the proportion statistic and appropriate controls as described in Chapter 3, the 
total number of candidate m5C sites in HeLa cells was determined. The criteria for the 
detection of candidate m5C sites were defined as ≥5 reads in all samples used in the 
model and ≥10% mean methylation across the control samples, as well as a FDR≤1%. 
This yielded a total of 4,241 candidate m5C sites in a wide variety of transcript biotypes, 
including tRNAs, other ncRNAs and mRNAs (Figure 4.1).  
 
As expected, a large number of candidate m5C sites were detected in tRNAs; 490 based 
on the global mapping and 185 based on the local mapping to tRNA sequences from 
tRNAdb. As detailed in section 3.2.3.A, local mapping of the data is a more accurate 
source for mature tRNA methylation and was thus used primarily in the following. As 
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the global mapping dataset also contains reads deriving from precursor tRNA (pre-
tRNA) molecules, it was of particular use for analysing the temporal relationship 
between processing and methylation. 
 
667 candidate m5C sites were detected in other ncRNAs and were distributed across 
various transcript biotypes. Interestingly, the majority of the candidate m5C sites 
detected were in mRNAs. The 1,564 candidate m5C sites detected in mRNAs ranged 
over 1,229 transcripts, indicating an average of ~1.3 candidate m5C sites per transcript. 
1,486 candidate m5C sites were also detected in unannotated intronic or intergenic 
regions that did not meet the criteria to be considered one of the other transcript 
biotypes. Transcripts in this category include previously unidentified lincRNAs and 
antisense transcripts of coding genes and intergenic regions. The complete list of 
candidate m5C sites in HeLa cells is located in Appendix 8.3. 
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Figure 4.1. Distribution of candidate m5C sites detected in HeLa cells across different 
transcript biotypes. 
≥5 reads in all samples used in the model and ≥10% mean methylation across the control 
samples was required for the detection of candidate m5C sites. FDR≤1% estimated by the 
Benjamini-Hochberg method. “Other structured RNA” refer to Rfam structured RNA entries 
and “ncRNA (UCSC)” refer to UCSC-annotated ncRNAs, which include long intergenic 
ncRNA (lincRNA) and unstructured RNA. The number of candidate m5C sites detected in each 
transcript biotype is indicated.  
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In order to gain insight into the abundance of m5C across transcript biotypes, the 
proportion of cytosines with ≥5 reads that exhibited candidate m5C sites in each 
transcript biotype was determined (Table 4.1). As expected, m5C in tRNAs was quite 
abundant, with 3.98% of cytosine positions being called as candidate m5C sites from the 
local mapping and 5.73% in tRNAs mapped globally. The abundance of m5C in 
mRNAs was much lower, with 0.08% of cytosines exhibiting candidate m5C sites. 
Interestingly, several categories of ncRNA had >1% cytosines as m5C sites, including 
rRNA, vault (vt) RNA, ubiquitous (u) RNA, 7SK RNA and 7SL RNA. 
 
Table 4.1. The proportion of cytosines with ≥5 reads containing candidate m5C sites across 
different transcript biotypes. 
Sample Number of m
5C 
sites 
Total number of 
C with reads ≥ 5 % m
5C 
Global tRNA 490 8553 5.73 
Local tRNA 185 4645 3.98 
mRNA 1564 1,966,054 0.08 
rRNA 24 2229 1.08 
snoRNA 57 5571 0.74 
7SL RNA 187 9671 1.95 
7SK RNA 84 5928 1.42 
uRNA 178 9318 1.91 
vtRNA 2 109 1.83 
miRNA 7 1330 0.53 
ncRNA (UCSC) 100 85,562 0.12 
Mitochondrial RNA 31 2140 1.45 
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4.2.1.B M5C SITES MEDIATED BY NSUN2 AND TRDMT1 
Using the proportion statistic, the distribution of candidate m5C sites across transcript 
biotypes called as NSUN2 or TRDMT1 targets based on bsRNA-seq were determined. 
The criteria for enzyme target site detection were defined as ≥5 reads in all samples and 
≥10% mean methylation across all control samples, as well as a FDR≤30%. This 
yielded a total of 393 candidate m5C sites called as NSUN2 targets and 120 called as 
TRDMT1 targets, with both RNA methyltransferases targeting various transcript 
biotypes (Figure 4.2).  
 
As expected, both enzymes were responsible for many candidate m5C sites in tRNAs, 
with NSUN2 targeting 108 candidate m5C sites and TRDMT1 targeting 15 candidate 
m
5C sites based on the local mapping of tRNAs. Interestingly, 118 candidate m5C sites 
in mRNAs were called as NSUN2 targets and 53 candidate m5C sites in mRNAs were 
called as TRDMT1 targets, substantially extending what was previously known about 
the substrate range of these enzymes. Additionally, 33 candidate m5C sites in other 
ncRNAs were called as NSUN2 targets, and 9 candidate m5C sites in other ncRNA were 
called as TRDMT1 targets. The complete lists of candidate m5C sites called as NSUN2 
or TRDMT1 targets are located in Appendix 8.3. 
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Figure 4.2. The distribution of candidate m5C sites across different transcript biotypes 
called as NSUN2 or TRDMT1 targets.  
≥5 reads in all samples used in the model and ≥10% mean methylation across the control 
samples was required for the detection of candidate m5C sites called as NSUN2 or TRDMT1 
targets. FDR≤30% estimated by the Benjamini-Hochberg method. The number of candidate 
m
5C sites detected in each transcript biotype is indicated.  
 
Overall, of the 4,241 candidate m5C sites that were detected in HeLa cells, only 513 
were called as NSUN2 or TRDMT1 targets. This is due to a combination of factors, 
although as this study was performed as an initial screen it is likely that there was 
under-calling of methyltransferase target sites due to incomplete methyltransferase 
knockdown.  
 
In order to understand the contribution of NSUN2 and TRDMT1 to methylation, the 
proportion of candidate m5C sites in each transcript biotype called as NSUN2 or 
TRDMT1 targets was determined and the bulk methylation levels in each transcript 
biotype were also determined for each sample (Figure 4.3). The proportion of candidate 
m
5C sites called as NSUN2 or TRDMT1 targets varied for each transcript biotype 
(Figure 4.3; pie charts). The two candidate m5C sites detected in vtRNAs were called as 
NSUN2 targets, while 34-96% of candidate m5C sites detected in other transcript 
biotypes were not called as NSUN2 or TRDMT1 targets. To calculate the bulk 
methylation level in each transcript biotype for each sample, the mean proportion of 
methylation was calculated in each sample for all candidate m5C sites detected in HeLa 
cells (Figure 4.3; bar charts). Knockdown of NSUN2 resulted in at least some depletion 
of methylation across all transcript biotypes, indicating that this enzyme has a very 
broad substrate range. The knockdown of TRDMT1 had a more modest and selective 
effect in that reduced mean methylation was only evident in tRNA, mRNA and 7SL 
RNA. 
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Figure 4.3. Contribution of NSUN2 and TRDMT1 to m5C across transcript biotypes based 
on bsRNA-seq.  
The proportion of candidate m5C sites called as NSUN2 or TRDMT1 targets (pie charts) and the 
mean methylation of candidate m5C sites in each sample within each transcript biotype (bar 
charts) were determined based on bsRNA-seq. NSUN2 targets=N, TRDMT1 targets=T and 
undetermined=U. 
 
4.2.2 M5C IN TRNA 
It was of interest to document the candidate m5C sites detected in tRNAs in HeLa cells, 
as well as determine the substrate specificity of NSUN2 and TRDMT1. A focus was 
placed on the tRNA structural positions, isotypes and isoacceptors that exhibited 
candidate m5C sites. The tRNA structural positions refer to the positions within the 
secondary structure of the tRNA. Currently, there are seven structural positions known 
to contain m5C, including C34, C38, C40, C48-C50 and C72 (see Figure 4.4). 
Isoacceptors refer to the sequence within the anti-codon of a tRNA that translates into 
an amino acid for translation. Isotypes refer to those tRNAs that translate into the same 
amino acid. For example, tRNAs that contain the sequences AAA and GAA within the 
anti-codon translate into the same amino acid of phenylalanine, but are different 
isoacceptors. Thus, the aim of this section was to investigate the substrate specificity of 
NSUN2 and TRDMT1 in tRNA structural positions, isotypes and isoacceptors. This 
analysis primarily focused on the candidate m5C sites detected from the local mapping 
of tRNAs and conclusions were drawn from this. However, for completeness, the 
analyses were also performed on candidate m5C sites detected from the global mapping 
of tRNAs. Our results were juxtaposed with those of two recent studies that have used 
complementary transcriptome-wide techniques to detect tRNA targets of NSUN2 [77, 
150] and TRDMT1 [77], which will be detailed in the discussion section of this chapter.  
 
An investigation was also made to confirm that m5C in tRNAs can occur prior to 
splicing and whether m5C can occur prior to 5’ and 3’ end processing. I implemented a 
candidate approach to assess whether m5C can be detected in tRNAs prior to splicing. 
As the global mapping of tRNAs enabled mapping of a small proportion of sequencing 
reads to pre-tRNAs, this, in addition to a candidate approach, was used to investigate 
whether tRNAs are modified prior to 5’ and 3’ end processing. 
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4.2.2.A TRNA STRUCTURAL POSITIONS AND ISOTYPES TARGETED BY 
NSUN2 AND TRDMT1 
In order to determine the tRNA structural positions and isotypes that exhibited 
candidate m5C sites and the specificity of NSUN2 and TRDMT1, the bsRNA-seq data 
was mined and cloverleaf structures indicative of the tRNA secondary structure were 
generated. The cloverleaf structures detail the location of candidate m5C sites within the 
structural positions and the tRNA isotypes exhibiting candidate sites in these positions 
(Figure 4.4). In addition, the proportion of candidate m5C sites that were called as 
NSUN2 or TRDMT1 targets for each structural position was determined, which are 
indicated by the pie charts. 
 
Candidate m5C sites were detected at all known structural positions except C72 (Figure 
4.4A). The lack of sites at C72 was possibly due to the declining coverage towards the 
3’ end of the tRNAs. NSUN2 was found to exclusively mediate m5C at C34 in tRNALeu 
and C40 at tRNAGly. >60% of candidate m5C sites detected at C48 and C49 were called 
as NSUN2 targets with the remainder undetermined, and candidate m5C sites at these 
positions were in a wide range of tRNA isotypes. In addition, there was high 
concordance in the tRNA isotypes exhibiting candidate m5C at these two positions; 10 
tRNA isotypes containing candidate m5C sites at C48 and C49 overlapped. 
Interestingly, candidate m5C sites were detected at C48 and C49 of a suppressor tRNA, 
which is an entirely novel finding. By contrast, only 5 tRNA isotypes exhibited 
candidate m5C sites at C50, and 35% of the tRNA isotypes exhibiting a candidate m5C 
site at this position were called as NSUN2 targets. Unlike NSUN2, TRDMT1 was 
found to almost exclusively modify C38 in tRNAAsp, tRNAGly and tRNAVal. A candidate 
m5C site at C48 was detected in tRNACys as a TRDMT1 target, but this would require 
validation to determine if this is a genuine site. 
 
Four non-canonical structural positions were found to exhibit candidate m5C sites 
including C30, C44, C56 and C61. The site at C30 was specific to tRNAHis and was 
called as a NSUN2 target. The candidate m5C site at C44 was found exclusively in 
tRNAGly and at C56 in tRNAIle. Finally, the candidate m5C site at C61 was detected in 
tRNAGly, tRNAMet and tRNAThr. 
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The structural distribution pattern of candidate m5C sites in tRNAs based on the global 
mapping was broadly similar to that based on the local mapping (Figure 4.4B). Here, all 
known structural positions exhibited candidate m5C sites, including C72. The ability to 
map the immature tRNAs by global mapping most likely resulted in more coverage at 
the 3’ end of the tRNA, allowing detection of this site. Three of the non-canonical 
structural positions that exhibited candidate m5C sites based on the local mapping were 
also detected in the global mapping, which included C30, C44 and C56. ~25% tRNAHis 
transcripts containing a candidate m5C site at C30 were mediated by NSUN2. 
Additional non-canonical structural positions that exhibited candidate m5C sites were 
also detected, including C17, C25, C51, C62, C63, C65, C67 and C68. 
 
In summary, 87% candidate m5C sites detected in tRNAs from the local mapping were 
in the anticipated structural positions; 99% of candidate m5C sites called as NSUN2 
targets were in the anticipated structural positions and 93% of candidate m5C sites 
called as TRDMT1 targets were in the anticipated structural positions. In addition, it is 
clear from this analysis that NSUN2 is responsible for the majority of m5C sites in 
tRNAs, targeting several different structural positions in a broad range of tRNA 
isotypes, while TRDMT1 almost exclusively mediated m5C at C38 in three tRNA 
isotypes.  
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Figure 4.4. tRNA structural positions and isotypes exhibiting candidate m5C sites called as 
NSUN2 and TRDMT1 targets. 
A) Generated using local tRNA mapping. B) Generated using global tRNA mapping. 
Red=NSUN2 targets, green=TRDMT1 targets, grey=undetermined. A particular structural 
position may contain multiple colours depending on whether the candidate m5C site was called 
as a NSUN2 target, TRDMT1 target or was undetermined. tRNA isotypes exhibiting candidate 
m
5C sites in these positions are indicated by the amino acid abbreviations. * indicates a 
suppressor tRNA. The different regions of the tRNA secondary structure are indicated in blue. 
The seven structural positions known to exhibit m5C sites are indicated in orange. 
 
4.2.2.B TRNA ISOACCEPTORS TARGETED BY NSUN2 AND TRDMT1 
The bsRNA-seq data was also mined for tRNA isoacceptors exhibiting candidate m5C 
sites, and a table was generated displaying the tRNA isoacceptors exhibiting candidate 
m
5C sites that were called as NSUN2 targets, TRDMT1 targets or were not 
undetermined. This table was generated to understand the specificity of NSUN2 and 
TRDMT1 for tRNA isoacceptors. 
 
In total, 29 tRNA isoacceptors were called as NSUN2 targets based on the local 
mapping, and 32 based on the global mapping (Figure 4.5). There was also high 
concordance between both methods of mapping, with 26 tRNA isoacceptors called as 
NSUN2 targets in common. Interestingly, there was no defined trend for tRNA 
isoacceptors that were targeted by NSUN2. 
 
In contrast to NSUN2, TRDMT1 was much more specific, targeting tRNAAsp(GUC), 
tRNAGly(GCC), tRNAVal(AAC), tRNAVal(CAC) and tRNACys(GCA). The candidate m5C site 
targeted by TRDMT1 in tRNACys(GCA) has not been previously identified, and this was 
also not at C38 known to be targeted by TRDMT1 (see section 4.2.2.A). The 14 
candidate m5C sites detected as TRDMT1 targets at C38 in these four tRNA 
isoacceptors were derived from different sequences of each tRNA isoacceptor. The 
tRNA isoacceptors exhibiting candidate m5C sites called as TRDMT1 targets in the 
global mapping were largely in agreement with the local mapping, with tRNAAsp(GUC), 
tRNAGly(GCC), tRNAVal(AAC) and  tRNAVal(CAC) all detected.  
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Thus, in addition to targeting a wide range of tRNA structural positions and isotypes, 
NSUN2 exhibits broad substrate specificity for different tRNA isoacceptors, while 
TRDMT1 was specific to four tRNA isoacceptors. 
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Figure 4.5. tRNA isoacceptors exhibiting candidate m5C sites called as NSUN2 and 
TRDMT1 targets. 
A) Generated using local tRNA mapping. B) Generated using global tRNA mapping. 
Red=NSUN2 targets, green=TRDMT1 targets, grey=undetermined. 
 
4.2.2.C VALIDATION OF CANDIDATE M5C SITES IN TRNA 
Given that the majority of candidate m5C sites measured by bsRNA-seq were detected 
in the anticipated structural positions, our additional MiSeq amplicon sequencing 
validation efforts were directed towards revealing the technical limitations of our 
mapping methods. Specifically, it was expected that several m5C sites in close 
proximity may escape detection due to the mismatch limits imposed in B-SOLANA 
(see section 3.3.2.B). To examine this further, five tRNAs exhibiting candidate m5C 
sites called as NSUN2 or TRDMT1 targets based on the local mapping were selected 
for validation. High coverage of the selected tRNAs was evident in the bsRNA-seq data, 
however a reduction in coverage in the 3’ end of the tRNA was observed (Figure 4.6; 
top panel). Indeed, the MiSeq validation revealed several additional candidate m5C sites 
that were not detected by bsRNA-seq (Figure 4.6; middle and bottom panels). 
Candidate m5C sites at C38, C40 and C49 in tRNAGly(GCC) were detected by bsRNA-
seq, but MiSeq amplicon sequencing detected additional m5C sites at C48 and C50. 
Similarly, a single candidate m5C site was detected at C38 in tRNAVal(AAC) based on 
bsRNA-seq, with MiSeq amplicon sequencing detecting additional m5C sites at C48 and 
C49.  
 
The candidate m5C site at C40 in tRNAGly(GCC) that was called as a NSUN2 target by 
bsRNA-seq was detected at low levels, and this site was detected at even lower levels 
by MiSeq amplicon sequencing. The proportion of methylation at this position based on 
MiSeq amplicon sequencing was 2-5% in the control samples, and <1% in the NSUN2 
knockdown sample. All candidate m5C sites detected at C38 and C48-50 in the selected 
tRNAs by bsRNA-seq were also validated by MiSeq amplicon sequencing. The 
candidate m5C sites detected at C38 in tRNAGly(GCC) and tRNAVal(AAC) exhibited 
depletion in the TRDMT1 knockdown sample by both bsRNA-seq and MiSeq amplicon 
sequencing, indicating that these sites are mediated by TRDMT1. The candidate m5C 
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sites detected at C48-50 in tRNAGly(GCC), tRNAGlu(CUC), tRNAThr(UGU), tRNAVal(AAC)  and 
tRNAVal(CAC) exhibited depletion in the NSUN2 knockdown sample by bsRNA-seq 
and/or MiSeq amplicon sequencing, indicating that these sites are mediated by NSUN2. 
 
 
Figure 4.6. Validation of candidate m5C sites in tRNAs by MiSeq amplicon sequencing. 
The top panel displays the coverage throughout the transcript in RPM based on bsRNA-seq, the 
middle panel displays the proportion of non-conversion based on bsRNA-seq, and the bottom 
panel displays the proportion of non-conversion in a segment of the transcript based on MiSeq 
amplicon sequencing. The bsRNA-seq data is based on the local mapping of tRNAs. The shades 
of grey in the middle panel indicate regions of the transcript where coverage was <5 reads based 
on bsRNA-seq. The tRNA structural positions with candidate m5C sites are indicated in red 
below the heatmap. The N and T indicate sites that were called as NSUN2 or TRDMT1 targets 
based on bsRNA-seq, respectively. The bsRNA-seq data is based on the local mapping of 
tRNAs. The MiSeq coverage ranged from 1,000-121,000 mappable sequencing reads.  
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4.2.2.D METHYLATION OF TRNAS PRIOR TO PROCESSING 
tRNAs are transcribed in the nucleolus and undergo end processing in the nucleolus and 
nucleoplasm, followed by addition of the 3’ CCA, splicing and final export into the 
cytoplasm (for a review see [268]), although the order of end processing and splicing 
can be reversed in several species [269, 270]. NSUN2 is predominantly localised in the 
nucleolus [99, 208] while TRDMT1 has been reported to localise predominantly in the 
nucleus [166]. As such, it was of interest to determine whether m5C in tRNAs can occur 
early in the tRNA biogenesis pathway.  
 
Two studies have reported that m5C at C34 of tRNALeu(CAA) specifically occurs prior to 
splicing, but this employed in vitro methylation assays [100, 148]. We have previously 
demonstrated that methylation at this position can occur prior to splicing based on low-
throughput Sanger bisulfite sequencing [58]. Furthermore, investigation into 
methylation prior to 5’ and 3’ end processing is lacking. Thus, it was of interest to 
independently validate that methylation of tRNAs can occur prior to splicing and also 
determine whether m5C can occur prior to 5’ and 3’ end processing of tRNAs. 
 
Methylation of tRNAs prior to splicing 
Out of the 631 tRNAs in the human genome, only 32 contain introns [271]. Several 
studies have shown that the nucleoside modification of tRNATyr(GUA) in yeast and 
tRNALeu(CAA) in yeast and humans occurs only prior to the removal of the intron. ψ at 
position 35 of tRNATyr(GUA) was reported to occur specifically prior to splicing [272]. 
Similarly, the formation of m5C at C34 in tRNALeu(CAA) was found to only occur in the 
presence of the intron in yeast and HeLa extract using in vitro methylation assays [100, 
148]. In this study, candidate m5C sites were only detected in two intron-containing 
tRNAs; at C34 in tRNALeu(CAA) and C48 in tRNATyr(GUA). As the bsRNA-seq coverage 
was low for tRNATyr(GUA), and the m5C site at C34 in tRNALeu(CAA) is a known site and 
was validated in this study (see Chapter 3), a focus was placed on tRNALeu(CAA). 
 
In order to independently validate that m5C at C34 of tRNALeu(CAA) can occur prior to 
splicing, sequencing reads from MiSeq amplicon sequencing were mapped to spliced 
and unspliced tRNALeu(CAA) (see Figure 3.28B). Indeed, both spliced and unspliced 
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tRNALeu(CAA) were methylated and the proportion of methylation was higher in the 
spliced tRNALeu(CAA) compared to unspliced tRNALeu(CAA), indicating that methylation 
of tRNAs can occur prior to splicing (Table 4.2). 
 
Table 4.2. Proportion of m5C at C34 in unspliced and spliced tRNALeu(CAA) based on MiSeq 
amplicon sequencing. 
Sample % m
5C for unspliced 
tRNALeu(CAA) 
% m5C for spliced 
tRNALeu(CAA) 
NSUN2 4.78% 31.32% 
TRDMT1 47.27% 58.12% 
DNMT1 52.67% 79.33% 
NTC 50.08% 78.05% 
 
Methylation of tRNAs prior to 5’ and 3’ end processing 
The major benefit of mapping tRNAs genome-wide to the full Rfam database was that it 
enabled the mapping of sequencing reads to pre-tRNAs. Interestingly, a small 
proportion of the 50 nt sequencing reads mapping to tRNAs were found to extend 
beyond the mature tRNA sequence by approximately 10-12 nt, indicating that a small 
amount of pre-tRNAs were sequenced. Thus, it was of interest to determine whether 
m5C can occur prior to 5’ and 3’ end processing. If candidate m5C sites were present in 
sequencing reads that extended beyond the mature ends of the tRNA, then this was 
suggestive of methylation occurring prior to end processing. 
 
Initially a candidate approach was used, focusing on the known m5C sites in 
tRNALeu(CAA) and tRNAAsp(GUC). As C34 in tRNALeu(CAA) is located close to the 5’ end of 
the tRNA and mediated by NSUN2, an examination was made into whether the 
sequencing reads spanning this m5C site also extended beyond the 5’ end. Indeed, m5C 
was evident in reads extending beyond the 5’ end of the tRNA, suggesting that NSUN2 
can mediate m5C prior to 5’ end processing of the tRNA (Figure 4.7A). C38 in 
tRNAAsp(GUC) is also located towards the 5’ end of the tRNA and is mediated by 
TRDMT1. Several sequencing reads exhibiting the m5C site extended beyond the 5’ end 
of the tRNA, suggesting that TRDMT1 can mediate m5C prior to 5’ end processing 
(Figure 4.7B). The m5C sites at C48 and C49 of tRNAAsp(GUC) are located towards the 3’ 
end of the tRNA and mediated by NSUN2, and it was evident that many of the 
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sequencing reads that extended beyond the 3’ end of the tRNA exhibited m5C sites at 
these two positions (Figure 4.7C). This suggests that NSUN2 can mediate m5C prior to 
3’ end processing of tRNAs. 
 
 
 
G C T T C C G A G T G T C A G G A T G G C C G A G T G G T C T A A G G C G C C A G A C T C A
G T T T T T G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G T T T T T G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G T T T T T G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G T T T T T G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G T T T T T G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G T T T T T G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G T T T T T G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G T T T T T G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G T T T T T G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G T T T T T G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G T T T T T G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G T T T T T G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G T T T T T G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
T T G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
T G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T T A
G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T T A
G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T T A
G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T T A
G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T T A
G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G A G T G T T A G G A T G G T T G G G T G G T T T A A G G T G T T A G A T T C A
G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A C T C A
G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T T A
G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T T A
G A G T G T T A G G A T G G T T G A G T G G T T T G A G G T G T T A G A T T T A
G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
G A G T G T T A G G A T G G T T G A G T G G T T T A A G G T G T T A G A T T C A
C345’ end
A)
B)
tRNALeu(CAA)
tRNAAsp(GUC)
T T C G T G C G G T T C C T C G T T A G T A T A G T G G T G A G T A T C C C C G C C T G T C A C G C G
T T T T T G T G G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A C G T
T T T T T G T G G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A C G T
T T T T T G T G G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A C G T
T T T T T G T G G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A C G T
T T T T T G T G G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A C G T
T T T T T G T G G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A C G T
T T T T T G T G G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A C G T
G T G T G T G G T T T T T T G T T A G T G T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
G T G T G T G G T T T T T T G T T A G T G T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
G T G T G T G G T T T T T T G T T A G T G T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
G T G T G T G G T T T T T T G T T A G T G T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
G T G T G T G G T T T T T T G T T A G T G T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
G T G T G T G G T T T T T T G T T A G T G T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
G T G T G T G G T T T T T T G T T A G T G T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
G T G T G T G G T T T T T T G T T A G T G T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
T G T G T G T T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
T G T G T G T T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
T G T G T T G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
T G T G T G T T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
T G T G T G T T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
T G T G T G G G T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
T G T G T G T T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
T G T G T T G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
T G T G T T G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
T G T G T T G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
T G T G T G G G T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
T G T G T G G G T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
T G T G T T G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
T G T G T G G G T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
T G T G T T G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
T G T G T G T T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
T G T G T T G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
T G T G T G T T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
T G T G T T G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
T G T G T G T T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
T G T G T T G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
T G T G T T G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
T G T G T G T T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
T G T G T G G G T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
T G T G T G T T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
G T G T G G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
G T G T G G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
G T G T G G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
G T G T G G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
G T G T G G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
G T G T G G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
G T G T G G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
G T G T G G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
G T G T G G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
G T G T G G T T T T T T G T T A G T A T A G T G G T G A G T A T T T T T G T T T G T T A T G T G
G T G T G G T T T T T T G T T A G T A T G T G G T G A G T A T T T T T G T T T G T T A T G T G
C385’ end
 186 
!
RNA m5C profiling of HeLa cells depleted of NSUN2 and TRDMT1 
!
! !
 
Figure 4.7. Representative snapshots from IGV depicting a subset of sequencing reads 
from the global tRNA mapping of tRNALeu(CAA) and  tRNAAsp(GUC) in the NTC sample. 
The grey bars represent 50 nt sequencing reads mapped to part of the locus. Unconverted 
cytosines represent m5C sites. A) m5C at C34 in tRNALeu(CAA) (chr1:249,168,044-249,168,089, + 
strand) in sequencing reads extending beyond the 5’ end. B) m5C at C38 in tRNAAsp(GUC) 
(chr12:96,429,789-96,429,839, + strand) in sequencing reads extending beyond the 5’ end. C) 
m
5C at C48 and C49 in tRNAAsp(GUC) (chr12:96,429,841-96,429,884) in sequencing reads 
extending beyond the 3’ end.  
 
As methylation prior to end processing was observed using a candidate approach, a 
global approach was used in which all tRNAs that exhibited candidate m5C sites based 
on the global mapping were examined for methylation prior to processing. The 
sequencing reads from the global mapping of the NTC sample were divided into two 
subsets; one containing no mismatches, and those containing ≥1 T-to-C mismatch 
corresponding to a candidate m5C site. Mean coverage plots of the two subsets of 
tRNAs were generated, which were anchored at either the 5’ or 3’ end of the tRNA. 
Modest coverage of sequencing reads that did not contain mismatches or candidate m5C 
sites was observed beyond the 5’ end of tRNAs, and coverage of sequencing reads 
containing ≥1 T-to-C mismatch beyond the 5’ end of the tRNA was also evident (Figure 
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4.8). This was also the case for the 3’ end (Figure 4.9). Thus, this suggests that m5C in 
tRNAs can occur prior to 5’ and 3’ end processing. 
 
 
Figure 4.8. Mean read coverage of all tRNAs containing candidate m5C sites anchored at 
the 5’ end of the mature tRNA in the NTC sample. 
All tRNAs found to contain candidate m5C sites based on the global mapping were divided into 
two subsets containing either A) no mismatches or B) ≥1 T-to-C mismatch. Mean coverage 
plots were anchored at the 5’ end of the mature tRNA sequences. The bottom panels show a 
zoomed view to 20 nt flanking either side of the 5’ end of the tRNA. Sequencing reads 
extending beyond the 5’ end of the tRNA are shown in the dotted rectangles.  
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Figure 4.9. Mean read coverage of all tRNAs containing candidate m5C sites anchored at 
the 3’ end of the mature tRNA in the NTC sample. 
All tRNAs found to contain candidate m5C sites based on the global mapping were divided into 
two subsets containing either A) no mismatches or B) ≥1 T-to-C mismatch. Mean coverage 
plots were anchored at the 3’ end of the mature tRNA sequences. The bottom panels show a 
zoomed view to 20 nt flanking either side of the 3’ end of the tRNA. Sequencing reads 
extending beyond the 3’ end of the tRNA are shown in the dotted rectangles.  
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4.2.3 M5C IN OTHER NCRNA 
4.2.3.A M5C IN RRNA 
40-75% of the sequencing reads from the bsRNA-seq mapped to rRNA (see section 
3.2.3.A). It is well known that no depletion method will completely remove rRNA and 
thus the bsRNA-seq data was mined for candidate m5C sites in rRNA. Applying our 
usual threshold criteria, a total of 24 candidate m5C sites were detected by bsRNA-seq 
in nuclear-encoded rRNA and 5 were detected in mitochondrial-encoded rRNA. Of the 
24 candidate m5C sites detected in nuclear-encoded rRNA, 20 were in 28S rRNA, 3 
were in 18S rRNA and 1 was in 5S rRNA. The previously identified m5C sites at C3782 
and C4447 in 28S rRNA were among these [2, 58, 59, 92, 273]. The coverage 
surrounding these known sites was substantial, with >700 reads in each sample. 
Additionally, >85% methylation was detected at both sites in all samples, suggesting 
that NSUN2 or TRDMT1 does not mediate these sites, in agreement with our previous 
study (Figure 4.10A) [58]. Interestingly, the m5C sites at these positions are equivalent 
to the m5C sites at C2278 and C2870 in yeast 25S rRNA, which are mediated by Rcm1 
[86, 92] and Nop2 [92], respectively (see section 1.3). The human orthologues of Rcm1 
and Nop2 are NSUN5A and NSUN1, respectively. Although catalytic activity of these 
human RNA:m5C methyltransferases have not been confirmed, it is possible that they 
mediate the m5C sites in 28S rRNA.  
 
Analysis of the rRNA-mapped reads is more likely to be affected by non-conversion 
artefacts due to inefficient denaturation, as rRNA folds into particularly strong and 
extensive structures. Thus, we applied additional thresholds to further enrich for 
genuine sites. As both known m5C sites exhibited substantial coverage and methylation 
in all samples, ≥500 reads and ≥70% methylation was set as additional thresholds for 
candidate m5C sites in rRNA. After applying these thresholds, one novel candidate m5C 
site remained, which exhibited >800 reads and >85% methylation in all samples. 
Examination of the sequencing reads surrounding the one novel candidate m5C site 
revealed 6 sites of non-conversion within a 10 nt window, suggesting that even this 
candidate is a result of inefficient denaturation of the strong secondary structure. 
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Of the 5 candidate m5C sites detected in mitochondrial-encoded rRNA, 4 were in 12S 
mitochondrial rRNA and 1 was in 16S mitochondrial rRNA. The known m5C site at 
C841 in 12S mitochondrial rRNA [58, 255] was detected by bsRNA-seq, exhibiting 
≥100 reads and ~40% methylation in all samples. This suggests that NSUN2 or 
TRDMT1 does not mediate this site, in agreement with our previous bsRNA-seq study 
(Figure 4.10B) [58]. It was recently reported that NSUN4 mediates m5C at the 
equivalent position in mice, thus it is highly likely that NSUN4 mediates this site in 
humans [97]. As with nuclear-encoded rRNAs, additional thresholds were applied to 
enrich for genuine sites. The thresholds used were ≥100 reads and ≥20% methylation in 
all samples, and no candidate sites remained after applying these thresholds. In 
agreement, the two candidate m5C sites detected upstream of the known site in 12S 
mitochondrial rRNA were not validated by MiSeq amplicon sequencing (performed by 
Mr. Andrew Shafik- data not shown), suggesting that these two sites were a result of 
non-conversion due to incomplete denaturation (Figure 4.10B). Similarly, the single 
candidate m5C site detected at 16S mitochondrial rRNA by bsRNA-seq was also not 
validated (performed by Mr. Andrew Shafik- data not shown).  
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Figure 4.10. The coverage and proportion of m5C at known sites in 28S rRNA and 12S 
mitochondrial rRNA.  
28S rRNA contains two known m5C sites at C3782 and C4447 and 12S mitochondrial rRNA 
contains one known m5C sites at C841. The top panel displays the coverage in RPM based on 
bsRNA-seq and the bottom panel displays the proportion of non-conversion based on bsRNA-
seq. The locations of the m5C sites relative to the start of the transcript are indicated in red 
below the heatmap. 
 
In summary, bsRNA-seq clearly detects the three known m5C sites in rRNA species, in 
addition to suggesting several additional candidate sites. Applying more conservative 
thresholds for such sites, as well as independent tests using MiSeq amplicon sequencing 
suggests that none of the additional sites are genuine. This highlights a residual 
sensitivity of bsRNA-seq to incomplete RNA denaturation. 
 
4.2.3.B M5C IN OTHER NCRNA 
643 candidate m5C sites were detected in a wide variety of ncRNAs in HeLa cells by 
bsRNA-seq, which encompassed miRNA, snoRNA, 7SK RNA, 7SL RNA, uRNA, 
vtRNA and other types of ncRNA. Of this, 30 were detected as NSUN2 targets and 9 
were detected as TRDMT1 targets. As NSUN2 was found to target more sites, a focus 
was placed on ncRNAs targeted by this enzyme.  
 
Five ncRNAs exhibiting candidate m5C sites detected as NSUN2 targets were selected 
for validation by MiSeq amplicon sequencing. These included the ncRNA component 
of RNase P (RPPH1), Small Cajal Body-Specific RNA (SCARNA2), snoRNA U62 
(SNORD62), NSUN5 pseudogene 2 (NSUN5P2) and a pseudogene located within the 
intron of CAGE1, all of which contained a single candidate m5C site. RPPH1 is the 
RNA component of RNase P, which is involved in the cleavage of the 5’ end of pre-
tRNAs along with a number of protein subunits [274], and has been reported to be 
required for efficient RNA Polymerase III transcription [275]. SCARNA2 and 
SNORD62 are C/D box guide RNAs that are part of small nucleolar ribonucleoproteins 
(snoRNPs) predicted to guide 2’-O-methylation of G25 and C61 in U2 snRNA [276] 
and A590 in 18S rRNA [277, 278], respectively. The function of NSUN5P2 and the 
pseudogene located in the intron of CAGE1 remain unknown. 
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We have previously discovered and validated the m5C site in RPPH1 [58], and two 
other studies have also validated this site [77, 78]. The m5C site in SCARNA2 has been 
previously discovered and validated in HeLa cells by Aza-IP [77]. The candidate m5C 
sites detected in SNORD62 and the pseudogenes were entirely novel. The proportion of 
methylation detected in each transcript varied from ~50%-90% in the TRDMT1 
knockdown, DNMT1 knockdown and NTC samples, and almost complete depletion of 
methylation was evident in the NSUN2 knockdown samples by bsRNA-seq and MiSeq 
amplicon sequencing, indicating that these sites were mediated by NSUN2 (Figure 
4.11). Thus, it is clear that m5C occurs in various ncRNA, including snoRNAs, 
lincRNAs and pseudogenes, and at least a subset of these are mediated by NSUN2. 
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Figure 4.11. Validation of candidate m5C sites in other ncRNA by MiSeq amplicon 
sequencing. 
The top panel displays the coverage in RPM based on bsRNA-seq, the middle panel displays the 
proportion of non-conversion based on bsRNA-seq, and the bottom panel displays the 
proportion of non-conversion based on MiSeq amplicon sequencing. The shades of grey in the 
middle panel indicate regions of the transcript where coverage was <5 reads based on bsRNA-
seq. Chromosomal locations of the candidate m5C sites are indicated in red below the heatmap. 
The N and T indicate sites that were called as NSUN2 or TRDMT1 targets based on bsRNA-
seq, respectively. The MiSeq coverage ranged from 40-110,000 mappable sequencing reads. 
 
4.2.3.C SEQUENCE AND STRUCTURAL CONTEXT OF M5C IN OTHER 
NCRNA 
Several studies have investigated the role of NSUN2 in mediating m5C sites in various 
ncRNA, although limited research has been performed to understand the sequences and 
structures that NSUN2 recognises to mediate m5C. Due to the low number of candidate 
m5C sites detected in each class of ncRNA, a global approach to investigate this was not 
applied here. Instead, a focus was placed on the context features around m5C sites in 
ncRNAs that have been validated as NSUN2 targets in this study or previous studies. 
To gain insight into the context features of m5C in the validated ncRNAs, secondary 
structures were obtained from the RNase P database [279] Rfam database [280] or RNA 
STRAND database [281]. Secondary structures were obtained for RPPH1, SNORD62 
and SCARNA2, but were not available for the pseudogenes (Figure 4.12A-C). The 
known features and domains for these ncRNAs are indicated in Figure 4.12. 
 
The m5C site in RPPH1 is located in the P12 domain, which has been proposed to be 
important for efficient transcription [274], suggesting that this site may regulate the role 
of RPPH1 in transcription. The site is located in a stem-loop junction in a GCA context, 
a structure that is similar to that exhibited in the variable loop junction around C48-50 
in tRNAs that NSUN2 targets.  
 
The canonical C/D boxes and novel C’/D’ snoRNA-like boxes in SCARNA2 and 
SNORD62 and the predicted binding sites of the substrate RNAs are indicated in Figure 
4.12B and C [276, 277]. The m5C site in SNORD62 is located within the loop of a stem-
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loop structure, and as with RPPH1 is in a GCA context (Figure 4.12B). The m5C site in 
SCARNA2 is located a few nucleotides upstream of a stem-loop structure in a CpG 
context (Figure 4.12C). Interestingly, the m5C sites in both guide RNAs are not located 
at the C/D boxes, C’/D’ boxes or the predicted binding site of the substrate RNAs, 
suggesting that m5C may not directly affect the modification of substrate RNAs of 
SCARNA2 and SNORD62. 
 
Secondary structures were also obtained for two vtRNAs, vtRNA1-1 and vtRNA1-3, 
which were detected as NSUN2 targets by bsRNA-seq (Figure 4.12D and E). Although 
independent validation of the candidate m5C sites in the vtRNAs was not attempted in 
this thesis, both have been previously reported and validated as NSUN2 targets [77, 78]. 
vtRNAs are evolutionarily conserved non-coding transcripts present in vault particles of 
eukaryotic cells [282]. These are cytoplasmic ribonucleoproteins of which their function 
remains elusive. In both cases, the candidate m5C site was located in the stem near the 
stem-loop junction. This structure is similar to that exhibited in tRNAs around positions 
C48-50 that NSUN2 targets and C30 in the anti-codon loop junction that NSUN2 was 
also found to target in this thesis. The candidate m5C sites in both vtRNAs were in a 
TCG context, which has been previously noted [78]. Interestingly, Hussain et al. 
recently reported that loss of NSUN2-mediated m5C sites in vtRNAs caused aberrant 
processing into small vtRNA fragments, termed svRNAs [78].  
 
Although secondary structures for NSUN5P2 and the pseudogene located within the 
CAGE1 were not available, the m5C sites were in a CpA and CpT context respectively. 
 
In summary, NSUN2 can recognise several different sequence and structural motifs in 
various ncRNA. Several of these structures resemble tRNA structural positions, 
however it is clear that NSUN2 is capable of recognising structures different to those 
exhibited in tRNAs, highlighting the multisite specificity of this enzyme. 
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Figure 4.12. Secondary structures of ncRNAs with validated m5C sites obtained either 
from the RNase P database, Rfam database or RNA STRAND. 
A) RPPH1, B) SNORD62 and C) SCARNA2 were detected and validated in this study. The 
domains in RPPH1 and C/D box domains and C’/D’ box snoRNA-like domains are indicated. 
The binding sites of the substrate RNAs that SCARNA2 and SNORD62 are predicted to guide 
are also indicated in black. D) vtRNA1-1 and E) vtRNA1-3 were detected by bsRNA-seq but 
validated by two published studies. The m5C sites are indicated in red.  
 
4.2.4 M5C IN MRNA 
The distribution and abundance of m5C in mRNA has recently come to the fore with our 
previous bsRNA-seq study [58]. However, an understanding of the substrate specificity 
of NSUN2 in mRNAs has remained elusive. The miCLIP study detected 312 mRNA 
targets of NSUN2, however this was not followed up in any detail [78]. The Aza-IP 
study detected only a single mRNA target of TRDMT1 [77]. As a result, this motivated 
further investigation into the distribution and structural and sequence context of m5C in 
mRNA. 
 
4.2.4.A DISTRIBUTION AND LOCATION BIAS OF M5C IN MRNA 
Candidate m5C sites in mRNA in HeLa cells were distributed throughout all regions of 
mRNA; 38% of the candidate m5C sites were in the 3’ UTR, 37% in the CDS, 23% in 
introns and 3% in the 5’ UTR (Figure 4.13A). To assess the location bias of candidate 
m5C sites in the 3’ UTR, 5’ UTR and CDS, the observed number of candidate m5C sites 
in these regions was compared with the expected number of candidate m5C sites 
detected in each region for cytosines with ≥5 reads. Candidate m5C sites were enriched 
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in the 3’ UTR (p=1.1x10-34, binomial test) and depleted in the 5’ UTR (p=1.0x10-19, 
binomial test) and CDS (p=1.3x10-10, binomial test) than expected at random (Figure 
4.13B). This highlights the non-random distribution of m5C in mRNA. 
 
 
Figure 4.13. The distribution and location bias of candidate m5C sites in mRNA. 
The distribution and enrichment of candidate m5C sites was determined for the total number of 
candidate m5C sites detected in mRNAs in HeLa cells. A) Distribution of candidate m5C sites in 
different regions of mRNA. B) Analysis of location bias of candidate m5C sites within mRNAs. 
The observed number of candidate m5C sites in the 3’ UTR, 5’ UTR and CDS in HeLa cells was 
compared with the expected number of candidate m5C sites for cytosines ≥5 reads. Candidate 
m
5C sites were enriched in the 3’ UTR (p=1.1x10-34, binomial test) and depleted in the 5’ UTR 
(p=1.0x10-19, binomial test) and CDS (p=1.3x10-10, binomial test). 
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4.2.4.B VALIDATION OF M5C SITES IN MRNA 
In order to validate that NSUN2 mediates m5C in mRNA, seven novel candidate m5C 
sites and three known m5C sites across nine mRNAs were selected for independent 
validation by MiSeq amplicon sequencing. A focus was made on candidate m5C sites 
targeted by NSUN2 in different regions of the mRNA, including the 5’ UTR, 3’ UTR 
and CDS. 
 
Sites in three mRNAs, CINP, NAPRT1 and NDUFB7, have been validated by Sanger 
bisulfite sequencing in our previous study [58]. bsRNA-seq again correctly called the 
known m5C site in NDUFB7 as a NSUN2 target. Interestingly, the known m5C site in 
CINP was not called as a NSUN2 target in the present study. The site was detected by 
bsRNA-seq in HeLa cells, however the NSUN2 knockdown sample did not have 
sufficient coverage across the site to meet our NSUN2 target selection criteria. The 
known m5C site in NAPRT1 had insufficient coverage for most samples in this study, 
and as such was not detected. All three known sites were selected for independent 
validation using MiSeq amplicon sequencing. 
 
Of the seven novel candidate m5C sites selected for validation, four were called as 
NSUN2 targets (MCFD2, RPS3, SCO1 and SZRD1), and two were not assigned to 
either methyltransferase (OSBPL8 and RTN3) based on bsRNA-seq. Interestingly, 
MCFD2 exhibited two candidate m5C sites in close proximity to each other, one called 
as a NSUN2 target and one as a TRDMT1 target, and as such both candidate sites were 
examined. Of the ten sites examined, nine were validated, and depletion of methylation 
was evident in the NSUN2 knockdown sample indicating that these m5C sites were 
mediated by NSUN2 (Figure 4.14). Interestingly, the candidate m5C sites in OSBPL8 
and RTN3 were validated as NSUN2-mediated sites despite not being called as a target 
of NSUN2 or TRDMT1 by bsRNA-seq. The candidate m5C site in MCFD2 called as a 
TRDMT1 target did not validate in this study. Examination of the sequencing reads 
spanning this candidate m5C site in MCFD2 revealed that this site was of low quality 
due to uncertainty in the colour calling by the SOLiDTM platform. In contrast, the 
sequencing reads that did not exhibit the candidate m5C sites were of higher quality 
(data not shown).  
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Overall, the MiSeq results emphasise the importance of NSUN2 as a mRNA modifying 
enzyme. Proper assessment of whether TRDMT1 does so too would require 
independent validation of its candidate sites. 
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Figure 4.14. Validation of candidate m5C sites in mRNA by MiSeq amplicon sequencing. 
The location of the m5C site relative to the regions in the mRNA is indicated at the top.  The top 
panel displays the coverage in RPM based on bsRNA-seq, the middle panel displays the 
proportion of non-conversion based on bsRNA-seq, and the bottom panel displays the 
proportion of non-conversion based on MiSeq amplicon sequencing. The shades of grey in the 
middle panel indicate regions of the transcript where coverage was <5 reads based on bsRNA-
seq. Chromosomal locations of the candidate m5C sites are indicated in red below the heatmap. 
The N and T indicate sites that were called as NSUN2 or TRDMT1 targets based on bsRNA-
seq, respectively. The MiSeq coverage ranged from 4,000-110,000 mappable sequencing reads. 
  
 204 
!
RNA m5C profiling of HeLa cells depleted of NSUN2 and TRDMT1 
!
! !
4.2.4.C STRUCTURAL AND SEQUENCE CONTEXT OF M5C IN MRNA 
In order to gain more insight into the structural and sequence context of m5C in mRNA 
and the substrate specificity of NSUN2, a preliminary investigation was made using the 
bsRNA-seq data. As there was a substantial number of candidate m5C sites detected in 
mRNAs in HeLa cells and >100 candidate m5C sites were called as NSUN2 targets, a 
computational search for enriched structural and sequence motifs was performed using 
the bsRNA-seq data. 
 
Structural context 
The structural context of m5C in mRNAs was investigated using CMFinder [241], with 
regions flanking 100 nt either end of subsets of candidate m5C sites in mRNAs. The 
structural context of m5C was investigated for all candidate m5C sites in mRNAs in 
HeLa cells, as well as candidate m5C sites called as NSUN2 targets. The final structures 
that were selected required significant enrichment, >30% of candidate m5C sites 
showing the structure and the distribution of candidate m5C sites localised on or 
surrounding the structural motif. 
 
No significant structural motif was evident when investigating sites in all regions of the 
mRNA together. For candidate m5C sites specifically in the CDS, a stem-loop motif 
was evident, with candidate m5C sites predominantly in a bulge midway along the stem 
(Figure 4.15A). Interestingly, candidate m5C sites in the 3’ UTR also yielded a stem-
loop motif, with sites predominantly located in the loop (Figure 4.15B). 
 
Several stem-loop motifs were enriched for candidate m5C sites targeted by NSUN2, 
with sites located either in the loop or the stem (Figure 4.15C-E). These enriched 
structures are similar to those detected for candidate m5C sites in ncRNAs found in this 
study. For example, the candidate m5C sites located in the loop of a stem-loop in 
mRNAs are reminiscent of structures exhibiting the m5C site in SNORD62. 
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Figure 4.15. Significant structural motifs identified by CMFinder for candidate m5C sites 
detected in mRNA.  
The red bases represent locations where candidate m5C sites were predominantly detected, with 
dark red indicating more enriched locations. Upper case letters indicate high frequency bases 
occurring at that location. Note that candidate m5C sites are not necessarily indicated by a “C” 
as other bases may be found there. A) All candidate m5C sites detected in the CDS, B) All 
candidate m5C sites detected in the 3’ UTR, C)-E) Candidate m5C sites in mRNAs called as 
NSUN2 targets. 
 
Sequence context  
To determine the sequence context of m5C in mRNA, sequence logos were generated 
using the seqLogo R package [242]. For the generation of sequencing logos, the 
nucleotides at each position were scaled according to their frequency and the entire 
stack of nucleotides at a given position was represented as the information content. 
When displayed, the bases were stacked on top of each other in increasing order of their 
frequencies. The sequence logos were generated for 25 nt flanking regions of candidate 
m5C sites in mRNAs, and were determined for all candidate m5C sites detected in 
mRNA in HeLa cells and candidate m5C sites in mRNA called as NSUN2 targets. As a 
comparison, sequence logos were also generated for candidate m5C sites in tRNAs 
called as NSUN2 targets. Furthermore, as a precaution and to remove any bias 
associated with aligning the bsRNA-seq data to non-CpG in silico bisulfite converted 
reference sequences, this analysis was performed on candidate m5C sites detected by 
aligning the sequencing reads to complete in silico bisulfite converted reference 
sequences only.  
 
In the case of all candidate m5C sites detected in HeLa cells, the position directly 
downstream of the candidate sites displayed no base preference, although the 
prevalence of a string of three Gs in the following positions was evident (Figure 4.16A). 
For candidate m5C sites called as NSUN2 targets, the preference for Gs at positions 2-4 
nt downstream was even stronger, and a mild preference for m5CpG or m5CpA over 
m5CpC or m5CpT was evident (Figure 4.16B). Interestingly, the sequence logo 
generated for candidate m5C sites in tRNAs called as NSUN2 targets also revealed a 
string of three Gs further downstream of the site, although in this case m5C 
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predominantly occurred in a CpC or CpG context (Figure 4.16C). The preference for 
m
5CpC and m5CpG in tRNAs is most likely influenced by m5C sites at C48-50 in 
tRNAs, where Cs and Gs are commonly located. The string of Gs evident in tRNAs is 
most likely influenced by the nucleotides at positions 51-53, of which ~60% tRNAs 
exhibiting candidate m5C sites in this thesis contained Gs at all three positions (see 
Appendix 8.5 for the tRNA Rfam structural alignment). 
 
 
Figure 4.16. Sequence logos surrounding candidate m5C sites in mRNA and tRNA. 
Sequence logos were generated using the seqLogo R package for 25 nt regions flanking the 
candidate m5C site. A) All candidate m5C sites in mRNAs, B) Candidate m5C sites in mRNAs 
called as NSUN2 targets, C) Candidate m5C sites in tRNAs called as NSUN2 targets.  
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The trend of NSUN2-mediated m5C sites in mRNAs occurring in a CpG and CpA 
context was also reflected in the mRNAs that were validated by MiSeq amplicon 
sequencing in this study. Out of the nine m5C sites validated as NSUN2 targets, three 
were in a CpG context (OSBPL8, SCO1, SZRD1), five were in a CpA context (CINP, 
MCFD2, NAPRT1, NDUFB7, RTN3), and one was in a CpT context (RPS3) (Table 4.3). 
Additionally, seven of the validated candidates exhibited at least two Gs positions 2-4 
downstream of the m5C site, in concordance with the sequence logo. 
 
Table 4.3. Sequence context of m5C sites discovered and validated as NSUN2 targets in 
this thesis. 
mRNA Sequence downstream of 
m5C site 
CINP m5CGGGC 
MCFD2 m5CAGGT 
NAPRT1 m5CAGGT 
NDUFB7 m5CAAGC 
OSBPL8 m5CGGGG 
RPS3 m5CTGGG 
RTN3 m5CAGGG 
SCO1 m5CGAGG 
SZRD1 m5CGCCC 
 
In summary, candidate m5C sites in mRNAs are present around stem-loop structures, 
with m5C sites located in both the stem and the loop. Candidate m5C sites called as 
NSUN2 targets demonstrated a slight preference for m5CpG or m5CpA and there was a 
propensity for sites to be upstream of Gs. This, once again, highlights the multisite 
specificity of NSUN2. 
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4.3 DISCUSSION 
In this chapter, I have investigated the distribution and abundance of m5C in RNA and 
the substrate range of NSUN2 and TRDMT1. I have extensively investigated the 
substrate specificity of NSUN2 and TRDMT1 in tRNAs and features of m5C in tRNAs, 
which have both confirmed previous reports and provided novel findings. I have also 
explored the specificity of NSUN2 in other ncRNAs and mRNAs, which have 
highlighted the versatility of this enzyme. In this section, I will discuss the outcomes of 
these findings. 
 
4.3.1 M5C SITES IN HELA CELLS 
4.3.1.A TOTAL M5C SITES IN HELA CELLS 
In this study, a total of 4,241 candidate m5C sites were detected in HeLa cells, which 
were distributed over tRNAs, other ncRNAs and mRNAs. Similarly, our previous 
bsRNA-seq study performed in HeLa cells revealed candidate m5C sites distributed over 
tRNAs, other ncRNA and mRNAs, however the number of candidate m5C sites detected 
was substantially more than this study, totalling to 10,530 sites [58]. Our previous 
bsRNA-seq study used SOCS-B to map the bsRNA-seq data, and ≥10 read coverage 
and ≥20% methylation were defined as thresholds to detect all candidate m5C sites. In 
this present study, B-SOLANA and a proportion statistic were used to align the data and 
detect candidate m5C sites. For detection of all candidate m5C sites in HeLa cells, ≥5 
reads in all samples used in the model and ≥10% mean methylation across the control 
samples were defined as the thresholds, as well as a FDR≤1%. Thus, it was expected 
that the variations in the mapping and candidate m5C site detection methodology used 
for each dataset would result in differences in the number of candidate m5C sites 
detected in RNA. While the use of a proportion statistic and more stringent criteria for 
the detection of candidate m5C sites in this thesis may have resulted in the 
underestimation of candidate m5C sites, it has most likely reduced the amount of false 
positives. Despite the different bioinformatics pipelines implemented for each study, 
both studies have detected candidate m5C sites in many transcript biotypes, and have 
demonstrated that m5C is abundant in mRNAs, significantly extending the known 
distribution of this modification in RNA. 
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In our previous HeLa bsRNA-seq study, tRNAs were uniquely mapped in a similar 
manner to the local mapping applied in this study, revealing 255 candidate m5C sites, a 
comparable number to this thesis. The proportion of cytosines exhibiting candidate m5C 
sites in tRNAs in our previous HeLa bsRNA-seq study was 8.7%, in comparison to 
3.98% based on the local mapping in this study. Interestingly, the coverage of cytosines 
in this thesis was substantially higher than that detected in our previous bsRNA-seq 
study, resulting in the lower density of m5C in tRNAs in this thesis. Furthermore, the 
global mapping of tRNAs yielded a total of 5.73% cytosines exhibiting candidate m5C 
sites, somewhat higher than the local mapping. The higher density of m5C in globally 
mapped tRNAs mapped is most likely a result of differences in the mapping. tRNAs 
that were mapped locally were mapped to a single representative sequence, resulting in 
the lower number of candidate m5C sites detected and cytosines with ≥ 5 reads in the 
tRNAs (see Table 4.1). As the global mapping could differentiate between identical 
tRNA sequences due to sequencing reads extending beyond the mature ends of the 
tRNA in some instances, a substantially higher number of candidate m5C sites were 
detected, although the number of cytosines with ≥ 5 reads was only double the amount 
detected for the local mapping. 
 
A total of 667 candidate m5C sites were detected in a wide variety of ncRNAs in this 
thesis. Our previous HeLa bsRNA-seq study yielded a total of 1,780 candidate m5C 
sites in various ncRNAs. However, the density of candidate sites in both studies was 
comparable, with 1.4% of cytosines in ncRNA containing m5C sites on average in this 
study, and 1.2% in the previous HeLa bsRNA-seq study.  
 
A total of 1,564 candidate m5C sites were detected in mRNAs in this study, in 
comparison to 8,495 candidate m5C sites detected in our previous HeLa bsRNA-seq 
study. The proportion of cytosines in mRNA containing candidate m5C sites in this 
study was 0.08%, lower than the 0.4% determined in our previous bsRNA-seq. The 
coverage of mRNAs in both studies were similar, however the stringent thresholds 
applied for the detection of candidate m5C sites in this present study resulted in a lower 
number of candidate m5C sites detected and therefore the lower density of m5C in 
mRNAs. Nevertheless, the thesis revealed ~1.3 m5C sites/mRNA, substantially more 
than previously thought based on chromatographic techniques. Investigation of hamster 
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cell mRNA nearly four decades ago revealed ~0.45 m5C sites/mRNA [26]. This 
indicates that bsRNA-seq is quite sensitive, detecting candidate m5C in mRNA at 
similar levels to m6A, where ~1.7 m6A peaks/mRNA were detected [57]. Both of our 
studies have substantially extended the previously known distribution of m5C in mRNA. 
 
4.3.1.B M5C SITES MEDIATED BY NSUN2 AND TRDMT1 
A total of 393 candidate m5C sites were detected as NSUN2 targets, and 120 as 
TRDMT1 targets in a wide variety of transcript biotypes, significantly extending what 
was previously known about the substrate specificity of these enzymes.  
 
NSUN2 was found to be primarily responsible for m5C sites in tRNAs, in agreement 
with the literature. Additionally, 118 candidate m5C sites in mRNAs and 34 candidate 
m
5C sites in various ncRNAs were called as NSUN2 targets. Recent complementary 
next-generation sequencing studies have reported NSUN2 to target tRNAs and some 
ncRNAs, but limited research has been performed to investigate mRNA substrates of 
NSUN2 [77, 78, 150]. The substrate range of TRDMT1 determined in this thesis was 
similar to that of NSUN2, but with lower numbers. The number of candidate m5C sites 
in tRNAs targeted by TRDMT1 was much smaller than that of NSUN2, which was 
expected as it has previously been shown to target only C38 in several different tRNAs 
[73, 77]. A total of 53 candidate m5C sites in mRNAs and 9 other ncRNAs were 
targeted by TRDMT1 based on the bsRNA-seq, potentially extending what was 
previously known about the substrate range of this enzyme. The candidate m5C sites 
detected in ncRNAs and mRNAs called as TRDMT1 targets would require validation, 
as this thesis was primarily focused on NSUN2. 
 
Out of the 4,241 candidate m5C sites detected in HeLa cells, only 513 were called as 
NSUN2 or TRDMT1 targets. This is due to a combination of factors, chief of which is 
that we were very likely massively under-calling methyltransferase target sites as this 
study was performed by (incomplete) methyltransferase knockdown and it was only 
powered as an initial screen. Indeed, a recent study in cells from Nsun2 and Trdmt1 
double knockout mice demonstrated that NSUN2 and TRDMT1 are responsible for all 
m5C sites in tRNAs in mice, and likely also in humans [149]. Thus, the ~34% of 
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candidate m5C sites in tRNAs detected in HeLa cells that were not called as NSUN2 or 
TRDMT1 targets represent a false negative discovery rate, at least for this transcript 
biotype. Candidate m5C sites in the other transcript biotypes that were detected in HeLa 
cells but not called as NSUN2 or TRDMT1 targets likely represent a mixture of false 
negative calls as well as genuine targets of other cellular RNA:m5C methyltransferases 
that are yet to be confirmed in humans.  
 
Implementation of cells exhibiting a permanent deletion of NSUN2 or TRDMT1 would 
be of benefit to overcome the incomplete depletion of the enzymes. To validate 
transcripts detected as NSUN2 targets by miCLIP, Blanco et al. and Hussain et al. 
performed bisulfite sequencing on RNA derived from human skin fibroblasts carrying a 
homozygous mutation of NSUN2 [78, 150]. Complete ablation of m5C was evident at 
NSUN2-mediated sites in NSUN2-/- human fibroblasts. Use of such a deletion cell line 
would increase the sensitivity of detection of candidate m5C sites by bsRNA-seq. 
 
4.3.1.C GLOBAL COMPARISON OF M5C SITES MEDIATED BY NSUN2 AND 
TRDMT1 WITH THE LITERATURE 
Several recent published studies have used complementary next-generation sequencing 
techniques to investigate m5C sites in RNA (see section 1.2.3). One of these studies 
used a technique known as Aza-IP for the detection of m5C sites that are targeted by 
NSUN2 and TRDMT1 in HeLa cells [77]. The second study used a combination of 
bisulfite sequencing and miCLIP focusing on NSUN2-mediated m5C sites in human 
fibroblasts and a number of other human and mouse tissues [78, 150]. Both studies 
relied on the irreversible covalent bond formed between the RNA methyltransferases 
and the RNA target, which were then immunoprecipitated and subjected to next-
generation sequencing, revealing NSUN2 and TRDMT1 target sites at single nucleotide 
resolution. In this section, I will make a comparison of the candidate m5C sites called as 
NSUN2 or TRDMT1 targets from the global mapping in this thesis with the Aza-IP [77] 
and miCLIP studies [78, 150]. In most cases, comparisons were made between this 
thesis and the Aza-IP study, which provided single nucleotide resolution for m5C sites 
called as NSUN2 or TRDMT1 targets. Although miCLIP and bisulfite sequencing are at 
single nucleotide resolution, the extended data for these publications did not provide 
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candidate m5C sites at single nucleotide resolution. Furthermore, the miCLIP studies 
only focused on NSUN2 targets. However, there were several individual examples that 
were the prime focus of the miCLIP studies that were compared.  
 
Initially, a comparison was made between the number of tRNAs called as NSUN2 
targets in all three studies. Both the Aza-IP and miCLIP studies mapped the tRNAs 
genome-wide and therefore the candidate m5C sites detected in tRNAs based on the 
global mapping in this thesis were compared to these studies. Almost 50% of the tRNAs 
called as NSUN2 targets in this thesis were in agreement with the Aza-IP and miCLIP 
studies, and nearly 60% were in agreement with at least one of these studies (Figure 
4.17). 
 
 
Figure 4.17. Comparison of the number of tRNAs exhibiting candidate m5C sites called as 
NSUN2 targets by bsRNA-seq, miCLIP and Aza-IP. 
The global mapping of tRNAs was used for this analysis. Comparisons were made with the 
miCLIP study [150] and Aza-IP study [77] The global mapping was used for this analysis. The 
total number of tRNAs containing candidate m5C sites called as NSUN2 targets in each study is 
indicated in brackets. 
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Further comparisons in the number of candidate m5C sites detected in tRNAs, other 
ncRNAs and mRNAs called as NSUN2 or TRDMT1 targets were made with the Aza-IP 
study. Of the 178 candidate m5C sites in tRNAs that were called as NSUN2 targets in 
this thesis, 60% overlapped with the candidate m5C sites detected by Aza-IP (Figure 
4.18A). Of the 31 candidate m5C sites detected in tRNAs as TRDMT1 targets, 77% 
were also detected by Aza-IP (Figure 4.18B). Thus, it is clear that there is high 
concordance between the two studies despite implementing very different techniques.  
 
Interestingly, the overlap between other ncRNAs and mRNAs was very low or non-
existent. Of the 33 candidate m5C sites detected as NSUN2 targets in other ncRNAs in 
this thesis, only 4 overlapped with the Aza-IP study, which included RPPH1, 
SCARNA2, vtRNA1-1 and vtRNA1-3 (Figure 4.18C). The same candidate m5C sites in 
vtRNA1-1 and vtRNA1-3 were also detected by miCLIP [78]. No candidate m5C sites 
in ncRNAs called as TRDMT1 targets in this thesis overlapped with the Aza-IP study, 
which only detected a single candidate m5C site in the pseudogene, KRT18P10 (Figure 
4.18D). NSUN2 was not reported to target any mRNAs by Aza-IP, however a single 
candidate m5C site in the mRNA, KRT18, was detected as a target of TRDMT1; this 
candidate m5C site was not detected in this thesis.  
 
It is interesting that the Aza-IP technique, which relies on irreversible binding of the 
RNA methyltransferases to the RNA, did not detect many candidate m5C sites in 
mRNAs. A possible reason for this is that mRNA may be present at much lower levels 
than tRNA and some other ncRNA, so the enzymes may bind preferentially to tRNAs 
and other ncRNAs, thus enriching them in comparison to mRNA. Additionally, HeLa 
cell lines vary across different laboratories and thus may also contribute to the 
differences observed in this thesis. Nevertheless, the limited detection of candidate m5C 
sites in mRNA by Aza-IP did not deter further investigation into this transcript biotype 
in this thesis. Despite the low overlap of candidate m5C sites detected in other ncRNAs 
in this thesis with the Aza-IP study, a subset of these sites were successfully validated 
by Aza-IP.  
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Figure 4.18. Comparison of candidate m5C sites in tRNAs and ncRNAs called as NSUN2 
or TRDMT1 targets by bsRNA-seq and Aza-IP. 
Comparisons were made with the Aza-IP study [77]. A) Candidate m5C sites in tRNAs detected 
as NSUN2 targets, B) m5C sites in tRNAs detected as TRDMT1 targets, C) Candidate m5C 
sites in other ncRNAs detected as NSUN2 targets, D) Candidate m5C sites in other ncRNAs 
detected as TRDMT1 targets. 
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4.3.2 M5C SITES IN TRNA 
The recent Aza-IP and miCLIP studies have focused heavily on m5C sites in tRNAs. 
The Aza-IP study investigated the tRNA structural positions targeted by NSUN2 and 
TRDMT1 and the miCLIP study focused primarily on tRNA isoacceptors targeted by 
NSUN2. In this thesis, I have thoroughly examined the tRNA structural positions, 
isotypes and isoacceptors that were called as NSUN2 and TRDMT1 targets by bsRNA-
seq. In the following sections, I will discuss the findings from this analysis and collate 
the findings from the Aza-IP and miCLIP studies for comparisons between all three 
studies. The tRNA structural positions targeted for methylation were compared to the 
Aza-IP study, and the tRNA isotypes and isoacceptors targeted for methylation were 
compared to both the Aza-IP and miCLIP studies. 
 
4.3.2.A TRNA STRUCTURAL POSITIONS AND ISOTYPES TARGETED BY 
NSUN2 AND TRDMT1 
In this thesis, candidate m5C sites were detected at all known structural positions except 
C72 by the local mapping, while candidate m5C sites were detected at all seven known 
structural positions from the global mapping. The lack of detection of candidate m5C 
sites at C72 from the local mapping was possibly a result of the declining coverage 
towards the 3’ end of the tRNA, which was exacerbated by specifically mapping to 
mature tRNA sequences. At least a proportion of the tRNAs exhibiting candidate m5C 
sites at the known structural positions were detected as NSUN2 or TRDMT1 targets, 
suggesting that NSUN2 and TRDMT1 are solely responsible for mediating m5C sites at 
these positions. This is highlighted by the study that reported that the knockout of 
Nsun2 and Trdmt1 in mice resulted in complete ablation of m5C in tRNAs (see section 
4.3.1.B) [149].  
 
Focusing on candidate m5C sites that were detected from the local mapping, NSUN2 
was found to mediate m5C at C34 exclusively in tRNALeu(CAA), C40 exclusively in 
tRNAGly(GCC) and C48-C50 in a wide range of tRNA isotypes. This is largely in 
agreement with previous literature, where NSUN2 has been shown to mediate m5C at 
C34 exclusively in tRNALeu(CAA) [100], C40 exclusively in tRNAGly(GCC) in yeast [98], 
mice [149] and more recently in humans [77], and C48-50 in several tRNA isotypes 
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[58, 98, 148, 149]. In contrast, TRDMT1 was found to mediate m5C sites at C38 in 
tRNAAsp(GUC), tRNAGly(GCC), tRNAVal(AAC)  and tRNAVal(CAC) only. TRDMT1 has been 
shown previously to mediate m5C at C38 in tRNAAsp(GUC) [58, 59, 159] in addition to 
tRNAGly(GCC) and tRNAVal(AAC) [73, 77], and more recently in tRNAVal(CAC) [77] in 
eukaryotes. A single candidate m5C site was detected at C48 in a single tRNACys(GCA) 
transcript as a TRDMT1 target, however this site is most likely mediated by NSUN2 
and was picked up as an artefact in this thesis. Overall, 87% of the candidate m5C sites 
detected in tRNAs in this thesis were in the anticipated structural positions, with 99% 
and 93% of NSUN2 and TRDMT1 targets located in these positions, respectively. 
 
The m5C sites detected in the known structural positions were also validated by MiSeq 
amplicon sequencing for five tRNAs. TRDMT1 was confirmed to mediate m5C at C38 
in tRNAAsp(GUC) (see Chapter 3), tRNAGly(GCC) and tRNAVal(AAC) and NSUN2 was 
confirmed to mediate C34 in tRNALeu(CAA) (see Chapter 3) and C48-50 in several 
different tRNA isotypes. Interestingly, methylation at C40 in tRNAGly was detected at 
low levels by MiSeq amplicon sequencing. The bsRNA-seq data revealed 
approximately 15% methylation in the control samples that was depleted in the NSUN2 
knockdown sample, however MiSeq amplicon sequencing revealed only 2-5% 
methylation in the control samples that was depleted to <1% in the NSUN2 knockdown 
sample. The Aza-IP study is the only other study to report m5C at C40 in tRNAGly(GCC) 
in humans as well as being mediated by NSUN2 [77]. However, subsequent validation 
by Sanger bisulfite sequencing revealed only 15% methylation, which was depleted in 
the NSUN2 knockdown sample. Thus, it is possible that tRNAGly(GCC) is methylated 
consistently at low levels in HeLa cells. 
 
Candidate m5C sites in several non-canonical structural positions were also detected by 
bsRNA-seq in this thesis. The local mapping detected candidate m5C sites in 4 non-
canonical structural positions, while the global mapping detected candidate m5C sites in 
11 non-canonical structural positions. The candidate m5C sites detected at C44 in 
tRNAGly and C61 in tRNAGly, tRNAMet and tRNAThr were not called as NSUN2 or 
TRDMT1 targets. In contrast, the candidate m5C site detected at C30 in tRNAHis was 
called as a NSUN2 target. The candidate m5C site at C56 was detected in both the local 
and global mapping, although the enzyme responsible for this site could not be 
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determined from the local mapping. The global mapping revealed that a small 
proportion of the tRNAs exhibiting the candidate m5C site at this position were called as 
NSUN2 targets, suggesting that NSUN2 may mediate this site.  
 
Global comparison with the Aza-IP and miCLIP studies 
The Aza-IP study also investigated the tRNA structural positions targeted by NSUN2 
and TRDMT1 in HeLa cells [77]. Although several of the structural positions with 
candidate m5C sites could not be determined as sole NSUN2 or TRDMT1 targets by 
bsRNA-seq in this thesis, the fact that a proportion of tRNA isotypes exhibiting 
candidate m5C sites in these positions were targeted by NSUN2 or TRDMT1 suggested 
that they were exclusively responsible for mediating methylation at these positions. As 
such, Figure 4.19 displays the structural positions that were targeted by NSUN2 or 
TRDMT1 in at least one tRNA in this thesis. 
 
The Aza-IP study revealed that six of the seven known structural positions were 
targeted by NSUN2 for methylation, and C38 was targeted by TRDMT1, which is in 
agreement with this thesis. The Aza-IP study reported 23 non-canonical structural 
positions exhibiting candidate m5C sites targeted by NSUN2, however the candidate 
sites in these positions are yet to be validated. Despite the larger number of non-
canonical structural positions targeted by NSUN2 in the Aza-IP study compared to this 
study, there was some overlap in these positions. The candidate m5C site at C30 in 
tRNAHis was detected as a NSUN2 target in both studies, and the candidate m5C site at 
C56 was also detected in both studies and this was found to be a NSUN2 target from the 
global mapping and Aza-IP.  
 
That candidate m5C sites were detected by bsRNA-seq and Aza-IP at C30 and C56 
suggest that these may be additional structural positions that NSUN2 targets, extending 
the currently known targets of NSUN2 in tRNAs and highlighting that this enzyme is 
multisite-specific. 
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Figure 4.19. Comparison of candidate m5C sites in tRNA structural positions called as 
NSUN2 or TRDMT1 targets by bsRNA-seq and Aza-IP. 
Comparisons were made between the global bsRNA-seq mapping, local bsRNA-seq mapping 
and Aza-IP study [77]. For a structural position to be considered a NSUN2 or TRDMT1 target, 
at least one tRNA must exhibit a candidate m5C site called as a NSUN2 or TRDMT1 target at 
the given position. The structural positions detected as NSUN2 and TRDMT1 targets by either 
study are indicated in red and green, respectively.  
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In addition to comparing the structural positions targeted for methylation by NSUN2 
and TRDMT1, a comparison was made between the tRNA isotypes that were called as 
NSUN2 and TRDMT1 targets in this thesis with the Aza-IP and miCLIP studies. 
 
The tRNA isotypes that were called as NSUN2 targets in all three studies were quite 
broad; of the 22 tRNA isotypes, 16 were called as NSUN2 targets by miCLIP, 18 by 
Aza-IP, 15 from the local mapping and 19 from the global mapping (Figure 4.20). In 
addition, there was high concordance in the tRNA isotypes called as NSUN2 targets in 
all studies, with 13 isotypes overlapping. This indicates that NSUN2 has a broad 
substrate range for tRNA isotypes in addition to being multisite-specific. In all studies, 
tRNAAsn and tRNASeC were not called as NSUN2 targets. These tRNAs do not exhibit 
cytosines at positions 48-50, which may partly explain the lack of m5C sites mediated 
by NSUN2 in these tRNAs. The Aza-IP study was the only study to report candidate 
m5C sites in tRNATrp that were mediated by NSUN2. 
 
Interestingly, this thesis was the first to report candidate m5C sites in tRNASup, a 
suppressor tRNA, which has not been previously identified as exhibiting m5C sites. 
Suppressor tRNAs are naturally occurring tRNAs that form from a mutation in the anti-
codon, resulting in the read-through of the stop codon and an amino acid being inserted 
instead, preventing truncation of the protein [283]. The subsequent result is the 
production of multiple polypeptides from a single gene. The existence of natural 
suppressor tRNAs provides an additional regulatory mechanism for gene expression and 
the presence of m5C in these tRNAs may regulate their function. Interestingly, Blanco et 
al. have reported that depletion of NSUN2-mediated m5C sites in tRNAs causes 
angiogenin-cleavage and accumulation of 5’ tRNA fragments [150]. Thus, the presence 
of m5C in tRNASup may stabilise this tRNA, allowing it to function in regulating gene 
expression. There is the possibility of m5C affecting tRNA charging by aminoacyl 
tRNA synthetases, however other modifications have been reported to affect this. 
Methylation of G37 (m1G37) of tRNAs in S. typhimurium has been shown to be 
important in promoting binding to aminoacyl tRNA synthetase [284]. Furthermore, this 
modification in S. cerevisiae prevents the mischarging of tRNAAsp by arginyl-tRNA 
synthetase [285].  
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The tRNA isotypes that were called as TRDMT1 targets were quite narrow, indicating 
that this particular enzyme has narrow specificity for tRNA structural positions and 
isotypes. In both this these and the Aza-IP study, TRDMT1 targeted tRNAAsp, tRNAGly 
and tRNAVal for methylation. Interestingly, the local mapping revealed candidate m5C 
sites mediated by TRDMT1 at tRNACys, while the global mapping revealed candidate 
m5C sites mediated by TRDMT1 in tRNAThr. As the different mapping methods 
resulted in inconsistencies with these two tRNA isotypes, this suggests that these may 
be artefacts. 
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Figure 4.20. Comparison of tRNA isotypes called as NSUN2 and TRDMT1 targets by 
bsRNA-seq, Aza-IP and miCLIP. 
Comparisons were made with the miCLIP study [150] and Aza-IP study [77]. A) Isotypes 
targeted by NSUN2, B) Isotypes targeted by TRDMT1. Comparisons were made between the 
local bsRNA-seq mapping, global bsRNA-seq mapping, miCLIP study and Aza-IP study. 
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4.3.2.B TRNA ISOACCEPTORS TARGETED BY NSUN2 AND TRDMT1 
Investigation into the tRNA isoacceptors that were targeted by each enzyme revealed 
that NSUN2 targeted not only a broad range of tRNA isotypes, but also a broad range of 
different isoacceptors within those isotypes. TRDMT1 was much more specific for 
isoacceptors in addition to structural positions and isotypes, targeting specifically 
tRNAAsp(GUC), tRNAGly(GCC), tRNAVal(AAC) and tRNAVal(CAC) in both the local and global 
mappings (see section 4.3.2.A).  
 
Global comparison with the Aza-IP and miCLIP studies 
Figure 4.21 illustrates the comparison of tRNA isoacceptors called as NSUN2 and 
TRDMT1 targets. The comparisons of tRNA isoacceptors called as NSUN2 targets 
were made between all studies and the comparison of tRNA isoacceptors targeted by 
TRDMT1 was made with the Aza-IP study. 
 
The miCLIP study detected 36 isoacceptors [150] and the Aza-IP detected 42 
isoacceptors [77] that were targeted by NSUN2. There was high concordance between 
these two studies, with 36 isoacceptors overlapping. Of the 29 isoacceptors called as 
NSUN2 targets from the local mapping, 28 overlapped with the Aza-IP study and 27 
overlapped with the miCLIP study. Of the 32 isoacceptors called as NSUN2 targets 
from the global mapping, 31 overlapped with the Aza-IP study and 30 overlapped with 
the miCLIP study. A total of 24 isoacceptors overlapped between all studies, indicating 
very high concordance between all datasets (Figure 4.21A). The only isoacceptor 
detected in this thesis that did not overlap with either of these published studies was 
tRNASup(UUA). The overlap in tRNA isoacceptors called as TRDMT1 targets in this 
thesis and Aza-IP was high, with 4 out of 5 isoacceptors overlapping with the Aza-IP 
study (Figure 4.21B).  
 
Early studies into the specificity of NSUN2 in tRNAs suggested that this was narrow, 
with in vitro methylation assays suggesting that NSUN2 could not introduce a methyl 
group to a number of human and yeast tRNAs at C48 and C49, while Trm4 in yeast 
could target these positions [100]. Our previous bsRNA-seq study in HeLa cells 
revealed that NSUN2 is responsible for m5C sites at C48 and C49 in tRNAAsp(GUC), 
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indicating a broader structural specificity in tRNAs [58]. The work in this thesis has 
demonstrated the specificity of NSUN2 and TRDMT1 on three different levels; tRNA 
structural positions, isotypes and isoacceptors. NSUN2 is a multisite-specific enzyme, 
targeting at least six tRNA structural positions with the possibility of targeting more, 
including at C30 and C56. NSUN2 was also found to target the majority of tRNA 
isotypes and a wide range of tRNA isoacceptors, highlighting its broad substrate range 
and confirming recently published studies. In contrast, the substrate specificity of 
TRDMT1 was found to be narrow in this thesis, almost exclusively targeting C38 in 
only four tRNA isoacceptors.  
 
The high concordance in the tRNA structural positions, isotypes and isoacceptors 
targeted for methylation by NSUN2 and TRDMT1 in this study with the literature 
indicates that the bsRNA-seq technique is sensitive in detecting m5C sites in tRNAs. 
The fact that these two published studies have employed complementary techniques to 
bsRNA-seq reiterates this point. The similarities highlight that the bsRNA-seq method 
is efficient in detecting m5C sites in various transcript biotypes.  
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Figure 4.21. Comparison of tRNA isoacceptors called as NSUN2 or TRDMT1 targets by 
bsRNA-seq, miCLIP  and Aza-IP. 
Comparisons were made with the miCLIP study [150] and Aza-IP study [77]. A) tRNA 
isoacceptors targeted by NSUN2, B) tRNA isoacceptors targeted by TRDMT1. 
 
4.3.2.C METHYLATION OF TRNA PRIOR TO PROCESSING 
One aspect of m5C in tRNAs that has had very little attention is the point at which 
methylation of tRNAs occurs during its biogenesis. The biogenesis of tRNAs is a very 
complex process that is still not well-understood, particularly in humans. Many of the 
studies investigating this process have focused on yeast, although many of the processes 
apply to higher eukaryotes (for a review, see [268]). Nuclear tRNAs in eukaryotes are 
transcribed by RNA Polymerase III as a pre-tRNA within the nucleus. Once transcribed, 
the pre-tRNA is bound by the La autoantigen at the 3’ end, protecting the 3’ end from 
endonucleolytic cleavage. This La-bound pre-tRNA is the substrate for RNase P, which 
processes the 5’ end of the pre-tRNA by a single endonucleolytic cleavage (for a 
review, see [286]). The location of 5’ end processing within the cell in yeast and 
humans is conflicting, with studies suggesting that RNase P RNA is localised to both 
the nucleolus and cytoplasm, in addition to the perinucleolar compartments that 
surround the edge of the nucleolus in several human cell lines [287, 288]. Following 
this, 3’ end processing is performed by tRNase Z within the nucleoplasm, followed by 
the addition of the 3’ CCA, splicing and export to the cytoplasm. Interestingly, the order 
of end processing and splicing can be reversed in several species [269, 270], although it 
is unknown whether splicing precedes end processing in humans. During this entire 
process, a number of nucleoside modifications take place at various stages, although the 
understanding of this is limited. That NSUN2 is localised in the nucleolus and 
TRDMT1 is localised in the nucleus suggest that methylation of tRNAs may occur prior 
to splicing and end processing, motivating further investigation. 
 
We detected two tRNAs containing introns that exhibited m5C sites, which included 
C34 in tRNALeu(CAA) and C48 in tRNATyr(GUA). Due to the low coverage of 
tRNATyr(GUA), this tRNA was not explored further. The intron of tRNALeu(CAA) is 22 nt 
long and located 3’ to the anti-codon, resulting in an elongated anti-codon stem [100, 
289].  Two studies thus far have reported that m5C at C34 in tRNALeu(CAA) is mediated 
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by NSUN2 only prior to splicing in yeast and humans [100, 148]. This was found to be 
specific to the sequence and structural context that NSUN2 recognises, as intron 
removal and mutations surrounding the cytosine resulted in lack of methylation in most 
cases. However, this relied on in vitro methylation assays and no studies have 
investigated this in vivo. In previous work, we have detected methylation of 
tRNALeu(CAA) prior to splicing using Sanger bisulfite sequencing, but this was not 
investigated any further [58]. In this thesis, the MiSeq amplicon sequencing data was 
mapped to spliced and unspliced versions of tRNALeu(CAA), and m5C was detected at 
C34 in both versions of the tRNA, indicating that methylation of this tRNA can occur 
prior to splicing. In addition, a higher proportion of methylation was detected in the 
spliced tRNA compared to the unspliced tRNA, suggesting that not all of the precursor 
transcripts have undergone methylation, while the mature transcript is mostly 
methylated. It is highly likely that methylation of this tRNA occurs immediately prior to 
splicing, however the possibility of methylation occurring after splicing cannot be 
discounted despite in vitro methylation assays indicating otherwise. It is possible that 
the intron may somehow affect m5C formation in the tRNA, but this has not been 
investigated further. 
 
Methylation of other tRNAs or at other structural positions prior to splicing has not 
been explored in great detail. One study has investigated m5C at C48 of tRNALeu(CAA) 
and reported that this can occur either before or after splicing based on in vitro 
methylation assays [148], however we did not detect this site in our present study. It is 
not unexpected that NSUN2 can mediate m5C at C48 in spliced and unspliced tRNAs, 
as the structure surrounding this region does not change upon splicing, unlike the anti-
codon region that C34 is located in [100, 272]. This suggests that the m5C site detected 
in this thesis at C48 in tRNATyr(GUA) may occur before or after splicing. However, as 
m5C at C34 in tRNALeu(CAA) can occur prior to splicing and the structure of the tRNA 
surrounding C48 does not change upon maturation, it is highly likely that m5C at C48 
predominantly occurs prior to splicing. 
 
Although the understanding of the order end processing and splicing of tRNAs in 
humans is limited, we were interested in whether m5C can also occur prior to 5’ and 3’ 
end processing. This study was the first to explore this in detail. The global mapping of 
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tRNAs without the 3’ CCA addition allowed the mapping of tRNAs that were not 
completely processed, although it was expected that the levels of pre-tRNAs would be 
low. Examination of sequencing reads mapping to tRNALeu(CAA) and tRNAAsp(GUC) in 
IGV revealed that a small proportion of the reads extended beyond the 5’ and 3’ ends of 
the mature tRNA and that a small proportion of these sequencing reads contained m5C 
sites mediated by NSUN2 and TRDMT1. This indicated that NSUN2 and TRDMT1 can 
mediate m5C prior to end processing of tRNAs. 
 
A global approach was also used where all tRNAs exhibiting candidate m5C sites based 
on the global mapping were divided into a subset containing no mismatches and those 
containing ≥1 T-to-C mismatch. It should be noted that while a T-to-C mismatch is 
indicative of candidate m5C sites, it could also potentially be non-conversion due to the 
RNA secondary structure, or possibly an error associated with colour-space sequencing. 
However, we have not detected these issues previously in tRNAs. T-to-C mismatches 
were detected in a small proportion of sequencing reads extending beyond the 5’ and 3’ 
ends of the tRNAs, suggesting that methylation can occur prior to end processing.  
 
It seems reasonable to contend that if methylation can occur prior to splicing and end 
processing of tRNAs, then it most likely will exclusively occur prior to splicing and end 
processing. It should be noted, however, that these results do not formally exclude that 
some methylation might also occur after maturation.  
 
4.3.3 M5C IN NCRNA 
In this thesis, candidate m5C sites were detected in a variety of ncRNA, encompassing 
miRNA, rRNA, snoRNA, uRNA, vtRNA, 7SK RNA, 7SL RNA and other ncRNA. A 
subset of candidate m5C sites detected in these transcripts were called as NSUN2 
targets, and an even smaller subset were called as TRDMT1 targets. Recent studies have 
discovered candidate m5C sites in several different ncRNA including vtRNA, snoRNA 
and 7SK RNA that were mediated by NSUN2 [58, 77, 78], however investigation into 
the sequence and substrate specificity of NSUN2 is lacking. In this section, I will 
discuss in detail the m5C sites detected in ncRNA, the sequence and structural 
specificity of NSUN2 in these transcripts and possible molecular implications of m5C in 
these transcripts.  
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4.3.3.A M5C IN RRNA 
In this thesis, I examined the candidate m5C sites detected in nuclear-encoded and 
mitochondrial-encoded rRNA. 24 candidate m5C sites were detected in nuclear-encoded 
rRNA, with the majority detected in 28S rRNA. The two known m5C sites at C3782 and 
C4447 in 28S rRNA were detected with high coverage and >85% methylation in all 
samples, suggesting that NSUN2 or TRDMT1 do not mediate these sites. Interestingly, 
the m5C sites at these positions are equivalent to the m5C sites at C2278 and C2870 in 
yeast 25S rRNA, which are mediated by Rcm1 [86, 92] and Nop2 [92], respectively. 
The human homologues of Rcm1 and Nop2 are NSUN5A and NSUN1, respectively. 
Although catalytic activity of these human RNA:m5C methyltransferases have not been 
confirmed, it is possible that they mediate the two known m5C sites in 28S rRNA.  
 
As previous studies have not yet detected other m5C sites in nuclear-encoded rRNA and 
clusters of non-conversion were evident in the rRNAs in this study, an investigation was 
made into the remaining candidate m5C sites detected in this study. As m5C at C3782 
and C4447 were detected with high coverage and high levels of methylation in all 
samples, additional stringent thresholds were applied to enrich for genuine candidate 
m
5C sites. This revealed no additional candidate m5C sites in nuclear-encoded rRNA in 
this study. 
 
5 candidate m5C sites were called in mitochondrial-encoded rRNA, including 4 in 12S 
mitochondrial rRNA and 1 in 16S mitochondrial rRNA. The known m5C site at C841 in 
12S mitochondrial rRNA was detected with high coverage and ~40% methylation in all 
samples, suggesting that NSUN2 or TRDMT1 does not mediate this site. It was recently 
reported that the mitochondrial-localised enzyme, NSUN4, mediates m5C formation at 
the equivalent position in mice [97]. As with NSUN1 and NSUN5A, the catalytic 
activity of the human orthologue remains to be explored, however it is highly likely that 
NSUN4 is responsible for m5C at C841 in 12S mitochondrial rRNA.  
 
Two of the candidate m5C sites detected in 12S mitochondrial rRNA in this thesis could 
not be validated, suggesting that these may be false positives as a result of incomplete 
denaturation. The one remaining candidate m5C site in 12S mitochondrial rRNA 
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exhibited low and inconsistent levels of methylation in all samples, suggesting that this 
may be also an artefact. Additional m5C sites in mitochondrial-encoded rRNA are yet to 
be confirmed. Several studies have proposed that NSUN4 mediates m5C at an unknown 
residue in 16S mitochondrial rRNA [95, 290, 291], however we were not able to 
validate the candidate m5C site detected in 16S mitochondrial rRNA in this thesis. In 
agreement with our finding, m5C was only detected at the one known site in 12S rRNA 
in mice by bisulfite sequencing [97]. 
 
The inability to detect depletion of m5C in the NSUN2 and TRDMT1 knockdown 
samples at these positions in human rRNA and that the yeast and mice orthologues of 
NSUN1, NSUN4 and NSUN5A mediate m5C at equivalent positions highlights the 
possibility of other active RNA:m5C methyltransferases in humans. It would be of 
benefit to explore these RNA:m5C methyltransferases in more detail in the future to 
understand their substrate range and specificity.  
 
4.3.3.B SEQUENCE AND STRUCTURAL CONTEXT OF M5C IN OTHER 
NCRNA 
In this thesis, I used a candidate approach to investigate the sequence and structures that 
NSUN2 may recognise to mediate m5C in ncRNA. I validated two previously 
discovered m5C sites in RPPH1 and SCARNA2, and novel m5C sites in SNORD62, 
NSUN5P2 and a pseudogene in the intron of CAGE1. These m5C sites were also 
validated as NSUN2 targets, indicating that NSUN2 is capable of mediating m5C in a 
broad range of transcript biotypes. 
 
To understand the context features around the m5C sites and the specificity of NSUN2 
in these transcripts, predicted and published secondary structures were obtained for 
RPPH1, SCARNA2 and SNORD62. Additionally, secondary structures were obtained 
for vtRNA1-1 and vtRNA1-3, which were detected by bsRNA-seq as NSUN2 targets 
and were previously detected and validated in HeLa cells, HEK293 cells and human 
fibroblasts [77, 78]. 
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RPPH1, SNORD62 and SCARNA2 are all involved in the processing and modification 
of different transcript biotypes. RPPH1, SNORD62 and SCARNA2 and the vtRNAs are 
either synthesised or function in the nucleolus where NSUN2 is predominantly 
localised. RPPH1, SNORD62 and vtRNAs are transcribed by RNA Polymerase III 
within the nucleolus [292], and it is speculated that RNase P and therefore RPPH1 
localises to the nucleolus (see section 4.3.2.C). SCARNA2 is independently transcribed 
by RNA Polymerase II but is predicted to function in the nucleolus [293].  
 
The m5C site in RPPH1 was in a GCA context and located in the stem-loop junction, a 
structure reminiscent of that surrounding C48-50 in tRNAs that NSUN2 targets. RPPH1 
is the ncRNA component of RNase P that functions in the 5’ end processing [274] and 
has been shown to be important for RNA Polymerase III transcription [274]. 
Interestingly, the RNA component of RNase P in bacteria and some archaea has been 
shown to mediate tRNA cleavage in the absence of RNase P protein subunits [294]. 
Recently, it has been reported that RPPH1 is capable of mediating cleavage of four pre-
tRNAs in the absence of protein in vitro, although the rate of cleavage was substantially 
lower than bacterial RNase P RNA [295]. This was suggested to be a result of RPPH1 
not exhibiting the P15/P16/P17 region, which plays an important role in substrate 
binding and catalysis in bacteria [296-298]. Additionally, it is suspected that the 
additional protein subunits of the RNase P complex function in enhancing this catalytic 
activity [295]. The m5C site detected and validated in this thesis was located in the P12 
domain. Interestingly, targeted cleavage of the P12 domain of RPPH1 by RNase H was 
reported to cause a substantial reduction in transcription of 7SL RNA, 5S rRNA and 
several tRNAs, suggesting that this domain is important for transcription [274]. Thus, it 
is possible that the m5C site in this domain may regulate RNA Polymerase III 
transcription, which could potentially provide an additional layer of gene regulation. 
 
The m5C site in SCARNA2 was in a CpG context and located between two stem-loops 
and the m5C site in SNORD62 was in GCA context and located within the loop of a 
stem-loop structure. The structural context of both of these sites thus appears to be 
different to those targeted by NSUN2 in tRNAs. The m5C sites in SCARNA2 and 
SNORD62 were not located within the C/D box and C’/D’ box domains that are 
predicted to guide modification of U2 and 18S rRNA, respectively. In addition, the m5C 
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sites were not located at the predicted binding sites of the substrate RNAs. This 
suggests that the m5C sites in these guide RNAs may not directly affect recognition and 
binding of the substrate RNA, although this remains to be explored further. 
 
The candidate m5C sites in the two vtRNAs were in a TCG context and located in the 
stem near the stem-loop junction, a structure consistent with that exhibited around C48-
50 in the variable loop junction and C30 in the anti-codon loop junction in tRNAs. It 
was recently reported that loss of NSUN2-mediated m5C sites in vtRNAs caused 
aberrant processing into svRNAs, with one fragment of vtRNA1-1 exhibiting a 
significant decrease in the absence of NSUN2 [78]. Previous studies have reported that 
svRNAs can induce silencing of transcripts in a similar manner to miRNAs [299]. This 
fragment was demonstrated to associate with both Ago2 and Ago3, and two potential 
target mRNAs of this fragment demonstrated increased expression in the absence of this 
fragment. This strongly suggests that m5C in vtRNAs regulates its processing into 
svRNAs that in turn may mediate gene expression.  
 
The m5C sites in NSUN5P2 and the pseudogene located within the CAGE1 intron were 
in a CpA and CpT context, respectively. Little information is available for the processed 
pseudogene located in the intron of CAGE1. However, NSUN5P2 is one of the two 
NSUN5 pseudogenes located in the same region as NSUN5. The function of this 
pseudogene is unknown, however a deletion of the region of chromosome 7 that 
constitutes NSUN5 and both pseudogenes was observed in patients suffering from 
William-Beuren syndrome, a disease characterised by a complex array of symptoms, 
including neurodevelopment disorders [300]. To this end it is not known which gene 
contributes to the phenotype, although this example suggests that pseudogenes may play 
an important role in biology and disease, and m5C may function in regulating these 
transcripts. 
 
Based on this analysis, it is clear NSUN2 can mediate m5C in different sequence and 
structural contexts. There is a clear propensity for NSUN2 to target sites near stem-loop 
structures that may resemble the stem-loop structures in tRNAs. However, it is evident 
that NSUN2 can target structures that are different to those exhibited in tRNAs. This 
suggests that other features besides the surrounding sequence and structure of the target 
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site may possibly aid in the recognition by NSUN2 to mediate m5C. This is in contrast 
to the narrow specificity of NSUN2 previously reported for unspliced tRNALeu(CAA) at 
C34, which was attributed to the surrounding sequence and structural context [98]. The 
presence of m5C in ncRNAs may regulate their role in processing, but this remains to be 
explored in further detail. 
 
4.3.4 M5C IN MRNA 
Early studies of RNA modifications using chromatographic techniques revealed that 
m
5C existed at low levels in cellular and viral mRNAs [26, 30, 47, 48]. Due to their low 
levels, it was initially thought that this was simply contamination and was never 
followed up. With the improvement to techniques, the presence of m5C in mRNA is 
coming to the fore, revealing its abundance in this transcript biotype [58]. With the 
exception of our previous HeLa bsRNA-seq study, no studies have focused on the 
abundance of m5C in mRNA and the substrate specificity of NSUN2 in these 
transcripts. In this thesis, I have shown that m5C is abundant in mRNAs and that a 
proportion of these candidates were called as NSUN2 or TRDMT1 targets. I have 
validated previously discovered and novel candidate m5C sites as targets of NSUN2, 
and have investigated the sequence and structural specificity of NSUN2 in mRNAs, 
demonstrating that NSUN2 is an important mRNA modifying enzyme. 
 
4.3.4.A DISTRIBUTION OF M5C IN MRNA 
Using the candidate m5C sites detected in mRNAs in HeLa cells, the distribution of 
m5C was determined throughout different regions of mRNA. Candidate m5C sites were 
distributed throughout all regions of mRNAs, including introns. The fact that candidate 
m5C sites were detected in introns suggests that methylation can occur prior to splicing, 
although further examination of sequencing reads would be required to determine if this 
is the case. Overall, a large number of candidate m5C sites were located in the 3’ UTR 
and CDS and were significantly enriched in the 3’ UTR, while candidate m5C sites were 
depleted in the CDS and 5’ UTR compared to the expected levels. The enrichment of 
candidate m5C sites in the 3’ UTR is consistent with our previous study, however sites 
were also enriched in the 5’ UTR in our previous study [58]. The fact that both studies 
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revealed a clear 3’ UTR enrichment of candidate m5C sites highlights the non-random 
distribution of this modification. 
 
Recent next-generation sequencing studies investigating the distribution and role of 
m6A in mRNA have also reported non-random distribution, being predominantly 
enriched near stop codons and the 5’ UTR, and were not present in poly(A) tails [22, 56, 
57]. Several studies have also investigated the molecular function of m6A in mRNA, 
reporting a potential role in mRNA stability and alternative splicing [57, 69, 105, 107, 
120]. Thus, the non-random distribution of m5C in mRNA is highly suggestive of an 
important regulatory role for this modification. Furthermore, the enrichment of m5C in 
the 3’ UTR implies a possible regulatory role through association with Ago and 
miRNAs. We have previously detected an enrichment of Ago footprints upstream of 
candidate m5C sites, using a publicly available HEK293 Ago PAR-CLIP dataset [58]. 
Although the PAR-CLIP was performed in a different human cell line, it is highly 
indicative of a role for m5C in post-transcriptional gene regulation through association 
with Ago. 
 
4.3.4.B VALIDATION OF M5C SITES IN MRNA 
The candidate m5C sites selected for validation were located in different regions of the 
mRNA, the majority of which were called as NSUN2 targets based on bsRNA-seq. 
Three of the m5C sites selected for validation were discovered and validated as NSUN2 
targets in our previous study and included CINP, NAPRT1 and NDUFB7 [58]. In this 
present study, NDUFB7 was called as a NSUN2 target by bsRNA-seq consistent with 
our previous validation by Sanger bisulfite sequencing [58]. In contrast, the m5C site in 
CINP was detected but was not called as a NSUN2 target due to insufficient coverage in 
the NSUN2 knockdown sample. The m5C site in NAPRT1 was not detected at all in this 
present study due to insufficient coverage in most samples. All three previously 
discovered and validated m5C sites were validated as NSUN2 targets in this study. In 
addition, the novel m5C sites detected in OSBPL8 and RTN3 were not called as NSUN2 
or TRDMT1 targets by bsRNA-seq in this study, but were validated as NSUN2-
mediated sites. This indicates that the number of candidate m5C sites detected by 
bsRNA-seq in this thesis as NSUN2 and TRDMT1 targets was an underestimation. 
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The novel m5C sites detected in RPS3, SCO1 and SZRD1 were discovered and validated 
as NSUN2-directed sites in this thesis. Interestingly, MCFD2 exhibited two candidate 
m
5C sites, with each enzyme targeting this transcript. Although a focus was placed on 
candidate m5C sites targeted by NSUN2, the candidate m5C site called as a TRDMT1 
target was in close proximity to the NSUN2 target site and as a result was included in 
the validation process. The m5C site called as a NSUN2 target was validated, however 
the candidate m5C called as a TRDMT1 target was not detected by MiSeq amplicon 
sequencing. Examination of the sequencing reads spanning this unvalidated candidate 
m5C site revealed that the site was of low quality due to uncertainty in the colour calling 
by the SOLiDTM platform.   
 
The validated m5C sites were in mRNAs that encoded proteins with varying functions 
in the cell, including components of the DNA replication complex (CINP [301]), blood 
coagulation (MCFD2 [302]), intracellular lipid receptors (OSBPL8), ribosomal proteins 
(RPS3), regulation of the production of beta-amyloid (RTN3 [303]) as well as proteins 
that function in electron transport and energy production (NAPRT1, NDUFB7 and 
SCO1). Thus, m5C in these transcripts may have a role in post-transcriptional gene 
regulation that may affect a number of different cellular processes.  
 
4.3.4.C STRUCTURAL AND SEQUENCE CONTEXT OF M5C IN MRNA 
Preliminary global analyses were performed to identify enriched structural and 
sequence motifs surrounding candidate m5C sites in mRNA that may be recognised by 
NSUN2. These analyses were performed for all candidate m5C sites detected in HeLa 
cells and candidate m5C sites called as NSUN2 targets. Understanding of the structural 
and sequence specificity of NSUN2 in mRNAs may elucidate the features of mRNA 
that may help achieve selective methylation. 
 
Candidate m5C sites detected in the CDS and 3’ UTR in HeLa cells were significantly 
enriched around stem-loop motifs, consistent with the structural motifs identified in the 
subset of ncRNAs investigated in this thesis. The candidate m5C sites in the CDS were 
enriched in the stem, where the location was slightly bulged, and those in the 3’ UTR 
were enriched in the loop. Similarly, candidate m5C sites called as NSUN2 targets were 
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enriched around stem-loop motifs, with sites located in the stem and the loop. Those 
candidate m5C sites enriched in the stem a few nucleotides upstream of the stem-loop 
junction were in a similar structural context to the candidate m5C sites called as NSUN2 
targets at C30 in the anti-codon junction of tRNAs and in the stem near the stem-loop 
junction in vtRNAs. The candidate m5C sites enriched in the loop are in a similar 
structural context to m5C site in SNORD62. This indicates that the structural motifs that 
are recognised by NSUN2 are broad although can be similar between transcript 
biotypes, and once again highlights the multisite specificity of this enzyme.  
 
No defined sequence motif was identified for candidate m5C sites in mRNAs, although 
prevalence of a string of Gs was evident 2-4 nt downstream for candidate m5C sites 
detected in HeLa cells and candidate m5C sites called as NSUN2 targets. In addition, 
there was a mild preference for m5CpG and m5CpA over m5CpT and m5CpC for 
candidate m5C sites called as NSUN2 targets. These features were highlighted for the 
m
5C sites validated in this study, which demonstrated a higher occurrence of m5CpG 
and m5CpA and a prevalence of Gs further downstream. Similarly, candidate m5C sites 
in tRNAs called as NSUN2 targets by bsRNA-seq showed a prevalence of Gs, although 
this was 3-5 nt downstream of the site. It is possible that NSUN2 may recognise the 
multiple Gs to mediate m5C, however as two of the validated mRNAs did not exhibit 
these Gs, this suggests that NSUN2 is capable of mediating m5C in different sequence 
contexts. Previously, we discovered increased frequency of C and G as flanking bases 
[58]. Furthermore, the NSUN2 miCLIP study performed in human fibroblasts also 
showed an enrichment of a CG dinucleotides at the NSUN2 target site, however this 
was detected as an overall enrichment in all transcript biotypes [78].  
 
In agreement with the findings for ncRNAs and tRNAs, these analyses highlight the 
multisite specificity of NSUN2. NSUN2 is capable of mediating m5C sites in different 
sequence and structural contexts in mRNA, suggesting that other features of the mRNA 
substrate may be required to achieve such selective methylation.   
 237 
!
RNA m5C profiling of HeLa cells depleted of NSUN2 and TRDMT1 
!
! !
4.3.5 CONCLUSIONS 
In this chapter, I have described the abundance and distribution of candidate m5C sites 
in HeLa cells as well as the substrate range of NSUN2 and TRDMT1 and specificity of 
NSUN2 in particular. I have shown that candidate m5C sites are present in tRNAs, other 
ncRNAs and mRNAs and that NSUN2 and TRDMT1 are responsible for targeting at 
least a subset of these transcripts. I have thoroughly investigated m5C in tRNAs and 
have independently confirmed findings from recently published studies. I have also 
provided evidence of m5C occurring prior to splicing and 5’ and 3’ end processing of 
tRNAs, the latter of which is a novel finding. I have validated novel m5C sites in 
ncRNAs and mRNAs as NSUN2 targets and have also shown that candidate m5C sites 
in mRNAs are enriched in the 3’ UTR, highlighting its non-random distribution that is 
suggestive of an important regulatory function. Furthermore, preliminary investigation 
into the substrate specificity of NSUN2 in ncRNAs and mRNAs have highlighted that 
NSUN2 is a multisite-specific RNA methyltransferase. These finding highlight the 
prevalence of m5C in mRNA and demonstrate for the first time that NSUN2 has a broad 
role in modifying mRNAs, in addition to some ncRNAs. 
 
4.4 CHAPTER HIGHLIGHTS 
• This study was performed as an initial screen to identify novel RNA targets of 
NSUN2 and TRDMT1. 
• 4,241 candidate m5C sites were detected in HeLa cells and distributed across tRNAs, 
other ncRNA and mRNAs, with the majority of candidate m5C sites detected in 
mRNAs. 
• 393 candidate m5C sites were called as NSUN2 targets and 120 as TRDMT1 targets 
in tRNAs, other ncRNAs and mRNAs.  !
4.4.1 TRNA 
• tRNA-focused bsRNA-seq data analysis confidently detected 185 candidate m5C 
sites in tRNAs, 87% of which were in one of seven anticipated structural positions: 
C34, C38, C40, C48-50 and C72. 
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• 108 of these sites were assigned to NSUN2. 107 of these sites were situated in 
positions, C34, C40, C48-50 across many different tRNA isotypes and isoacceptors. 
Thus, all positions known to be targeted by NSUN2 except C72 were revealed here. 
This demonstrated that NSUN2 is responsible for the large majority of m5C sites in 
tRNAs, while displaying selectivity for several structural positions. 
• TRDMT1 was assigned to 15 sites, with 14 of these sites at a single structural 
position, C38, in four tRNA types: tRNAAsp(GUC), tRNAGly(GCC), tRNAVal(AAC) and 
tRNAVal(CAC). Thus, TRDMT1 is much more restricted in its tRNA substrate range. 
• The above findings on NSUN2 and TRDMT1 tRNA substrate range and specificity 
revealed several newly detected individual sites of m5C in tRNA, while broadly 
concurring with a large body of published work, including the recent transcriptome-
wide studies by us and others. 
• MiSeq amplicon sequencing of biological replicates confirmed that NSUN2 mediates 
m
5C sites at C48-50 of several tRNAs, and TRDMT1 mediates m5C at C38 of 
tRNAGly(GCC) and tRNAVal(CAC). 
• MiSeq amplicon sequencing demonstrated that m5C in tRNAs can occur prior to 
splicing, independently confirming previously published work.  
• Analysis of bsRNA-seq reads mapping to pre-tRNA sequences across all tRNA loci 
exhibiting candidate m5C sites showed, for the first time, that cytosines in tRNAs are 
modified prior to 5’ and 3’ end processing. 
 
4.4.2 OTHER NCRNA 
• bsRNA-seq detected 667 candidate m5C sites in other ncRNAs, 33 and 9 of which 
were assigned to NSUN2 and TRDMT1, respectively. 
• The bsRNA-seq data was selectively mined for m5C sites in ncRNAs. 
• It confidently detected the previously known m5C sites at C3782 and C4447 in 28S 
rRNA and C841 in 12S mitochondrial RNA, which were refractory to NSUN2 or 
TRDMT1 knockdown. This matched with expectations that the m5C:RNA 
methyltransferases NSUN5A, NSUN1 and NSUN4, respectively, are responsible for 
these sites, as shown in yeast and/or mice. 
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• NSUN2-mediated m5C sites in SCARNA2 and RPPH1 were detected by bsRNA-seq 
and validated by MiSeq amplicon sequencing, independently confirming recently 
published work.  
• Similarly, entirely novel m5C sites in SNORD62, NSUN5P2 and the pseudogene in 
the intron of CAGE1 were discovered and validated as NSUN2 targets.  
• Visual inspection of the local context around the NSUN2-mediated m5C sites in 
RPPH1, SCARNA2, SNORD62, vtRNA1-1 and vtRNA1-3 indicated variability in 
secondary structure and sequence, highlighting the multisite specificity of this 
enzyme. 
 
4.4.3 MRNA 
• bsRNA detected 1,564 candidate m5C sites in mRNAs, 118 and 53 of which were 
assigned to NSUN2 and TRDMT1, respectively. 
• Candidate m5C sites were enriched in the 3’ UTR of mRNAs, which is a hotspot for 
regulatory motifs, suggesting a role for m5C in post-transcriptional gene control.  
• Focusing on NSUN2 targets, MiSeq amplicon sequencing of biological replicates 
confirmed previously known NSUN2 target sites in CINP, NAPRT1 and NDUFB7, 
as well as validating the novel NSUN2 target sites in MCFD2, OSBPL8, RPS3, 
RTN3, SCO1 and SZRD1. 
• Motif searches in the vicinity of all mRNA candidate m5C sites, or the NSUN2-
targeted subset, revealed that stem-loop containing structures were enriched as was a 
string of Gs 2-4 nt downstream of the m5C site. There was also a slight preference 
for m5CpG and m5CpA. Some of these features are reminiscent of NSUN2 sites in 
tRNA, hinting at a unifying principle underlying NSUN2 substrate recognition in 
different RNA biotypes that warrants further investigation. 
• Overall, these findings highlight the unexpected prevalence of m5C sites in mRNAs 
and demonstrate for the first time that NSUN2 has a broad role in modifying 
mRNAs. 
  
!
!
CHAPTER FIVE 
EXPLORING THE 
MOLECULAR FUNCTIONS OF 
M5C IN MRNA
  241 
!
Exploring the molecular functions of m5C in mRNA 
!
! !
5.1 INTRODUCTION 
The availability of next-generation sequencing technologies that has enabled 
transcriptome-wide mapping of several RNA modifications has begun to profoundly 
change the understanding of their prevalence in the transcriptome. Nucleoside 
modifications including m5C, m6A and ψ are not confined to specific ncRNAs of the 
translational machinery but are further non-randomly distributed throughout the 
transcriptome, suggesting that they serve multiple regulatory functions. There has been 
a flurry of research in this field of “epitranscriptomics”, and an initial understanding of 
the molecular functions of these nucleoside modifications in mRNA is beginning to 
emerge. For instance, a number of studies have implemented transcriptome-wide 
sequencing technologies for the detection of m6A, revealing its abundance in mRNA 
[56, 57, 68, 69]. This has enabled the investigation of the molecular function of m6A in 
mRNA, with an emerging consensus that it is involved in regulating mRNA stability 
and alternative splicing [57, 69, 105, 107, 120].  
 
The investigation of the molecular functions of m5C in RNA has primarily focused on 
rRNAs, tRNAs and recently also vtRNAs. In tRNAs, m5C mediated by TRDMT1 at 
C38 in tRNAAsp(GUC), tRNAGly(GCC) and tRNAVal(AAC) in D. melanogaster protects the 
tRNAs against ribonuclease cleavage, and loss of this modification results in decreased 
viability under stress conditions [73]. In humans, angiogenin mediates stress-induced 
cleavage of tRNAs and in vitro cleavage of tRNAs in D. melanogaster by human 
angiogenin was reduced when TRDMT1 was overexpressed [73, 304]. Recently, it was 
reported that disruption of NSUN2 and TRDMT1 in mice led to a decrease in tRNA 
steady-state levels and an overall decrease in the rate of protein synthesis [149]. A 
recent study has also revealed that the absence of NSUN2, and therefore ablation of 
m5C in vtRNAs and the majority of m5C sites in tRNAs, resulted in aberrant processing 
into svRNAs [78, 150]. svRNAs can associate with Ago and regulate gene expression in 
a similar manner to miRNAs, suggesting that m5C in vtRNAs may regulate gene 
expression of mRNAs [299]. 
 
The role of m5C in mRNAs remains elusive, however we have previously reported 
enrichment of Ago footprints upstream of m5C sites in mRNA, while another post-
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transcriptional regulator, Pumilio 2 (PUM2), showed no enrichment in these regions 
[58]. This points to a role for m5C in mRNA in post-transcriptional gene regulation, 
motivating further research into this area. 
 
The aim of this chapter was to investigate the molecular functions of m5C in mRNA in 
further detail. The roles of m5C in mRNA may be diverse and context-dependent, thus 
an investigation was made into several possible molecular functions for this 
modification. We achieved this using bioinformatics analysis of the newly generated 
HeLa methyltransferase knockdown bsRNA-seq data as well as experimental 
investigations using a candidate approach and focusing on NSUN2 mRNA targets. 
 
5.2 RESULTS 
The following sections detail investigations into the molecular functions of m5C in 
mRNA. Mapping of the MiSeq amplicon sequencing data was performed by Dr. Brian 
J. Parker, who also performed the global analyses of the bsRNA-seq data in 
consultation with myself. I performed the experimental investigations including RT-
qPCR and sucrose density gradient centrifugation. I also performed the statistical 
analyses of the experimental data with the help of Dr. Teresa Neeman using GenStat at 
the Statistical Consulting Unit. 
 
5.2.1 GENE SET ENRICHMENT AND GO ANALYSES OF 
METHYLATED MRNAS 
To gain insight into the molecular functions of m5C in mRNA, gene set enrichment 
analyses (GSEA) and GO analyses were performed on the bsRNA-seq data. GO terms 
are grouped into three ontologies; biological process, molecular function and cellular 
component [305]. GO analysis was performed using the topGO R package [247] to 
determine which biological processes were significant for mRNAs exhibiting candidate 
m5C sites. The elim method was used for this analysis, which investigated the GO terms 
from bottom to top to ensure the most specific terms were scored. This method also 
iteratively removes genes that mapped to significant GO terms before scoring the parent 
terms. An example of a parent term is “membrane organisation and biogenesis”, which 
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can have the progeny “membrane fusion”, which is more specific. GSEA provides a 
more general analysis focusing on related gene sets involved in certain pathways or 
complexes using the Kyoto Encyclopedia of Genes and Genomes (KEGG). This 
provides a link between a set of genes in the genome with a network of interacting 
molecules such as a pathway or complex [306, 307]. Pathways include metabolism, 
genetic information processing, environmental information processing, cellular 
processes, organismal systems and human diseases. Thus, it represents a higher order of 
biological function. For this analysis, the gage R package was used [246]. 
 
Both sets of analyses were performed on all mRNAs exhibiting candidate m5C sites in 
HeLa cells, as well as mRNAs with candidate m5C sites called as NSUN2 and 
TRDMT1 targets, based on the bsRNA-seq data. The background set used to detect 
enrichment were all expressed genes from the bsRNA-seq, which was defined as at least 
one cytosine within a gene having ≥5 reads.  
 
GSEA using the gage R package did not reveal enrichment of particular pathways or 
complexes for all candidate m5C site-containing mRNAs in HeLa cells, as well as 
mRNAs with candidate m5C sites called as NSUN2 and TRDMT1 targets. For the set of 
all candidate m5C site-containing mRNAs in HeLa cells, GO terms relating to a diverse 
range of cellular processes were enriched (Table 5.1). GO terms enriched for the list of 
NSUN2- or TRDMT1-targeted transcripts were similarly diverse (Tables 5.2 & 5.3). 
Interestingly, several GO terms relating to mRNA metabolism were enriched in all three 
lists of genes (coloured in green in the following tables). The process of mRNA 
translation was particularly prominent, with all three phases including initiation, 
elongation and termination being represented. The full list of enriched GO terms are in 
Appendix 8.7. 
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Table 5.1. GO term enrichment of mRNAs containing candidate m5C sites in HeLa cells 
based on topGO. 
The top 30 biological processes in order of significance are listed.  
Term ID Term Description 
Number of 
significant 
transcripts  
P-value 
GO:0006415 translational termination 71 5.7E-30 
GO:0044281 small molecule metabolic process 759 1.4E-28 
GO:0044419 interspecies interaction between organisms 71 1.1E-25 
GO:0015031 protein transport 224 1.1E-19 
GO:0007165 signal transduction 333 1E-18 
GO:0051301 cell division 66 7.6E-18 
GO:0000084 S phase of mitotic cell cycle 42 8.5E-18 
GO:0007596 blood coagulation 74 1.2E-17 
GO:0007411 axon guidance 42 8.5E-17 
GO:0030154 cell differentiation 197 2.2E-16 
GO:0008284 positive regulation of cell proliferation 50 2.5E-16 
GO:0006457 protein folding 54 2.5E-16 
GO:0042493 response to drug 39 1.8E-15 
GO:0016032 viral reproduction 132 2.3E-15 
GO:0008283 cell proliferation 132 1.9E-14 
GO:0000216 M/G1 transition of mitotic cell cycle 32 2.3E-14 
GO:0002479 antigen processing and presentation of 
exogenous peptide antigen via MHC class I, 
TAP-dependent 
32 2.3E-14 
GO:0048011 nerve growth factor receptor signaling 
pathway 
34 3.4E-14 
GO:0016071 mRNA metabolic process 179 6.8E-14 
GO:0045944 positive regulation of transcription from 
RNA polymerase II promoter 
37 9.5E-14 
GO:0030168 platelet activation 33 9.6E-14 
GO:0055085 transmembrane transport 75 1.3E-13 
GO:0007049 cell cycle 178 2.1E-13 
GO:0006886 intracellular protein transport 164 2.2E-13 
GO:0006916 anti-apoptosis 45 2.2E-13 
GO:0042981 regulation of apoptosis 156 8.7E-13 
GO:0006810 transport 430 9.3E-13 
GO:0000398 nuclear mRNA splicing, via spliceosome 48 3E-12 
GO:0019221 cytokine-mediated signaling pathway 43 3.7E-12 
GO:0045892 negative regulation of transcription, DNA-
dependent 
62 3.7E-12 
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Table 5.2. GO term enrichment of NSUN2-targeted mRNAs in HeLa cells based on 
topGO. 
The top 30 biological processes in order of significance are listed.  
Term ID Term Description 
Number of 
significant 
transcripts  
P-value 
GO:0006413 translational initiation 16 0.00000014 
GO:0006414 translational elongation 14 0.00000036 
GO:0044281 small molecule metabolic process 82 0.0000049 
GO:0006200 ATP catabolic process 6 0.000016 
GO:0048513 organ development 26 0.000022 
GO:0006987 
activation of signaling protein activity 
involved in unfolded protein response 6 0.000023 
GO:0051084 'de novo' posttranslational protein folding 6 0.000032 
GO:0006415 translational termination 11 0.000044 
GO:0008283 cell proliferation 19 0.000054 
GO:0051384 response to glucocorticoid stimulus 5 0.000079 
GO:0000184 
nuclear-transcribed mRNA catabolic process, 
nonsense-mediated decay 11 0.000082 
GO:0019538 protein metabolic process 62 0.000086 
GO:0019083 viral transcription 11 0.000093 
GO:0055085 transmembrane transport 11 0.00012 
GO:0019221 cytokine-mediated signaling pathway 8 0.00014 
GO:0006614 
SRP-dependent cotranslational protein 
targeting to membrane 11 0.00015 
GO:0030168 platelet activation 7 0.00017 
GO:0008150 biological_process 135 0.00027 
GO:0009888 tissue development 12 0.00027 
GO:0006355 regulation of transcription, DNA-dependent 20 0.00042 
GO:0010605 
negative regulation of macromolecule 
metabolic process 14 0.00043 
GO:0071310 cellular response to organic substance 24 0.00057 
GO:0001701 in utero embryonic development 5 0.00066 
GO:0010646 regulation of cell communication 12 0.00074 
GO:0019752 carboxylic acid metabolic process 16 0.00079 
GO:0009057 macromolecule catabolic process 24 0.00081 
GO:0071495 cellular response to endogenous stimulus 10 0.00091 
GO:0009607 response to biotic stimulus 8 0.00095 
GO:0006810 transport 47 0.0011 
GO:0006120 
mitochondrial electron transport, NADH to 
ubiquinone 4 0.00113 
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Table 5.3. GO term enrichment of TRDMT1-targeted mRNAs in HeLa cells based on 
topGO. 
The top 30 biological processes in order of significance are listed.  
Term ID Term Description 
Number of 
significant 
transcripts  
P-value 
GO:0044238 primary metabolic process 36 0.000015 
GO:0006457 protein folding 6 0.000023 
GO:0000184 
nuclear-transcribed mRNA catabolic process, 
nonsense-mediated decay 6 0.00016 
GO:0006468 protein phosphorylation 8 0.00034 
GO:0006413 translational initiation 6 0.00047 
GO:0051495 
positive regulation of cytoskeleton 
organization 2 0.00067 
GO:0018279 protein N-linked glycosylation via asparagine 3 0.0007 
GO:0006259 DNA metabolic process 8 0.00072 
GO:0044237 cellular metabolic process 36 0.00095 
GO:0006936 muscle contraction 3 0.00099 
GO:0006415 translational termination 5 0.00103 
GO:0010564 regulation of cell cycle process 5 0.0011 
GO:0032413 
negative regulation of ion transmembrane 
transporter activity 2 0.0011 
GO:0048468 cell development 8 0.00114 
GO:0006414 translational elongation 5 0.00131 
GO:0019083 viral transcription 5 0.00147 
GO:0045787 positive regulation of cell cycle 2 0.00164 
GO:0051208 sequestering of calcium ion 2 0.00164 
GO:0055007 cardiac muscle cell differentiation 2 0.00164 
GO:0030029 actin filament-based process 4 0.00171 
GO:0006614 
SRP-dependent cotranslational protein 
targeting to membrane 5 0.00183 
GO:0009968 negative regulation of signal transduction 4 0.00184 
GO:0071310 cellular response to organic substance 6 0.00191 
GO:0043687 post-translational protein modification 3 0.00199 
GO:0043161 
proteasomal ubiquitin-dependent protein 
catabolic process 4 0.00213 
GO:0007059 chromosome segregation 3 0.00251 
GO:0006974 response to DNA damage stimulus 5 0.00261 
GO:0007276 gamete generation 5 0.00264 
GO:0010604 
positive regulation of macromolecule 
metabolic process 8 0.00264 
GO:0033554 cellular response to stress 9 0.00274 
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5.2.2 INVESTIGATING THE ASSOCIATION OF M5C WITH 
AGO AND MIRNAS 
The role of a given m5C site in mRNA is likely context-dependent, suggesting that this 
modification may serve different molecular functions (see Figure 1.5). Previously, we 
found enrichment of Ago footprints upstream of candidate m5C sites in mRNAs in 
addition to enrichment of m5C sites in the 3’ UTR, suggesting a relationship between 
m
5C and Ago [58]. These analyses were done with Ago PAR-CLIP data from HEK293 
cells, as no direct HeLa cell data was available at the time. As discussed in Chapter 4, 
candidate m5C sites were again found to be enriched in the 3’ UTR based on the newly 
generated HeLa methyltransferase knockdown dataset. To investigate the potential 
relationship between m5C sites and Ago further, the newly generated HeLa 
methyltransferase knockdown data was integrated with HeLa Ago2 HITS-CLIP data 
that is now publicly available [308]. The published study performed HITS-CLIP on 
HeLa cells transfected with a miRNA mimic and a non-targeting control. For this 
analysis, the control HITS-CLIP dataset was integrated with the bsRNA-seq data. The 
bsRNA-seq data was also integrated with a publicly available HeLa HuR PAR-CLIP 
dataset [244]. As a negative control, candidate m5C sites detected were assigned random 
positions within the same genomic region. 
 
This analysis was performed on all candidate m5C sites detected in HeLa cells, as the 
datasets for the NSUN2 and TRDMT1 knockdown samples were too small and resulted 
in substantial noise. Genomic coordinates from the bsRNA-seq data were aligned with 
those in the Ago2 and HuR datasets and the footprint density of Ago2 and HuR were 
examined across regions in the 3’ UTR and CDS flanking candidate m5C sites. A 2.8-
fold enrichment of Ago2 footprints relative to the random shuffled control was evident 
in the 3’ UTR within 25 nt upstream on average of candidate m5C sites (p≈0, 
permutation test, 10 repetitions) (Figure 5.1A). Similarly, a 2.3-fold enrichment of 
Ago2 footprints relative to the random shuffled control was evident in the CDS within 
25 nt upstream on average of candidate m5C sites (p≈0, permutation test, 10 repetitions) 
(Figure 5.1B). No enrichment of HuR was detected near candidate m5C sites in the 3’ 
UTR (p=0.0910, permutation test, 10 repetitions) or CDS (p=0.2727, permutation test, 
10 repetitions) relative to the random shuffled control.   
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Figure 5.1. HeLa Ago2 and HuR footprint density surrounding candidate m5C sites in 
mRNA. 
The HeLa methyltransferase knockdown dataset was integrated with the HeLa Ago2 HITS-
CLIP dataset [308] and HuR PAR-CLIP dataset [244]. Spatial distribution summary plots were 
generated by anchoring at candidate m5C sites in mRNAs in the 3’ UTR and CDS. The random 
shuffled control was generated by randomly reassigning the genomic location of candidate m5C 
sites to another position within each region. 500 nt regions flanking the candidate m5C sites are 
shown. A) Significant enrichment of Ago2 footprints was evident upstream of candidate m5C 
sites in the 3’ UTR relative to the random shuffled control (p≈0, permutation test, 10 
repetitions). No enrichment of HuR footprints was evident near candidate m5C sites in the 3’ 
UTR (p=0.0910, permutation test, 10 repetitions). B) A significant enrichment of Ago2 
footprints was evident upstream of candidate m5C sites in the CDS relative to the random 
shuffled control (p≈0, Permutation test, 10 repetitions). No enrichment of HuR footprints was 
evident near candidate m5C sites in the CDS (p=0.2727, Permutation test, 10 repetitions). 
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To investigate the relationship of Ago2 and m5C in more detail, the density of 
conserved miRNA target sites surrounding all candidate m5C sites in HeLa cells was 
determined in the 3’ UTR and CDS. 7-mer motifs were selected genome-wide that 
showed a PhyloP conservation score of >1.3 and were divided into subsets based on 
whether they were the reverse complement of miRNA seed regions in miRBase v19. 
The PhyloP score is a measure of how conserved a base is, and a score of >1.3 retains 
only those motifs that are moderately to highly conserved. The conserved 7-mer motifs 
that were the reverse complement of miRNA seed regions in miRBase v19 were used as 
the final set of conserved miRNA target sites. The conserved 7-mer motifs that were not 
the reverse complement of miRNA seed regions in miRBase v19 were used as a 
negative control. As an additional negative control, candidate m5C sites were assigned 
random positions within the same genomic region. 
 
The 3’ UTR showed a 55% decrease of 7-mer miRNA targets at candidate m5C sites 
relative to the random shuffled control (p≈0, permutation test, 10 repetitions) (Figure 
5.2A). A 36% decrease of 7-mer miRNA targets at candidate m5C sites relative to the 
random shuffled control was evident in the CDS (p≈0, permutation test, 10 repetitions) 
(Figure 5.2B). The spatial distribution summary plot for candidate m5C sites in the 3’ 
UTR was noisier than the CDS; this is attributed to the smaller length of the 3’ UTR 
compared to the CDS and the smaller number of data points for this analysis. 
 
Depletion of non-miRNA 7-mer motifs was not observed in either the 3’ UTR or CDS, 
although a slight enrichment was evident in the CDS. To determine whether the 
depletion of miRNA motifs was a result of a lower cytosine frequency within these 
regions, miRNA target density was determined surrounding unmethylated cytosines, 
with no depletion evident. 
 
The analysis performed in this section indicates a potential role for m5C in post-
transcriptional gene regulation through association with Ago2. 
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Figure 5.2. Density of conserved 7-mer motifs surrounding candidate m5C sites in mRNA. 
Conserved miRNA target sites were determined by ensuring they exhibited a PhyloP 
conservation score of >1.3 and were the reverse complement of miRNA seed regions in 
miRBase v19. Spatial distribution summary plots were generated by anchoring at candidate m5C 
sites in the 3’ UTR and CDS with the conserved 7-mer motif density on the y-axis. The density 
of those conserved 7-mer motifs that were not the reverse complement of miRNA seed regions 
in miRBase v19 were also determined as a negative control. To determine if the depletion of 
conserved 7-mer miRNA motifs at candidate m5C sites was a result of biases in the distribution 
of bases, the density of conserved 7-mer miRNA motifs was plotted for unmethylated cytosines. 
The random shuffled control was generated by randomly reassigning the genomic location of 
candidate m5C sites to another position within each region. 200 nt regions flanking the 
candidate m5C sites are shown. A) Depletion of miRNA target sites was evident at candidate 
m
5C sites in the 3’ UTR relative to the random shuffled control (p≈0, permutation test, 10 
repetitions). B) Depletion of miRNA target sites was evident at candidate m5C sites in the CDS 
relative to the random shuffled control (p≈0, permutation test, 10 repetitions).  
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5.2.3 ANALYSIS OF GLOBAL STEADY-STATE LEVELS OF 
METHYLATED MRNAS 
It was of interest to perform an initial screen to determine if depletion of m5C in 
mRNAs resulted in a change in their steady-state level, by making additional use of the 
HeLa methyltransferase knockdown bsRNA-seq data. As NSUN2 was found to target a 
larger number of mRNAs compared to TRDMT1, this analysis was performed on 
NSUN2-targeted mRNAs and the fold-change determined between the NSUN2 
knockdown sample and TRDMT1 knockdown and NTC samples as controls. The 
DNMT1 knockdown sample was excluded from this analysis on the basis that DNMT1 
causes substantial pleiotropic changes in gene expression.  
 
The analysis was performed using Voom weighting of raw read counts over UCSC 
canonical genes and the differential expression determined using the Limma pipeline 
[240]. The Limma pipeline uses a moderated t-test to detect significantly differentially 
expressed transcripts. As the data used for this analysis was based on next-generation 
sequencing, Voom weighting was applied where those transcripts with higher read 
counts (higher confidence) were given a higher weight. 
 
The mean expression level in counts per million (CPM) of NSUN2-targeted mRNAs 
was determined for the NSUN2 knockdown sample relative to the controls. In addition, 
to determine if the knockdown of NSUN2 resulted in an indirect global effect on 
expression such as affecting transcription, the mean expression levels were determined 
for mRNAs without detectable methylation for the NSUN2 knockdown sample relative 
to the controls. Compared to the mean expression level of unmethylated mRNAs, the 
NSUN2-targeted mRNAs exhibited an 11.9% decrease in mean steady-state expression 
levels in the NSUN2 knockdown sample (p=2 x 10-4, Wilcoxon test) (Figure 5.3). Thus, 
as NSUN2 knockdown is unlikely to selectively affect transcription of its target, this 
analysis suggests a role for NSUN2-mediated m5C sites in stabilising mRNA. 
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Figure 5.3. Global analysis of the average steady-state level of mRNAs containing 
candidate m5C sites called as NSUN2 targets based on bsRNA-seq. 
Expression over each category was determined using the Limma pipeline and Voom weighting 
of raw read counts. The mean expression level of mRNAs called as NSUN2 targets was 
determined in CPM and the fold-change (FC) between the NSUN2 knockdown sample and the 
TRDMT1 knockdown and NTC samples was calculated. The mean expression fold-change was 
also calculated for unmethylated mRNAs as a control. A significant decrease in the mean 
expression of NSUN2-targeted transcripts was evident compared to unmethylated mRNAs  
(p=2 x 10-4, Wilcoxon test). Data represented as mean fold-change of expression of all mRNAs 
in each category with SEM. 
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5.2.4 ANALYSIS OF STEADY-STATE LEVELS OF 
METHYLATED MRNAS USING RT-QPCR 
A 11.9% decrease in the mean steady-state level of NSUN2-targeted mRNAs in the 
NSUN2 knockdown sample might be driven by a small reduction in levels consistently 
for many mRNAs among the group, or a more diverse response with a pronounced 
change for some examples. A consistent but small change would be hard to detect using 
RT-qPCR, nevertheless, a candidate approach using RT-qPCR was implemented to 
explore whether evidence for the latter scenario could be obtained. 
 
Two approaches were used to examine the effect of m5C on mRNA steady-state levels. 
First, an investigation was made into whether the knockdown of NSUN2 and therefore 
the depletion of m5C in mRNA resulted in a decrease in expression of each individual 
mRNA. As a second approach, an investigation was made into whether a decrease in the 
mean steady-state level in all mRNAs that were interrogated was evident, similar to the 
global analysis used for the bsRNA-seq data. 
 
5.2.4.A DETERMINING HOUSEKEEPING GENES FOR NORMALISATION OF 
RT-QPCR DATA 
Careful selection of housekeeping genes for the normalisation of the RT-qPCR data was 
made to ensure they did not contain candidate m5C sites, which may affect their steady-
state levels. A list of housekeeping genes was determined from [309] and were filtered 
to remove any transcripts that exhibited candidate m5C sites or a large standard 
deviation in expression between samples based on the bsRNA-seq data (see Appendix 
8.8). Ultimately, three housekeeping genes were selected based on these selection 
criteria and included the transcripts MRPL9, H2AFV and TCF25. The geometric mean 
of these three housekeeping genes was calculated for final normalisation of the 
expression data.  
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5.2.4.B STEADY-STATE LEVEL ANALYSIS OF CANDIDATE MRNAS 
TARGETED BY NSUN2 
The expression levels of six mRNAs that were validated to contain m5C sites mediated 
by NSUN2 were investigated in the NSUN2 knockdown, TRDMT1 knockdown and 
NTC samples. These included MCFD2, NAPRT1, NDUFB7, OSBPL8, RTN3 and 
SZRD1. As with the global analysis, the DNMT1 knockdown sample was removed from 
this investigation. Both the TRDMT1 knockdown and NTC samples were used as 
controls in which mRNA expression levels of NSUN2 targets were expected to remain 
unchanged. 
 
Six biological replicates of the RNA methyltransferase knockdown samples were used 
for this analysis. This included the three biological replicates described in Chapter 3 of 
which one was used for the validation of candidate m5C sites in Chapter 4, and an 
additional three biological replicate knockdowns that were performed by myself. 
Bisulfite conversion and knockdown efficiency were assessed for two of three new 
biological replicates by MiSeq amplicon sequencing. A segment of the non-humanised 
R-Luc in vitro transcript and the depletion of m5C at the known sites in tRNAAsp(GUC) 
and tRNALeu(CAA) were assessed for bisulfite conversion efficiency and knockdown 
efficiency, respectively.  
 
In tRNAAsp(GUC), depletion from ~70% methylation in the NTC samples to ~7% in the 
TRDMT1 knockdown samples was evident at C38 (Figure 5.4A). Depletion from ~94% 
methylation in the NTC samples to ~45% in the NSUN2 knockdown samples was 
evident at C48 and C49. In unspliced tRNALeu(CAA), depletion from ~50% methylation 
in the NTC samples to ~7% in the NSUN2 knockdown samples was evident at C34, 
while in the spliced transcript, depletion from ~85% methylation in the NTC samples to 
~20% in the NSUN2 knockdown samples was evident (Figure 5.4B). Thus, this 
indicates sufficient knockdown of NSUN2 and TRDMT1. Additionally, efficient 
bisulfite conversion was evident in all samples (Figure 5.4C). 
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Figure 5.4. Confirmation of depletion of m5C at known target sites of NSUN2 and 
TRDMT1 in the replicate NSUN2 and TRDMT1 knockdown samples. 
A) MiSeq amplicon sequencing of tRNAAsp(GUC) showed depletion of m5C at C38 in the 
TRDMT1 knockdown samples and C48 and C49 in the NSUN2 knockdown samples. B) MiSeq 
amplicon sequencing of tRNALeu(CAA) showed depletion of m5C at C34 in the NSUN2 
knockdown samples. The tRNA structural positions with known m5C sites are indicated in red 
below the heatmap. The N and T indicate sites that are directed by NSUN2 and TRDMT1. C) 
MiSeq amplicon sequencing of a segment of the non-humanised R-Luc in vitro transcript 
showed efficient bisulfite conversion. Numbers below the heatmap indicate the segment of the 
non-humanised R-Luc in vitro transcript interrogated relative to the start of the transcript. 
MiSeq amplicon sequencing was performed on two out of three of the biological replicate 
knockdowns. The MiSeq amplicon sequencing coverage ranged from 35,000-244,000 mappable 
sequencing reads. 
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To ensure that all six mRNAs that were interrogated for steady-state levels by RT-qPCR 
exhibited the expected amounts of methylation, MiSeq amplicon sequencing was 
performed for two out of three new biological replicates of the NSUN2 knockdown, 
TRDMT1 knockdown and NTC samples. Thus, out of the six biological replicates used 
for this analysis, m5C sites were examined in three biological replicates, including the 
knockdown samples used for the validation of candidate m5C sites in Chapter 4. Figure 
5.5 shows a schematic of the samples used for the analysis of candidate steady-state 
levels. 
 
 
Figure 5.5. Schematic demonstrating the samples used for the validation of candidate m5C 
sites and those used for the analysis steady-state levels. 
RNAi-mediated knockdown (KD) of the methyltransferases were performed twice in triplicate. 
One replicate from biological replicate batch 1 was used for the validation of candidate m5C 
sites in Chapter 4. Two replicates from biological replicate batch 2 were used for the validation 
of candidate m5C sites in the six mRNAs interrogated for steady-state levels. All six replicates 
were used for the steady-state level analysis in this thesis.  
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All six mRNAs exhibited methylation in the NTC samples and depletion of methylation 
in the NSUN2 knockdown samples, confirming that these m5C sites were mediated by 
NSUN2 in at least three of the six biological replicates (Figure 5.6) One replicate of the 
TRDMT1 knockdown samples exhibited methylation in all six mRNAs, while the other 
only exhibited methylation in five mRNAs, with MCFD2 not containing the m5C site in 
this replicate. As a result, the expression level of MCFD2 was not examined in this 
replicate. In addition, the MiSeq coverage of MCFD2 in one replicate of the NTC 
sample was quite low, with only 16 reads. This may be a result of a low and incorrect 
amount of amplicon being pooled prior to MiSeq library preparation. 
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Figure 5.6. Validation of m5C sites in six mRNAs in which steady-state levels were 
investigated by RT-qPCR in the replicate NSUN2 and TRDMT1 knockdown samples. 
MiSeq amplicon sequencing was performed on two out of three of the new biological replicates 
of the NSUN2 knockdown (N), TRDMT1 knockdown (T) and NTC samples. Chromosomal 
locations of the m5C sites are indicated in red below the heatmap. The MiSeq amplicon 
sequencing coverage ranged from 16-230,000 mappable sequencing reads. 
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As the m5C sites in the six mRNAs were confirmed as NSUN2 targets in several 
replicates, RT-qPCR was performed to examine the expression levels of these 
transcripts. The RT-qPCR revealed that there was no significant difference in the 
steady-state levels of these transcripts in the NSUN2 knockdown sample compared to 
the controls (Figure 5.7). Interestingly, although it was hypothesised that knockdown of 
TRDMT1 would not result in a change in the expression of these transcripts, a modest 
yet significant increase in expression of MCFD2 and NDUFB7 relative to both the 
NSUN2 knockdown and NTC samples was observed. RTN3 showed increased 
expression in the TRDMT1 knockdown sample relative to the NSUN2 knockdown 
sample and SZRD1 showed decreased expression in the TRDMT1 knockdown sample 
relative to the NSUN2 knockdown and NTC samples. 
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Figure 5.7. Steady-state level of mRNAs validated to contain NSUN2-mediated m5C sites 
in the HeLa methyltransferase knockdown cells. 
Expression levels of mRNAs validated to contain m5C sites regulated by NSUN2 were 
determined using RT-qPCR in NSUN2 knockdown sample as well as TRDMT1 knockdown 
and NTC samples, the latter two which were controls. Expression levels were normalised to the 
geometric mean of H2AFV, MRPL9 and TCF25 mRNA levels. Data shown as mean fold-
change relative to NTC with SEM (n=5-6). There was no significant difference in mRNA 
steady-state levels in the NSUN2 knockdown sample compared to the NTC sample. A 
significant increase in MCFD2 and RTN3 expression levels and significant decrease in SZRD1 
expression levels was evident in the TRDMT1 knockdown sample (** p<0.01, * p<0.05, two-
way ANOVA with Fisher’s protected least significant difference post-hoc analysis). 
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For the statistical analysis, a two-way ANOVA was used due to the batch variation 
between the biological replicates (Figure 5.8). Batch variation is common with studies 
where different batches of cells were used. In this case, the siRNA knockdowns were 
performed in triplicate in one batch of HeLa cells, while the second set of knockdowns 
were performed in triplicate in another batch of HeLa cells. A two-way ANOVA took 
into account two variables, including the batch variation, which was removed from this 
statistical analysis, and variation due to siRNA knockdown, which was the variation of 
interest. The initial analysis of variance determined whether there was a difference 
between all samples by determining the means. In the case where a variance was 
detected (p<0.05), a post-hoc analysis using Fisher’s protected least significance test 
was performed to determine which of the samples varied (Table 5.4). The complete 
output from the statistical analysis is located in Appendix 8.9. 
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Figure 5.8. Batch variation evident after RT-qPCR of mRNAs validated to contain 
NSUN2-mediated m5C sites. 
Expression levels are normalised to the geometric mean of H2AFV, MRPL9 and TCF25. Data is 
not shown as mean fold-change relative to NTC to illustrate the batch variation. Data shown as 
mean with SEM (n=2-3).  
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Table 5.4. Two-way ANOVA statistical analysis to determine differences in expression 
levels of NSUN2-targeted mRNAs. 
Transcript 
Analysis 
of 
variance 
p-value 
Least 
significant 
difference 
of means 
Mean of mRNA expression 
Significant against 
TRDMT1 or NTC 
based on post-hoc 
analysis? 
 NSUN2 TRDMT
1 
NTC TRDMT1 NTC 
MCFD2 0.003 0.376 1.219 1.893 1.293 Yes No 
NAPRT1 0.468 N/A N/A N/A 
NDUFB7 0.049 0.193 0.862 1.080 0.869 Yes No 
OSBPL8 0.255 N/A N/A N/A 
RTN3 0.032 0.239 1.204 1.531 1.421 Yes No 
SZRD1 0.011 0.189 1.211 0.906 1.120 Yes No 
 
5.2.4.C ANALYSIS OF OVERALL STEADY-STATE LEVEL OF CANDIDATE 
MRNAS TARGETED BY NSUN2 
Similar to the analysis used on the bsRNA-seq data, the mean steady-state level over all 
six NSUN2-targeted mRNAs was investigated in the NSUN2 knockdown sample. In 
order to do this, a secondary two-way ANOVA analysis was performed to determine 
whether the trend detected in the bsRNA-seq was also detected using the RT-qPCR 
candidate approach. There was no significant decrease in the mean steady-state level of 
the candidate mRNAs detected in the NSUN2 knockdown sample compared to the 
controls (Table 5.5). However, TRDMT1 showed a significant increasing trend 
compared to both the NSUN2 knockdown and NTC samples.  
 
Table 5.5. Two-way ANOVA statistical analysis to determine differences in overall steady-
state levels of NSUN2-targeted mRNAs. 
Treatment 
Analysis of 
variance p-
value 
Least 
significant 
difference 
of means 
Mean of 
all 
transcripts 
Mean of all 
transcripts 
in NTC 
Significant 
against NTC 
based on post-hoc 
analysis  
NSUN2 
<0.001 0.134 
1.05 
1.08 
No 
TRDMT1 1.25 Yes 
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The inability to detect a change in the steady-state levels of the six NSUN2-targeted 
mRNAs upon NSUN2 knockdown is most likely a result of the limitations of the 
sensitivity of the RT-qPCR assay to detect the subtle decrease found in the global 
analysis. In addition, the global analysis revealed a decrease over all NSUN2-targeted 
mRNAs, suggesting the possibility of a small group of these transcripts exhibiting a 
pronounced decrease that may have not been exhibited in the six candidates examined 
by RT-qPCR. The RT-qPCR assay thus failed to provide evidence for an effect of m5C 
on the steady-state levels of the six chosen candidate mRNAs. 
 
5.2.5 INVESTIGATING THE ROLE OF M5C IN TRANSLATION 
An investigation was made into whether m5C may function in post-transcriptional gene 
regulation through regulation of mRNA translation. Depending on the context of the 
m5C site, translation may be regulated in different ways. We hypothesised that if m5C is 
involved in regulation of translation, the proportion of methylated mRNA molecules 
should be different when comparing translated with non-translated molecules. As 
detailed below, sucrose density gradient centrifugation was employed to separate 
mRNAs with validated m5C sites into populations of different translation state. 
 
5.2.5.A ASSESSING THE REPRODUCIBILITY OF BISULFITE CONVERSION 
AND PCR AMPLIFICATION 
The candidate approach employed for the investigation of m5C in regulating translation 
involved PCR amplification of validated candidates at different translation states 
followed by MiSeq amplicon sequencing to determine the proportion of methylation at 
each translation state. One of the caveats of this approach is the possibility of the 
abundance of a transcript affecting the bisulfite conversion efficiency or causing PCR 
amplification biases that may result in variability in the proportion of methylation. To 
address this, an experiment was designed in which aliquots from a single HeLa RNA 
sample were bisulfite converted at different times with fresh sodium bisulfite solution. 
MiSeq amplicon sequencing was performed for various transcript biotypes with 
validated m5C sites in order to compare the proportion of methylation within each 
transcript of each replicate. PCR of each amplicon was performed in triplicate for each 
replicate, as previously described (Figure 5.9).  
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Figure 5.9. Experimental design to investigate the reproducibility of bisulfite conversion 
and PCR amplification.  
A single HeLa RNA sample that had been previously DNase-treated was divided into three 
separate tubes and bisulfite converted at different times using freshly made sodium bisulfite 
solution. The bisulfite-converted RNA samples were reverse transcribed as previously described 
and PCR amplification of known m5C sites were performed in triplicate for each HeLa sample. 
The triplicate PCR products were pooled and MiSeq amplicon libraries were prepared then 
sequenced. 
HeLa RNA (DNase-treated)
Bisulfite conversion of three aliquots separately & cDNA synthesis
HeLa 1 HeLa 2 HeLa 3
RT+ RT- RT+ RT- RT+ RT-
PCR amplification of known m5C sites in triplicate
Pooling of triplicate PCR amplicons for each sample, MiSeq library preparation & sequencing
Equal amounts of RNA aliquoted 
into three separate tubes
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Several transcript biotypes were investigated, including mRNAs, tRNAs and another 
ncRNA. These included CINP, MCFD2, NAPRT1, NDUFB7, RTN3, SZRD1, RPPH1, 
tRNAAsp(GUC) and tRNALeu(CAA), which all contain validated m5C sites. In addition to 
sequencing these transcripts, a segment of the non-humanised R-Luc in vitro transcript 
was sequenced to ensure efficient bisulfite conversion; >99% mean cytosine conversion 
was evident in all HeLa cell replicates (Figure 5.10 and Table 5.6). 
 
 
Figure 5.10. Confirmation of bisulfite conversion in each HeLa technical replicate by 
MiSeq amplicon sequencing. 
One segment of the non-humanised R-Luc in vitro transcript was amplified and subjected to 
MiSeq amplicon sequencing. Numbers below the heatmap indicate the segment of the transcript 
interrogated relative to the start of the transcript. The MiSeq amplicon sequencing coverage 
ranged from 34,000-42,000 mappable sequencing reads.  
 
 
Table 5.6. Mean cytosine conversion of the non-humanised R-Luc in vitro transcript. 
Replicate Mean cytosine conversion (%) 
1 99.83 
2 99.20 
3 99.86 
 
Examination of the proportion of methylation for the mRNAs revealed some variability 
between the technical replicates (Figure 5.11). The proportion of methylation in CINP, 
NDUFB7, RTN3 and SZRD1 was relatively consistent between the replicates. The 
proportion of methylation in MCFD2 was consistent between two replicates, however 
the third replicate exhibited approximately half the proportion of methylation compared 
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to first two replicates. There was also some variability between the replicates in 
NAPRT1. In contrast, the proportion of methylation in RPPH1, tRNAAsp(GUC) and 
tRNALeu(CAA) were consistent between all replicates. As MCFD2 and NAPRT1 showed 
greater variability in the proportion of methylation in each replicate, these transcripts 
were removed from the translation analysis. 
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Figure 5.11. The proportion of methylation at m5C sites in three HeLa cell technical 
replicates as determined by MiSeq amplicon sequencing. 
The location of the m5C sites is indicated below the heatmap. The bar charts to the right 
represent the proportion of methylation at m5C sites in each transcript for the three HeLa cell 
technical triplicates. The MiSeq amplicon sequencing coverage ranged from 6,000-246,000 
mappable sequencing reads. 
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5.2.5.B SUCROSE DENSITY GRADIENT CENTRIFUGATION AND POLYSOME 
FRACTIONATION 
In order to investigate the role of m5C in regulating translation, sucrose density gradient 
centrifugation was performed using two biological replicates of HeLa cells. A 17.5%-
50% sucrose gradient was generated, which, after ultracentrifugation separated mRNAs 
into those co-sedimenting with multiple ribosomes (polysomes) from those that co-
sediment with a single ribosome. Those transcripts associated with polysomes, and 
therefore more actively translated, settle down to the higher density sucrose, whereas 
those transcripts that are associated with a single ribosome are not highly translated and 
are within the lower density sucrose. 
 
HeLa cells were seeded at a density of 7 x 106 cells per 15 cm cell culture dish and 
incubated with cycloheximide to a final concentration of 0.1 mg/mL for 3 min at 37°C 
in order to inhibit translation. Cell culture media was removed and cells were washed 
twice with ice-cold PBS containing 0.1 mg/mL cycloheximide. Following this, cells 
were lysed and the cleared lysate was loaded onto the sucrose gradient and centrifuged 
at 35,000 rpm for 2 h 15 min at 4°C. The polysome gradient was then fractionated into 
24 tubes while measuring the absorbance at 254 nm (Figure 5.12).  
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Figure 5.12. Schematic of sucrose density gradient centrifugation. 
The HeLa cell lysate was carefully pipetted onto at 17.5-50% sucrose gradient in a polyallomer 
tube and centrifuged at 35,000 rpm for 2 h 15 min at 4°C. mRNA associated with polysomes 
settle to the higher density sucrose while mRNA associated with a single ribosome are within 
the lower density sucrose. The gradient was then fractionated into 24 tubes while measuring 
absorbance at 254 nm. 
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As expected, three peaks corresponding to the 40S subunit, 60S subunit and the 80S 
ribosome were observed (Figure 5.13A). Polysomes were clearly visible and more 
abundant than the ribosome and ribosome subunits. Collected fractions were 
precipitated overnight with three volumes of ethanol and 4 µL glycogen in preparation 
for RNA extraction. A technical challenge with RNA extraction from sucrose gradients 
is achieving uniform quality and efficiency for each fraction as a result of varying 
amounts of RNA in each fraction, and the high concentration of sucrose in the heavier 
fractions interfering with phase separation in typical phenol-based extraction steps. To 
address the issue of differences in amounts of RNA, 1 ng of R-Luc 3xB pA in vitro 
transcript was spiked into each fraction prior to overnight precipitation to correct for 
differences in RNA recovery and reverse transcription efficiency. The sucrose was 
removed by precipitation of the total nucleic acid and protein with ethanol, and washing 
the precipitate with 70% ethanol. The RNA was then extracted using Tri Reagent®, the 
fractions were combined to 12 fractions and the RNA examined on a RNA 6000 Nano 
Chip (Figure 5.13B). It was clear that tRNAs were predominantly present in the first 
three fractions, and 18S and 28S rRNA were visible from the fourth fraction. To reduce 
the number of samples further, the fractions were combined again to 6 fractions. For the 
remainder of this chapter, the fractions will be referred to by their final combined 
number.  
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Figure 5.13. Absorbance trace at 254 nm of HeLa cells and analysis of the RNA integrity 
after polysome gradient fractionation. 
HeLa cells were seeded at a density of 7 x 106 cells per 15 cm dish and harvested 24 h later in 
lysis buffer, and subjected to density gradient ultracentrifugation. A) The absorbance profile at 
254 nm was recorded and fractions collected. The polysomes, ribosome (80S) and ribosome 
subunits (40S and 60S) are indicated. B) After spiking in R-Luc 3xB pA in vitro transcript, 
RNA was extracted from each fraction and its integrity analysed on a RNA 6000 Nano Chip. 
Equal amounts of RNA were loaded onto the RNA 6000 Nano Chip. Final fraction numbers are 
indicated at the bottom. Bands corresponding to tRNA as well as 18S and 28S rRNA are 
indicated. 
 
5.2.5.C TRANSLATION EFFICIENCY OF CANDIDATE MRNAS 
The mRNAs that were focused on for the investigation of the relationship between m5C 
and translation state were those that were validated in Chapter 4. As CINP, NDUFB7, 
RTN3 and SZRD1 showed minimal variability in the proportion of methylation in 
technical replicates as described in the previous section, these candidates were 
investigated. Additional candidates with validated m5C sites were also selected out of 
interest, including OSBPL8, RPS3 and SCO1. The gradient distribution of these mRNAs 
was examined using RT-qPCR to determine the translation efficiency of the transcripts 
(Figure 5.16; line graph). The RT-qPCR data was normalised to R-Luc 3xB pA and 
represented as a percentage of the total amount of each mRNA collected from the 
fractionation. Most mRNAs were predominantly associated with polysomes and thus 
were translated well. The gradient distribution of RPS3 showed two peaks and was 
more variable between replicates, which most likely is a result of differences in the cell 
growth rate between cell populations. As expected, minimal amounts of mRNA were 
present in fraction 1, and as a result this fraction was removed from this investigation. 
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5.2.5.D PREPARATION OF FRACTIONS FOR MISEQ AMPLICON 
SEQUENCING  
To assess the methylation levels of each mRNA at different translation states, the 
fractions were bisulfite converted, reverse transcribed and amplicons of the mRNAs 
exhibiting validated m5C sites were PCR amplified in triplicate. As a negative control 
for methylation and to ensure high bisulfite conversion efficiency, two segments of the 
non-humanised R-Luc in vitro transcript were amplified. Determining the best positive 
control for methylation was not trivial; tRNAs have been previously used but as can be 
seen from Figure 5.13, the distribution of tRNAs was primarily limited to fractions 2 
and 3. PCR amplification of tRNAAsp(GUC) and tRNALeu(CAA) was attempted but as 
expected, amplification was only successful in fractions 2 and 3. As a result, PCR 
amplification of 28S rRNA was performed to examine methylation at the known m5C 
sites at C3782 and C4447. Although limited 28S rRNA was visible in the first two 
fractions based on the RNA 6000 Nano Chip, it was expected that rRNA would still be 
highly abundant in these fractions. PCR amplification of 28S rRNA was successful in 
all fractions and was therefore used as a positive control for bisulfite conversion. Using 
28S rRNA as a positive control for bisulfite conversion was beneficial in that both m5C 
sites exhibited high levels of methylation based on bsRNA-seq (see section 4.2.3.A). 
However, it was expected that the level of methylation in 28S rRNA in the earlier 
fractions may be lower as a result of the requirement for m5C at these sites for 
translation [92].  
 
After pooling the amplicons for each fraction and performing the library preparation as 
previously described, the libraries were subjected to MiSeq amplicon sequencing. High 
and even coverage was evident throughout the two segments of the non-humanised R-
Luc in vitro transcripts and high bisulfite conversion efficiency was evident, with 
>99.5% conversion evident in both segments (Figure 5.14 and Table 5.7).  
 
 276 
!
Exploring the molecular functions of m5C in mRNA 
!
! !
 
Figure 5.14. Confirmation of bisulfite conversion in polysome fractions for each replicate 
by MiSeq amplicon sequencing. 
Two different segments of the non-humanised R-Luc in vitro transcript were amplified and 
subjected to MiSeq amplicon sequencing. Numbers below the heatmap indicate the segment of 
the transcript interrogated relative to the start of the transcript. The MiSeq amplicon sequencing 
coverage ranged from 80,000-274,000 mappable sequencing reads.  
 
Table 5.7. Mean cytosine conversion of the non-humanised R-Luc in vitro transcript. 
Sample 
Mean conversion percentage (%) 
Non-humanised R-Luc in 
vitro transcript segment 1 
Non-humanised R-Luc in 
vitro transcript segment 2 
Replicate 1 
Fraction 2 99.82 99.77 
Fraction 3 99.92 99.88 
Fraction 4 99.92 99.93 
Fraction 5 99.89 99.86 
Fraction 6 99.76 99.88 
Replicate 2 
Fraction 2 99.67 99.59 
Fraction 3 99.82 99.69 
Fraction 4 99.82 99.65 
Fraction 5 99.92 99.59 
Fraction 6 99.93 99.83 
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Examination of the proportion of methylation at C3782 in 28S rRNA revealed 80%-
100% methylation throughout all fractions, indicating that conversion of m5C to uracil 
did not occur at this site (Figure 5.15A). Clusters of non-conversion were evident in the 
segment containing m5C at C4447 in several fractions of both replicates, which is most 
likely a result of incomplete denaturation of the secondary structure of 28S rRNA 
(Figure 5.15B). The m5C site at this location was distinguishable, revealing a high 
proportion of methylation in the majority of fractions. Interestingly, fraction 2, 
corresponding to free ribosomes and ribosomal subunits, showed a clear trend towards 
lower rRNA methylation in comparison to the remaining fractions containing actively 
translating ribosomes, consistent with a requirement for m5C at these sites for 
translation [92]. Despite clear detection of the m5C site at all fractions, it is difficult to 
interpret whether the methylation proportion is truly an indication of m5C, or if it is a 
result of the non-conversion.  
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Figure 5.15. Confirmation of known m5C sites in 28S rRNA by MiSeq amplicon 
sequencing. 
A) m5C site at C3782 in 28S rRNA and B) m5C site at C4447 in 28S rRNA. The proportion of 
methylation in each fraction is indicated in the bottom bar graphs as the mean with SEM (n=2). 
Numbers below the heatmap indicate the segment of the transcript interrogated relative to the 
start of the transcript. The MiSeq amplicon sequencing coverage ranged from 92,000-320,000 
mappable sequencing reads.  
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5.2.5.E INVESTIGATING THE RELATIONSHIP BETWEEN M5C IN MRNA 
AND TRANSLATION 
Next, the proportion of methylation at the m5C sites in the mRNAs was determined at 
different translation states (Figure 5.16; bar graphs). As mentioned previously, it is 
possible that the role of m5C in regulating translation may be context-dependent and 
therefore the location of the m5C site in these transcripts was also taken into account. 
CINP, NDUFB7, SCO1 and SZRD1 had relatively similar proportions of methylation 
throughout different translation states, with the m5C sites being located in either the 
CDS or 3’ UTR. OSBPL8 exhibited a m5C site in the 5’ UTR and the proportion of 
methylation was slightly variable, which may be a result of PCR amplification biases. 
 
Interestingly, although the m5C site located in the CDS of RPS3 was not highly 
methylated, a decreasing trend in methylation with increasing translation was evident; 
the methylation decreased from ~12% in fraction 2 to ~6% in fraction 6. This m5C site 
is located 10 nt downstream of an Ago2 footprint based on the HeLa Ago2 HITS-CLIP 
dataset [308], consistent with the global finding that Ago2 footprints are enriched 
upstream of m5C sites in the CDS (see section 5.2.2). The proportion of methylation at 
the m5C site located in the 3’ UTR of RTN3 showed an increasing trend with increasing 
translation state, with the proportion increasing from ~50% in fraction 2 to ~80% in 
fraction 6. This m5C site is ~500 nt downstream of putative binding sites of miR-206 
and miR-218 based on TargetScan [310]. Furthermore, this site was located 219 nt 
upstream of an Ago2 footprint, and 673 nt downstream of another Ago2 footprint. 
 
In summary, the majority of mRNAs examined in this investigation did not exhibit a 
trend in methylation with translation state. However, the m5C sites in RPS3 and RTN3 
exhibited clear trends in methylation with mRNA translation state, suggesting that m5C 
might affect translation for some methylated mRNAs. Methylation correlated with 
translation state in opposite ways for these examples, suggesting that such a role of m5C 
would have to be context-dependent. 
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Figure 5.16. Gradient distribution and methylation profiles of mRNAs validated to 
contain m5C sites mediated by NSUN2 at different translation states. 
For the gradient distribution (line graph) RT-qPCR was performed on reverse transcribed RNA 
extracted from the polysome gradients and the data normalised to the R-Luc 3xB pA in vitro 
transcript that was spiked into each fraction prior to RNA extraction. The data is expressed as 
the percentage of total amount of each mRNA extracted from the polysome gradient. For the 
methylation profiles (bar graphs), MiSeq amplicon sequencing was performed on fractions 2 to 
6 of HeLa polysome gradients. The location of the m5C site in the mRNA is indicated above the 
graphs. The MiSeq amplicon sequencing coverage ranged from 15,000-360,000 mappable 
sequencing reads. Data is shown as mean with SEM (n=2). 
 
5.3 DISCUSSION 
In this chapter, I have described the first study to investigate the molecular functions of 
m5C in mRNA. I have analysed the bsRNA-seq dataset in order to gain insight into the 
role of m5C in post-transcriptional gene regulation. To follow this up further, RT-qPCR 
and sucrose density gradient centrifugation were performed using candidates that were 
validated to contain m5C sites mediated by NSUN2. 
 
The GSEA and GO analysis of candidate m5C sites in HeLa cells did not reveal any 
enrichment of complexes or pathways. The GO terms that were enriched were diverse 
and included mRNA metabolism, in particular all three phases of translation. Thus, 
while m5C is present in transcripts that encode proteins of diverse cellular functions, it 
is also present in transcripts that encode proteins involved in mRNA metabolism, 
suggesting that m5C regulates diverse processes involved in post-transcriptional gene 
regulation. 
 
5.3.1 AGO2 AND MIRNA ANALYSES  
An investigation was initially made into the relationship of m5C with Ago2 and 
miRNAs. Previously, we integrated our HeLa bsRNA-seq data with a publicly available 
HEK293 Ago PAR-CLIP dataset, where an enrichment of Ago footprints was evident 
upstream of candidate m5C sites in the CDS and 3’ UTR of mRNAs [58]. Examination 
of another RNA binding protein, PUM2, revealed no enrichment within the 1000 nt 
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flanking regions of candidate m5C sites. To follow this observation up further, a similar 
analysis was performed in this study, where HeLa Ago2 HITS-CLIP data was integrated 
with the candidate m5C sites detected in the 3’ UTR and CDS of mRNAs in HeLa cells 
based on the newly generated HeLa methyltransferase knockdown bsRNA-seq data. 
Concurring with our previous study, enrichment of Ago2 footprints was evident 
upstream within 25 nt of candidate m5C sites in the 3’ UTR and CDS. Examination of 
another RBP, HuR, showed no enrichment around candidate m5C sites. 
 
To investigate this relationship further, the density of 7-mer miRNA targets was 
determined in regions surrounding candidate m5C sites in the 3’ UTR and CDS. 
Interestingly, depletion in the density of 7-mer miRNA targets was evident at candidate 
m
5C sites in the 3’ UTR and CDS. This depletion was confirmed to not be a result of 
uneven base distribution in these regions, such as lower frequency of cytosines.  
 
These findings suggest that m5C sites are devoid in regions of mRNA that are bound by 
RISC but are enriched downstream of this complex. m5C may either mediate or block 
the action of RISC, highlighting a potential role for m5C in post-transcriptional gene 
regulation. The mechanisms in which this could possibly occur through include 
regulating mRNA stability or translation, as miRNA/RISC are known to affect both 
processes. 
 
5.3.2 MRNA STEADY-STATE LEVEL ANALYSES 
To investigate the molecular functions of m5C in mRNA further, an investigation was 
also made into the role of m5C in regulating mRNA steady-state levels. An initial 
analysis involved determining whether depletion of m5C in NSUN2-targeted mRNAs in 
the NSUN2 knockdown sample relative to the TRDMT1 knockdown and NTC samples 
affected the overall expression levels of these mRNAs compared to unmethylated 
mRNAs using the bsRNA-seq data. Although bisulfite conversion results in 
fragmentation of the RNA, fragmentation is also required for standard RNA-seq 
indicating that the expression levels determined from the bsRNA-seq data were likely 
true representations of the expression levels. This analysis revealed a 11.9% decrease in 
average steady-state expression of NSUN2-targeted mRNAs in the NSUN2 knockdown 
sample compared to unmethylated mRNAs. This suggests that m5C may function to 
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stabilise mRNA, potentially through preventing the binding of RISC and other 
regulatory factors. 
 
To investigate the role of m5C in regulating mRNA steady-state levels further, a 
candidate approach using RT-qPCR was implemented, focusing on the mRNAs that 
were validated to contain m5C sites mediated by NSUN2. Although a subtle decrease in 
the steady-state level over many mRNA targets of NSUN2 was observed in the bsRNA-
seq data, it was possible that there may be a few candidates that exhibited a stronger 
change in levels. Six mRNAs that were validated to contain m5C sites mediated by 
NSUN2 were investigated, with no changes in the steady-state levels of these transcripts 
evident in the NSUN2 knockdown sample. The overall steady-state level of all six 
mRNAs was also investigated in the NSUN2 knockdown sample, with no significant 
changes observed. A likely explanation for this is the limited sensitivity of the RT-
qPCR assay in addition to the small number of candidates interrogated; it is possible 
that the subtle decrease in mRNA steady-state levels observed in the bsRNA-seq data 
may only be evident over many NSUN2-targeted mRNAs.  
 
It must also be noted that RNA-seq and RT-qPCR cannot differentiate between 
expression changes due to changes in the rate of transcription or RNA decay. However, 
the possibility of the global rate of transcription being affected upon NSUN2 
knockdown is unlikely; the global analysis performed using the bsRNA-seq data 
showed a minimal effect on the steady-state level of transcripts with no detectable m5C 
sites upon NSUN2 knockdown. However, there is the possibility of the rate of 
transcription of individual genes being affected, such as the housekeeping genes used 
for this assay, which may have negated the subtle decrease in mRNA steady-state 
levels, resulting in the inability to detect these changes. 
 
Interestingly, in some instances, the expression levels of the NSUN2-targeted mRNAs 
in the TRDMT1 knockdown sample were significantly higher compared to both the 
NSUN2 knockdown and NTC samples, although the reasoning behind this remains 
elusive. It is possible that the knockdown of TRDMT1 may have resulted in indirect 
changes in steady-state levels. As mentioned in Chapter 1, TRDMT1 was initially 
thought to be a DNA methyltransferase due to its strong homology with DNA 
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methyltransferases, although its role in methylating DNA remains controversial. Several 
published studies reported conflicting results for TRDMT1 methylating DNA, with 
some studies reporting low levels of DNA methylation in non-specific contexts in 
various species, including D. melanogaster [164, 311-313]. Furthermore, a study that 
investigated DNA methylation by human TRDMT1 using in vitro assays reported low 
levels of DNA methylation in a CpG context [314]. Although this needs to be explored 
further, it is possible that human TRDMT1 may have residual DNA methyltransferase 
activity that could result in gene repression. Thus, the knocking down of TRDMT1 may 
have resulted in an indirect increase in the expression levels of these transcripts.  
 
5.3.3 MRNA TRANSLATION ANALYSIS 
To investigate the role of m5C in regulating translation, a candidate approach was used 
focusing on mRNAs that were validated to contain m5C sites in Chapter 4. It was 
hypothesised that if m5C in mRNA is involved in regulating translation, then the 
proportion of methylation in the mRNA would differ within each translation state.  
 
The reasoning behind the candidate approach was to ensure that the m5C sites in the 
mRNAs investigated were genuine as determined by MiSeq amplicon sequencing in 
Chapter 4. A drawback with this approach, however, was the possibility of PCR 
amplification biases of low abundant transcripts, although this has not been previously 
investigated. Examination of the proportion of methylation of previously validated 
transcripts in technical replicates revealed that some of the mRNAs exhibited variability 
in methylation. Therefore, those mRNAs that exhibited variability in the proportion of 
methylation between technical replicates, such as MCFD2 and NAPRT1, were removed 
from further analysis. 
 
Seven mRNAs exhibiting validated m5C sites were investigated further to determine the 
relationship between m5C and translation state using sucrose density gradient 
centrifugation. Examination of the gradient distribution of these transcripts revealed that 
the majority were associated with polysomes and were therefore actively translated. 
While the majority of RPS3 transcripts were associated with polysomes, a substantial 
proportion of the transcript was associated with a single ribosome. RPS3 is a component 
of the 40S subunit, which forms part of the domain associated with translation initiation 
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[315]. Translation of ribosomal proteins is largely dependent on cell growth, where they 
are actively translated in fast growing cells in order to contribute to the active 
translation of other mRNAs. The presence of multiple peaks in the gradient distribution 
of RPS3 was most likely an indication of differences in the cell growth within the 
population of cells, resulting in different translation efficiencies of RPS3. This is also 
the most likely explanation for the slight differences in the gradient distribution of RPS3 
between the biological replicates. 
 
MiSeq amplicon sequencing of the seven mRNAs demonstrated variability in the 
proportion of methylation between the mRNAs, with no consistent trend observed. 
Several transcripts, including CINP, NDUFB7, SCO1 and SZRD1 exhibited similar 
proportions of methylation at all translation states, while OSBPL8 exhibited slightly 
more variability with no discernible trend. Two mRNAs showed interesting trends in 
the proportion of methylation with translation state. RPS3 exhibited decreasing 
methylation with increasing translation. RTN3 exhibited increasing methylation with 
increasing translation. While each trend was only present in a single mRNA, it is 
suggestive that m5C can affect translation and that the role of m5C in mRNA may be 
context-dependent. The m5C site in the CDS of RPS3 is located 10 nt downstream of a 
HeLa Ago2 footprint, consistent with the global finding of Ago2 enrichment upstream 
of candidate m5C sites in mRNA. This suggests that m5C in this transcript may mediate 
the binding of RISC to inhibit translation. In contrast, the m5C site in the 3’ UTR of 
RTN3 was not near any putative or known miRNA binding sites, or HeLa Ago2 
footprints, suggesting that this m5C site affects translation through a different 
mechanism than that of the miRNA pathway, such as recruitment or blocking of other 
RBPs. 
 
5.3.4 CONCLUSIONS 
In this chapter, I performed the first study to investigate the molecular functions of m5C 
in mRNA. The HeLa methyltransferase bsRNA-seq data showed an enrichment of 
Ago2 footprints upstream of candidate m5C sites in the CDS and 3’ UTR of mRNAs 
and depletion of miRNA target sites at candidate m5C sites in these regions. This 
suggests a regulatory interaction between m5C and RISC. Global analysis of mRNA 
steady-state levels using the bsRNA-seq data indicated a subtle decrease in the mean 
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steady-state levels of NSUN2-targeted mRNAs in the NSUN2 knockdown sample, 
however the subtle changes observed could not be confirmed using a candidate 
approach by RT-qPCR. I investigated the role of m5C in mRNA translation, which 
revealed two mRNAs that exhibited trends in the proportion of methylation with 
translation state. RPS3, which contains a m5C site in the CDS, demonstrated a 
decreasing trend in methylation with increasing translation. RTN3, which contains a 
m
5C site in the 3’ UTR, showed an increasing trend in methylation with translation 
state. These findings suggest that the molecular functions of m5C in mRNA may be 
context-dependent.  
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5.4 CHAPTER HIGHLIGHTS 
• mRNAs exhibiting candidate m5C sites were enriched in a broad range of GO terms, 
which prominently included those related to the translation processes. 
• Correlating matched HeLa cell datasets revealed that Ago2 footprints were enriched 
upstream of candidate m5C sites in both the 3’ UTR and CDS of mRNAs. 
Conversely, m5C sites were depleted at the portion of conserved miRNA target sites 
that match the miRNA seed, again in both the 3’ UTR and CDS. 
• This confirms and extends our previously published findings and indicates regulatory 
interactions between m5C and RISC. 
• A statistically significant 11.9% decrease in mean steady-state expression level of 
NSUN2-targeted mRNAs was seen in NSUN2 knockdown cells, compared to 
unmethylated mRNAs. RT-qPCR of six chosen NSUN2 target mRNAs failed to 
validate this effect. 
• This suggests a subtle role for m5C formation by NSUN2 in stabilising a subset of its 
target mRNAs that is revealed only when averaging over many target mRNAs. 
• The relationship between m5C status and polysome association was assessed for 
seven NSUN2-targeted mRNAs (one site in the 5’ UTR, three sites each in the CDS 
and 3’ UTR). 
• Two examples displayed a correlation between m5C level and translation state: with 
increasing polysome density RPS3 showed a decreasing proportion of m5C at a site 
in the CDS, while RTN3 exhibited increasing proportion of m5C at a site in the 3’ 
UTR. 
• The m5C site in RPS3 was 10 nt downstream of an Ago2 footprint, while Ago2 
footprints were not evident near the m5C site in RTN3. 
• This suggests that m5C formation by NSUN2 affects translation of target mRNAs in 
different ways and in a context-dependent manner. 
• Overall, these findings provide several correlative links between the presence of m5C 
in mRNAs and several aspects of post-transcriptional gene regulation. mRNA 
stability and translation emerge as the processes most likely to be affected. The 
underlying mechanisms remain to be explored. 
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6.1 INTRODUCTION 
NSUN2 is involved in a number of biological processes, including Myc-induced 
proliferation of skin cells and mitotic spindle stability [99, 211, 213]. Recently, GWAS 
have identified a number of mutations in NSUN2, including missense, nonsense and 
splicing mutations that cause intellectual disabilities [147, 209, 210]. These studies 
indicate a role for NSUN2 in normal cognitive development. 
  
Several studies have reported that m5C in tRNA promotes mRNA translation through 
stabilisation of tRNAs [149, 150]. A recent study investigated the role of tRNA 
methylation in neuro-developmental disorders and linked this to cellular stress [150]. 
Loss of NSUN2 in patient fibroblasts and mice resulted in decreased tRNA methylation, 
leading to angiogenin-dependent endonucleolytic cleavage of tRNAs and an 
accumulation of 5’ tRNA-derived fragments. The biological effect of this was decreased 
mRNA translation and induction of the cellular stress response that ultimately resulted 
in decreased cell size and increased apoptosis of neurons. This is the first study to 
suggest a link between tRNA m5C methylation and neuro-degenerative disorders. 
 
NSUN2 shows low expression in most tissues, with higher expression in the testis [99, 
207, 316]. However, it is activated by the oncogene, Myc, and is overexpressed in a 
variety of tumours including breast, colorectal and oral cancers [99, 207, 317]. 
Investigation of several breast cancer cell lines revealed >1.5-fold increase in NSUN2 
mRNA compared to normal breast tissue. Immunofluorescence staining also indicated 
an increase in NSUN2 protein, although this was not quantified and the increase was 
variable between cell lines [317]. Examination of NSUN2 expression in prostate tumour 
samples by immunohistochemistry also revealed an increase in NSUN2 compared to 
matched normal tissues [207].  
 
The role of RNA m5C in cancer has not yet been explored. The potential function of 
m5C in tRNA promoting mRNA translation and the fact that deregulation of translation 
can contribute to the development of various cancers, warrants investigation into the 
role of m5C in RNA in cancer [318, 319]. In this thesis, I have found that m5C is present 
across multiple transcript biotypes and m5C in mRNA mediated by NSUN2 has a subtle 
and context-dependent effect on post-transcriptional gene regulation. 
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Thus, the first aim of this chapter was to determine the differences in the RNA m5C 
profiles of normal prostate cells and prostate cancer cells using bsRNA-seq. The cell 
lines used for this study were primary prostate epithelial cells (PrEC) and a prostate 
adenocarcinoma cell line derived from the left supraclavicular lymph node metastasis 
from a 50 year old Caucasian male (LNCaP). These cell lines were an attractive choice 
for an exploration of whether m5C in RNA functions in cancer due to the availability of 
epigenomic and transcriptomic data of these cell lines from Professor Susan Clark. 
Findings from bsRNA-seq, particularly any differential RNA methylation sites between 
normal and cancer cells could be related back to these other available data sets. 
However, due to the lack of validatable differences in the RNA m5C profiles, the 
investigation shifted focus towards the candidate m5C sites in common between PrEC 
and LNCaP cells. An integrative comparison with the HeLa methyltransferase 
knockdown dataset was also performed to confirm patterns of methylation and validate 
individual candidate m5C sites across multiple cell lines. 
 
6.2 RESULTS 
The following sections document the comparative analysis of candidate m5C sites in 
RNA in PrEC and LNCaP cells, as well as an integrative comparative analysis with 
HeLa cells. Dr. Brian J. Parker mapped the bsRNA-seq data and MiSeq amplicon 
sequencing data and I performed all experimental work and comparative analyses 
between the cell lines. 
 
6.2.1 EXPRESSION LEVEL OF NSUN2 IN PREC AND 
LNCAP CELLS 
As NSUN2 was reported as overexpressed in prostate tumours when compared to 
normal prostate tissues, the mRNA and protein levels of NSUN2 were determined in 
PrEC and LNCaP cells. RT-qPCR revealed a 1.4-fold increase in NSUN2 in LNCaP 
cells compared to PrEC cells, although this did not reach statistical significance (Figure 
6.1A). Examination of NSUN2 protein levels by western blotting showed more than 
two-fold higher NSUN2 protein levels in LNCaP cells compared to PrEC cells, and this 
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was consistent between two biological replicates (Figure 6.1B). Therefore, the pair of 
cell lines broadly replicates the documented tendency towards overexpression in cancer 
and we hypothesised that an increase in NSUN2 in LNCaP cells may result in additional 
m
5C sites in RNA, or an increase in the stoichiometry of methylation at a particular m5C 
site.  
 
As discussed in Chapter 4, knockdown of NSUN2 in HeLa cells resulted in more than 
five-fold depletion of NSUN2 mRNA and almost complete depletion of NSUN2 protein, 
causing substantial depletion of m5C at NSUN2-mediated sites. Therefore, the two-fold 
overexpression of NSUN2 in LNCaP cells was expected to cause more subtle increases 
in methylation, indicating that a screen by bsRNA-seq should feature at least some level 
of biological replication. 
 
 
Figure 6.1. NSUN2 levels in PrEC and LNCaP cells based on RT-qPCR and western 
blotting.  
A) NSUN2 mRNA expression levels are relative to the geometric mean of B2M, SDHA and TBP 
mRNA expression levels. Data is shown as mean with SEM (n=3). There was no significant 
difference in the expression of NSUN2 in LNCaP cells compared to PrEC cells (p=0.0755, 
Student’s t-test). B) Representative western blot of PrEC and LNCaP whole cell lysate against 
NSUN2. α-tubulin was used as a loading control. Numbers below the blot represent the protein 
levels relative to PrEC cells based on densitometry with SEM (n=2). 
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6.2.2 KNOCKDOWN OF NSUN2  IN LNCAP CELLS  
In this thesis, NSUN2 was found to mediate m5C sites in a broad range of transcript 
biotypes in HeLa cells. NSUN2 was also knocked down in LNCaP cells to determine if 
candidate m5C sites detected by bsRNAseq in LNCaP cells were mediated by NSUN2 
using MiSeq amplicon sequencing. Several attempts were also made to knock down 
NSUN2 in PrEC cells, but the cells did not survive the process. 
 
The RNAi-mediated knockdown was performed in triplicate, and a single sample was 
used for the validation of candidate m5C sites by MiSeq amplicon sequencing. 
Confirmation of NSUN2 knockdown was assessed by RT-qPCR, western blotting and 
MiSeq amplicon sequencing of the controls. >90% knockdown of NSUN2 mRNA was 
evident in LNCaP cells, with almost complete protein depletion (Figure 6.2A and B). 
Depletion of m5C at the known NSUN2 target sites was evident in tRNAAsp(GUC) and 
tRNALeu(CAA). ~90% methylation was detected in the LNCaP NTC sample at C48 and 
C49 in tRNAAsp(GUC), which was depleted to ~67% and ~47% in the LNCaP NSUN2 
knockdown sample, respectively (Figure 6.2C). Depletion of m5C in the NSUN2 
knockdown sample was confirmed at C34 in spliced and unspliced tRNALeu(CAA) (Figure 
6.2D). ~35% methylation in the unspliced tRNA was evident in the LNCaP NTC 
sample compared to only ~5% in the LNCaP NSUN2 knockdown sample. For spliced 
tRNALeu(CAA), ~70% methylation was evident in the LNCaP NTC sample compared to 
only ~13% in the NSUN2 knockdown sample. Thus, this confirms depletion of NSUN2 
in LNCaP cells. Efficient bisulfite conversion was also evident in a segment of the non-
humanised in vitro transcript for both samples (Figure 6.2E). 
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Figure 6.2. Confirmation of RNAi-mediated knockdown of NSUN2 in LNCaP cells and 
verification of bisulfite conversion efficiency. 
A) NSUN2 mRNA expression levels in the NSUN2 knockdown and NTC samples relative to 
the geometric mean of MRPL9, H2AFV and TCF25 mRNA expression levels. Data shown as 
mean fold-change relative to NTC with SEM (n=3). Depletion of NSUN2 mRNA in the NSUN2 
knockdown sample is evident. B) Western blot showing NSUN2 protein levels in the NSUN2 
knockdown and NTC samples. α-tubulin was used as a loading control. Depletion of NSUN2 
protein is evident in the NSUN2 knockdown sample. C) MiSeq amplicon sequencing of 
tRNAAsp(GUC) in the NSUN2 knockdown and NTC samples. Depletion of m5C is evident in the 
NSUN2 knockdown sample at C48 and C49. D) MiSeq amplicon sequencing of tRNALeu(CAA) in 
the NSUN2 knockdown and NTC samples. Depletion of m5C is evident in the NSUN2 
knockdown sample at C34. The line in the heatmap of the spliced tRNALeu(CAA) indicates the 
region spliced. The tRNA structural positions with the known m5C sites are indicated in red 
below the heatmap. N= NSUN2 target sites. E) MiSeq amplicon sequencing of a segment of the 
non-humanised R-Luc in vitro transcript confirming efficient bisulfite conversion in both 
samples. The MiSeq coverage ranged from 1,000-75,000 mappable sequencing reads.  
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6.2.3 DIFFERENTIAL M5C SITES  
6.2.3.A GLOBAL DISTRIBUTION OF DIFFERENTIAL M5C SITES 
As detailed in Chapter 3, bsRNA-seq was performed on two biological replicates of 
PrEC and LNCaP cells. Additionally, bsRNA-seq, MiSeq amplicon sequencing and 
Sanger bisulfite sequencing of the R-Luc in vitro transcripts, tRNAAsp(GUC) and 
tRNALeu(CAA) indicated that all samples were efficiently bisulfite converted.  
 
Using the proportion statistic and appropriate controls, the number and distribution of 
candidate differential m5C sites in RNA detected in PrEC and LNCaP cells were 
determined. The criteria for the detection of these candidate sites were chosen as ≥5 
reads in all samples and ≥10% mean methylation across the control samples. As only 
few candidate differential m5C sites were detectable when requiring stringent statistical 
criteria, a FDR≤40% was used. This yielded 426 candidate m5C sites that were 
hypermethylated in PrEC cells and 389 candidate m5C sites that were hypermethylated 
in LNCaP cells (Figure 6.3). 
 
The majority of the candidate differential m5C sites were detected in mRNAs, although 
a small number of candidate sites were detected in various ncRNA classes. While the 
global mapping of the tRNAs revealed five candidate differential m5C sites 
hypermethylated in LNCaP cells, the local mapping revealed no candidate differential 
m5C sites in tRNAs. The complete lists of candidate differential m5C sites in PrEC and 
LNCaP cells are located in Appendix 8.3. 
 295 
!
Comparison of the RNA m5C profiles of PrEC, LNCaP & HeLa cells 
!
! !
 
Figure 6.3. The distribution of candidate differential m5C sites across different transcript 
biotypes in PrEC and LNCaP cells. 
≥5 reads in all samples and ≥10% mean methylation across the control samples was required for 
the detection of candidate differential m5C sites. FDR≤40% was estimated by the Benjamini-
Hochberg method. The number of candidate differential m5C sites detected in each transcript 
biotype is indicated.  
Hypermethylated in LNCaP
Hypermethylated in PrEC
unannotated
intronic/intergenic: 113
mRNA: 257
Global tRNA: 5 (local tRNA: 0)
snoRNA: 1
ncRNA (UCSC): 11
uRNA: 1
7SL RNA: 1
unannotated
intronic/intergenic: 134
mRNA: 275
7SK RNA: 2
snoRNA: 2
ncRNA (UCSC): 10
uRNA: 1
7SL RNA: 2
A)
B)
 296 
!
Comparison of the RNA m5C profiles of PrEC, LNCaP & HeLa cells 
!
! !
6.2.3.B DIFFERENTIAL M5C SITES IN MRNA  
Further investigation into mRNAs was motivated by the preferential detection of 
candidate differential m5C sites in this transcript biotype. Although the candidate 
differential m5C sites were hypermethylated in either PrEC or LNCaP cells, it was 
curious that these hypermethylated candidate sites were almost exclusively detected in 
one cell line and not the other. In addition to candidates exhibiting high coverage and 
reasonable amounts of methylation, sequencing reads were inspected in IGV prior to 
selection for validation (see section 3.2.5.A). It was noted that the majority of candidate 
differential m5C sites were called based on sequencing reads with poor quality values or 
were otherwise potentially compromised (see below). 
 
Nevertheless, three mRNAs exhibiting candidate differential m5C sites that were either 
hypermethylated in PrEC or LNCaP cells were selected for validation to investigate 
whether these were artefacts. In the case that they did validate, a focus was placed on 
transcripts that encoded proteins with functional importance in cell growth and in the 
cancer process. This included SOX4, FTSJ3 and another candidate m5C site in SZRD1. 
The candidate m5C site in SOX4 was hypermethylated in LNCaP cells and this mRNA 
encodes a transcription factor that is overexpressed in a number of cancers, including 
prostate cancer, contributing to cellular transformation, cell survival and metastasis 
[320-324]. Recently, SOX4 was reported as essential for epithelial to mesenchymal 
transition (EMT), cell survival in vitro and for primary tumour growth and metastasis in 
vivo [325]. The candidate m5C site in FTSJ3 was hypermethylated in PrEC cells and 
this mRNA encodes a protein that is a putative homologue of Spb1 protein in yeast, 
which is involved in the methylation of G2922 within the catalytic centre of the 
ribosome [326]. FTSJ3 has been reported to function in cell proliferation and pre-rRNA 
processing [327]. The candidate m5C site in SZRD1 that was hypermethylated in PrEC 
cells was interesting in that it was an additional candidate m5C site detected upstream of 
that validated in both PrEC and LNCaP cells (see section 6.2.9). Multiple m5C sites in a 
single mRNA have not yet been validated. 
 
Examination of the sequencing reads spanning the candidate m5C site in SOX4 indicated 
that they were of high sequencing quality. However, MiSeq amplicon sequencing 
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revealed clusters of non-converted cytosines primarily in a CpG context that were not 
apparent by bsRNA-seq, and this was also confirmed by Sanger bisulfite sequencing 
(Figure 6.4A). It is interesting that bsRNA-seq did not detect the clusters of non-
conversion in SOX4 despite the alignment of the sequencing reads globally to non-CpG 
in silico bisulfite converted references. However, we have previously found that clusters 
of non-converted cytosines were evident in longer PCR amplicons derived from highly 
structured rRNA compared to shorter amplicons (see section 3.2.1.C). The insert size 
used for SOLiD™ 5500XL sequencing was 50-120 nt in contrast to the amplicons 
generated for MiSeq amplicon sequencing and Sanger bisulfite sequencing which were 
~200 bp. Thus, the shorter fragments used for bsRNA-seq were most likely bisulfite 
converted more efficiently compared to the longer fragments amplified for MiSeq 
amplicon sequencing and Sanger bisulfite sequencing. This possibly resulted in the 
inability to detect the clusters of non-conversion by bsRNA-seq while clearly being 
detected by MiSeq amplicon sequencing and Sanger bisulfite sequencing. Interestingly, 
non-conversion was not detected in PrEC cells by bsRNA-seq. It is possible that the 
detection of clusters of non-conversion may also depend on the sample preparation, 
which is suggested by the different levels of non-conversion exhibited in SOX4 in each 
LNCaP replicate by bsRNA-seq. This is also highlighted by the variations in levels of 
non-conversion exhibited in each sample by MiSeq amplicon sequencing. Overall, the 
detection of this candidate m5C site in SOX4 by bsRNA-seq was most likely a false 
positive due to RNA secondary structure. 
 
The candidate m5C sites detected in FTSJ3 and SZRD1 in PrEC cells could also not be 
validated (Figure 6.4B and C). Examination of the bsRNA-seq sequencing reads in IGV 
revealed that the candidate m5C site detected in FTSJ3 in PrEC cells was downstream 
and adjacent to a G-to-A SNP (Figure 6.5A). The Single Nucleotide Polymorphism 
Database (dbSNP), which catalogues annotated SNPs generated by the National Centre 
for Biotechnology Information (NCBI), indicated that this SNP is annotated 
(rs9910549) [328]. Furthermore, PrEC and LNCaP RNA-seq data provided by 
Professor Susan Clark confirmed the presence of this SNP in 76% of the sequencing 
reads (data not shown). Interestingly, 13-34% of the bsRNA-seq sequencing reads 
mapping to this region contained the SNP, which exhibited a high quality score. A large 
proportion of sequencing reads that did not contain the SNP exhibited a low quality 
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score at that base. Due to the low quality calling of the non-SNP base, the bases 
adjacent to this were of low quality, causing the incorrect calling of a candidate m5C 
site. In contrast, the high quality score at that base resulted in the correct calling of a 
converted cytosine. LNCaP cells do not exhibit a SNP at this position and all bases were 
of high quality, resulting in the correct calling of a converted cytosine. Similarly, the 
candidate m5C site in SZRD1 was of low quality due to the low quality calling of the 
adjacent base, resulting in the incorrect calling of a candidate m5C site (Figure 6.5B). 
 
In summary, many of the candidate differential m5C sites in mRNA were called based 
on sequencing reads with poor quality values or were otherwise potentially 
compromised, which was highlighted by the inability to validate a subset of these sites. 
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Figure 6.4. Lack of validation of candidate differential m5C sites in mRNA by MiSeq 
amplicon sequencing in PrEC and LNCaP cells. 
A) SOX4, B) FTSJ3, C) SZRD1. The location of the m5C site relative to the regions in the 
mRNA is indicated at the top. The top panel displays the coverage in RPM based on bsRNA-
seq, the middle panel displays the proportion of non-conversion based on bsRNA-seq, and the 
bottom panel displays the proportion of non-conversion based on MiSeq amplicon sequencing. 
The shades of grey in the middle panel indicate regions of the transcript where coverage was <5 
reads based on bsRNA-seq. Chromosomal locations of the candidate m5C sites are indicated in 
red below the heatmap. The MiSeq coverage ranged from 29,000-56,000 mappable sequencing 
reads. 
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Figure 6.5. Representative snapshots from IGV depicting a subset of sequencing reads 
containing candidate m5C sites that could not be validated in PrEC cells.  
The grey bars represent 50 nt sequencing reads mapped to part of the locus. A) FTSJ3. 
Unconverted guanines represent the false positive site (chr17:61,901,997-61,902,036, - strand), 
B) SZRD1. Unconverted cytosines represent the false positive site (chr1:16,722,266-16,722,328, 
+ strand). Low quality bases are transparent. 
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6.2.4 STOICHIOMETRY OF M5C SITES IN COMMON 
BETWEEN PREC AND LNCAP CELLS 
Instead of leading to sites of pronounce differential methylation, another plausible 
consequence of NSUN2 overexpression in cancer would be that the stoichiometry of 
methylation is altered more subtly across many or all NSUN2 target sites. Thus, this 
was determined for candidate m5C sites that were in common between PrEC and 
LNCaP cells. Details of the number and distribution of candidate m5C sites in common 
between PrEC and LNCaP cells will be addressed in the following section.  
 
The mean proportion of methylation was calculated for each transcript biotype that 
contained candidate m5C sites in each cell line. In almost all cases, the proportion of 
methylation was approximately the same in PrEC and LNCaP cells (Figure 6.6). 
Interestingly, the single candidate m5C site detected in the vtRNA, vtRNA1-3, exhibited 
a significantly higher proportion of m5C in LNCaP cells compared to PrEC cells, with 
LNCaP cells having ~35% methylation and PrEC cells ~10% methylation. Examination 
of the sequencing reads mapping to vtRNA1-3 indicated high quality detection of the 
candidate m5C site in both cell lines, indicating that this site was not compromised by 
issues exhibited by candidate differential m5C sites (Figure 6.7). This candidate m5C 
site was also detected in HeLa cells as a NSUN2 target in this thesis and the Aza-IP 
study, as well as in HEK293 cells and human fibroblasts by miCLIP (see section 
4.3.3.B) [77, 78]. Due to the lack of time, this candidate m5C site was not followed up. 
 
These findings have demonstrated that a moderate increase in NSUN2 in LNCaP cells 
did not result in a substantial increase in the stoichiometry of methylation across most 
transcript biotypes, with the exception of an individual vtRNA. 
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Figure 6.6. Mean methylation detected in each sample for all candidate m5C sites in 
common between PrEC and LNCaP cells based on bsRNA-seq. 
The bar charts display the mean methylation at candidate m5C sites in common between PrEC 
and LNCaP cells within each transcript biotype. A single vtRNA, vtRNA1-3, exhibited a 
significantly higher proportion of methylation in LNCaP cells compared to PrEC cells (* 
p<0.05, Student’s t-test). Data represented as mean with SEM (n=2). 
 
 
Figure 6.7. Representative snapshot from IGV depicting a subset of sequencing reads 
mapping to vtRNA1-3 surrounding the candidate m5C site. 
The grey bars represent 50 nt sequencing reads mapped to part of the locus. Unconverted 
cytosines represent the candidate m5C site. The sequencing reads span chr5:140,105,740-
140,105,798 (+ strand). 
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6.2.5 M5C SITES IN COMMON BETWEEN PREC AND LNCAP 
CELLS 
The original aim of this investigation was to perform a comparative screen of 
differential m5C sites in PrEC and LNCaP cells and to relate the findings back to the 
available epigenomic and transcriptomic data reported in these cell lines by Professor 
Susan Clark, particularly to sites of differential DNA methylation in the genome. Due to 
the difficulty with validating candidate differential m5C sites, this aim was abandoned 
and an in-depth analysis of candidate m5C sites in common between PrEC and LNCaP 
cells and an integrative comparison with the HeLa methyltransferase knockdown 
dataset instead emerged as promising lines of investigation. This was of particular 
interest to confirm patterns of methylation and validate individual candidate m5C sites 
across multiple cell lines. 
 
Using the proportion statistic and appropriate controls, the total number of candidate 
m5C sites in common between PrEC and LNCaP cells was determined. The criteria for 
the detection of common candidate m5C sites were defined as ≥5 reads in all samples 
and ≥10% mean methylation across all samples, as well as a FDR≤1%. This yielded a 
total of 5,653 candidate m5C sites in common between PrEC and LNCaP cells in a wide 
variety of transcript biotypes, including tRNAs, other ncRNAs and mRNAs (Figure 
6.8). 438 candidate m5C sites were detected in tRNAs from the global mapping, and 
180 candidate m5C sites were detected in tRNAs from the local mapping. Additionally, 
559 candidate m5C sites were detected in other ncRNAs and were distributed across 
various transcript biotypes. Interestingly, excluding unannotated intronic and intergenic 
regions, the majority of the candidate m5C sites were detected in mRNAs, with 2,223 
candidate m5C sites called. The complete list of candidate m5C sites in common 
between PrEC and LNCaP cells is located in Appendix 8.3. 
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Figure 6.8. The distribution of candidate m5C sites across different transcript biotypes in 
PrEC and LNCaP cells. 
≥5 reads in all samples and ≥10% mean methylation across the control samples was required for 
the detection of candidate m5C sites in common between PrEC and LNCaP cells. FDR≤1% was 
estimated by the Benjamini-Hochberg method. The number of candidate m5C sites detected in 
each transcript biotype is indicated. 
 
6.2.6 GLOBAL COMPARISON WITH HELA CELLS 
In order to compare the RNA m5C profiles of PrEC, LNCaP and HeLa cells, an 
integrative comparison of the PrEC and LNCaP (prostate) cell dataset and HeLa 
methyltransferase knockdown dataset was performed. This section will detail the global 
comparison of candidate m5C sites in PrEC and LNCaP cells with those in HeLa cells. 
It should be noted that the total number of candidate m5C sites in PrEC and LNCaP 
cells could not be determined based on the statistical model used to detect candidate 
m5C sites. As a result, the global comparisons made in this section were between all 
candidate m5C sites in HeLa cells and candidate m5C sites in common between PrEC 
and LNCaP cells.  
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rRNA: 22
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A direct comparison between the HeLa and prostate candidate m5C sites was not trivial 
due to the differences in the number of controls used for each dataset (see section 
3.2.3.B). To make the datasets more comparable, RPM expression thresholds were used 
for transcripts exhibiting candidate m5C sites (Figure 6.9). This was particularly 
important to ensure that transcripts with candidate m5C sites had relatively high 
expression in both datasets. The thresholds selected for trial ranged from 0.1-100 RPM 
(Table 6.1). Interestingly, as the expression threshold was increased, the proportion of 
overlapping candidate m5C sites in HeLa cells and prostate cells also increased, which 
was a result of an increasing restriction to the highly expressed tRNAs. The overlap of 
candidate m5C sites for each transcript biotype between all three cell lines is listed in 
Appendix 8.10 
 
Figure 6.9. Schematic demonstrating the steps taken to make the HeLa methyltransferase 
knockdown and prostate datasets comparable.  
The controls to detect candidate m5C sites in HeLa cells and candidate m5C sites in common 
between PrEC and LNCaP cells were different. To make the datasets more comparable and to 
remove lowly expressed transcripts, RPM expression thresholds were applied. Comparisons for 
tRNAs were based on the local mapping. 
m5C sites detected in HeLa cells
TRDMT1 KD, DNMT1 KD, NTC
NSUN2 KD, DNMT1 KD, NTC
+
m5C sites detected in both 
PrEC & LNCaP cells
 
 ≥5 reads in all samples used 
in model and ≥10% mean 
methylation across controls
PrEC 1, PrEC 2, LNCaP 1, 
LNCaP 2
3,936 candidate m5C sites 5,395 candidate m5C sites
RPM expression threshold
Exclusion of lowly expressed transcripts
 
 Numbers based on 
local mapping of tRNAs
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Table 6.1. Overlap of candidate m5C sites detected in HeLa cells and sites in common 
between PrEC and LNCaP cells at different RPM expression thresholds.  
Candidate m5C sites in tRNAs were based on the local mapping. 
RPM 
cut-off 
Number of m5C 
sites in HeLa 
cells 
Number of m5C 
sites in prostate 
cells 
Number of 
overlapping m5C 
sites 
% overlapping 
m5C sites 
0.1 3933 5345 2250 53.1 
0.5 2552 2223 1457 59.2 
1 1569 1201 987 70.5 
5 570 408 437 81.2 
10 375 283 298 80.3 
20 253 185 1922 82.1 
50 142 95 120 81.6 
100 86 68 78 83.0 
 
In order to examine the overlap between HeLa cells and prostate cells in more detail, an 
expression threshold of 1 RPM was selected. This threshold was selected to focus on 
transcripts with sufficient coverage to quantify methylation and eliminate lowly 
expressed transcripts that may only be expressed in one dataset. At this threshold, 
mRNAs were still well-represented, whereas at higher expression thresholds the number 
of mRNAs was relatively low. For tRNAs, 88% of the candidate m5C sites detected in 
the prostate cells overlapped with HeLa cells, indicating high concordance between 
each dataset (Figure 6.10A). Interestingly, 82% of the candidate m5C sites detected in 
other ncRNAs in prostate cells overlapped with HeLa cells (Figure 6.10B). The overlap 
of candidate m5C sites in mRNAs between prostate cells and HeLa cells was still 
substantial at 46% (Figure 6.10C).  
 
In summary, the global comparison between PrEC and LNCaP cells and HeLa cells 
showed high concordance between the datasets, indicating that methylation patterns are 
conserved across multiple cell lines. 
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Figure 6.10. Comparison of candidate m5C sites in different transcript biotypes in prostate 
cells and HeLa cells.  
An expression threshold of 1 RPM was used for the comparison between the prostate dataset 
and HeLa methyltransferase knockdown dataset. A) Candidate m5C sites detected in tRNAs 
from the local mapping, B) Candidate m5C sites detected in other ncRNA, C) Candidate m5C 
sites detected in mRNAs. 
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6.2.7 M5C SITES IN COMMON IN TRNA  
A total of 180 candidate m5C sites in tRNAs were in common between PrEC and 
LNCaP cells from the local mapping. These numbers are comparable to the candidate 
m
5C sites detected in tRNAs in HeLa cells and the comparison revealed that 88% of 
candidate m5C sites in tRNAs overlapped between all three cell lines. Therefore, it was 
of interest to document the candidate m5C sites detected in tRNA structural positions, 
isotypes and isoacceptors in PrEC and LNCaP cells, and to compare this with those 
detected in HeLa cells. As bsRNA-seq was not performed on NSUN2 and TRDMT1 
knockdown samples in PrEC and LNCaP cells, comparisons were made with all 
candidate m5C sites detected in tRNAs in HeLa cells in this thesis. Due to the high 
expression of tRNAs, a RPM expression threshold was not applied. As with HeLa cells 
in Chapter 4, the analyses in this section primarily focused on candidate m5C sites 
detected from the local mapping.  
 
6.2.7.A TRNA STRUCTURAL POSITIONS AND ISOTYPES EXHIBITING M5C 
SITES  
As with HeLa cells, the PrEC and LNCaP bsRNA-seq data was mined to determine the 
tRNA structural positions and isotypes in those structural positions that exhibited 
candidate m5C sites in PrEC and LNCaP cells. A tRNA cloverleaf structure was then 
generated to visualise this (Figure 6.11). 
 
Candidate m5C sites were detected in most known structural positions, except C40 and 
C72, in PrEC and LNCaP cells (Figure 6.11A). Candidate m5C sites detected at C34 
were exclusively in tRNALeu, and at C38 were in tRNAAsp, tRNAGly and tRNAVal. 
Candidate m5C sites at C48 and C49 were widespread across 10 and 13 different tRNA 
isotypes, respectively, and 7 isotypes overlapped between the two positions. In contrast, 
only 5 tRNA isotypes exhibited candidate m5C sites at C50. Five non-canonical 
structural positions exhibited candidate m5C sites in PrEC and LNCaP cells, including 
C27, C44, C56, C61 and C62. The candidate m5C site at C27 was detected exclusively 
in tRNALeu, at C44 exclusively in tRNAGly, and at C56 exclusively in tRNAIle. The 
candidate m5C sites at C61 were detected in tRNAMet and tRNAThr, and at C62 in 
tRNAMet. 
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The global mapping of tRNAs revealed candidate m5C sites in all known structural 
positions (Figure 6.11B). The inability to detected candidate m5C sites at C40 by the 
local mapping may be a result of identical tRNA sequences being mapped to a single 
representative sequence, causing dilution of the candidate m5C site so that it was not 
detectable by the local mapping. As with HeLa cells, coverage towards the 3’ end of the 
tRNA when locally mapped possibly resulted in the inability to detect m5C at C72. A 
total of 11 non-canonical structural positions exhibited candidate m5C sites based on the 
global mapping. Three of these non-canonical structural positions were detected in the 
local mapping, including C27, C44 and C56, although the number of isotypes exhibiting 
candidate m5C sites at these positions was higher in the global mapping. 
 
In summary, 96% of candidate m5C sites in tRNAs that were in common between PrEC 
and LNCaP cells were in the anticipated structural positions. 
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Figure 6.11. tRNA structural positions and isotypes containing candidate m5C sites in 
PrEC and LNCaP cells. 
A) The blue circles represent tRNA structural positions exhibiting candidate m5C sites from the 
local tRNA mapping. B) The green circles represent tRNA structural positions exhibiting 
candidate m5C sites from the global tRNA mapping. tRNA isotypes containing m5C sites in 
these positions are indicated by the amino acid abbreviations. * indicates a suppressor tRNA. 
The different regions of the tRNA secondary structure are indicated. The seven structural 
positions known to exhibit m5C sites are indicated in orange. 
 
Comparison with HeLa cells 
For the comparison of the tRNA structural positions exhibiting candidate m5C sites 
between prostate cells and HeLa cells, a tRNA cloverleaf structure was generated 
indicating the positions in which candidate m5C sites were detected in prostate cells and 
HeLa cells from the local mapping. In addition, the bsRNA-seq data was mined to 
determine the tRNA isotypes methylated at these positions that were in common 
between all three cell lines.  
 
This yielded a total of 8 out of 10 structural positions exhibiting candidate m5C sites in 
common, with 5 of these being in the canonical structural positions (Figure 6.12A). In 
addition, the tRNA isotypes targeted at C34, C38, C48, C49 and C50 in PrEC and 
LNCaP cells were in complete agreement with HeLa cells. 
 
Candidate m5C sites were detected at the non-canonical structural positions at C44, C56 
and C61 in all three cell lines. As with the known structural positions, the tRNA 
isotypes at the non-canonical structural positions exhibiting candidate m5C sites in 
PrEC and LNCaP cells were in complete agreement with HeLa cells. Interestingly, the 
candidate m5C sites detected at C27 and C62 in PrEC and LNCaP cells were not 
detected in HeLa cells, and the candidate m5C site detected at C30 in HeLa cells was 
not detected in PrEC and LNCaP cells. 
 
The bsRNA-seq data was also mined to compare the tRNA isotypes that contained 
candidate m5C sites between prostate cells and HeLa cells, regardless of the structural 
positions. The tRNA isotypes that exhibited candidate m5C sites in PrEC and LNCaP 
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cells were broad, with 16 of 22 tRNA isotypes methylated (Figure 6.12B). In addition, 
14 out of 16 tRNA isotypes overlapped with HeLa cells, indicating high concordance in 
tRNA isotypes containing candidate m5C sites. 
 
From this analysis, 80% of tRNA structural positions and 88% of tRNA isotypes that 
exhibited candidate m5C sites in PrEC and LNCaP cells were in agreement HeLa cells. 
 
 
Figure 6.12. Comparison of tRNA structural positions and isotypes exhibiting candidate 
m5C sites detected by bsRNA-seq in PrEC and LNCaP cells with HeLa cells. 
Comparisons are based on the local mapping of tRNAs. A) tRNA structural positions exhibiting 
candidate m5C sites in PrEC and LNCaP cells (blue) and HeLa cells (purple). Amino acid 
abbreviations indicate tRNA isotypes in agreement between all three cell lines at each structural 
position. B) tRNA isotypes exhibiting candidate m5C sites in PrEC and LNCaP cells (blue) and 
HeLa cells (purple). 
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6.2.7.B TRNA ISOACCEPTORS EXHIBITING M5C SITES 
The PrEC and LNCaP bsRNA-seq data was also mined to determine the tRNA 
isoacceptors exhibiting candidate m5C sites in both PrEC and LNCaP cells, and a table 
was generated for the visualisation of this data (Figure 6.13). The local mapping of 
tRNA data yielded a total of 35 tRNA isoacceptors containing candidate m5C sites in 
both PrEC and LNCaP cells. These isoacceptors were broad, where multiple 
isoacceptors of a number of isotypes contained m5C sites. Global mapping of the 
bsRNA-seq data yielded a total of 38 isoacceptors that contained candidate m5C sites in 
both PrEC and LNCaP cells. Interestingly, 83% of the tRNA isoacceptors exhibiting 
candidate m5C sites from the local mapping were in agreement with the global mapping. 
 
 
Figure 6.13. tRNA isoacceptors exhibiting candidate m5C sites in PrEC and LNCaP cells. 
The blue and green circles represent tRNA isoacceptors exhibiting candidate m5C sites based on 
the local and global mapping, respectively. 
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Comparison with HeLa cells 
A comparison of the tRNA isoacceptors containing candidate m5C sites in PrEC and 
LNCaP cells was made with those in HeLa cells. Based on the local mapping, 33 out of 
35 tRNA isoacceptors exhibiting candidate m5C sites overlapped with those detected in 
HeLa cells (Figure 6.14). Thus, as with the tRNA structural positions and isotypes, 
>90% tRNA isoacceptors exhibiting candidate m5C sites in PrEC and LNCaP cells were 
in agreement with HeLa cells. 
 
 
Figure 6.14. Comparison of tRNA isoacceptors exhibiting candidate m5C sites in PrEC 
and LNCaP cells with HeLa cells. 
The comparison was based on all m5C sites detected in HeLa cells regardless of the 
methyltransferase that mediates the m5C site. 
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6.2.7.C VALIDATION OF M5C SITES IN TRNA 
In order to confirm patterns of m5C in tRNAs across multiple cell lines, four tRNAs 
exhibiting candidate m5C sites in PrEC and LNCaP cells that were also validated in 
HeLa cells were selected for validation by MiSeq amplicon sequencing. This included 
tRNAGlu(CUC), tRNAGly(GCC), tRNAThr(UGU) and tRNAVal(CAC). As with HeLa cells, the 
coverage of the tRNAs selected were high based on the bsRNA-seq, with all tRNAs 
exhibiting declining coverage towards the 3’ end (Figure 6.15; top panel).  
 
As with the m5C sites in tRNAs in HeLa cells, there was an underrepresentation of 
multiple m5C sites in tRNAGlu(CUC) and tRNAGly(GCC) detected by bsRNA-seq in PrEC 
and LNCaP cells. Candidate m5C sites were detected at C38 and C50 of tRNAGly(GCC) 
from the bsRNA-seq, but the validation revealed additional m5C sites at C48 and C49 
(Figure 6.15; middle and bottom panels). Also, the candidate m5C sites detected at C49 
and C50 of tRNAGlu(CUC) from the bsRNA-seq appeared to be underrepresented 
compared to MiSeq amplicon sequencing.  
 
In all cases, the candidate m5C sites detected by bsRNA-seq were validated, including at 
C49 and C50 in tRNAGlu(CUC), C48 in tRNAThr(UGU) and C48 and C49 in tRNAVal(CAC). 
Depletion of m5C at C48-50 was evident in the NSUN2 knockdown sample, indicating 
that NSUN2 mediates m5C at these positions in LNCaP cells in addition to HeLa cells. 
Interestingly, mild depletion of m5C was evident at C38 of tRNAGly(GCC) in the NSUN2 
knockdown sample by MiSeq amplicon sequencing, although this was validated as a 
TRDMT1-mediated site in HeLa cells in this thesis and by previous studies [73, 77].  
 
In summary, it is clear that m5C sites in at least 4 tRNAs are present across multiple cell 
lines, and these sites are mediated NSUN2 in both LNCaP and HeLa cells. 
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Figure 6.15. Validation of candidate m5C sites in tRNAs in PrEC and LNCaP cells by 
MiSeq amplicon sequencing. 
The top panel displays the coverage throughout the transcript in RPM based on bsRNA-seq, the 
middle panel displays the proportion of non-conversion based on bsRNA-seq, and the bottom 
panel displays the proportion of non-conversion in a segment of the transcript based on MiSeq 
amplicon sequencing. The tRNA structural positions with candidate m5C sites are indicated in 
red below the heatmap. The bsRNA-seq data is based on the local mapping of tRNAs. The 
MiSeq coverage ranged from 800-72,000 mappable sequencing reads. 
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6.2.8 M5C SITES IN COMMON IN OTHER NCRNA 
The bsRNA-seq yielded 559 candidate m5C sites in other ncRNA that were in common 
between PrEC and LNCaP cells. Furthermore, 82% of candidate m5C sites detected in 
ncRNA in PrEC and LNCaP cells were in concordance with HeLa cells. As such, two 
candidate m5C sites were selected for validation to confirm individual sites across 
multiple cell lines. Interestingly, the NSUN2-mediated m5C sites detected in SCARNA2 
and SNORD62 in HeLa cells were also detected in PrEC and LNCaP cells by bsRNA-
seq. Both m5C sites were validated by MiSeq amplicon sequencing in PrEC and LNCaP 
cells (Figure 6.16). Strong depletion of methylation was observed at both m5C sites in 
the LNCaP NSUN2 knockdown sample, with the m5C site in SCARNA2 depleting to 7% 
and the m5C site in SNORD62 depleting to 8%, indicating that NSUN2 mediates these 
sites in LNCaP cells. 
 
In summary, it is clear that m5C sites in several ncRNAs can be present across multiple 
cell lines, and these sites are mediated NSUN2 in both LNCaP and HeLa cells. 
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Figure 6.16. Validation of candidate m5C sites in other ncRNA in PrEC and LNCaP cells 
by MiSeq amplicon sequencing. 
The top panel displays the coverage in RPM based on bsRNA-seq, the middle panel displays the 
proportion of non-conversion based on bsRNA-seq, and the bottom panel displays the 
proportion of non-conversion based on MiSeq amplicon sequencing. Chromosomal locations of 
the candidate m5C sites are indicated in red below the heatmap. The MiSeq coverage ranged 
from 18,000-70,000 mappable sequencing reads.  
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6.2.9 M5C SITES IN COMMON IN MRNA 
The majority of candidate m5C sites in common between PrEC and LNCaP cells were 
in mRNAs and the comparison with HeLa cells also indicated 46% of candidate m5C 
sites in mRNAs were in common between all three cell lines. To confirm these patterns, 
candidate m5C sites detected and validated in mRNA in HeLa cells that were also 
detected in PrEC and LNCaP cells were selected for validation by MiSeq amplicon 
sequencing. These included the m5C sites in OSBPL8, RTN3 and SZRD1 that were 
validated as NSUN2 targets in HeLa cells (see section 4.2.4.B). An additional four 
novel candidate m5C sites detected in PrEC and LNCaP cells were also selected for 
validation to confirm patterns across the two cell lines and to determine if these sites 
were mediated by NSUN2 in LNCaP cells. This included candidate m5C sites in NEK7, 
PLD3, PWP2 and SRRT. 
 
The m5C sites in OSBPL8, RTN3 and SZRD1 were validated in both PrEC and LNCaP 
cells (Figure 6.17). Depletion of m5C was evident in the LNCaP NSUN2 knockdown 
sample in RTN3 and SZRD1, where m5C levels depleted to 8% and <1%, respectively, 
indicating that these sites are also mediated by NSUN2 in LNCaP cells. Although 
OSBPL8 was validated as a NSUN2 target in HeLa cells, little methylation was detected 
in the LNCaP NTC sample in addition to the LNCaP NSUN2 knockdown. Interestingly, 
an unconverted cytosine was instead evident one base downstream in the NTC sample. 
Thus, it could not be concluded that NSUN2 mediated this m5C site in LNCaP cells in 
addition to HeLa cells. 
 
The novel candidate m5C sites detected in NEK7, PLD3, PWP2 and SRRT were also 
validated by MiSeq amplicon sequencing. Interestingly, the level of m5C in NEK7 in 
PrEC 1 detected by MiSeq amplicon sequencing was substantially lower than that 
detected by bsRNA-seq. bsRNA-seq detected ~40% methylation at this site, whilst 
MiSeq amplicon sequencing detected ~5% methylation in this sample. Similarly, <1% 
methylation was detected in the LNCaP NSUN2 knockdown and NTC samples based 
on MiSeq amplicon sequencing. In contrast, PrEC 2, LNCaP 1 and LNCaP 2 exhibited 
~40-50% methylation. It is possible that the variability in the proportion of methylation 
may be attributed to PCR amplification biases (see section 5.2.5.A). Although this m5C 
site was validated, the site was not a convincing NSUN2 target due to the lack of 
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methylation in both the LNCaP NSUN2 knockdown and NTC samples. In contrast, 
depletion of methylation in the LNCaP NSUN2 knockdown sample was evident in 
PWP2 and SRRT, indicating that NSUN2 mediates m5C in these transcripts in LNCaP 
cells. The candidate m5C site validated in PLD3 in PrEC and LNCaP cells was not 
convincingly depleted upon NSUN2 knockdown in LNCaP cells. Therefore, this was 
not a convincing NSUN2-mediated site in LNCaP cells. 
 
These findings have provided evidence that NSUN2-mediated m5C sites in at least 
seven mRNAs are conserved across multiple cell lines. 
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Figure 6.17. Validation of candidate m5C sites in mRNA in PrEC and LNCaP cells by 
MiSeq amplicon sequencing. 
The location of the m5C site relative to the regions in the mRNA is indicated at the top. The top 
panel displays the coverage in RPM based on bsRNA-seq, the middle panel displays the 
proportion of non-conversion based on bsRNA-seq, and the bottom panel displays the 
proportion of non-conversion based on MiSeq amplicon sequencing. The shades of grey in the 
middle panel indicate regions of the transcript where coverage was <5 reads based on bsRNA-
seq. Chromosomal locations of the candidate m5C sites are indicated in red below the heatmap. 
The MiSeq coverage ranged from 10,000-70,000 mappable sequencing reads. 
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6.3 DISCUSSION  
The original aim of this investigation was to perform a comparative screen of candidate 
differential m5C sites in PrEC and LNCaP cells and to relate the findings back to the 
available epigenomic and transcriptomic data reported in these cell lines. Previous 
studies have reported increased levels of NSUN2 in a number of cancers and it was 
observed in this thesis that NSUN2 was overexpressed more than two-fold in LNCaP 
cells compared to PrEC cells. As such, it was originally hypothesised that an increase in 
NSUN2 may result in either an increased number of m5C sites in LNCaP cells 
compared to PrEC cells, or an increase in the stoichiometry of methylation at m5C sites 
detected in both cell lines. However, candidate differential m5C sites could not be 
validated and as such, I used the data to compare candidate m5C sites across multiple 
cell lines and to validate individual candidates across transcript biotypes. Here, I will 
discuss the outcomes of these findings. 
 
6.3.1 DIFFERENTIAL M5C SITES IN PREC AND LNCAP 
CELLS 
6.3.1.A NCRNAS 
The local mapping of tRNAs revealed no candidate differential m5C sites in either cell 
line or increased stoichiometry of methylation in LNCaP cells. Only a small number of 
candidate differential m5C sites were detected in other ncRNA and as a result, these 
candidates were not investigated in great detail. Investigation into the stoichiometry of 
methylation of candidate m5C sites in common between PrEC and LNCaP cells in 
different ncRNAs indicated little difference between each cell line. A single vtRNA, 
vtRNA1-3, showed significantly more methylation in LNCaP cells compared to PrEC 
cells. Although this site was not independently validated in this thesis, it was detected as 
a NSUN2 target in HeLa cells in this thesis and two other studies [77, 78], and Hussain 
et al. reported that loss of NSUN2-mediated methylation in vtRNA1-1 caused decreased 
processing into svRNAs that can associate with Ago2 and Ago3 and potentially induce 
silencing of mRNA (see section 4.3.3.B) [78]. Although this was only detected in 
vtRNA1-1, it is possible that the difference in stoichiometry of m5C in vtRNA1-3 in 
PrEC and LNCaP cells may result in changes in the processing of this transcript into 
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smaller fragments. This may contribute to variations in gene expression in PrEC and 
LNCaP cells that may result in the differences associated with normal and cancer cells. 
 
6.3.1.B MRNAS 
While m5C in tRNAs was reported to promote mRNA translation through stabilisation, 
this does not disregard other factors contributing to the regulation of translation. The 
thesis has provided several correlative links between the presence of m5C in mRNAs 
and several aspects of post-transcriptional gene regulation, including mRNA stability 
and translation. Thus, it was originally of interest to investigate the differences in m5C 
in mRNA in PrEC and LNCaP cells that could potentially contribute to the deregulation 
of translation commonly seen in cancer. 
 
It was curious that the majority of candidate differential m5C sites detected by bsRNA-
seq were almost exclusively detected in one cell line and not the other, rather than being 
hypermethylated. Additionally, examination of the sequencing reads mapping to the 
differential mRNA candidates in IGV revealed that the majority of candidate m5C sites 
exhibited low quality scores, suggesting that these may be artefacts. To determine if this 
was the case, three mRNAs containing candidate differential m5C sites were selected for 
further interrogation by MiSeq amplicon sequencing. Analysis of the candidate m5C site 
in SOX4 by MiSeq amplicon sequencing and Sanger bisulfite sequencing revealed that 
this site was most likely an artefact due to incomplete denaturation of the RNA. This 
issue is not trivial to overcome. For the bisulfite conversion of RNA, a compromise was 
made between efficient denaturation and limiting fragmentation of the RNA, suggesting 
that some transcripts may still exhibit these clusters (see section 3.2.1.B). While 
reducing the amplicon size would limit the detection of these clusters, the short insert 
size used for bsRNA-seq resulted in the detection of a single non-converted cytosine in 
SOX4 as a convincing candidate m5C site. In the case of 28S rRNA, the bsRNA-seq 
revealed clusters of non-converted cytosines despite the short insert size possibly due to 
the substantially strong secondary structure (see section 4.2.3.A). Increasing the insert 
or amplicon size may increase the probability of detecting clusters of non-conversion, 
however these clusters would be identifiable by the examination of the sequencing reads 
that surround these regions. Ultimately, optimisation of a m5C antibody for the 
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detection of regions exhibiting candidate m5C sites by MeRIP, which was attempted in 
this thesis, would be of benefit as clusters of non-conversion due to inefficient 
denaturation would not be detected. Coupling this technique with bsRNA-seq would 
enable detection of candidate m5C sites at single nucleotide resolution in addition to 
removal of secondary structure artefacts. 
 
The candidate differential m5C sites in FTSJ3 and SZRD1 failed to validate for different 
reasons to that of SOX4. The candidate m5C site in FTSJ3 was only detected in PrEC 
cells and an annotated G-to-A SNP was located upstream and adjacent to the candidate 
m5C site. The SNP was of high quality after examination in IGV, however a small 
subset of sequencing reads that did not contain the SNP exhibited low quality calling of 
the base. The low quality calling of this base resulted in the low quality calling of 
adjacent bases including the candidate m5C site. This ultimately resulted in the detection 
of a false positive site. This SNP was not detected in LNCaP cells and the base at this 
location was of high quality, resulting in the correct calling of a converted cytosine. 
Similarly, the candidate m5C site in SZRD1 was of low quality, resulting in a false 
positive.  
 
Taken together, the small number of candidate differential m5C sites detected and the 
inability to validate a subset of these sites in PrEC and LNCaP cells suggests that the 
RNA m5C profiles of each cell line are largely similar. This indicates that increased 
NSUN2 in LNCaP cells did not result in an obvious increase number of m5C sites or 
increase in the stoichiometry of m5C in this thesis. The similar RNA m5C profiles is not 
unexpected, as this study was performed as an initial screen and in combination with the 
moderate overexpression of NSUN2 in LNCaP cells compared to the strong depletion 
of methylation observed in NSUN2 knockdown cells suggests that any differences 
detected would be subtle. Therefore, it is possible that the level of overexpression 
exhibited in LNCaP cells was not sufficient enough to confer hypermethylation of RNA 
detectable in this screen.  
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6.3.2 M5C SITES IN COMMON BETWEEN PREC AND LNCAP 
CELLS  
An investigation into the m5C sites in common between PrEC and LNCaP cells was 
made. A comparative analysis with HeLa cells was also performed in order to confirm 
patterns of methylation and validate individual m5C sites across multiple cell lines. 
 
The bsRNA-seq and subsequent bioinformatics pipeline used yielded a total of 5,653 
candidate m5C sites in common between PrEC and LNCaP cells. 2,223 candidate m5C 
sites were detected in mRNAs, 180 candidate m5C sites in tRNAs from the local 
mapping and 559 candidate m5C sites distributed over other ncRNAs. The wide 
distribution of candidate m5C sites in various transcript biotypes among three cell lines 
indicates that this modification is not just limited to tRNAs and highlights a functional 
importance in other transcript biotypes. 
 
6.3.2.A GLOBAL COMPARISON WITH HELA CELLS 
As a different number of control samples were used for the detection of candidate m5C 
sites in the prostate dataset and HeLa dataset, they were not directly comparable. To 
make the datasets more comparable, an expression threshold for transcripts containing 
m5C sites detected in each dataset was used. An expression threshold of 1 RPM enabled 
detection of tRNAs as well other ncRNA and mRNAs. This revealed high concordance 
between prostate cells and HeLa cells for all transcript biotypes. 88% of the candidate 
m5C sites in tRNAs in common between PrEC and LNCaP cells were detected in HeLa 
cells at this expression threshold. The large overlap of candidate m5C sites in tRNAs 
between all cell lines suggests that m5C in tRNAs plays an important functional role in 
all cellular contexts, which has been highlighted by several previous studies that 
reported increased cleavage of tRNAs devoid of m5C sites [73, 149, 150]. Interestingly, 
a study that disrupted NSUN2 and TRDMT1 in mice not only reported ablation of all 
m5C sites in tRNAs, but also reduced steady-state levels of the tRNAs [149]. 
Additionally, reduced rate of protein synthesis was observed in Nsun2 and Trdmt1 
double knockout mouse embryonic fibroblasts (MEFs), although other factors such as 
mRNA methylation may also contribute to this [149]. This finding highlights the 
importance of m5C in tRNA fidelity, regardless of the cellular context, and also 
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suggests that a slight deregulation in this modification in tRNAs may compromise the 
cell. 
 
The candidate m5C sites detected in other ncRNAs were also highly concordant 
between all cell lines, with 82% of candidate m5C sites in common between PrEC, 
LNCaP and HeLa cells. The candidate m5C sites in mRNAs were also highly 
concordant between all cell lines, although this was slightly lower at 46%, suggesting 
that m5C in mRNAs is more dynamic and may largely depend on the cellular context. 
The high concordance of candidate m5C sites in other ncRNAs and mRNAs between 
three different cell lines indicates that this modification is not randomly distributed, 
suggesting important regulatory functions for this modification in mRNA and ncRNA. 
 
6.3.2.B M5C SITES IN TRNAS 
The local mapping of tRNAs revealed that all candidate m5C sites detected in tRNAs 
were in common between PrEC and LNCaP cells, highlighting the importance of this 
modification for the fidelity of tRNAs. As with Chapter 4, candidate m5C sites in tRNA 
structural positions, isotypes and isoacceptors were investigated and these were 
compared with all candidate m5C sites detected in HeLa cells. In this section, I will 
discuss the outcomes of these findings. As absence of NSUN2 and TRDMT1 in mice 
was reported to result in complete ablation of m5C in tRNAs [149], the tRNA structural 
positions, isotypes and isoacceptors exhibiting candidate m5C sites in PrEC and LNCaP 
cells were also juxtaposed with the NSUN2 and TRDMT1 Aza-IP study [77]. As the 
Aza-IP study mapped tRNAs globally, comparisons were made between candidate m5C 
sites detected from both the local and global mapping of tRNAs with the Aza-IP study.  
 
The local mapping of tRNAs revealed that 96% of candidate m5C sites were located at 
five of the seven known structural positions in PrEC and LNCaP cells. Interestingly, 
candidate m5C sites were not detected at C40, which may be a result of identical tRNA 
sequences being mapped to a single representative sequence, causing dilution of the 
candidate m5C site so that it was not detectable in the local mapping. This is highlighted 
by the fact that the level of methylation detected at this positions in tRNAGly(GCC) in 
HeLa cells in this thesis was low (see section 4.2.2.C). In the case of C72, declining 
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coverage towards the 3’ end of the tRNA when mapped locally possibly resulted in the 
inability to detect m5C at this position from the local mapping.  
 
Candidate m5C sites detected at the anticipated structural positions and the tRNA 
isotypes in these positions in prostate cells were largely in agreement with those 
detected in HeLa cells in this thesis and the Aza-IP study, in addition to previous 
literature (Figure 6.18A). This includes m5C at C34 in tRNALeu(CAA) [100], C38 in 
tRNAAsp(GUC) [58, 59, 77, 159], tRNAGly(GCC) [73, 77], tRNAVal(AAC) [73, 77] and 
tRNAVal(CAC) [77], and C48-50 in a broad range of tRNA isotypes [58, 98, 148, 149]. 
There was high concordance in the tRNA isotypes targeted for methylation at C48-50 
with the Aza-IP study, with >85% tRNA isotypes exhibiting candidate m5C sites at each 
of these positions in PrEC and LNCaP cells overlapping with the Aza-IP study (data not 
shown). 
 
Candidate m5C sites were located in five non-canonical structural positions in PrEC and 
LNCaP cells, including C27, C44, C56, C61 and C62. The candidate m5C sites detected 
at C44, C56 and C62 were also detected in HeLa cells, and the tRNA isotypes at these 
positions were in complete agreement. Interestingly, four of the five non-canonical 
structural positions exhibiting candidate m5C sites in PrEC and LNCaP cells were also 
detected by Aza-IP, including C27, C56, C61 and C62. The tRNA isotypes methylated 
at these positions differed between each study, with substantially more isotypes detected 
by Aza-IP (data not shown). However, there was some overlap including m5C at C27 in 
tRNALeu and m5C at C61 in tRNAMet. As expected, the global mapping of tRNAs in 
PrEC and LNCaP cells showed a stronger overlap, with candidate m5C sites detected at 
C56 in tRNAAla, tRNAArg and tRNAGln overlapping with the Aza-IP study. The high 
concordance of the non-canonical tRNA structural positions exhibiting candidate m5C 
sites between PrEC and LNCaP cells, HeLa cells in this thesis and by Aza-IP, highlight 
that these positions are more commonly modified than previously thought.  
  
The tRNA isotypes exhibiting candidate m5C sites in PrEC and LNCaP cells were 
broad, with the local mapping revealing 16 isotypes containing candidate m5C sites, and 
the global mapping revealing 21 isotypes containing candidate m5C sites. As with the 
structural positions, there was high concordance between both mapping methods, with 
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all 16 tRNA isotypes in the local mapping overlapping with the global mapping. In 
addition to being in agreement with HeLa cells in this thesis, the data was largely in 
agreement with the Aza-IP study, with 18 candidate m5C sites from the global mapping 
and 15 from the local mapping overlapping with the Aza-IP study (Figure 6.18B). 
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Figure 6.18. Comparison of tRNA structural positions and isotypes exhibiting candidate 
m5C sites in PrEC and LNCaP cells with the Aza-IP study [77].  
All candidate m5C sites in common between PrEC and LNCaP cells were compared with 
NSUN2 and TRDMT1 targeted tRNAs. A) tRNA structural positions, B) tRNA isotypes.  
 
The local and global mapping of the tRNAs revealed a wide variety of tRNA 
isoacceptors exhibiting candidate m5C sites in PrEC and LNCaP cells; 35 isoacceptors 
contained at least one candidate m5C site based on the local mapping, and 38 
isoacceptors based on the global mapping. Both methods of mapping were largely in 
agreement, with 33 isoacceptors overlapping. Furthermore, ~95% of the tRNA 
isoacceptors containing candidate m5C sites in PrEC and LNCaP cells were in 
agreement with HeLa cells in this thesis and >90% were in agreement with the Aza-IP 
study (Figure 6.19).  
 
 
Figure 6.19. Comparison of tRNA isoacceptors exhibiting candidate m5C sites in PrEC 
and LNCaP cells with the Aza-IP study [77]. 
All candidate m5C sites in common between PrEC and LNCaP cells were compared with 
NSUN2 and TRDMT1 targeted tRNAs. 
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Analysis of the candidate m5C sites in tRNAs that were in common between PrEC and 
LNCaP cells and the comparison with HeLa cells has revealed high concordance 
between all three cell lines on three different levels; tRNA structural positions, isotypes 
and isoacceptors. Several of the tRNAs containing candidate m5C sites in all three cell 
lines were also validated in PrEC and LNCaP cells, and NSUN2 mediated m5C sites at 
C34 and C48-50 in LNCaP cells in addition to HeLa cells. Comparison of the tRNA 
structural positions, isotypes and isoacceptors with the NSUN2 and TRDMT1 Aza-IP 
study also revealed strong agreement with PrEC and LNCaP cells. This suggests that 
tRNAs are consistently and highly modified under different cellular contexts, 
highlighting the importance of this modification in tRNA fidelity.  
 
6.3.2.C M5C SITES IN OTHER NCRNA 
559 candidate m5C sites detected in various classes of ncRNA were in common between 
PrEC and LNCaP, and the integrative comparison with HeLa cells performed in this 
chapter also revealed high concordance with HeLa cells. To confirm these patterns, the 
m5C sites detected and validated in SCARNA2 and SNORD62 in HeLa cells, which were 
also detected in PrEC and LNCaP cells, were selected for validation in PrEC and 
LNCaP cells. The m5C sites in both ncRNAs were validated in both cell lines and were 
also confirmed as NSUN2 targets in LNCaP cells. Detection and validation of the same 
NSUN2-mediated m5C sites in the selected ncRNAs in multiple cell lines highlights that 
m5C in ncRNAs is not random and can exist in various cellular contexts. This suggests 
that m5C in other ncRNA may play a regulatory role. While m5C in vtRNAs has been 
reported to regulate their processing into smaller fragments [78], the role of m5C in 
other ncRNA transcript biotypes remains to be explored. Possible molecular functions 
of m5C in ncRNA include regulating stability and association with proteins, although 
this remains to be explored in further detail. 
 
Comparison of candidate m5C sites with the NSUN2 and TRDMT1 Aza-IP study 
showed little overlap, with only m5C sites in RPPH1, SCARNA2 and vtRNA1-3 in 
common with PrEC and LNCaP cells [77]. It is possible that many m5C sites detected in 
ncRNAs in PrEC and LNCaP cells may be mediated by other enzymes besides NSUN2 
and TRDMT1. Another plausible explanation for the differences, which was discussed 
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in Chapter 4, is the difference in the sensitivity of the techniques. Aza-IP may enrich 
tRNAs due to their high abundance and high density of m5C, which may have resulted 
in the depletion of other ncRNAs and mRNAs containing m5C sites (see section 
4.3.1.C). The fact that there was high concordance in m5C sites detected in PrEC and 
LNCaP cells with HeLa cells in this thesis suggests that the differences were not 
necessarily attributed to different cellular contexts, but more likely a result of the 
sensitivity of the different techniques. 
 
6.3.2.D M5C SITES IN MRNA 
With the exception of candidate m5C sites in unannotated and intronic regions, the 
majority of the candidate m5C sites in common between PrEC and LNCaP cells were in 
mRNA. As with tRNAs and other ncRNAs, there was high concordance in the 
candidate m5C sites in mRNAs between PrEC, LNCaP and HeLa cells, with 46% of 
candidate m5C sites in agreement between all three cell lines. To confirm patterns of 
methylation in mRNA across multiple cell lines, a subset of candidate m5C sites in 
mRNAs was validated by MiSeq amplicon sequencing. The mRNAs selected for 
validation encoded proteins of various cellular processes, and several of these 
transcripts were detected and validated as NSUN2-mediated m5C sites in HeLa cells, 
including OSBPL8, RTN3 and SZRD1. The m5C sites in all three mRNAs were 
validated in PrEC and LNCaP cells, and the sites in RTN3 and SZRD1 were also 
mediated by NSUN2 in LNCaP cells. The m5C site in OSBPL8 was not detected in 
either the NSUN2 knockdown or NTC samples in LNCaP cells, although it is highly 
likely that this site is also mediated by NSUN2 in LNCaP cells.  
 
Four novel m5C sites in mRNAs validated in PrEC and LNCaP cells were not detected 
in HeLa cells, and included NEK7, PLD3, PWP2 and SRRT. The proteins encoded by 
these transcripts have broad biological functions, suggesting that m5C in mRNA may 
regulate stability or translation of transcripts encoding proteins that are involved in 
broad biological processes. NEK7 is part of the NIMA-related family of 
serine/threonine kinases involved in the mitotic signalling cascade [329]. PLD3 is a 
non-classical and poorly characterised member of the PLD family of phospholipases, 
with members of the family involved in catalysing the hydrolysis of 
 336 
!
Comparison of the RNA m5C profiles of PrEC, LNCaP & HeLa cells 
!
! !
phosphatidylcholine to phosphatidic acid [330]. Members of the PLD family are 
activated during a number of different cellular events, including vesicle trafficking, cell 
migration and mitosis, and were reported to be deregulated in a number of cancers [330-
333]. Recently, GWAS of late-onset Alzheimer’s disease families reported a rare coding 
variant of PLD3 (Val232Met) that increased the risk of the development of Alzheimer’s 
disease [334]. The m5C site in PLD3 was located ~400 nt upstream of this variant, 
suggesting that it would not contribute to the variant. PWP2 is homologous to the yeast 
Pwp2 and is a nucleolar protein reported to be involved in pre-rRNA processing [335, 
336]. SRRT is a nuclear cap-binding protein involved in cell proliferation and studies 
suggest that it is required for miRNA-mediated silencing [337-339]. The m5C sites in 
PWP2 and SRRT were mediated by NSUN2 in LNCaP cells, whereas depletion of 
methylation in PLD3 was not observed in the NSUN2 knockdown sample, suggesting 
that either residual NSUN2 after knockdown may have still methylated this site or 
another methyltransferase may mediate this modification. The m5C site in NEK7 was 
not detected in the NSUN2 knockdown and NTC samples in LNCaP cells and therefore 
it could not be concluded whether NSUN2 mediates this site. 
 
As with tRNAs and other ncRNAs, it is clear that patterns of m5C in mRNAs are 
conserved across multiple cell lines and can be mediated by the same enzyme, 
indicating the non-random distribution of this modification in RNA. 
 
6.3.3 CONCLUSIONS 
This was the first study to compare the RNA m5C profiles of normal and cancer cells. 
Several hundred differential m5C sites were detected in PrEC and LNCaP cells, with the 
majority of sites present in mRNAs. Examination of the sequencing reads of the 
bsRNA-seq data indicated that a large proportion of the candidate m5C sites were of low 
quality and most likely artefacts, which was highlighted by the inability to validate a 
subset of these sites. The m5C sites that were in common between PrEC and LNCaP 
cells showed little difference in the stoichiometry of methylation, with only a single 
vtRNA showing higher proportion of methylation in LNCaP cells compared to PrEC 
cells. This suggests that the RNA m5C profiles of PrEC and LNCaP cells were largely 
similar, and that the higher expression of NSUN2 in LNCaP cells did not result in an 
increase in the number of m5C sites or stoichiometry at a particular m5C site.  
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I compared the RNA m5C profiles between PrEC and LNCaP cells and successfully 
detected 5,653 candidate m5C sites across various transcript biotypes that were in 
common between PrEC and LNCaP cells, with several successfully validated. In 
addition to being in common between PrEC and LNCaP cells, a large number of 
candidate m5C sites were in agreement with HeLa cells. A small subset of these m5C 
sites in tRNAs, other ncRNAs and mRNAs were validated in PrEC and LNCaP cells, 
and were mediated by NSUN2 in LNCaP cells in addition to HeLa cells. There was also 
high concordance in the tRNA structural positions, isotypes and isoacceptors containing 
m5C sites in all three cell lines and the literature, highlighting the important role of m5C 
in tRNA stability. Taken together, this indicates that m5C patterns are conserved across 
multiple cell lines, suggesting a regulatory role for this modification in a number of 
transcript biotypes. 
 
6.4 CHAPTER HIGHLIGHTS 
• NSUN2 was overexpressed more than two-fold in LNCaP cells compared to PrEC 
cells. 
 
6.4.1 DIFFERENTIAL M5C SITES 
• Candidate m5C sites that were differentially methylated between PrEC and LNCaP 
cells were difficult to detect; reducing the FDR criteria to ≤40% allowed the listing 
of 426 candidate sites as hypermethylated in PrEC cells and 389 candidate m5C sites 
that were hypermethylated in LNCaP cells, with the majority of candidate sites in 
mRNAs. 
• Visual inspection revealed that many of these candidate differential m5C sites were 
called based on sequencing reads with poor quality values or were otherwise 
potentially compromised. 
• Three mRNA candidates were analysed by MiSeq amplicon sequencing and failed to 
validate. The site in SOX4 was likely called as a result of incomplete denaturation of 
the RNA, while the sites in FTSJ3 and SZRD1 were called based on reads with poor 
quality values. 
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• The stoichiometry of m5C for candidate m5C sites in common between PrEC and 
LNCaP cells were indistinguishable for most transcript biotypes. A single vtRNA, 
vtRNA1-3, showed significantly higher methylation in LNCaP cells compared to 
PrEC cells.!
 
6.4.2 M5C SITES IN COMMON 
• 5,653 candidate m5C sites were in common between PrEC and LNCaP cells. 
• Using a 1 RPM expression threshold, there was high concordance in the candidate 
m5C sites detected in prostate cells with HeLa cells; 88% of candidate m5C sites in 
tRNAs, 82% in other ncRNAs and 46% in mRNAs were in common between PrEC, 
LNCaP and HeLa cells. 
• All candidate m5C sites in tRNAs were in common between PrEC and LNCaP cells. 
There was also high concordance with those detected in HeLa cells. This suggests 
that m5C in tRNA is important for fidelity. 
• The m5C sites validated in the ncRNAs SCARNA2 and SNORD62 in HeLa cells were 
also validated in PrEC and LNCaP cells. Both m5C sites were mediated by NSUN2 
in LNCaP cells.  
• The m5C sites validated in the mRNAs OSBPL8, RTN3 and SZRD1 were also 
validated in PrEC and LNCaP cells. The m5C sites in RTN3 and SZRD1 were also 
mediated by NSUN2 in LNCaP cells.  
• Novel m5C sites were validated in NEK7, PLD3, PWP2 and SRRT in PrEC and 
LNCaP cells. The m5C sites in PWP2 and SRRT were mediated by NSUN2 in 
LNCaP cells. Convincing depletion of m5C in PLD3 in the NSUN2 knockdown 
sample was not evident. 
• These findings indicate that patterns of m5C in tRNAs, other ncRNAs and mRNA are 
conserved across different cellular contexts and are mediated by the same enzyme. 
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7.1 DISCUSSION 
In this chapter, I will discuss the outcomes of this thesis and the importance of this 
study for the understanding of m5C in RNA.  
 
There are currently >100 nucleoside modifications known in RNA, which were 
identified over several decades mostly by studying the ncRNAs of the translational 
machinery (tRNA, rRNA). Notable exceptions were m6A and m5C, which were also 
found at low levels in cellular and viral mRNAs [20-39, 47, 48]. Recent next-generation 
sequencing studies in the emerging field of “epitranscriptomics” have mapped sites of 
m
5C [58], m6A [56, 57] and now also ψ [53-55] throughout the transcriptome including 
mRNAs, hinting at currently hidden regulatory functions. This raises many questions, 
including whether several or perhaps many of the other nucleoside modifications may 
also be distributed throughout the transcriptome. Investigations into m5C, m6A and ψ all 
faced the challenge of identifying the writers, readers and erasers of these modifications 
and deciphering the molecular functions, particularly in mRNA. m6A currently leads the 
way, with an emerging consensus that it is involved in mRNA stability and alternative 
splicing [57, 69, 105, 107, 120]. The discovery of ψ in mRNA in the last year has meant 
that limited investigations into its molecular function have been performed, although 
initial analysis suggests a stabilising role in mRNA [54]. Another challenge is whether 
these modifications are static or dynamic, with indications for m6A and ψ that many of 
the sites are preserved across tissues and species, although there is also evidence that a 
subset of sites respond to changed conditions such as stress or meiosis in yeast [53-57, 
67]. 
 
While next-generation sequencing has revealed the abundance and distribution of m5C 
throughout the transcriptome, the understanding of the enzymology, molecular 
functions and biological implications of this modification in mRNA remain to be 
explored in greater detail. This thesis has greatly extended what was previously known 
about the substrate range of NSUN2 and TRDMT1, revealing multiple novel target sites 
in mRNAs and some ncRNAs, while consolidating our knowledge of their range of sites 
in tRNAs. Previous studies have primarily focused on m5C sites mediated by NSUN2 
and TRDMT1 in tRNAs and other ncRNAs, with limited detection or exploration of 
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m
5C sites in mRNAs [77, 78]. Thus, this was also the first study to explore candidate 
m
5C sites in mRNAs in detail and explore the molecular functions of m5C in mRNA. 
  
NSUN2 has been reported by several studies to be overexpressed in cancer, however 
there is a lack of studies investigating the RNA m5C profiles across normal and cancer 
cells [99, 207, 317]. This was the first study to perform a comparative analysis of the 
RNA m5C profiles of normal and cancer cells to investigate differential m5C sites that 
may contribute to cancer. Little difference in the RNA m5C profiles was evident 
between PrEC and LNCaP cells and as such this motivated a comparative analysis of 
candidate m5C sites in common between PrEC and LNCaP cells with candidate m5C 
sites detected in HeLa cells to investigate the presence of m5C in different cellular 
contexts.  
 
To summarise, this is the first study to extensively interrogate the substrate range of 
NSUN2 and TRDMT1, the specificity of NSUN2 in a range of transcript biotypes and 
the molecular functions of m5C in mRNA. Additionally, this is the first study to perform 
a comparative analysis of RNA m5C profiles between normal and cancer cells. 
 
7.1.1 SUBSTRATE RANGE OF NSUN2 AND TRDMT1 
One of the major aims of this thesis was to investigate the substrate range and 
specificity of NSUN2 and TRDMT1 by coupling RNAi-mediated knockdown of the 
enzymes with bsRNA-seq. In addition to detecting thousands of candidate m5C sites in 
a wide variety of transcript biotypes in HeLa cells, NSUN2 and TRDMT1 were found 
to mediate m5C sites in tRNAs, other ncRNAs and mRNAs. I found that the majority of 
candidate m5C sites that were called as NSUN2 or TRDMT1 targets were in mRNAs, 
substantially extending what was previously known about the substrate range of these 
enzymes.  
 
Concurring with recent complementary transcriptome-wide studies, 87% of candidate 
m5C sites detected in tRNAs were in the anticipated structural positions, with 99% of 
NSUN2 targets at C34 and C48-50 in a broad range of tRNA isotypes and isoacceptors, 
and 93% of TRDMT1 targets at C38 exclusively in tRNAAsp(GUC), tRNAGly(GCC), 
tRNAVal(AAC) and tRNAVal(CAC). As with tRNAs, NSUN2 was found to be multisite-
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specific in other ncRNAs and mRNAs, mediating m5C within stem-loop structures. 
Several of the structures surrounding the m5C sites in ncRNAs and mRNAs were 
reminiscent of those in tRNAs, although there were other structural features that were 
targeted by this enzyme. As with the structures, NSUN2 was found to target different 
sequences in ncRNA, and a computational analysis of candidate m5C sites in mRNA 
called as NSUN2 targets revealed a slight preference for CpA and CpG and an 
abundance of Gs 2-4 bases downstream of the targeted cytosine. It is unclear whether 
these features are sufficient to mediate m5C by NSUN2 or if there are additional 
structural or sequence requirements that were not detected in this thesis to mediate m5C. 
It is also possible that other features besides the sequence and structure are required for 
selective methylation of RNA by NSUN2. One possible scenario is the presence of 
proteins or RNA that may help guide NSUN2 to mediate m5C in transcripts. 
 
These findings have extended the previously known substrate specificity of NSUN2, 
highlighting its multisite specificity. While the role of TRDMT1 in modifying ncRNA 
and mRNA are yet to be explored in detail, I have provided evidence in this thesis that 
NSUN2 is an important mRNA modifying enzyme, in addition to modifying tRNAs and 
other ncRNAs. 
 
7.1.2 M5C PRIOR TO PROCESSING OF TRANSCRIPTS 
In this thesis, I also examined methylation of tRNAs prior to end processing and 
splicing and have provided evidence of methylation occurring prior to both. I have 
provided evidence in this thesis of m5C in tRNALeu(CAA) occurring prior to splicing, 
confirming previous reports [100, 148]. In addition, the global tRNA mapping data was 
analysed to determine if m5C can occur prior to end processing of tRNAs, with evidence 
that it does. To this end, it is not known whether end processing precedes splicing of 
tRNAs in humans, with conflicting evidence in other species. In S. cerevisiae, end 
processing generally occurs prior to splicing [269, 340, 341], however when grown 
under high temperatures some tRNAs undergo splicing first, suggesting that the order of 
processing in yeast is dependent on growth conditions [269]. Similarly, based on 
Xenopus oocyte injection experiments, the amount of pre-tRNATyr introduced into the 
nucleus influenced which process occurred first [270]. Injection of low amounts of pre-
tRNATyr into the nucleus resulted in splicing occurring first, however in the case of high 
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amounts of pre-tRNATyr, end processing preceded splicing. Thus, the findings in this 
thesis are consistent with both scenarios and indicate that m5C in tRNA occurs early 
during biogenesis, most likely in the nucleolus, and suggests that this may be the case 
for other transcript biotypes (Figure 7.1). Although the bsRNA-seq library was not 
enriched for pre-mRNAs, candidate m5C sites were detected in introns, suggestive of 
m5C in mRNAs occurring prior to splicing. Similarly, the transcriptome-wide studies of 
m
6A also detected m6A in introns [56, 57]. Thus, it is possible that many of the 
nucleoside modifications in RNA occur early during RNA biogenesis. 
 
 
Figure 7.1. Schematic demonstrating m5C in tRNA prior to end processing and splicing. 
Transcription and end processing of pre-tRNAs occurs in the nucleolus. As shown in this thesis, 
methylation of tRNAs can occur prior to end processing and splicing. 
 
7.1.3 DIFFERENTIAL RNA M5C PROFILES BETWEEN 
NORMAL AND CANCER CELLS 
Another major goal of this thesis was to examine the differences in the RNA m5C 
profiles of PrEC and LNCaP cells and relate any findings of this back to the available 
epigenomic and transcriptomic data of these cell lines. I found a two-fold increase in 
NSUN2 in LNCaP cells compared to PrEC cells and hypothesised a subtle increase in 
either the number of m5C sites or an increase in the stoichiometry of m5C in LNCaP 
cells. In contrast to the number of candidate m5C sites in common between PrEC and 
m5C
pre-tRNA
m5C
m5C
End processing
Splicing
Nucleolus
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LNCaP cells, only a small number of candidate m5C sites were differentially 
methylated. Furthermore, examination of the sequencing reads revealed that a 
substantial number of candidate differential m5C sites called were a result of low quality 
bases and this was confirmed by MiSeq amplicon sequencing. In addition, the 
stoichiometry of m5C of candidate m5C sites in common between PrEC and LNCaP 
cells were relatively similar across transcript biotypes, although vtRNA1-3 exhibited a 
significantly higher proportion of methylation in LNCaP cells compared to PrEC cells. 
As m5C in vtRNAs has been reported to regulate its processing into svRNAs, this 
suggests that an increase the proportion of m5C in vtRNA1-3 may increase its 
processing into smaller fragments to induce gene silencing in LNCaP cells. In turn, this 
may contribute to the differences in gene expression profiles between the two cell lines. 
With the exception of vtRNA1-3, these findings indicate that the two-fold increase in 
NSUN2 did not result in detectable hypermethylation in LNCaP cells and as a result the 
RNA m5C profiles of PrEC and LNCaP cells were largely similar. It is possible that the 
higher level of NSUN2 in LNCaP cells may function elsewhere, given its broad 
biological role in various cellular processes. This could potentially be in mitosis where 
NSUN2 is involved in mitotic spindle stability independent of its methyltransferase 
activity [211], and where mitotic deregulation is a hallmark of cancer cells. NSUN2 is 
also phosphorylated at Ser139 by Aurora-B during disassembly of the nucleolus, 
suppressing its methyltransferase activity (see section 1.4.4) [208]. It is possible that the 
overexpressed NSUN2 in LNCaP cells may in fact be phosphorylated, resulting in little 
difference in the RNA m5C profiles between PrEC and LNCaP cells. Thus, the 
overexpressed NSUN2 in LNCaP cells may function to stabilise the mitotic spindle 
necessary for fast-dividing cells such as cancer cells.  
 
7.1.4 SIMILAR M5C PATTERNS ARE PRESENT ACROSS 
MULTIPLE CELL LINES 
The vast majority of the candidate m5C sites detected in PrEC and LNCaP cells were in 
common. This motivated a comparative analysis between PrEC, LNCaP and HeLa cells. 
Using a RPM threshold between the two datasets generated in this thesis to eliminate 
lowly expressed transcripts that may be present in only one dataset, >70% candidate 
m5C sites detected were in common between all three cell lines; >80% candidate m5C 
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sites detected in tRNAs and other ncRNAs, and 46% of candidate m5C sites in mRNAs 
were in common between all three cell lines. These patterns of methylation were 
confirmed in four tRNAs, two ncRNAs and several mRNAs as NSUN2 targets in HeLa 
cells and LNCaP cells. Interestingly, similar patterns of m6A were reported between 
normal and cancer tissues as well as different stress conditions, although a subset of 
dynamically modulated sites were also detected across different conditions [57]. Thus, 
as with m6A, the findings in this thesis demonstrate that RNA m5C patterns are highly 
conserved across multiple human cell lines, further pointing towards a functional 
importance of m5C not only in tRNA, but other ncRNA and mRNA.  
 
7.1.5 MOLECULAR FUNCTION OF M5C IN MRNA  
One of the major goals of this thesis was to explore the molecular functions of m5C in 
mRNA. Due to the limited detection of m5C in mRNA in previous studies, this is the 
first study to investigate this in some detail. In this thesis, m5C sites were significantly 
enriched in the 3’ UTR, which is a hotspot for regulatory motifs, suggesting a role for 
m
5C in post-transcriptional gene control. Consistent with this finding, enrichment of 
Ago2 footprints was evident upstream of m5C sites and a depletion of miRNA target 
sites was evident at m5C sites, indicating that m5C sites are enriched downstream of 
RISC and depleted at RISC binding sites in mRNA, suggesting regulatory interactions 
between m5C and RISC. In agreement with a role in post-transcriptional gene 
regulation, a subtle decrease in the mean steady-state level of NSUN2-targeted mRNAs 
in the NSUN2 knockdown sample based on bsRNA-seq was evident, highlighting a 
subtle role for NSUN2-mediated m5C sites in mRNA stability. Thus, this suggests 
antagonistic interactions between m5C and Ago2 and miRNAs. 
 
In addition, a correlation of m5C with translation state was observed which was found to 
be context-dependent. The m5C site in the CDS of RPS3 resulted in a subtle decrease in 
methylation with translation state, indicating that m5C in this transcript is negatively 
correlated with its translation. This m5C site was 10 nt downstream of an Ago2 
footprint, consistent with our global findings, suggesting that at least for this transcript 
m5C may mediate binding of RISC to inhibit translation. In contrast, the proportion of 
m5C in RTN3 increased with translation state and in addition was not near any Ago2 
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footprints or putative miRNA binding sites, suggesting that m5C in this transcript may 
interact with other RBPs to mediate translation. While we observed an enrichment of 
Ago2 footprints upstream of candidate m5C sites, this does not preclude m5C from 
interacting with other RBPs to mediate post-transcriptional gene regulation. In 
particular, secondary structures such as stem-loops within the 3’ UTR can promote or 
block binding of RBPs to mediate gene expression. The finding in this thesis that m5C is 
enriched in stem-loop structures in mRNAs suggests that this modification may regulate 
the binding of RBPs to the 3’ UTR, in addition to Ago2. 
 
The findings in this thesis have provided correlative links between m5C and mRNA 
stability and translation, although the underlying mechanisms need to be explored in 
further detail. Furthermore, the molecular functions reported in this thesis for mRNA 
are consistent with those reported for rRNA [92], tRNA [73, 149, 150, 304] and vtRNA 
[78], where m5C has been demonstrated to regulate stability and translation. Thus, there 
is an emerging picture that m5C in RNA largely functions in regulating stability and 
translation (Figure 7.2).  
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Figure 7.2. Confirmed and speculative molecular functions of m5C in RNA. 
Studies have provided evidence for the molecular functions of m5C in rRNA [92], tRNA [73, 
149, 150, 304] and vtRNA [78]. This thesis has provided evidence for a correlative link between 
m
5C and stability and translation. Molecular functions in RPPH1 and snoRNA are speculative. 
Those molecular functions related to translation are indicated in green, while those related to 
stability are indicated in purple.  
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7.2 FUTURE DIRECTIONS 
Following from this thesis, future work would focus more heavily on the substrate range 
and specificity of TRDMT1. A focus on TRDMT1 mediating m5C in other transcript 
biotypes is lacking. The Aza-IP study has revealed a single m5C site in the mRNA 
KRT18 as a TRDMT1 target, but this was not validated [77]. This thesis has provided 
evidence of TRDMT1 mediating m5C in a range of transcript biotypes and thus 
warrants validation and further investigation. In addition, this thesis has provided 
evidence of other RNA:m5C methyltransferases mediating m5C sites in rRNA, such as 
NSUN1, NSUN4 and NSUN5A, which are yet to be confirmed as active 
methyltransferases in humans. Exploring the substrate range of these enzymes, possibly 
through deletion cell lines, would substantially extend the known enzymology of m5C 
in RNA. 
 
In this thesis, I have provided several correlative links between m5C in mRNA and post-
transcriptional gene regulation. Extending what has been discovered in this thesis 
warrants further investigation. The steady-state level analyses performed in this thesis 
could not differentiate between changes in expression as a result of changes in the rate 
of transcription or stability of the mRNA. As the presence of m5C in mRNA is not 
likely to affect the rate of transcription, investigating the role of m5C specifically in 
mRNA stability is enticing. This could be achieved by knocking down NSUN2 and 
TRDMT1 (or use of deletion cell lines) followed by treatment with the transcription 
inhibitor, Actinomycin-D, over a time course. The extracted RNA can then be subjected 
to RNA-seq to investigate the stability of transcripts exhibiting m5C sites mediated by 
NSUN2 or TRDMT1. The benefit of this approach is that this investigation is not just 
limited to mRNAs. Several studies have used a similar approach to investigate the role 
of m6A in mRNA stability, which revealed an inverse correlation of m6A with stability 
[105, 120]. Similarly, an extension of the candidate approach used in this thesis to 
explore the role of m5C in translation should be investigated by coupling sucrose 
density gradient centrifugation of at least three biological replicates with RNA-seq, in 
addition to retaining the resolution of the polysome fractions collected to investigate 
gradual changes in the proportion of methylation with translation state. Both 
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transcriptome-wide approaches would provide a wealth of data for the role of m5C in 
mRNA in stability and translation. 
 
Another tantalising direction for the understanding of m5C in RNA is the identification 
of m5C-binding proteins, including writers, erasers and readers. Erasers and readers of 
m5C have not yet been discovered, and there is the possibility of other writers mediating 
m
5C, as described above. FTO and ALKBH5 have been recently discovered as m6A 
erasers, and FTO mediates m6A removal by initially oxidising it to N6-
hydroxymethyladenosine (hm6A) and N6-formyladenosine (f6A) [342]. Interestingly, a 
similar approach is employed by the TET hydroxylases for oxidation of m5C to hm5C 
and f5C in DNA [262, 264, 265, 343], and a recent study has reported that TET 
hydroxylases can mediate hm5C formation in RNA in vitro (see section 3.3.2.E) [263]. 
Therefore, the role of TET hydroxylases in oxidising and possibly removing m5C in 
RNA warrants further investigation. The discovery of m5C-binding proteins could be 
investigated by generating RNA baits containing m5C and coupling this with mass 
spectrometry. A similar approach was employed for the discovery of the m6A reader, 
YTHDF2 [57], which led to a subsequent study that has provided substantial evidence 
for a role of m6A in mRNA destabilisation [120]. Thus, identification of m5C readers 
using this procedure could also elucidate the molecular functions of m5C in RNA. 
 
Investigation into the possibility of proteins or RNAs guiding NSUN2 or TRDMT1 to 
target transcripts for methylation warrants further investigation in order to understand 
the mechanism of methylation. A possible experiment to identify guide proteins is 
immunoprecipitation of NSUN2 or TRDMT1 followed by mass spectrometry. 
Following identification of possible guide protein(s), the level of m5C can be 
investigated at known target sites of NSUN2 or TRDMT1 with and without knockdown 
of the interacting protein to determine if it does function in guiding either 
methyltransferase. For the investigation of guide RNAs, small RNA-seq could be 
performed to enrich for small RNAs. Following this, sequence complementarity 
between small RNAs and the sequence surrounding m5C sites targeted by NSUN2 or 
TRDMT1 could be investigated in a similar manner to the detection of snoRNAs and 
their targets. However, this would be quite a difficult experiment to perform, as it is not 
known what type of transcripts would help guide m5C methylation.  
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Although this thesis suggests antagonistic interactions between m5C and Ago2 and 
miRNAs, there is also the possibility of Ago/miRNAs recruiting NSUN2 to promote 
methylation. Co-immunoprecipitation experiments with NSUN2 and Ago could be used 
to investigate this further. Additionally, following from this and the work performed in 
this thesis, the relationship between m5C sites and Ago could be studied in greater detail 
by coupling immunoprecipitation of Ago2-bound RNA with bisulfite sequencing to 
examine the levels of m5C surrounding Ago2 binding sites. The RNA that was not 
immunoprecipitated by Ago2 can also be examined by bisulfite sequencing as a 
comparison. Furthermore, in addition to investigating the stability of NSUN2-targeted 
transcripts upon NSUN2 knockdown compared to the NTC as mentioned earlier in this 
chapter, this can be followed up by examining the stability of NSUN2-targeted 
transcripts that are also miRNA controlled. 
 
Following from this, the biological role of m5C in RNA should be further investigated. 
A possible approach is performing transcriptome-wide screens of m5C in different 
tissues and comparing the RNA m5C profiles in a similar way to this thesis. The 
understanding of the molecular functions of m5C in RNA in addition to the RNA m5C 
profiles provided from these screens could possibly shed light on the biological role of 
m5C in RNA. In particular, investigating the RNA m5C profiles from brains of patients 
that exhibited intellectual disabilities caused by mutations in NSUN2 is an enticing 
direction. A recent study has reported a link between depletion of NSUN2-mediated 
m5C sites in tRNAs with accumulation of 5’ tRNA-derived fragments, decreased 
mRNA translation, activation of stress pathways and increased apoptosis of neurons, 
although m5C in mRNA or other ncRNAs was not investigated [150]. Understanding 
the biological role of m5C in RNA could provide further insight into their role in human 
diseases and may be a therapeutic target in the future. 
 
7.3 CONCLUDING REMARKS 
The overall aims of this thesis were to improve and establish methods for the detection 
of m5C in RNA, to determine the RNA targets of NSUN2 and TRDMT1 and the 
specificity of NSUN2, investigate the molecular functions of m5C in mRNA and 
compare the RNA m5C profiles across multiple cell lines, including normal and cancer 
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cells. This was the first study to perform these investigations and thus this thesis has 
achieved these aims. 
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8.1 SEQUENCES FOR THE R-LUC IN VITRO  TRANSCRIPTS 
 
Humanised R-Luc in vitro transcript 
TCCAAGGTGTACGACCCCGAGCAACGCAAACGCATGATCACTGGGCCTCAGTGGTGGGCTCGCT
GCAAGCAAATGAACGTGCTGGACTCCTTCATCAACTACTATGATTCCGAGAAGCACGCCGAGAA
CGCCGTGATTTTTCTGCATGGTAACGCTGCCTCCAGCTACCTGTGGAGGCACGTCGTGCCTCAC
ATCGAGCCCGTGGCTAGATGCATCATCCCTGATCTGATCGGAATGGGTAAGTCCGGCAAGAGCG
GGAATGGCTCATATCGCCTCCTGGATCACTACAAGTACCTCACCGCTTGGTTCGAGCTGCTGAA
CCTTCCAAAGAAAATCATCTTTGTGGGCCACGACTGGGGGGCTTGTCTGGCCTTTCACTACTCC
TACGAGCACCAAGACAAGATCAAGGCCATCGTCCATGCTGAGAGTGTCGTGGACGTGATCGAGT
CCTGGGACGAGTGGCCTGACATCGAGGAGGATATCGCCCTGATCAAGAGCGAAGAGGGCGAGAA
AATGGTGCTTGAGAATAACTTCTTCGTCGAGACCATGTCCCAAGCAAGATCATGCGGAAACTGG
AGCCTGAGGAGTTCGCTGCCTACCTGGAGCCATTCAAGGAGAAGGGCGAGGTTAGACGGCCTAC
CCTCTCCTGGCCTCGCGAGATCCCTCTCGTTAAGGGAGGCAAGCCCGACGTCGTCCAGATTGTC
CGCAACTACAACGCCTACCTTCGGGCCAGCGACGATCTGCCTAAGATGTTCATCGAGTCCGACC
CTGGGTTCTTTTCCAACGCTATTGTCGAGGGAGCTAAGAAGTTCCCTAACACCGAGTTCGTGAA
GGTGAAGGGCCTCCACTTCAGCCAGGAGGACGCTCCAGATGAAATGGGTAAGTACATCAAGAGC
TTCGTGGAGCGCGTGCTGAAGAACGAGCAGTAACGAGCAGTAA 
Non-humanised R-Luc in vitro transcript 
ATGATCCAGAACAAAGGAAACGGATGATAACTGGTCCGCAGTGGTGGGCCAGATGTAAACAAAT
GAATGTTCTTGATTCATTTATTAATTATTATGATTCAGAAAAACATGCAGAAAATGCTGTTATT
TTTTTACATGGTAACGCGGCCTCTTCTTATTTATGGCGACATGTTGTGCCACATATTGAGCCAG
TAGCGCGGTGTATTATACCAGACCTTATTGGTATGGGCAAATCAGGCAAATCTGGTAATGGTTC
TTATAGGTTACTTGATCATTACAAATATCTTACTGCATGGTTTGAACTTCTTAATTTACCAAAG
AAGATCATTTTTGTCGGCCATGATTGGGGTGCTTGTTTGGCATTTCATTATAGCTATGAGCATC
AAGATAAGATCAAAGCAATAGTTCACGCTGAAAGTGTAGTAGATGTGATTGAATCATGGGATGA
ATGGCCTGATATTGAAGAAGATATTGCGTTGATCAAATCTGAAGAAGGAGAAAAAATGGTTTTG
GAGAATAACTTCTTCGTGGAAACCATGTTGCCATCAAAAATCATGAGAAAGTTAGAACCAGAAG
AATTTGCAGCATATCTTGAACCATTCAAAGAGAAAGGTGAAGTTCGTCGTCCAACATTATCATG
GCCTCGTGAAATCCCGTTAGTAAAAGGTGGTAAACCTGACGTTGTACAAATTGTTAGGAATTAT
AATGCTTATCTACGTGCAAGTGATGATTTACCAAAAATGTTTATTGAATCGGACCCAGGATTCT
TTTCCAATGCTATTGTTGAAGGTGCCAAGAAGTTTCCTAATACTGAATTTGTCAAAGTAAAAGG
TCTTCATTTTTCGCAAGAAGATGCACCTGATGAAATGGGAAAATATATCAAATCGTTCGTTGAG
CGAGTTCTCAAAAATGAACAATAATTCTAGAGCGGCCGCTTCGAGCAGACATGATAAGATACAT
TGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGT
GATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCA
 354 
!
Appendix 
!
! !
TTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTA
CAAATGTGGTAAAATCGATAAGGATCCAAAAAAAAAAAAAAAAAAAAAAA 
 
 
Due to the large size, the following appendix files have been included digitally. Please 
refer to the attached CD. 
 
8.2 R SCRIPT FOR STRUCTURAL MOTIF ANALYSES 
The following .sh file details the shell script used for the structural analyses. 
 
8.3 CANDIDATE M5C SITES IN HELA CELLS, PREC AND LNCAP 
CELLS 
The following Excel files list the candidate m5C sites detected in HeLa cells, and PrEC 
and LNCaP cells. 
 
HeLa: The following Excel files contain the full list of candidate m5C sites detected in 
HeLa cells from the global and local mapping. Each file contains three sheets with a list 
of the total number of candidate m5C sites (HeLa), candidate m5C sites called as 
NSUN2 targets (NSUN2) and candidate m5C sites called as TRDMT1 targets 
(TRDMT1). 
 
Prostate: The following Excel files contain three sheets with the full list of candidate 
m5C sites in common between PrEC and LNCaP cells (Prostate), candidate m5C sites 
hypermethylated in PrEC cells (PrEC) and candidate m5C sites hypermethylated in 
LNCaP cells (LNCaP) from the global and local mapping. On the following page are 
brief descriptions of the headings in these files. 
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genomic_location  genomic location of candidate m5C site 
reads    total number of reads 
TCreads   number of reads that are T or C only 
ratio    non-conversion % 
genes    names of transcripts with candidate m5C site 
genomic_region  genomic region of candidate m5C site 
P.Value    p-value 
Adj.P.Val   adjusted p-value (FDR) 
struRNAs:    type of ncRNA 
tRNA_type   tRNA isotype/isoacceptors 
 
Additional local mapping headings 
chr coordinates of transcripts with candidate m5C sites 
chr_start/end location of candidate m5C site  
desc  description of transcripts with candidate m5C sites 
genomic_coord genomic location of transcripts with candidate m5C sites  
 
8.4 GLOBAL AND LOCAL TRNA ALIGNMENTS 
The following Excel files list the candidate m5C sites in tRNAs based on the global and 
local mapping, whether they were called as NSUN2 or TRDMT1 targets, and the 
structural position of the candidate m5C sites. These files were used to determine the 
tRNA structural positions, isotypes and isoacceptors containing candidate m5C sites. 
 
8.5 RFAM STRUCTURAL ALIGNMENT OF TRNAS EXHIBITING 
CANDIDATE M5C SITES FROM THE LOCAL MAPPING 
The following .pdf file displays the tRNA Rfam structural alignment generated from the 
local mapping and the location of candidate m5C sites within the tRNAs.  
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8.6 MISEQ AMPLICON SEQUENCING OF TRANSCRIPTS EXHIBITING 
M5C SITES 
The following .bed files list the coverage and methylation % of cytosines in segments of 
the transcripts subjected for m5C site validation by MiSeq amplicon sequencing. 
 
8.7 GSEA AND GO ANALYSIS FOR CANDIDATE M5C SITES IN HELA 
CELLS 
The following .txt files display the outcome of the GSEA. The following Excel files 
contain the full list of enriched GO terms of transcripts containing candidate m5C sites. 
These analyses were performed for all candidate m5C sites in mRNA in HeLa cells 
(HeLa), NSUN2-targeted mRNA (NSUN2) and TRDMT1-targeted mRNA (TRDMT1). 
There are three sheets per file showing biological processes (BP), molecular functions 
(MF) and cellular components (CC). 
 
8.8 COMPLETE LIST OF HOUSEKEEPING GENES FOR RT-QPCR 
The following Excel file contains the list of housekeeping genes from [309] that did not 
contain detectable levels of m5C by bsRNA-seq.  
 
8.9 STATISTICAL ANALYSIS FOR RT-QPCR GENE EXPRESSION 
ANALYSIS 
The following .rtf files display the output from GenStat for the analysis of RT-qPCR 
data in Chapter 5. 
 
8.10 OVERLAP OF CANDIDATE M5C SITES IN PREC, LNCAP AND 
HELA CELLS 
The following Excel file displays the overlap of candidate m5C sites in common 
between PrEC and LNCaP cells, and HeLa cells for each transcript biotype from 0.1-
100 RPM. 
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